

(19)



(11)

**EP 2 861 595 B9**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Claims DE 1**  
**Claims EN 1, 12, 13, 18, 19**  
**Claims FR 1, 13**

(51) Int Cl.:

**C07D 471/14** <sup>(2006.01)</sup>      **C07D 471/22** <sup>(2006.01)</sup>  
**C07D 491/22** <sup>(2006.01)</sup>      **C07D 495/14** <sup>(2006.01)</sup>  
**C07D 498/14** <sup>(2006.01)</sup>      **A61K 31/519** <sup>(2006.01)</sup>  
**A61K 31/4375** <sup>(2006.01)</sup>      **A61P 35/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**21.06.2017 Bulletin 2017/25**

(86) International application number:

**PCT/US2013/045309**

(45) Date of publication and mention of the grant of the patent:

**21.12.2016 Bulletin 2016/51**

(87) International publication number:

**WO 2014/007951 (09.01.2014 Gazette 2014/02)**

(21) Application number: **13783125.1**

(22) Date of filing: **12.06.2013**

**(54) SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS**

SUBSTITUIERTE TRICYCLISCHE VERBINDUNGEN ALS FGFR-INHIBITOREN

COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

- **ZHANG, Colin**  
Ambler, Pennsylvania 19002 (US)
- **HE, Chunhong**  
Chadds Ford, Pennsylvania 19317 (US)
- **SUN, Yaping**  
Hockessin, Delaware 19707 (US)
- **LU, Liang**  
Hockessin, Delaware 19707 (US)
- **QIAN, Ding-Quan**  
Newark, Delaware 19702 (US)
- **XU, Meizhong**  
Hockessin, Delaware 19707 (US)
- **ZHUO, Jincong**  
Garnet Valley, Pennsylvania 19060 (US)
- **YAO, Wenqing**  
Chadds Ford, Pennsylvania 19317 (US)

(30) Priority: **13.06.2012 US 201261659245 P**

**21.08.2012 US 201261691463 P**

**20.12.2012 US 201261740012 P**

**08.03.2013 US 201361774841 P**

(43) Date of publication of application:

**22.04.2015 Bulletin 2015/17**

(60) Divisional application:

**16203866.5 / 3 176 170**

(73) Proprietor: **Incyte Holdings Corporation**

**Wilmington, DE 19803 (US)**

(74) Representative: **Carpmaels & Ransford LLP**

**One Southampton Row**

**London WC1B 5HA (GB)**

(72) Inventors:

- **WU, Liangxing**  
Wilmington, Delaware 19082 (US)

(56) References cited:

**WO-A2-99/61444**

**WO-A2-2006/124731**

**WO-A2-2007/134259**

**EP 2 861 595 B9**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- GHORAB M M ET AL: "SYNTHESIS OF SOME SULFUR CONTAINING TETRAHYDROBENZOÄBÜTHIENO(PYRIDINES, QUINOLINES, OXAZINES AND PYRIMIDINES) AS POSSIBLE RADIOPROTECTIVE AND ANTINEOPLASTIC AGENTS", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, TAYLOR & FRANCIS INC, US, vol. 134/135, 1 January 1998 (1998-01-01), pages 57-76, XP008040341, ISSN: 1042-6507
- EISSA: "Synthesis and evaluation of some surface active agents from long chain fatty amine", GRASAS Y ACEITES, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (SPANISH NATIONAL RESEARCH COUNCIL), SPAIN, vol. 58, no. 4, 1 January 2007 (2007-01-01), pages 379-389, XP009175543, ISSN: 0017-3495

**Description****FIELD OF THE INVENTION**

5 [0001] The present invention relates to tricyclic compounds, and pharmaceutical compositions including the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

**BACKGROUND OF THE INVENTION**

10 [0002] The Fibroblast Growth Factor Receptors (FGFR) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFR1-4) that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation. Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005). Aberrant activation of this pathway either through overexpression of FGF ligands or FGFR or activating mutations in the FGFRs can lead to tumor development, progression, and resistance to conventional cancer therapies. In human cancer, genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand-independent receptor activation have been described. Large scale DNA sequencing of thousands of tumor samples has revealed that components of the FGFR pathway are among the most frequently mutated in human cancer. Many of these activating mutations are identical to germline mutations that lead to skeletal dysplasia syndromes. Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities (Reviewed in Knights and Cook Pharmacology & Therapeutics, 2010; Turner and Grose, Nature Reviews Cancer, 2010).

25 [0003] Therefore, development of inhibitors targeting FGFR may be useful in the clinical treatment of diseases that have elevated FGF or FGFR activity.

30 [0004] The cancer types in which FGF/FGFRs are implicated include, but are not limited to:

carcinomas (e.g., bladder, breast, cervical, colorectal, endometrial, gastric, head and neck, kidney, liver, lung, ovarian, prostate); hematopoietic malignancies (e.g., multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, acute myelogenous leukemia, non-Hodgkin lymphoma, myeloproliferative neoplasms, and Waldenstrom's Macroglobulinemia);

35 and other neoplasms (e.g., glioblastoma, melanoma, and rhabdosarcoma). In addition to a role in oncogenic neoplasms, FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achondroplasia and craniosynostosis syndromes. WO2006/124731 discloses heteroaryl compounds to treat diseases or disorders associated with abnormal or deregulated kinase activity.


40 [0005] There is a continuing need for the development of new drugs for the treatment of cancer and other diseases, and the FGFR inhibitors described herein help address this need.

**SUMMARY OF THE INVENTION**

45 [0006] The present invention is directed to a compound of Formula II:

50

55



or a pharmaceutically acceptable salt thereof, wherein constituent variables are defined hereinbelow.

**[0007]** The present invention is further directed to a pharmaceutical composition comprising a compound of Formula II, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

**[0008]** The present invention is further directed to a compound of Formula II, or a pharmaceutically acceptable salt thereof, for use in treating cancer.

**[0009]** The present invention is further directed to a compound of Formula II, or a pharmaceutically acceptable salt thereof, for use in treating a myeloproliferative disease.


**[0010]** The present invention is further directed to a compound of Formula II, or a pharmaceutically acceptable salt thereof, for use in treating a skeletal or chondrocyte disorder.

**[0011]** The present invention is further directed to the use of a compound of Formula II, or a pharmaceutically acceptable salt thereof, in therapy.

**[0012]** The present invention is further directed to the use of a compound of Formula II, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in therapy.

### DETAILED DESCRIPTION

**[0013]** The present invention is related to an FGFR inhibitor which is a compound of Formula II:



or a pharmaceutically acceptable salt thereof, wherein:

W is NR<sup>9</sup>;

X is CR<sup>15</sup> or N;

R<sup>1</sup> is H, NR<sup>A</sup>R<sup>B</sup>, halo, and C<sub>1-3</sub> alkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from H, CN, C(O)NR<sup>cR<sup>d</sup></sup>, and C<sub>1-7</sub> alkyl, wherein said C<sub>1-7</sub> alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, OR<sup>a</sup>, CN, NR<sup>cR<sup>d</sup></sup>, and C(O)NR<sup>cR<sup>d</sup></sup>; or R<sup>2</sup> and R<sup>3</sup> together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring or a 4-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, OR<sup>a</sup>, SR<sup>a</sup>, C(O)R<sup>b</sup>, C(O)NR<sup>cR<sup>d</sup></sup>, C(O)OR<sup>a</sup>, OC(O)R<sup>b</sup>, OC(O)NR<sup>cR<sup>d</sup></sup>, NR<sup>cR<sup>d</sup></sup>,



heteroaryl, 3-10 membered heterocycloalkyl, CN, NO<sub>2</sub>, OR<sup>a5</sup>, SR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, OC(O)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>C(O)R<sup>b5</sup>, NR<sup>c5</sup>C(O)OR<sup>a5</sup>, NR<sup>c5</sup>C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(=NR<sup>e5</sup>)R<sup>b5</sup>, C(=NR<sup>e5</sup>)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>C(=NR<sup>e5</sup>)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>S(O)R<sup>b5</sup>, NR<sup>c5</sup>S(O)<sub>2</sub>R<sup>b5</sup>, NR<sup>c5</sup>S(O)<sub>2</sub>NR<sup>c5</sup>R<sup>d5</sup>, S(O)R<sup>b5</sup>, S(O)NR<sup>c5</sup>R<sup>d5</sup>, S(O)<sub>2</sub>R<sup>b5</sup>, and S(O)<sub>2</sub>NR<sup>c5</sup>R<sup>d5</sup>; wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a5</sup>, SR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, OC(O)NR<sup>c5</sup>R<sup>d5</sup>, C(=NR<sup>e5</sup>)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>C(=NR<sup>e5</sup>)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>C(O)R<sup>b5</sup>, NR<sup>c5</sup>C(O)OR<sup>a5</sup>, NR<sup>c5</sup>C(O)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>S(O)R<sup>b5</sup>, NR<sup>c5</sup>S(O)<sub>2</sub>R<sup>b5</sup>, NR<sup>c5</sup>S(O)<sub>2</sub>NR<sup>c5</sup>R<sup>d5</sup>, S(O)R<sup>b5</sup>, S(O)NR<sup>c5</sup>R<sup>d5</sup>, S(O)<sub>2</sub>R<sup>b5</sup>, and S(O)<sub>2</sub>NR<sup>c5</sup>R<sup>d5</sup>;

each R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>a1</sup>, R<sup>b1</sup>, R<sup>c1</sup>, R<sup>d1</sup>, R<sup>a2</sup>, R<sup>b2</sup>, R<sup>c2</sup>, R<sup>d2</sup>, R<sup>a3</sup>, R<sup>b3</sup>, R<sup>c3</sup>, R<sup>d3</sup>, R<sup>a5</sup>, R<sup>b5</sup>, R<sup>c5</sup>, and R<sup>d5</sup> is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, or (4-10 membered heterocycloalkyl)-C<sub>1-4</sub> alkyl, wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, and (4-10 membered heterocycloalkyl)-C<sub>1-4</sub> alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c</sup> and R<sup>d</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c1</sup> and R<sup>d1</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c2</sup> and R<sup>d2</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c3</sup> and R<sup>d3</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c3</sup> and R<sup>d3</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

$S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ ;


or any  $R^{c5}$  and  $R^{d5}$  together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, 5-6 membered heteroaryl,  $C_{1-6}$  haloalkyl, halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ , wherein said  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ ;

each  $R^{e1}$ ,  $R^{e2}$ ,  $R^{e3}$ , and  $R^{e5}$  is independently selected from H,  $C_{1-4}$  alkyl, CN,  $OR^{a6}$ ,  $SR^{b6}$ ,  $S(O)_2R^{b6}$ ,  $C(O)R^{b6}$ ,  $S(O)_2NR^{c6}R^{d6}$ , and  $C(O)NR^{c6}R^{d6}$ ;

each  $R^{a6}$ ,  $R^{b6}$ ,  $R^{c6}$ , and  $R^{d6}$  is independently selected from H,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{2-4}$  alkenyl, and  $C_{2-4}$  alkynyl, wherein said  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl, and  $C_{2-4}$  alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylamino, di( $C_{1-4}$  alkyl)amino,  $C_{1-4}$  haloalkyl, and  $C_{1-4}$  haloalkoxy;

or any  $R^{c6}$  and  $R^{d6}$  together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo,  $C_{1-6}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylamino, di( $C_{1-4}$  alkyl)amino,  $C_{1-4}$  haloalkyl, and  $C_{1-4}$  haloalkoxy; and each  $R^{e6}$  is independently selected from H,  $C_{1-4}$  alkyl, and CN.

**[0014]** In some embodiments, the present invention is related to an FGFR inhibitor which is a compound of Formula II:



II

or a pharmaceutically acceptable salt thereof, wherein:

W is  $NR^9$ ;

X is  $CR^{15}$  or N;

$R^1$  is H,  $NR^A R^B$ , halo, and  $C_{1-3}$  alkyl;

$R^2$  and  $R^3$  are each independently selected from H, CN,  $C(O)NR^c R^d$ , and  $C_{1-7}$  alkyl, wherein said  $C_{1-7}$  alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo,  $OR^a$ , CN,  $NR^c R^d$ , and  $C(O)NR^c R^d$ ; or  $R^2$  and  $R^3$  together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring or a 4-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl, CN,  $OR^a$ ,  $SR^a$ ,  $C(O)R^b$ ,  $C(O)NR^c R^d$ ,  $C(O)OR^a$ ,  $OC(O)R^b$ ,  $OC(O)NR^c R^d$ ,  $NR^c R^d$ ,  $NR^c C(O)R^b$ , and  $NR^c C(O)OR^a$ ;

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are each independently selected from H, halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, CN,  $OR^{a1}$ ,  $SR^{a1}$ ,  $C(O)R^{b1}$ ,  $C(O)NR^{c1}R^{d1}$ ,  $C(O)OR^{a1}$ ,  $OC(O)R^{b1}$ ,  $OC(O)NR^{c1}R^{d1}$ ,  $NR^{c1}R^{d1}$ ,  $NR^{c1}C(O)R^{b1}$ ,  $NR^{c1}C(O)OR^{a1}$ ,  $NR^{c1}C(O)NR^{c1}R^{d1}$ ,  $C(=NR^{e1})R^{b1}$ ,  $C(=NR^{e1})NR^{c1}R^{d1}$ ,  $NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}$ ,  $NR^{c1}S(O)R^{b1}$ ,  $NR^{c1}S(O)_2R^{b1}$ ,  $NR^{c1}S(O)_2NR^{c1}R^{d1}$ ,  $S(O)R^{b1}$ ,  $S(O)NR^{c1}R^{d1}$ ,  $S(O)_2R^{b1}$ , and  $S(O)_2NR^{c1}R^{d1}$ ; wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, and 3-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl, CN,  $NO_2$ ,  $OR^{a1}$ ,  $SR^{a1}$ ,  $C(O)R^{b1}$ ,  $C(O)NR^{c1}R^{d1}$ ,  $C(O)OR^{a1}$ ,  $OC(O)R^{b1}$ ,  $OC(O)NR^{c1}R^{d1}$ ,

$C(=NR^{e1})NR^{c1}R^{d1}$ ,  $NR^{c1}C(=NR^{e1})NR^{c1}R^{d1}$ ,  $NR^{c1}R^{d1}$ ,  $NR^{c1}C(O)R^{b1}$ ,  $NR^{c1}C(O)OR^{a1}$ ,  $NR^{c1}C(O)NR^{c1}R^{d1}$ ,  $NR^{c1}S(O)R^{b1}$ ,  $NR^{c1}S(O)_2R^{b1}$ ,  $NR^{c1}S(O)_2NR^{c1}R^{d1}$ ,  $S(O)R^{b1}$ ,  $S(O)NR^{c1}R^{d1}$ ,  $S(O)_2R^{b1}$ , and  $S(O)_2NR^{c1}R^{d1}$ ;

$R^9$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, or (3-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl, wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, and (3-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from  $R^{9a}$ ;

each  $R^{9a}$  is independently selected from  $Cy^1$ , halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl, CN,  $NO_2$ ,  $OR^{a2}$ ,  $SR^{a2}$ ,  $C(O)R^{b2}$ ,  $C(O)NR^{c2}R^{d2}$ ,  $C(O)OR^{a2}$ ,  $OC(O)R^{b2}$ ,  $OC(O)NR^{c2}R^{d2}$ ,  $C(=NR^{e2})NR^{c2}R^{d2}$ ,  $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$ ,  $NR^{c2}R^{d2}$ ,  $NR^{c2}C(O)R^{b2}$ ,  $NR^{c2}C(O)OR^{a2}$ ,  $NR^{c2}C(O)NR^{c2}R^{d2}$ ,  $NR^{c2}S(O)R^{b2}$ ,  $NR^{c2}S(O)_2R^{b2}$ ,  $NR^{c2}S(O)_2NR^{c2}R^{d2}$ ,  $S(O)R^{b2}$ ,  $S(O)NR^{c2}R^{d2}$ ,  $S(O)_2R^{b2}$ , and  $S(O)_2NR^{c2}R^{d2}$ , wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from  $Cy^1$ , halo, CN,  $NO_2$ ,  $OR^{a2}$ ,  $SR^{a2}$ ,  $C(O)R^{b2}$ ,  $C(O)NR^{c2}R^{a2}$ ,  $C(O)OR^{a2}$ ,  $OC(O)R^{b2}$ ,  $OC(O)NR^{c2}R^{a2}$ ,  $C(=NR^{e2})NR^{c2}R^{d2}$ ,  $NR^{c2}C(=NR^{e2})NR^{c2}R^{d2}$ ,  $NR^{c2}R^{d2}$ ,  $NR^{c2}C(O)R^{b2}$ ,  $NR^{c2}C(O)OR^{a2}$ ,  $NR^{c2}C(O)NR^{c2}R^{d2}$ ,  $NR^{c2}S(O)R^{b2}$ ,  $NR^{c2}S(O)_2R^{b2}$ ,  $NR^{c2}S(O)_2NR^{c2}R^{d2}$ ,  $S(O)R^{b2}$ ,  $S(O)NR^{c2}R^{d2}$ ,  $S(O)_2R^{b2}$ , and  $S(O)_2NR^{c2}R^{d2}$ ;

$R^{10}$  is selected from halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN,  $NO_2$ ,  $OR^{a3}$ ,  $SR^{a3}$ ,  $C(O)R^{b3}$ ,  $C(O)NR^{c3}R^{d3}$ ,  $C(O)OR^{a3}$ ,  $OC(O)R^{b3}$ ,  $OC(O)NR^{c3}R^{d3}$ ,  $NR^{c3}R^{d3}$ ,  $NR^{c3}C(O)R^{b3}$ ,  $NR^{c3}C(O)OR^{a3}$ ,  $NR^{c3}C(O)NR^{c3}R^{d3}$ ,  $C(=NR^{e3})R^{b3}$ ,  $C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}S(O)R^{b3}$ ,  $NR^{c3}S(O)_2R^{b3}$ ,  $NR^{c3}S(O)_2NR^{c3}R^{d3}$ ,  $S(O)R^{b3}$ ,  $S(O)NR^{c3}R^{d3}$ ,  $S(O)_2R^{b3}$ , and  $S(O)_2NR^{c3}R^{d3}$ ; wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from  $R^{10a}$ ;

$R^{15}$  is selected from H, halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, CN,  $NO_2$ ,  $OR^{a3}$ ,  $SR^{a3}$ ,  $C(O)R^{b3}$ ,  $C(O)NR^{c3}R^{d3}$ ,  $C(O)OR^{a3}$ ,  $OC(O)R^{b3}$ ,  $OC(O)NR^{c3}R^{d3}$ ,  $NR^{c3}R^{d3}$ ,  $NR^{c3}C(O)R^{b3}$ ,  $NR^{c3}C(O)OR^{a3}$ ,  $NR^{c3}C(O)NR^{c3}R^{d3}$ ,  $C(=NR^{e3})R^{b3}$ ,  $C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}S(O)R^{b3}$ ,  $NR^{c3}S(O)_2R^{b3}$ ,  $NR^{c3}S(O)_2NR^{c3}R^{d3}$ ,  $S(O)R^{b3}$ ,  $S(O)NR^{c3}R^{d3}$ ,  $S(O)_2R^{b3}$ , and  $S(O)_2NR^{c3}R^{d3}$ ; wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, and 3-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from  $R^{10a}$ ;

each  $R^{10a}$  is independently selected from  $Cy^2$ , halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl, CN,  $NO_2$ ,  $OR^{a3}$ ,  $SR^{a3}$ ,  $C(O)R^{b3}$ ,  $C(O)NR^{c3}R^{d3}$ ,  $C(O)OR^{a3}$ ,  $OC(O)R^{b3}$ ,  $OC(O)NR^{c3}R^{d3}$ ,  $NR^{c3}R^{d3}$ ,  $NR^{c3}C(O)R^{b3}$ ,  $NR^{c3}C(O)OR^{a3}$ ,  $NR^{c3}C(O)NR^{c3}R^{d3}$ ,  $C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}R^{d3}$ ,  $NR^{c3}C(O)R^{b3}$ ,  $NR^{c3}C(O)OR^{a3}$ ,  $NR^{c3}C(O)NR^{c3}R^{d3}$ ,  $NR^{c3}S(O)R^{b3}$ ,  $NR^{c3}S(O)_2R^{b3}$ ,  $NR^{c3}S(O)_2NR^{c3}R^{d3}$ ,  $S(O)R^{b3}$ ,  $S(O)NR^{c3}R^{d3}$ ,  $S(O)_2R^{b3}$ , and  $S(O)_2NR^{c3}R^{d3}$ , wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from  $Cy^2$ , halo, CN,  $NO_2$ ,  $OR^{a3}$ ,  $SR^{a3}$ ,  $C(O)R^{b3}$ ,  $C(O)NR^{c3}R^{d3}$ ,  $C(O)OR^{a3}$ ,  $OC(O)R^{b3}$ ,  $OC(O)NR^{c3}R^{d3}$ ,  $C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}R^{d3}$ ,  $NR^{c3}C(O)R^{b3}$ ,  $NR^{c3}C(O)OR^{a3}$ ,  $NR^{c3}C(O)NR^{c3}R^{d3}$ ,  $NR^{c3}S(O)R^{b3}$ ,  $NR^{c3}S(O)_2R^{b3}$ ,  $NR^{c3}S(O)_2NR^{c3}R^{d3}$ ,  $S(O)R^{b3}$ ,  $S(O)NR^{c3}R^{d3}$ ,  $S(O)_2R^{b3}$ , and  $S(O)_2NR^{c3}R^{d3}$ ;

$R^A$  and  $R^B$  are each independently selected from H,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, or (3-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl, wherein said  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, and (3-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylamino, di( $C_{1-4}$  alkyl)amino,  $C_{1-4}$  haloalkyl, and  $C_{1-4}$  haloalkoxy;

$Cy^1$ , and  $Cy^2$  are each independently selected from  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, CN,  $NO_2$ ,  $OR^{a5}$ ,  $SR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5}R^{d5}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $OC(O)NR^{c5}R^{d5}$ ,  $NR^{c5}R^{d5}$ ,  $NR^{c5}C(O)R^{b5}$ ,  $NR^{c5}C(O)OR^{a5}$ ,  $NR^{c5}C(O)NR^{c5}R^{d5}$ ,  $C(=NR^{e5})R^{b5}$ ,  $C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}S(O)R^{b5}$ ,  $NR^{c5}S(O)_2R^{b5}$ ,  $NR^{c5}SS(O)_2NR^{c5}R^{d5}$ ,  $S(O)R^{b5}$ ,  $S(O)NR^{c5}R^{d5}$ ,  $S(O)_2R^{b5}$ , and  $S(O)_2NR^{c5}R^{d5}$ ; wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, and 3-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl, CN,  $NO_2$ ,  $OR^{a5}$ ,  $SR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5}R^{d5}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $OC(O)NR^{c5}R^{d5}$ ,  $C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}R^{d5}$ ,  $NR^{c5}C(O)R^{b5}$ ,  $NR^{c5}C(O)OR^{a5}$ ,  $NR^{c5}C(O)NR^{c5}R^{d5}$ ,  $NR^{c5}S(O)R^{b5}$ ,  $NR^{c5}S(O)_2R^{b5}$ ,  $NR^{c5}S(O)_2NR^{c5}R^{d5}$ ,  $S(O)R^{b5}$ ,  $S(O)NR^{c5}R^{d5}$ ,  $S(O)_2R^{b5}$ , and  $S(O)_2NR^{c5}R^{d5}$ ;





$C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from  $Cy^2$ , halo, CN,  $NO_2$ ,  $OR^{a3}$ ,  $SR^{a3}$ ,  $C(O)R^{b3}$ ,  $C(O)NR^{c3}R^{d3}$ ,  $C(O)OR^{a3}$ ,  $OC(O)R^{b3}$ ,  $OC(O)NR^{c3}R^{d3}$ ,  $C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$ ,  $NR^{c3}R^{d3}$ ,  $NR^{c3}C(O)R^{b3}$ ,  $NR^{c3}C(O)OR^{a3}$ ,  $NR^{c3}C(O)NR^{c3}R^{d3}$ ,  $NR^{c3}S(O)R^{b3}$ ,  $NR^{c3}S(O)_2R^{b3}$ ,  $NR^{c3}S(O)_2NR^{c3}R^{d3}$ ,  $S(O)R^{b3}$ ,  $S(O)NR^{c3}R^{d3}$ ,  $S(O)_2R^{b3}$ , and  $S(O)_2NR^{c3}R^{d3}$ ;

$R^A$  and  $R^B$  are each independently selected from H,  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, or (4-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl, wherein said  $C_{1-4}$  alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, and (4-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio,  $C_{1-4}$  alkylamino, di( $C_{1-4}$  alkyl)amino,  $C_{1-4}$  haloalkyl, and  $C_{1-4}$  haloalkoxy;

$Cy^1$ , and  $Cy^2$  are each independently selected from  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN,  $NO_2$ ,  $OR^{a5}$ ,  $SR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5}R^{d5}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $OC(O)NR^{c5}R^{d5}$ ,  $NR^{c5}R^{d5}$ ,  $NR^{c5}C(O)R^{b5}$ ,  $NR^{c5}C(O)OR^{a5}$ ,  $NR^{c5}C(O)NR^{c5}R^{d5}$ ,  $C(=NR^{e5})R^{b5}$ ,  $C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}S(O)R^{b5}$ ,  $NR^{c5}S(O)_2R^{b5}$ ,  $NR^{c5}S(O)_2NR^{c5}R^{d5}$ ,  $S(O)R^{b5}$ ,  $S(O)NR^{c5}R^{d5}$ ,  $S(O)_2R^{b5}$ , and  $S(O)_2NR^{c5}R^{d5}$ ; wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{1-6}$  haloalkyl, CN,  $NO_2$ ,  $OR^{a5}$ ,  $SR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5}R^{d5}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $OC(O)NR^{c5}R^{d5}$ ,  $C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}C(=NR^{e5})NR^{c5}R^{d5}$ ,  $NR^{c5}R^{d5}$ ,  $NR^{c5}C(O)R^{b5}$ ,  $NR^{c5}C(O)OR^{a5}$ ,  $NR^{c5}C(O)NR^{c5}R^{d5}$ ,  $NR^{c5}S(O)R^{b5}$ ,  $NR^{c5}S(O)_2R^{b5}$ ,  $NR^{c5}S(O)_2NR^{c5}R^{d5}$ ,  $S(O)R^{b5}$ ,  $S(O)NR^{c5}R^{d5}$ ,  $S(O)_2R^{b5}$ , and  $S(O)_2NR^{c5}R^{d5}$ ;

each  $R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^{a1}$ ,  $R^{b1}$ ,  $R^{c1}$ ,  $R^{d1}$ ,  $R^{a2}$ ,  $R^{b2}$ ,  $R^{c2}$ ,  $R^{d2}$ ,  $R^{a3}$ ,  $R^{b3}$ ,  $R^{c3}$ ,  $R^{d3}$ ,  $R^{a5}$ ,  $R^{b5}$ ,  $R^{c5}$ , and  $R^{d5}$  is independently selected from H,  $C_{1-6}$  alkyl,  $C_{1-4}$  haloalkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, or (4-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl, wherein said  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{6-10}$  aryl,  $C_{3-10}$  cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl,  $C_{6-10}$  aryl- $C_{1-4}$  alkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl, (5-10 membered heteroaryl)- $C_{1-4}$  alkyl, and (4-10 membered heterocycloalkyl)- $C_{1-4}$  alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from  $C_{1-4}$  alkyl,  $C_{1-4}$  haloalkyl, halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ ;

or any  $R^c$  and  $R^d$  together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, 5-6 membered heteroaryl,  $C_{1-6}$  haloalkyl, halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ , wherein said  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ ;

or any  $R^{c1}$  and  $R^{d1}$  together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, 5-6 membered heteroaryl,  $C_{1-6}$  haloalkyl, halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ , wherein said  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$ , and  $S(O)_2NR^{c6}R^{d6}$ ;

or any  $R^{c2}$  and  $R^{d2}$  together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl, 4-7 membered heterocycloalkyl,  $C_{6-10}$  aryl, and 5-6 membered heteroaryl,  $C_{1-6}$  haloalkyl, halo, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,



3 substituents independently selected from R<sup>9a</sup>.

**[0022]** In some embodiments, R<sup>9</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, 3-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, or C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, each optionally substituted with with 1, 2, or 3 substituents independently selected from R<sup>9a</sup>.

**[0023]** In some embodiments, R<sup>9</sup> is H, C<sub>1-6</sub> alkyl optionally substituted by OH, C<sub>3-10</sub> cycloalkyl, 3-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, or C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl.

**[0024]** In some embodiments, R<sup>9</sup> is H, C<sub>1-6</sub> alkyl optionally substituted by OH, C<sub>3-10</sub> cycloalkyl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, or C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl.

**[0025]** In some embodiments, R<sup>9</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, 3-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, or C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl.

**[0026]** In some embodiments, R<sup>9</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, or C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl.

**[0027]** In some embodiments, R<sup>9</sup> is C<sub>1-6</sub> alkyl.

**[0028]** In some embodiments, R<sup>9</sup> is methyl.

**[0029]** In some embodiments, R<sup>9</sup> is phenyl optionally substituted with with 1, 2, or 3 substituents independently selected from R<sup>9a</sup>.

**[0030]** In some embodiments, R<sup>9</sup> is 5-10 membered heteroaryl optionally substituted with with 1, 2, or 3 substituents independently selected from R<sup>9a</sup>.

**[0031]** In some embodiments, R<sup>9</sup> is pyridyl optionally substituted with with 1, 2, or 3 substituents independently selected from R<sup>9a</sup>.

**[0032]** In some embodiments, R<sup>9</sup> is pyridyl.

**[0033]** In some embodiments, R<sup>2</sup> and R<sup>3</sup> are each independently selected from H, CN, C(O)NR<sup>cR<sup>d</sup></sup>, and C<sub>1-7</sub> alkyl, wherein said C<sub>1-7</sub> alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, OR<sup>a</sup>, CN, NR<sup>cR<sup>d</sup></sup>, and C(O)NR<sup>cR<sup>d</sup></sup>.

**[0034]** In some embodiments, R<sup>2</sup> and R<sup>3</sup> are each H.

**[0035]** In some embodiments, each of R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> is H.

**[0036]** In some embodiments, each of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>12</sup>, and R<sup>13</sup> is H.

**[0037]** In some embodiments, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each independently selected from H, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1R<sup>d1</sup></sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1R<sup>d1</sup></sup>, NR<sup>c1R<sup>d1</sup></sup>, NR<sup>c1C(O)R<sup>b1</sup></sup>, NR<sup>c1C(O)OR<sup>a1</sup></sup>, NR<sup>c1C(O)NR<sup>c1R<sup>d1</sup></sup></sup>, C(=NR<sup>e1</sup>)R<sup>b1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1R<sup>d1</sup></sup>, NR<sup>c1C(=NR<sup>e1</sup>)NR<sup>c1R<sup>d1</sup></sup></sup>, NR<sup>c1S(O)R<sup>b1</sup></sup>, NR<sup>c1S(O)<sub>2</sub>R<sup>b1</sup></sup>, NR<sup>c1S(O)<sub>2</sub>NR<sup>c1R<sup>d1</sup></sup></sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1R<sup>d1</sup></sup>, S(O)<sub>2</sub>R<sup>b1</sup>, and S(O)<sub>2</sub>NR<sup>c1R<sup>d1</sup></sup>; wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1R<sup>d1</sup></sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1R<sup>d1</sup></sup>, C(=NR<sup>e1</sup>)NR<sup>c1R<sup>d1</sup></sup>, NR<sup>c1C(=NR<sup>e1</sup>)NR<sup>c1R<sup>d1</sup></sup></sup>, NR<sup>c1R<sup>d1</sup></sup>, NR<sup>c1C(O)R<sup>b1</sup></sup>, NR<sup>c1C(O)OR<sup>a1</sup></sup>, NR<sup>c1C(O)NR<sup>c1R<sup>d1</sup></sup></sup>, NR<sup>c1S(O)R<sup>b1</sup></sup>, NR<sup>c1S(O)<sub>2</sub>R<sup>b1</sup></sup>, NR<sup>c1S(O)<sub>2</sub>NR<sup>c1R<sup>d1</sup></sup></sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1R<sup>d1</sup></sup>, S(O)<sub>2</sub>R<sup>b1</sup>, and S(O)<sub>2</sub>NR<sup>c1R<sup>d1</sup></sup>.

**[0038]** In some embodiments, at least one of R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> is other than H.

**[0039]** In some embodiments, at least two of R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> is other than H.

**[0040]** In some embodiments, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each independently selected from H, halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, and OR<sup>a1</sup>.


**[0041]** In some embodiments, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each independently selected from H, halo, and methoxy.

**[0042]** In some embodiments, R<sup>5</sup> and R<sup>7</sup> are both methoxy and R<sup>4</sup>, R<sup>6</sup>, and R<sup>8</sup> are each independently selected from H and halo.

**[0043]** In some embodiments, R<sup>4</sup> is halo, R<sup>5</sup> is methoxy, R<sup>6</sup> is H, R<sup>7</sup> is methoxy, and R<sup>8</sup> is halo.

**[0044]** In some embodiments, R<sup>15</sup> is selected from H, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3R<sup>d3</sup></sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3R<sup>d3</sup></sup>, NR<sup>c3R<sup>d3</sup></sup>, NR<sup>c3C(O)R<sup>b3</sup></sup>, NR<sup>c3C(O)OR<sup>a3</sup></sup>, NR<sup>c3C(O)NR<sup>c3R<sup>d3</sup></sup></sup>, C(=NR<sup>e3</sup>)R<sup>b3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3R<sup>d3</sup></sup>, NR<sup>c3C(=NR<sup>e3</sup>)NR<sup>c3R<sup>d3</sup></sup></sup>, NR<sup>c3S(O)R<sup>b3</sup></sup>, NR<sup>c3S(O)<sub>2</sub>R<sup>b3</sup></sup>, NR<sup>c3S(O)<sub>2</sub>NR<sup>c3R<sup>d3</sup></sup></sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3R<sup>d3</sup></sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3R<sup>d3</sup></sup>; wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R<sup>10a</sup>.

**[0045]** In some embodiments, the compound has Formula II:



II

[0046] In some embodiments, the compound has Formula II.

[0047] In some embodiments where the compound has Formula II, W is NR<sup>9</sup>.

[0048] In some embodiments where the compound has Formula II, X is CR<sup>15</sup>.

[0049] In some embodiments where the compound has Formula II, X is CH.

[0050] In some embodiments, R<sup>15</sup> is H or 5-10 membered heteroaryl optionally substituted by C<sub>1-6</sub> alkyl.

[0051] In some embodiments, R<sup>10</sup> is C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, or C(O)NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy<sup>2</sup>, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>2</sup>, halo, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>.

[0052] In some embodiments, R<sup>10</sup> is C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, or C(O)NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy<sup>2</sup>, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>2</sup>, halo, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>.

[0053] In some embodiments where the compound has Formula II, R<sup>10</sup> is C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, CN, or C(O)NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 3-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R<sup>10</sup>.

[0054] In some embodiments where the compound has Formula II, R<sup>10</sup> is C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, or C(O)NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R<sup>10a</sup>.

[0055] In some embodiments where the compound has Formula II, R<sup>10</sup> is methyl, ethyl, phenyl, pyrazolyl, piperidinyl, tetrahydropyridinyl, CN, or C(O)NR<sup>c3</sup>R<sup>d3</sup>, wherein said methyl, ethyl, phenyl, pyrazolyl, piperidinyl, and tetrahydropyridinyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>2</sup>, NR<sup>c3</sup>R<sup>d3</sup>, and C<sub>1-6</sub> alkyl optionally substituted with OR<sup>a3</sup>.

[0056] In some embodiments where the compound has Formula II, R<sup>10</sup> is phenyl, pyrazolyl, piperidinyl, tetrahydropyridinyl, CN, or C(O)NR<sup>c3</sup>R<sup>d3</sup>, wherein said phenyl, pyrazolyl, piperidinyl, and tetrahydropyridinyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>2</sup> and C<sub>1-6</sub> alkyl optionally substituted with OR<sup>a3</sup>.

[0057] In some embodiments where the compound has Formula II, R<sup>10</sup> is (4-methylpiperazin-1-yl)phenyl, 1-methyl-

1H-pyrazolyl, 1-(2-hydroxyethyl)-1H-pyrazolyl, methylaminocarbonyl, cyano, 1-methyl-1,2,3,6-tetrahydropyridinyl, 1-methylpiperidin-4-yl, dimethylaminocarbonyl, (3-hydroxyazetid-1-yl)carbonyl, (3-hydroxypyrrolidin-1-yl)carbonyl, (4-methylpiperazin-1-yl)carbonyl, cyclopropylaminocarbonyl, (3-cyanopyrrolidin-1-yl)carbonyl, (3-hydroxypiperidin-1-yl)carbonyl, tetrahydro-2H-pyran-4-yl, (4-methylpiperazin-1-yl)carbonyl, morpholin-4-ylcarbonyl, or (4,4-difluoropiperidin-1-yl)carbonyl.

**[0058]** In some embodiments where the compound has Formula II, R<sup>10</sup> is (4-methylpiperazin-1-yl)phenyl, 1-methyl-1H-pyrazolyl, 1-(2-hydroxyethyl)-1H-pyrazolyl, methylaminocarbonyl, cyano, 1-methyl-1,2,3,6-tetrahydropyridinyl, 1-methylpiperidin-4-yl, dimethylaminocarbonyl, (3-hydroxyazetid-1-yl)carbonyl, (3-hydroxypyrrolidin-1-yl)carbonyl, (4-methylpiperazin-1-yl)carbonyl, cyclopropylaminocarbonyl, (3-cyanopyrrolidin-1-yl)carbonyl, or (3-hydroxypiperidin-1-yl)carbonyl.

**[0059]** In some embodiments where the compound has Formula II, R<sup>10</sup> is (4-methylpiperazin-1-yl)phenyl, 1-methyl-1H-pyrazolyl, 1-(2-hydroxyethyl)-1H-pyrazolyl, methylaminocarbonyl, cyano, 1-methyl-1,2,3,6-tetrahydropyridinyl, 1-methylpiperidin-4-yl, dimethylaminocarbonyl, (3-hydroxyazetid-1-yl)carbonyl, (3-hydroxypyrrolidin-1-yl)carbonyl, (4-methylpiperazin-1-yl)carbonyl, cyclopropylaminocarbonyl, (3-cyanopyrrolidin-1-yl)carbonyl, (3-hydroxypiperidin-1-yl)carbonyl, morpholin-4-ylmethyl, (4-methylpiperazin-1-yl)methyl, 4-ethylpiperazin-1-yl)methyl, 4-(2-hydroxyethyl)piperazin-1-yl)methyl, cyanoethylpiperazinylmethyl, cyanopiperidinylmethyl, cyanopyrrolidinylmethyl, (1-methylpiperidin-4-yl)aminomethyl, (tetrahydrofuran-3-ylamino)methyl, 1H-imidazol-1-ylmethyl, 1H-pyrazol-1-ylmethyl, (1-methyl-1H-pyrazol-4-yl)methyl, 2-pyridin-2-ylethyl, 2-morpholin-4-ylethyl, 2-(diethylamino)ethyl, 2-(3-fluoroazetid-1-yl)ethyl, 2-(3-methoxyazetid-1-yl)ethyl, (4-ethylpiperazin-1-yl)methyl, 3-(dimethylamino)pyrrolidin-1-yl)methyl, 2-(4-ethylpiperazin-1-yl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl, (pyridin-3-yloxy)methyl, (2-oxopyridin-1(2H)-yl)methyl, (3-cyanoazetid-1-yl)methyl, (3-fluoroazetid-1-yl)methyl, or (3-hydroxyazetid-1-yl)methyl.

**[0060]** In some embodiments where the compound has Formula II, R<sup>10</sup> is morpholin-4-ylmethyl, (4-methylpiperazin-1-yl)methyl, 4-ethylpiperazin-1-yl)methyl, (4-methylpiperazin-1-yl)methyl, 4-(2-hydroxyethyl)piperazin-1-yl)methyl, cyanoethylpiperazinylmethyl, cyanopiperidinylmethyl, cyanopyrrolidinylmethyl, (1-methylpiperidin-4-yl)aminomethyl, (tetrahydrofuran-3-ylamino)methyl, 1H-imidazol-1-ylmethyl, 1H-pyrazol-1-ylmethyl, (1-methyl-1H-pyrazol-4-yl)methyl, 2-pyridin-2-ylethyl, 2-morpholin-4-ylethyl, 2-(diethylamino)ethyl, 2-(3-fluoroazetid-1-yl)ethyl, 2-(3-methoxyazetid-1-yl)ethyl, (4-ethylpiperazin-1-yl)methyl, 3-(dimethylamino)pyrrolidin-1-yl)methyl, or 2-(4-ethylpiperazin-1-yl)ethyl, 2-(4-methylpiperazin-1-yl)ethyl.

**[0061]** In some embodiments where the compound has Formula II, R<sup>10</sup> is morpholin-4-ylmethyl, (4-methylpiperazin-1-yl)methyl, 4-ethylpiperazin-1-yl)methyl, (4-methylpiperazin-1-yl)methyl, 4-(2-hydroxyethyl)piperazin-1-yl)methyl, cyanoethylpiperazinylmethyl, cyanopiperidinylmethyl, cyanopyrrolidinylmethyl, 1H-imidazol-1-ylmethyl, 1H-pyrazol-1-ylmethyl, (1-methyl-1H-pyrazol-4-yl)methyl, (4-ethylpiperazin-1-yl)methyl, or 3-(dimethylamino)pyrrolidin-1-yl)methyl.

**[0062]** In some embodiments where the compound has Formula II, R<sup>10</sup> is 2-pyridin-2-ylethyl, 2-morpholin-4-ylethyl, 2-(diethylamino)ethyl, 2-(3-fluoroazetid-1-yl)ethyl, 2-(3-methoxyazetid-1-yl)ethyl, 2-(4-ethylpiperazin-1-yl)ethyl, or 2-(4-methylpiperazin-1-yl)ethyl.

**[0063]** In some embodiments R<sup>10</sup> is C<sub>1-6</sub> alkyl optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>2</sup>, NR<sup>c3</sup>R<sup>d3</sup>, and C<sub>1-6</sub> alkyl optionally substituted with OR<sup>a3</sup>.

**[0064]** In some embodiments R<sup>10</sup> is C<sub>1-6</sub> alkyl optionally substituted with 4-7 membered heterocycloalkyl wherein said 4-7 membered heterocycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, OR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, and NR<sup>c5</sup>C(O)R<sup>b5</sup>.


**[0065]** In some embodiments where the compound has Formula II, R<sup>10</sup> is C<sub>1-6</sub> alkyl optionally substituted with 4-7 membered heterocycloalkyl wherein said 4-7 membered heterocycloalkyl is selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydrofuranyl, and azetidyl, and wherein said 4-7 membered heterocycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, OR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, and NR<sup>c5</sup>C(O)R<sup>b5</sup>.

**[0066]** In some embodiments R<sup>c3</sup> and R<sup>d3</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, and NR<sup>c6</sup>R<sup>d6</sup>.

**[0067]** In some embodiments Cy<sup>2</sup> is selected from 4-7 membered heterocycloalkyl optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a5</sup>, SR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, OC(O)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>C(O)R<sup>b5</sup>, NR<sup>c5</sup>C(O)OR<sup>a5</sup>, NR<sup>c5</sup>C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(=NR<sup>e5</sup>)R<sup>b5</sup>, C(=NR<sup>e5</sup>)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>C(=NR<sup>e5</sup>)NR<sup>c5</sup>R<sup>d5</sup>, NR<sup>c5</sup>S(O)R<sup>b5</sup>, NR<sup>c5</sup>S(O)<sub>2</sub>R<sup>b5</sup>, NR<sup>c5</sup>S(O)<sub>2</sub>NR<sup>c5</sup>R<sup>d5</sup>, S(O)R<sup>b5</sup>, S(O)NR<sup>c5</sup>R<sup>d5</sup>, S(O)<sub>2</sub>R<sup>b5</sup>, and S(O)<sub>2</sub>NR<sup>c5</sup>R<sup>d5</sup>.

**[0068]** In some embodiments where the compound has Formula II, R<sup>10</sup> is other than H.

**[0069]** In some embodiments, the compound has Formula IIa:



IIa.

**[0070]** It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

**[0071]** At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C<sub>1-6</sub> alkyl" is specifically intended to individually disclose methyl, ethyl, C<sub>3</sub> alkyl, C<sub>4</sub> alkyl, C<sub>5</sub> alkyl, and C<sub>6</sub> alkyl.

**[0072]** At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term "a pyridine ring" may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.

**[0073]** The term "n-membered" where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.

**[0074]** For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R.

**[0075]** As used herein, the phrase "optionally substituted" means unsubstituted or substituted.

**[0076]** As used herein, the term "substituted" means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency.

**[0077]** As used herein, the term "C<sub>i-j</sub>", where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, C<sub>1-6</sub> alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.

**[0078]** As used herein, the term "alkyl", employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some embodiments, the alkyl group contains 1 to 7, 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl, *tert*-butyl, n-pentyl, 2-methyl-1-butyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, n-heptyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl.

**[0079]** As used herein, "alkenyl", employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, *sec*-butenyl, and the like.

**[0080]** As used herein, "alkynyl", employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.

**[0081]** As used herein, "halo" or "halogen", employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or Cl.

**[0082]** As used herein, the term "haloalkyl", employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

Example haloalkyl groups include  $\text{CF}_3$ ,  $\text{C}_2\text{F}_5$ ,  $\text{CHF}_2$ ,  $\text{CCl}_3$ ,  $\text{CHCl}_2$ ,  $\text{C}_2\text{Cl}_5$ , and the like.

**[0083]** As used herein, the term "alkoxy", employed alone or in combination with other terms, refers to a group of formula -O-alkyl. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

**[0084]** As used herein, "haloalkoxy", employed alone or in combination with other terms, refers to a group of formula -O-(haloalkyl). In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. An example haloalkoxy group is  $-\text{OCF}_3$ .

**[0085]** As used herein, "amino", employed alone or in combination with other terms, refers to  $\text{NH}_2$ .

**[0086]** As used herein, the term "alkylamino", employed alone or in combination with other terms, refers to a group of formula -NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms. Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.

**[0087]** As used herein, the term "dialkylamino", employed alone or in combination with other terms, refers to a group of formula -N(alkyl)<sub>2</sub>. Example dialkylamino groups include dimethylamino, diethylamino, dipropylamino (e.g., di(n-propyl)amino and di(isopropyl)amino), and the like. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.

**[0088]** As used herein, the term "alkylthio", employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.

**[0089]** As used herein, the term "cycloalkyl", employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term "cycloalkyl" also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as adamantan-1-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro[2.5]octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C<sub>3-7</sub> monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl, octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

**[0090]** As used herein, the term "cycloalkylalkyl", employed alone or in combination with other terms, refers to a group of formula cycloalkyl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, 1 to 3, 1 to 2, or 1 carbon atom(s). In some embodiments, the alkyl portion is methylene. In some embodiments, the cycloalkyl portion has 3 to 10 ring members or 3 to 7 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl portion is monocyclic. In some embodiments, the cycloalkyl portion is a C<sub>3-7</sub> monocyclic cycloalkyl group.

**[0091]** As used herein, the term "heterocycloalkyl", employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadamantan-1-yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [1,4-dioxo-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, or about 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 2 to 20 carbon atoms, 2 to 15 carbon atoms, 2 to 10 carbon atoms, or about 2 to 8 carbon atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C<sub>2-7</sub> monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, tetrahydropyran ring, tetrahydropyridine, azetidine ring, or tetrahydrofuran ring.

**[0092]** As used herein, the term "heterocycloalkylalkyl", employed alone or in combination with other terms, refers to a group of formula heterocycloalkyl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, 1 to 3, 1 to 2, or 1 carbon

atom(s). In some embodiments, the alkyl portion is methylene. In some embodiments, the heterocycloalkyl portion has 3 to 10 ring members, 4 to 10 ring members, or 3 to 7 ring members. In some embodiments, the heterocycloalkyl group is monocyclic or bicyclic. In some embodiments, the heterocycloalkyl portion is monocyclic. In some embodiments, the heterocycloalkyl portion is a C<sub>2-7</sub> monocyclic heterocycloalkyl group.

**[0093]** As used herein, the term "aryl", employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl.

**[0094]** As used herein, the term "arylalkyl", employed alone or in combination with other terms, refers to a group of formula aryl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, 1 to 3, 1 to 2, or 1 carbon atom(s). In some embodiments, the alkyl portion is methylene. In some embodiments, the aryl portion is phenyl. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the arylalkyl group is benzyl.

**[0095]** As used herein, the term "heteroaryl", employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrol, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In some embodiments, the heteroaryl group has from 3 to 10 carbon atoms, from 3 to 8 carbon atoms, from 3 to 5 carbon atoms, from 1 to 5 carbon atoms, or from 5 to 10 carbon atoms. In some embodiments, the heteroaryl group contains 3 to 14, 4 to 12, 4 to 8, 9 to 10, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4, 1 to 3, or 1 to 2 heteroatoms.

**[0096]** As used herein, the term "heteroarylalkyl", employed alone or in combination with other terms, refers to a group of formula heteroaryl-alkyl-. In some embodiments, the alkyl portion has 1 to 4, 1 to 3, 1 to 2, or 1 carbon atom(s). In some embodiments, the alkyl portion is methylene. In some embodiments, the heteroaryl portion is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl portion has 5 to 10 carbon atoms.

**[0097]** The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.

**[0098]** Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like. Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

**[0099]** Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

**[0100]** Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.

[0101] The term, "compound," as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted.

[0102] All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated.

5 [0103] In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99%  
10 by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

[0104] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

15 [0105] The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate  
20 base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977).  
25

### 30 *Synthesis*

[0106] Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.

35 [0107] The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

40 [0108] Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.

45 [0109] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g.,  $^1\text{H}$  or  $^{13}\text{C}$ ), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

50 [0110] The expressions, "ambient temperature," "room temperature," and "r.t.," as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.

[0111] Compounds of the invention can be prepared according to numerous preparatory routes known in the literature. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.

55 [0112] A series of urea derivatives of formula **5** can be prepared by the methods outlined in **Scheme 1**. Compound **2** can be prepared by treating suitable amines  $\text{R}^9\text{NH}_2$  with aldehyde **1**; followed by reductive amination with aniline **3** to provide diamino compound **4**. Cyclization of diamino compound **4** with triphosgene or equivalent including, but not limited to, carbonyldiimidazole (CDI), phosgene, diphosgene, etc. can afford the urea derivatives of formula **5**.


## Scheme 1

5

10

15

20



25

30

**[0113]** Similarly, a series of urea derivatives of formula 9 can be prepared by the methods outlined in **Scheme 2**. The ketone 6 can be obtained by reaction of the aldehyde 1 with appropriate Grignard reagent  $\text{R}^2\text{MgX}$  or alkyllithium  $\text{R}^2\text{Li}$  followed by oxidation. Conversion of the ketone 6 to the corresponding amino ketone 7 can be achieved by displacement of the chlorine with an appropriate amine  $\text{R}^9\text{NH}_2$ . The diamino derivative 8 can be obtained by reductive amination of the ketone 7 with aniline 3 using a suitable reducing agent such as, but not limited to, sodium cyanoborohydride, or sodium borohydride. Cyclization of diamino compound 8 with triphosgene or carbonyldiimidazole (CDI), phosgene, diphosgene, etc. can afford the urea derivatives of formula 9.


## Scheme 2

35

40

45


50



55


**[0114]** A series of aniline derivatives 14 can be prepared according to the procedures outlined in **Scheme 3**. Displacement of fluorine in compound 10 with benzylamine ( $\text{BnNH}_2$ ) provides the aniline 11 which can be converted to bis-ether by reacting with a suitable sodium alkoxide ( $\text{NaOR}$  where R is, e.g., methyl, alkyl, or  $\text{R}^{\text{a}1}$ ) followed by saponification to provide acid 12. Compound 13 can be obtained by de-carboxylation of benzoic acid 12, followed by hydrogenation to remove the protecting group to afford aniline 14.

## Scheme 3




[0115] A series of aniline derivatives **18** can be prepared according to the procedures outlined in **Scheme 4**. Compound **16** can be obtained by treatment of the aniline **15** (where R = methyl or alkyl) with acetic anhydride or acetyl chloride at low temperature. Treatment of compound **16** with sulfuryl chloride can afford compound **17** which can be then converted to the aniline derivatives **18** by removal of the acetyl group under basic conditions.

## Scheme 4




[0116] A series of aniline derivatives **21** can be prepared according to the procedures outlined in **Scheme 5**. Treatment of compound **16** with Selectfluor® can provide the desired mono-fluoride **19** which can then be converted to compound **20** by treating with sulfuryl chloride. The acetyl group of **20** can be removed under basic conditions to give the aniline derivatives **21**.

## Scheme 5




A series of 1H-pyrrolo[2,3-b]pyridine urea derivatives **26** can be prepared according to the procedures outlined in **Scheme 6**. Protection of the 1H-pyrrolo[2,3-b]pyridine urea **22**, which can be prepared according to the procedures described in **Scheme 1**, with suitable protection reagents such as PhSO<sub>2</sub>Cl under basic conditions can afford the corresponding protected urea **23**. The urea halide **24** (L = halo) can be prepared by treatment of the urea **23** with a strong base such as, but not limited to, LDA, LiHMDS, NaHMDS or butyllithium in an inert solvent such as THF, ether, or HMPA at low temperature to provide the metallated intermediate, and followed by treatment with a halogen reagent such as iodine, bromine, 1,2-dibromo-1,1,2,2-tetrachloroethane, NBS or NIS. Deprotection of the urea halide **24** can give the corresponding deprotected product **25**, which can be further converted to the desired urea derivatives **26** by Suzuki coupling with an appropriate boronic acid or ester R<sup>10</sup>B(OR<sup>n</sup>)<sub>2</sub> (R<sup>n</sup> = H or alkyl).

## Scheme 6



[0117] Alternatively, a series of 1H-pyrrolo[2,3-b]pyridine urea derivatives **30** can be prepared according to the procedures outlined in **Scheme 7**. Compound **27** can be prepared using procedures as described in the **Scheme 6**. Chlorination of compound **27** with sulfonyl chloride can give dichloride **28** ( $X^1 = X^2 = \text{Cl}$ ). Treating compound **27** with Selectfluor® can yield fluoro-substituted compound **28** ( $X^1 = X^2 = \text{F}$ ). The protecting group of compound **28** can be removed then followed by Suzuki coupling of compound **29** with an appropriate boronic acid or ester  $\text{R}^{10}\text{B}(\text{OR}'')_2$  ( $\text{R}'' = \text{H}$  or alkyl) as described above to provide 1H-pyrrolo[2,3-b]pyridine urea derivatives **30**.

## Scheme 7



[0118] A series of amide derivatives **33** can be prepared according to the methods outlined in **Scheme 8**. The carboxylic acid **31** can be obtained by treating the protected urea **23** with a strong base such as, but not limited to, LDA, LiHMDS, NaHMDS, or butyllithium in an inert solvent such as THF, ether, or HMPA at low temperature, and followed by addition of dry-ice to the reaction mixture. Deprotection of the carboxylic acid **31** yields the corresponding acid **32**, which can be converted to the amide **33** by coupling with an appropriate amine (e.g.,  $\text{NHR}^{\text{c3}}\text{R}^{\text{d3}}$ ) in the presence of a suitable amide coupling reagent such as, but not limited to, HATU, HBTU, BOP, EDCI/HOBT, EDCI/HOAT, or CDI. Alternatively, the

amide **33** can be obtained by conversion of the acid **32** to the corresponding chloride by treating with oxalyl chloride or thionyl chloride followed by reacting with the appropriate amine.

5


## Scheme 8

10

15

20

25



**[0119]** A series of urea derivatives **37** can be prepared according to the procedures outlined in **Scheme 9**. Protection of the 1H-pyrrolo[2,3-b]pyridine urea **34** can be achieved by reacting with suitable protection reagent (PG) under basic conditions to afford the urea **35**. Alkylation of the urea **35** with an alkyl halide (e.g., R<sup>9</sup>-halide) under basic conditions can yield the corresponding substituted urea **36**, followed by removal of the protection group PG under conditions standard in the art to provide the final compound **37**.

35


## Scheme 9

40

45

50


55



**[0120]** A series of urea derivatives **41** can be prepared according to the procedures outlined in **Scheme 10**. Urea **38** can be treated with pyridinium tribromide or bromine to give the dibromo and/or monobromo intermediates **39** and **40**,


respectively, which can be then subjected to a Zn/acetic acid-mediated reduction to afford the urea derivatives **41**.

Scheme 10



**[0121]** A series of 3H-imidazo[4,5-b]pyridine urea derivatives **50** can be prepared according to the procedures outlined in **Scheme 11**. Condensation of the pyridinyl diamine **42** (CAS # 1131604-99-3) with an appropriate acid  $R^{10}COOH$  under acidic condition such as  $H_3PO_4$  or polyphosphoric acid (PPA) at elevated temperature can yield 3H-imidazo[4,5-b]pyridine **43**. The free NH functional group of compound **43** can be protected by treating it with PG-Cl such as (but not limited to)  $MeOCH_2Cl$  or  $SEMCl$ , under basic conditions. Palladium catalyzed coupling of compound **44** with tributyl(vinyl)stannane can afford compound **45** which can be then subjected to ozonolysis to give the corresponding aldehyde **46**. The chlorine in compound **46** can be displaced with an appropriate amine  $R^9NH_2$  to yield the corresponding amino aldehyde **47**. The diamino derivative **48** can be obtained by reductive amination of the amino aldehyde **47** with aniline **3** using a suitable reducing agent such as, but not limited to, sodium cyanoborohydride, or sodium borohydride. Cyclization of diaminocompound **48** with triphosgene can afford the urea derivatives **49**. Removal of the protecting group PG in **49** can give the urea derivatives **50**.


## Scheme 11



[0122] A series of urea derivatives **51** can be prepared according to the procedures outlined in **Scheme 12**. The free NH functional group of compound **52** ( $R^{14} = H$ , CAS #1034769-88-4) can be protected by a suitable protecting group to afford the protected product **53**. Palladium catalyzed coupling of compound **53** with tributyl(vinyl)stannane can afford compound **54** which can then be subjected to ozonolysis to give the corresponding aldehyde **55**. The chlorine group of **55** can be displaced with an appropriate amine  $R^9NH_2$  to yield the corresponding amino aldehyde **56**. The diamino derivative **57** can be obtained by reductive amination of the amino aldehyde **56** with aniline **3** using a suitable reducing agent such as, but not limited to, sodium cyanoborohydride, or sodium borohydride. Cyclization of the diamino compound **57** with triphosgene or equivalent can afford the urea derivatives **58**. Removal of the protecting group of **58** can provide the urea derivatives **51**.


[0123] Compounds disclosed herein having thieno[3,2-b]pyridine cores can also be made according to **Scheme 12** starting with 6-bromo-7-chloro-thieno[3,2-b]pyridine (CAS# 875340-63-9) in place of **52**.

## Scheme 12



[0124] A series of urea derivatives of Formula 5 can be alternatively prepared by the procedures outlined in **Scheme 13**. Reductive amination of aldehyde derivatives **1** with aniline **3** can generate the chloro-compound **59**. Palladium-catalyzed amination of compound **59** can afford the diamino-compound **4**. The urea derivative **5** can be obtained by intramolecular cyclization of compound **4** with triphosgene or equivalent.


## Scheme 13



[0125] A series of aza-oxindole derivatives **62** can be prepared according to the procedures outlined in Scheme 14. Alkylation of compound **60**, which can be prepared from compound **36** using similar conditions as described in Scheme 10, under basic conditions such as but not limited to  $\text{Cs}_2\text{CO}_3$ , NaH and etc. can generate compound **61**. Removal of the protecting group can afford the aza-oxindole derivatives **62**.


25

## Scheme 14



[0126] A series of lactam derivatives **64** can be prepared according to the procedures outlined in Scheme 15. Palladium catalyzed coupling of chloro-compound **59** with potassium ethyl malonate or equivalent, followed by *in situ* intramolecular cyclization can generate the lactam **63**, which can be then alkylated to afford the lactam derivative **64**.

## Scheme 15




25

[0127] A series of cyclic carbamate derivatives **67** can be prepared according to the procedures outlined in Scheme **16**. Displacement of the chloride in compound **59** by alkoxide under basic conditions can form compound **65**, which can react with chloroformate or equivalent to give the carbamate compound **66**. Removal of the protecting group followed by *in situ* cyclization of compound **66** can afford the cyclic carbamate derivative **67**.

30


## Scheme 16



55


[0128] As disclosed herein a series of pyrazolo[3,4-b]pyridine urea derivatives **51** can be prepared alternatively according to the procedures outlined in Scheme **17**. Halogenation of compound **68**, which can be generated by using procedures as described in Scheme **12** or Scheme **13**, with a suitable reagent such as, but not limited to NCS, NBS or NIS can give the corresponding halide **69** (L = Cl, Br or I). Coupling of the halide **69** with R<sup>14</sup>-M, where M is a boronic acid, boronic ester or an appropriately substituted metal reagent (e.g., M is B(OR)<sub>2</sub>, SnBu<sub>3</sub> or ZnBr), under standard Suzuki, Stille or Negishi coupling conditions can give compound **51**.

## Scheme 17




**[0129]** A series of tricyclic amino-derivatives **74** can be prepared according to the procedures outlined in Scheme **18**. Protection of the 1H-pyrrolo[2,3-b]pyridine derivative **70** with 65 suitable protecting reagents such as, for example, PhSO<sub>2</sub>Cl under basic conditions can afford the corresponding protected compound **71**. Treatment of compound **71** with a strong base such as, for example, lithium diisopropylamide (LDA), butyllithium, or lithium bis(trimethylsilyl)amide (LiHMDS) in an inert solvent such as THF at low temperature can afford the metallated intermediate, which can be quenched with a suitable formyl-reagent such as, for example, dimethylformamide (DMF) to provide the aldehyde derivative **72**. The amino-derivative **74** can be prepared by reductive amination of aldehyde **72** with an appropriate amine (e.g. NHR<sup>c3</sup>R<sup>d3</sup>) to give compound **73**, followed by removal of the PhSO<sub>2</sub>-protecting group in the presence of a suitable base such as, for example, K<sub>2</sub>CO<sub>3</sub>, KOH, KO<sup>t</sup>Bu, or tetra-n-butylammonium fluoride (TBAF).

## Scheme 18



**[0130]** Alternatively, compound **74** can be prepared according to the procedures outlined in Scheme **19**. Removal of the PhSO<sub>2</sub>-protecting group in compound **72** in the presence of a suitable base such as, for example, K<sub>2</sub>CO<sub>3</sub>, KOH, KO<sup>t</sup>Bu or tetra-n-butylammonium fluoride (TBAF), can generate compound **75**. Reductive amination of aldehyde **75** with an appropriate amine (e.g. NHR<sup>c3</sup>R<sup>d3</sup>) can give compound **74**.


## Scheme 19



15 **[0131]** A series of tricyclic amino-derivatives **80** can be prepared according to the procedures outlined in Scheme **20**. Suzuki coupling of compound **76** (L = halogen), which can be prepared using similar procedures as described in Scheme **6**, with an appropriate boronic acid or ester can provide the vinyloether derivative **77**, which then can be hydrolyzed in aqueous acidic conditions to give the aldehyde derivative **78**. Reductive amination of aldehyde **78** with an appropriate amine (e.g.  $\text{NHR}^{\text{c3}}\text{R}^{\text{d3}}$ ) can give compound **79**, followed by removal of the  $\text{PhSO}_2$ -protecting group in the presence of a suitable base such as, for example,  $\text{K}_2\text{CO}_3$ ,  $\text{KOH}$ ,  $\text{KO}^t\text{Bu}$  or tetra-n-butylammonium fluoride (TBAF), to provide the amino-derivatives **80**.

20

## Scheme 20

*Methods of Use*

**[0132]** Compounds of the invention can inhibit activity of one or more FGFR enzymes. For example, the compounds of the invention can be used to inhibit activity of an FGFR enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a compound of the invention to the cell, individual, or patient.

50

**[0133]** In some embodiments, the compounds of the invention are inhibitors of one or more of FGFR1, FGFR2, FGFR3, and FGFR4. In some embodiments, the compounds of the invention inhibit each of FGFR1, FGFR2, and FGFR3. In some embodiments, the compounds of the invention are selective for one or more FGFR enzymes. In some embodiments, the compounds of the invention are selective for one or more FGFR enzymes over VEGFR2. In some embodiments, the selectivity is 2-fold or more, 3-fold or more, 5-fold or more, 10-fold or more, 50-fold or more, or 100-fold or more.

55

**[0134]** As FGFR inhibitors, the compounds of the invention are useful in the treatment of various diseases associated with abnormal expression or activity of FGFR enzymes or FGFR ligands.

**[0135]** For example, the compounds of the invention are useful in the treatment of cancer. Example cancers include bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas), ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer (e.g. exocrine pancreatic carcinoma), stomach cancer, thyroid cancer, skin cancer (e.g., squamous cell carcinoma).

**[0136]** Further example cancers include hematopoietic malignancies such as leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelofibrosis), Waldenstrom's Macroglobulinemia, hairy cell lymphoma, and Burkett's lymphoma.

**[0137]** Other cancers treatable with the compounds of the invention include glioblastoma, melanoma, and rhabdosa-rcoma.

**[0138]** Other cancers treatable with the compounds of the invention include gastrointestinal stromal tumors.

**[0139]** In addition to oncogenic neoplasms, the compounds of the invention can be useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.

**[0140]** The compounds of the invention may further be useful in the treatment of fibrotic diseases, such as where a disease symptom or disorder is characterized by fibrosis. Example fibrotic diseases include liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing.

**[0141]** In some embodiments, the compounds of the invention can be used in the treatment of a hypophosphatemia disorder such as, for example, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia.

**[0142]** As used herein, the term "cell" is meant to refer to a cell that is *in vitro*, *ex vivo* or *in vivo*. In some embodiments, an *ex vivo* cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an *in vitro* cell can be a cell in a cell culture. In some embodiments, an *in vivo* cell is a cell living in an organism such as a mammal.

**[0143]** As used herein, the term "contacting" refers to the bringing together of indicated moieties in an *in vitro* system or an *in vivo* system. For example, "contacting" the FGFR enzyme with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the FGFR enzyme.

**[0144]** As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

**[0145]** As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.

**[0146]** As used herein the term "treating" or "treatment" refers to 1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; 2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (*i.e.*, arresting further development of the pathology and/or symptomatology), or 3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (*i.e.*, reversing the pathology and/or symptomatology).

#### *Combination Therapy*

**[0147]** One or more additional pharmaceutical agents or treatment methods such as, for example, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, immunotherapies, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, *etc.*), and/or kinase (tyrosine or serine/threonine), epigenetic or signal transduction inhibitors can be used in combination with the compounds of the present invention for treatment of diseases, disorders or conditions associated with FGF ligand, receptor or pathway activation. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

**[0148]** Suitable agents for use in combination with the compounds of the present invention for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy. Compounds of this invention may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors.

Suitable examples are anti-estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megestrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds of the present invention. These include

anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone).

**[0149]** Compounds of the present invention may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Fit-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapatinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c-Met may be used in combination with FGFR inhibitors. These include (onartumzumab, tivantinib, INC-280). Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Alk (or EML4-ALK) include crizotinib.

**[0150]** Angiogenesis inhibitors may be efficacious in some tumors in combination with FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib

**[0151]** Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds of the present invention include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.

**[0152]** Agents against the PI3 kinase include but are not limited to topilalisib, idelalisib, buparlisib. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of JAK (ruxolitinib), Hsp90 (tanespimycin), cyclin dependent kinases (palbociclib), HDACs (panobinostat), PARP (olaparib), and proteasomes (bortezomib, carfilzomib) can also be combined with compounds of the present invention.

**[0153]** Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

**[0154]** Other suitable agents for use in combination with the compounds of the present invention include chemotherapy combinations such as platinum-based doublets used in lung cancer (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane).

**[0155]** Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin, and gemcitabine.

**[0156]** Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN- $\alpha$ ), etoposide, and teniposide.

**[0157]** Other cytotoxic agents include navelbene, CPT-11, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.

**[0158]** Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; leucovorin; tegafur; and haematopoietic growth factors.

**[0159]** Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF).

**[0160]** Other anti-cancer agent(s) include antibody therapeutics to costimulatory molecules such as CTLA-4, 4-1BB and PD-1, or antibodies to cytokines (IL-10, TGF- $\beta$ , etc.).

**[0161]** Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine

receptors, including CCR2 and CCR4.

**[0162]** Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.

**[0163]** Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.

**[0164]** Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ).

#### *Pharmaceutical Formulations and Dosage Forms*

**[0165]** When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions which refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

**[0166]** This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

**[0167]** In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

**[0168]** Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

**[0169]** The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

**[0170]** The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

**[0171]** For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present

invention. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.

**[0172]** The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

**[0173]** The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

**[0174]** Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

**[0175]** The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

**[0176]** The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

**[0177]** The therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1  $\mu\text{g}/\text{kg}$  to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

**[0178]** The compounds of the invention can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, antiinflammatory agents and the like.

#### *Labeled Compounds and Assay Methods*

**[0179]** Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging but also in assays, both *in vitro* and *in vivo*, for localizing and quantitating the FGFR enzyme in tissue samples, including human, and for identifying FGFR enzyme ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes FGFR enzyme assays

that contain such labeled compounds.

**[0180]** The present invention further includes isotopically-labeled compounds of the invention. An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to  $^2\text{H}$  (also written as D for deuterium),  $^3\text{H}$  (also written as T for tritium)  $^{11}\text{C}$ ,  $^{13}\text{C}$ ,  $^{14}\text{C}$ ,  $^{13}\text{N}$ ,  $^{15}\text{N}$ ,  $^{15}\text{O}$ ,  $^{17}\text{O}$ ,  $^{18}\text{O}$ ,  $^{18}\text{F}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{82}\text{Br}$ ,  $^{75}\text{Br}$ ,  $^{76}\text{Br}$ ,  $^{77}\text{Br}$ ,  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{125}\text{I}$  and  $^{131}\text{I}$ . The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for *in vitro* FGFR enzyme labeling and competition assays, compounds that incorporate  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{82}\text{Br}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , or  $^{35}\text{S}$  will generally be most useful. For radio-imaging applications  $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{125}\text{I}$ ,  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{131}\text{I}$ ,  $^{75}\text{Br}$ ,  $^{76}\text{Br}$  or  $^{77}\text{Br}$  will generally be most useful.

**[0181]** It is understood that a "radio-labeled" or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$  and  $^{82}\text{Br}$ .

**[0182]** Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.

**[0183]** A radio-labeled compound of the invention can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio-labeled compound of the invention to the FGFR enzyme. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the FGFR enzyme directly correlates to its binding affinity.

#### Kits

**[0184]** The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of FGFR-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

**[0185]** The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of one or more FGFR's as described below.

#### EXAMPLES

**[0186]** Experimental procedures for compounds of the invention are provided below. Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 series, LC/MSD, Column: Waters Sunfire™ C<sub>18</sub> 5 μm, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: 0.025% TFA in acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 1.5 mL/minute.

**[0187]** Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:

pH = 2 purifications: Waters Sunfire™ C<sub>18</sub> 5 μm, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: 0.1% TFA in acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimiza-

tion", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute.


pH = 10 purifications: Waters XBridge C<sub>18</sub> 5 μm, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH<sub>4</sub>OH in water and mobile phase B: 0.15% NH<sub>4</sub>OH in acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute.

**[0188]** Compounds which are not within the scope of the claims are described for reference purposes.

### Example 1


#### 3-(3,5-Dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0189]**



Step 1: 4-(methylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde


**[0190]**



**[0191]** A mixture of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (CAS # 958230-19-8) from Adesis, cat #4-263; Synnovator, cat #PBN2011188: 2.71 g, 15 mmol) and methylamine (33 wt. % in ethanol, 24 mL, 200 mmol) in 2-methoxyethanol (6 mL) was heated to 110 °C and stirred overnight in a sealed pressure flask. Then the reaction mixture was cooled to room temperature and concentrated. The residue was dissolved in HCl solution (1 N, 25 mL) and heated to 50 °C. After stirring for 2 h, the reaction mixture was cooled to room temperature and neutralized with saturated NaHCO<sub>3</sub> solution. The light yellow precipitate was collected via filtration, washed with water and hexanes then dried in vacuo to afford the desired product (2.54 g, 97 %) as a light yellow solid. LC-MS calculated for C<sub>9</sub>H<sub>10</sub>N<sub>3</sub>O [M+H]<sup>+</sup> m/z: 176.1; found 176.1.

Step 2: 5-[(3,5-dimethoxyphenyl)amino]methyl-N-methyl-1H-pyrrolo[2,3-b]pyridin-4-amine

**[0192]**



5

10 **[0193]** To a mixture of 4-(methylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (1.75 g, 10 mmol) and 3,5-dimethoxy-benzenamine (2.30 g, 15.0 mmol) in ethanol (50 mL) was added acetic acid (8.5 mL, 150 mmol). The resulting light yellow suspension was heated to reflux. After stirring for 3 h, the resulting red solution was cooled to room temperature and sodium cyanoborohydride (1.9 g, 30 mmol) was added. The reaction mixture was stirred at room temperature overnight then neutralized with saturated Na<sub>2</sub>CO<sub>3</sub> solution. The mixture was extracted with ethyl acetate (EtOAc). The organic layer was washed with water and brine then dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was purified by column (Biotage®): 40 g silica gel column, eluted with 0 to 10 % MeOH/DCM to afford the desired product (2.33 g, 75 %) as a light yellow solid. LC-MS calculated for C<sub>17</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> m/z: 313.2; found 313.1.

20 *Step 3: 3-(3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

25 **[0194]** To a stirred solution of 5-[(3,5-dimethoxyphenyl)amino]methyl-N-methyl-1H-pyrrolo[2,3-b]pyridin-4-amine (16 mg, 0.05 mmol) and triethylamine (21 μL, 0.15 mmol) in tetrahydrofuran (1.5 mL) was added triphosgene (18 mg, 0.06 mmol) in tetrahydrofuran (0.5 mL) at 0 °C. The resulting yellow suspension was stirred at 0 °C for 30 min then NaOH solution (1 N, 1 mL) was added. All the precipitate dissolved to afford two layers of solutions and the reaction mixture was stirred at 0 °C for another 30 min. The organic layer containing the desired product was purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>18</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 339.1; found: 339.1.


30

### Example 2

#### 3-(3,5-Dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0195]**

35



40

45 **[0196]** This compound was prepared using procedures analogous to those described for *Example 1* with ammonium hydroxide solution replacing methylamine and the reaction temperature raised to 130 °C in *Step 1*. LC-MS calculated for C<sub>17</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 325.1; found: 325.1.


### Example 3

50

#### 3-(3,5-Dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0197]**

55




**[0198]** This compound was prepared using procedures analogous to those described for *Example 1* with ethylamine (2 M in THF) replacing methylamine and the reaction temperature raised to 130 °C in *Step 1*. LC-MS calculated for  $C_{19}H_{21}N_4O_3$   $[M+H]^+$  m/z: 353.2; found: 353.1.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.18 (s, 1H), 8.12 (s, 1H), 7.58 - 7.53 (m, 1H), 6.75 (d,  $J = 2.9$  Hz, 1H), 6.56 (d,  $J = 2.2$  Hz, 2H), 6.42 (t,  $J = 2.2$  Hz, 1H), 4.86 (s, 2H), 4.21 (q,  $J = 6.9$  Hz, 2H), 3.75 (s, 6H), 1.38 (t,  $J = 6.9$  Hz, 3H).

#### Example 4

#### 1-Cyclopropyl-3-(3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0199]**




**[0200]** This compound was prepared using procedures analogous to those described for *Example 1* with cyclopropylamine replacing methylamine and the reaction temperature raised to 130 °C in *Step 1*. LC-MS calculated for  $C_{20}H_{21}N_4O_3$   $[M+H]^+$  m/z: 365.2; found: 365.2.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.20 (s, 1H), 8.16 (s, 1H), 7.55 - 7.51 (m, 1H), 7.03 (d,  $J = 2.5$  Hz, 1H), 6.54 (d,  $J = 2.2$  Hz, 2H), 6.39 (t,  $J = 2.2$  Hz, 1H), 4.77 (s, 2H), 3.74 (s, 6H), 3.39 - 3.33 (m, 1H), 1.14 - 1.08 (m, 2H), 0.76 - 0.66 (m, 2H).

#### Example 5

#### 1-(Cyclopropylmethyl)-3-(3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0201]**



**[0202]** This compound was prepared using procedures analogous to those described for *Example 1* with cyclopropylmethylamine replacing methylamine and the reaction temperature raised to 130 °C in *Step 1*. LC-MS calculated for  $C_{21}H_{23}N_4O_3$   $[M+H]^+$  m/z: 379.2; found: 379.1.


## Example 6

## 1-Benzyl-3-(3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

5 [0203]

10

15



[0204] This compound was prepared using procedures analogous to those described for *Example 1* with benzylamine replacing methylamine and the reaction temperature raised to 130 °C in *Step 1*. LC-MS calculated for C<sub>24</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 415.2; found: 415.2.

20

## Example 7


## 3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

25

[0205]

30

35




*Step 1*: 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

40

[0206]

45

50



[0207] To a stirred solution of 5-[(3,5-dimethoxyphenyl)amino]methyl-N-methyl-1H-pyrrolo[2,3-b]pyridin-4-amine (*Example 1*, *step 2*: 2.33 g, 7.46 mmol) and triethylamine (3.1 mL, 22 mmol) in tetrahydrofuran (50 mL) was added triphosgene (2.66 g, 8.95 mmol) in tetrahydrofuran (20 mL) at 0 °C. The resulting yellow suspension was stirred at 0 °C for 30 min then NaOH solution (1 N, 20 mL) was added. All the precipitate dissolved to give two layers of solutions and the reaction mixture was stirred at 0 °C for another 30 min. The mixture was extracted with ethyl acetate (EtOAc). The

55

## EP 2 861 595 B9

organic layers were combined and washed with water, brine then dried over  $\text{Na}_2\text{SO}_4$ . The solvents were removed under reduced pressure. The residue was dissolved in tetrahydrofuran (50 mL) and cooled to 0 °C then sodium hydride (60 wt. % dispersion in mineral oil, 600 mg, 15 mmol) was added in three portions. The resulting brown solution was stirred at 0 °C for 30 min then benzenesulfonyl chloride (1.4 mL, 11 mmol) was added dropwise. After stirring at 0 °C for 30 min, the reaction was quenched with water and the mixture was extracted with EtOAc. The organic layers were combined and washed with water, brine then dried over  $\text{Na}_2\text{SO}_4$ . The solvents were removed under reduced pressure and the residue was purified by column (Biotage®): 40 g silica gel column, eluted with 20 to 50 % EtOAc/Hexanes to give a light yellow solid which was triturated with diethyl ether to give the pure product (2.75 g, 77 %) as a white solid. LC-MS calculated for  $\text{C}_{24}\text{H}_{23}\text{N}_4\text{O}_5\text{S}$   $[\text{M}+1]^+$  m/z: 479.1; found: 479.1.


*Step 2: 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0208]** To a stirred solution of 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (29 mg, 0.06 mmol) in acetonitrile (3 mL, 60 mmol) at 0 °C was added sulfuryl chloride (7.36  $\mu\text{L}$ , 0.09 mmol) in dichloromethane (0.2 mL) dropwise over 5 min. The resulting light yellow solution was stirred at 0 °C for 10 min, at which time LC-MS indicated complete consumption of the starting material. The reaction was quenched with saturated  $\text{NaHCO}_3$  solution at 0 °C then extracted with EtOAc. The organic layer was washed with water, brine and dried over  $\text{Na}_2\text{SO}_4$ . The solvent was removed under reduced pressure. The residue and potassium carbonated (50 mg, 0.36 mmol) were dissolved in methanol (9.5 mL) and water (0.5 mL). The resulting solution was heated to 65 °C and stirred for 2 h. The mixture was purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $\text{C}_{18}\text{H}_{18}\text{ClN}_4\text{O}_3$   $[\text{M}+\text{H}]^+$  m/z: 373.1; found: 373.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  12.05 (s, 1H), 8.07 (s, 1H), 7.53 - 7.48 (m, 1H), 6.85 (d,  $J$  = 2.1 Hz, 1H), 6.79 (d,  $J$  = 2.7 Hz, 1H), 6.73 (d,  $J$  = 2.7 Hz, 1H), 4.89 (d,  $J$  = 13.4 Hz, 1H), 4.66 (d,  $J$  = 13.4 Hz, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.66 (s, 3H).

### Example 8

**3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0209]**




**[0210]** This compound was formed in the same reaction as described for *Example 7, Step 2*. Purified by RP-HPLC (pH = 2) to afford the pure product as a white solid. LC-MS calculated for  $\text{C}_{18}\text{H}_{17}\text{Cl}_2\text{N}_4\text{O}_3$   $[\text{M}+\text{H}]^+$  m/z: 407.1; found: 407.1.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  12.07 (s, 1H), 8.06 (s, 1H), 7.53 - 7.48 (m, 1H), 7.00 (s, 1H), 6.86 (d,  $J$  = 2.6 Hz, 2H), 4.73 (s, 2H), 3.96 (s, 6H), 3.66 (s, 3H).

### Example 9

**3-(2,4-Dichloro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0211]**




**[0212]** This compound was formed as a minor-product in the same reaction as described for *Example 7, Step 2*. Purified by RP-HPLC (pH = 2) to afford the pure compound as a white solid. LC-MS calculated for  $C_{18}H_{17}Cl_2N_4O_3$   $[M+H]^+$  m/z: 407.1; found: 407.0.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  11.96 (s, 1H), 8.05 (s, 1H), 7.51 - 7.46 (m, 1H), 7.28 (s, 1H), 6.83 (br, 1H), 4.95 (d,  $J = 12.9$  Hz, 1H), 4.69 (d,  $J = 12.9$  Hz, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 3.66 (s, 3H).

### Example 10

#### 3-(3,5-Dimethoxyphenyl)-1-methyl-8-[4-(4-methylpiperazin-1-yl)phenyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0213]**




*Step 1: Preparation of lithium diisopropylamide (LDA) solution (1 M in THF)*

**[0214]** To a cooled (-78 °C) solution of N,N-diisopropylamine (0.14 mL, 1.0 mmol) in tetrahydrofuran (0.46 mL) was added n-butyllithium (2.5 M in hexanes, 0.40 mL, 1.0 mmol) dropwise. The mixture was stirred at -78 °C for 5 min then warmed to 0 °C and stirred for 20 min to afford 1 mL of 1 M LDA solution in THF.

*Step 2: 8-bromo-3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0215]**




**[0216]** To a cooled (-78 °C) solution of 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 7, Step 1*; 49 mg, 0.10 mmol) in tetrahydrofuran (3 mL) was added freshly prepared lithium diisopropylamide (LDA) solution (1 M in THF, 0.30 mL) dropwise. The resulting solution was stirred at -78 °C for 30 min then a solution of 1,2-dibromo-1,1,2,2-tetrachloroethane (37 mg, 0.11 mmol) in tetrahy-

dofuran (0.2 mL) was added. After stirring at -78 °C for 1 h, the reaction was quenched with saturated NH<sub>4</sub>Cl solution at -78 °C then warmed to room temperature. The mixture was extracted with EtOAc. The organic layers were combined then washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under reduced pressure. The residue was used in the next step without further purification. LC-MS calculated for C<sub>24</sub>H<sub>22</sub>BrN<sub>4</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 557.0; found: 557.1.

Step 3: 3-(3,5-dimethoxyphenyl)-1-methyl-8-[4-(4-methylpiperazin-1-yl)phenyl]-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0217]



[0218] A mixture of 8-bromo-3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (12 mg, 0.022 mmol), 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine (from Alfa Aesar, cat# H51659, 13 mg, 0.043 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium (II) complexed with dichloromethane (1:1) (4 mg, 0.004 mmol), and potassium carbonate (6.0 mg, 0.043 mmol) was dissolved in 1,4-dioxane (3 mL) then water (0.3 mL) was added. The mixture was degassed then back-filled with nitrogen. This process was repeated for three times. The reaction mixture was heated to 90 °C and stirred for 1 h, at which time LC-MS indicated the reaction was complete. The mixture was cooled to room temperature and concentrated. The residue was purified by column (Biotage®): 12 g silica gel column, eluted with 0 to 10 % MeOH/DCM to afford the desired product (12 mg, 86 %) as a yellow solid. LC-MS calculated for C<sub>35</sub>H<sub>37</sub>N<sub>6</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 653.3; found: 653.3.


Step 4: 3-(3,5-dimethoxyphenyl)-1-methyl-8-[4-(4-methylpiperazin-1-yl)phenyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0219] To a stirred solution of 3-(3,5-dimethoxyphenyl)-1-methyl-8-[4-(4-methylpiperazin-1-yl)phenyl]-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (12 mg, 0.02 mmol) in tetrahydrofuran (2 mL) was added potassium t-butoxide (1 M in THF, 0.2 mL). The resulting yellow solution was stirred at room temperature for 15 min then diluted with methanol and purified by RP-HPLC (pH = 2) to afford the desired product as a yellow solid. LC-MS calculated for C<sub>29</sub>H<sub>33</sub>N<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 513.3; found: 513.3. <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.27 (s, 1H), 8.00 (s, 1H), 7.89 (d, J = 8.8 Hz, 2H), 7.15 (s, 1H), 7.11 (d, J = 8.9 Hz, 2H), 6.55 (d, J = 2.1 Hz, 2H), 6.40 (t, J = 2.1 Hz, 1H), 4.83 (s, 2H), 3.98 (br, 2H), 3.75 (s, 6H), 3.70 (s, 3H), 3.54 (br, 2H), 3.18 (br, 2H), 3.05 (br, 2H), 2.88 (s, 3H).

#### Example 11

3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0220]




**[0221]** This compound was prepared using procedures analogous to those described for *Example 10* with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine. LC-MS calculated for  $C_{22}H_{23}N_6O_3$   $[M+H]^+$   $m/z$ : 419.2; found: 419.2.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.34 (s, 1H), 8.22 (s, 1H), 8.01 (d,  $J = 1.6$  Hz, 2H), 7.02 (d,  $J = 1.5$  Hz, 1H), 6.55 (d,  $J = 2.2$  Hz, 2H), 6.40 (t,  $J = 2.2$  Hz, 1H), 4.84 (s, 2H), 3.90 (s, 3H), 3.75 (s, 6H), 3.67 (s, 3H).

### Example 12


**3-(3,5-Dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide**

**[0222]**



*Step 1: 3-(3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid*


**[0223]**



**[0224]** To a cooled ( $-78$  °C) solution of 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (44 mg, 0.092 mmol) in tetrahydrofuran (3 mL) was added LDA solution (freshly prepared, 1M in THF, 0.30 mL, 0.3 mmol) dropwise. The resulting solution was stirred at  $-78$  °C for 30 min then dry  $CO_2$  gas (prepared from dry ice by passing through a drying tube) was bubbled into the reaction mixture for 30 min. The mixture was warmed to room temperature slowly and acidified with 1 N HCl then extracted with EtOAc. The organic layer was washed with water, brine then dried over  $Na_2SO_4$ . The solvent was removed under reduced pressure. The residue was used in the next step without further purification. LC-MS calculated for  $C_{25}H_{23}N_4O_7S$   $[M+H]^+$   $m/z$ : 523.1; found: 523.2.

Step 2: 3-(3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0225]



[0226] The crude product from Step 1 and benzotriazol-1-yloxytris(dimethylamino)-phosphoniumhexafluorophosphate (41 mg, 0.092 mmol) were dissolved in tetrahydrofuran (5 mL) then triethylamine (38  $\mu$ L, 0.28 mmol) was added. The mixture was stirred at room temperature for 5 min then methylamine (2 M in THF, 140  $\mu$ L, 0.28 mmol) was added. After stirring at room temperature for 30 min, the reaction mixture was diluted with EtOAc then washed with water, brine and dried over  $\text{Na}_2\text{SO}_4$ . The solvents were removed under reduced pressure and the residue was purified by column (Biotage®): 12 g silica gel column, eluted with 30 to 100 % EtOAc/Hexanes to afford the desired product (21 mg, 43 %). LC-MS calculated for  $\text{C}_{26}\text{H}_{26}\text{N}_5\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$  m/z: 536.2; found: 536.1.


Step 3: 3-(3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0227] To a stirred solution of 3-(3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide (21 mg, 0.039 mmol) in tetrahydrofuran (3 mL) was added potassium tert-butoxide (1 M in THF, 0.4 mL, 0.4 mmol). The resulting yellow solution was stirred at room temperature for 15 min then diluted with MeOH and purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $\text{C}_{20}\text{H}_{22}\text{N}_5\text{O}_4$   $[\text{M}+\text{H}]^+$  m/z: 396.2; found: 396.2.

### Example 13


3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0228]



Step 1: 8-bromo-3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0229]



**[0230]** To a cooled (0 °C) solution of 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (96 mg, 0.20 mmol) in acetonitrile (3 mL) was added a solution of sulfuryl chloride (16  $\mu$ L, 0.20 mmol) in methylene chloride (1 mL) dropwise. After stirring at 0 °C for 5 min, the reaction was quenched with water then extracted with EtOAc. The organic layer was then washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (3 mL, 40 mmol) and cooled to -78 °C then LDA solution (freshly prepared, 1M in THF, 0.70 mL, 0.70 mmol) was added. The resulting yellow solution was stirred at -78 °C for 30 min then a solution of 1,2-dibromo-1,1,2,2-tetrachloroethane (72 mg, 0.22 mmol) in 0.5 mL of THF was added. The resulting brown solution was stirred at -78 °C for 1 h, at which time LC-MS indicated the reaction was complete. The reaction was quenched with saturated NH<sub>4</sub>Cl solution at -78 °C then warmed to room temperature. The mixture was extracted with EtOAc and the organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure and the residue was purified by Biotage®: 12 g silica gel column, eluted with 0 to 5 % EtOAc/DCM to afford the desired product (45 mg, 38%) as a yellow solid.


*Step 2: 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0231]** A mixture of 8-bromo-3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (15 mg, 0.025 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (10 mg, 0.051 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (1:1) (2 mg, 0.002 mmol) and potassium carbonate (10. mg, 0.076 mmol) was dissolved in 1,4-dioxane (3 mL, 40 mmol) then water (0.3 mL, 20 mmol) was added. The mixture was degassed then back-filled with nitrogen three times. The resulting red solution was heated to 90 °C and stirred for 30 min, at which time LC-MS indicated the reaction was complete. The reaction mixture was cooled to room temperature and diluted with EtOAc then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (3 mL) then potassium tert-butoxide (1M in THF, 0.2 mL, 0.2 mmol) was added. The resulting yellow solution was stirred at room temperature for 30 min then diluted with MeOH and purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>22</sub>H<sub>22</sub>ClN<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 453.1; found: 453.1. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  12.25 (s, 1H), 8.20 (s, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 7.00 (d, J = 1.8 Hz, 1H), 6.78 (d, J = 2.7 Hz, 1H), 6.73 (d, J = 2.7 Hz, 1H), 4.87 (d, J = 13.4 Hz, 1H), 4.64 (d, J = 13.4 Hz, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.80 (s, 3H), 3.67 (s, 3H).

#### Example 14


**3-(2-Chloro-3,5-dimethoxyphenyl)-8-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0232]**



Step 1: 8-bromo-3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0233]**



**[0234]** To a solution of 8-bromo-3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (15 mg, 0.025 mmol) in tetrahydrofuran (3 mL) was added potassium tert-butoxide (1 M in THF, 0.1 mL, 0.1 mmol). After stirring at room temperature for 20 min, the reaction was quenched with water then extracted with EtOAc. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure and the residue was used in the next step without further purification. LC-MS calculated for C<sub>18</sub>H<sub>17</sub>BrClN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 451.0; found: 451.0.

Step 2: 3-(2-chloro-3,5-dimethoxyphenyl)-8-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


**[0235]** A mixture of the crude product from Step 1, 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethanol (12 mg, 0.051 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1:1) (2 mg, 0.002 mmol), and potassium carbonate (10 mg, 0.076 mmol) was dissolved in 1,4-dioxane (3 mL) and water (0.3 mL). The reaction mixture was degassed then back-filled with nitrogen three times. The resulting solution was heated to 90 °C. After stirring for 7 h, the reaction mixture was cooled to room temperature and diluted with MeOH, then filtered and purified by RP-HPLC (pH = 10) to afford the product as a yellow solid. LC-MS calculated for C<sub>23</sub>H<sub>24</sub>ClN<sub>6</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 483.2; found: 483.2.

**Example 15**

**3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-5-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0236]**

EP 2 861 595 B9




**[0237]** This compound was prepared using procedures analogous to those described for *Example 14, Step 2* with 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethanol and a reaction time of 2 h. LC-MS calculated for  $C_{22}H_{22}ClN_6O_3$   $[M+H]^+$  m/z: 453.1; found: 453.1.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.31 (s, 1H), 8.06 (s, 1H), 7.52 (d,  $J = 1.9$  Hz, 1H), 7.07 (s, 1H), 6.79 (d,  $J = 2.7$  Hz, 1H), 6.76 (d,  $J = 1.9$  Hz, 1H), 6.73 (d,  $J = 2.7$  Hz, 1H), 4.90 (d,  $J = 13.4$  Hz, 1H), 4.65 (d,  $J = 13.4$  Hz, 1H), 4.07 (s, 3H), 3.87 (s, 3H), 3.81 (s, 3H), 3.70 (s, 3H).

**Example 16**


**3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbonitrile**

**[0238]**



*Step 1: 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbonitrile*

**[0239]**



**[0240]** This compound was prepared using procedures analogous to those described for *Example 13, Step 1* with 4-methylbenzenesulfonyl cyanide replacing 1,2-dibromo-1,1,2,2-tetrachloroethane. The reaction mixture was purified by RP-HPLC (pH = 10) to afford the desired product as a white solid.

*Step 2: 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbonitrile*

**[0241]** The phenylsulfonyl-protecting group was removed using similar conditions as described in *Example 10, Step*


## EP 2 861 595 B9

4. The product was purified by RP-HPLC (pH = 10) to afford a white solid. LC-MS calculated for  $C_{19}H_{17}ClN_5O_3$   $[M+H]^+$  m/z: 398.1; found: 398.0.

### Example 17

3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0242]




[0243] This compound was prepared using procedures analogous to those described for *Example 10* with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydro-pyridine replacing 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-piperazine. Purified by RP-HPLC (pH = 2) to afford the pure product as a white solid. LC-MS calculated for  $C_{24}H_{28}N_5O_3$   $[M+H]^+$  m/z: 434.2; found: 434.2.

### Example 18

3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methylpiperidin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0244]




[0245] A mixture of 3-(3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (8 mg, 0.02 mmol) and palladium (10 wt. % on carbon, 10 mg, 0.009 mmol) was dissolved in methanol (5 mL). The reaction mixture was stirred under a balloon of hydrogen at room temperature for 2 h, at which time LC-MS indicated the reaction was complete. The mixture was filtered and purified by RP-HPLC (pH = 2) to afford the product as a white solid. LC-MS calculated for  $C_{24}H_{30}N_5O_3$   $[M+H]^+$  m/z: 436.2; found: 436.2.

### Example 19


3-(3,5-Dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0246]



Step 1: 3-(3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid

[0247]



[0248] To a stirred solution of 3-(3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (prepared as described in Example 12, Step 1; 1 eq.) in THF was added potassium tert-butoxide (1M in THF, 5 eq.). The resulting mixture was stirred at room temperature for 20 min then acidified with 1N HCl. The mixture was diluted with water then extracted with dichloromethane/isopropyl alcohol (2:1). The organic layers were combined and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under reduced pressure and the residue was used in the next step without further purification. LC-MS calculated for C<sub>19</sub>H<sub>19</sub>N<sub>4</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 383.1; found: 383.1.

Step 2: 3-(3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide


[0249] To a solution of 3-(3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (13 mg, 0.034 mmol) and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (16 mg, 0.037 mmol) in N,N-dimethylformamide (4 mL) was added triethylamine (50 μL, 0.3 mmol) and dimethylamine (2M in THF, 80 μL, 0.2 mmol). The mixture was stirred at room temperature for 30 min, at which time LC-MS indicated the reaction was complete. The mixture was diluted with MeOH then purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>21</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 410.2; found: 410.2.

Example 20

3-(3,5-Dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0250]

5



10


**[0251]** This compound was prepared using procedure analogous to those for *Example 19, Step 2* with azetidin-3-ol hydrochloride replacing dimethylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{22}H_{24}N_5O_5$   $[M+H]^+$  m/z: 438.2; found: 438.2.

### 15 Example 21

**3-(3,5-Dimethoxyphenyl)-8-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

20 **[0252]**

25



30

**[0253]** This compound was prepared using procedure analogous to those for *Example 19, Step 2* with 3-pyrrolidinol replacing dimethylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{23}H_{26}N_5O_5$   $[M+H]^+$  m/z: 452.2; found: 452.2.

35


### Example 22

**3-(3,5-Dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

40

**[0254]**

45



50


**[0255]** This compound was prepared using procedure analogous to those for *Example 19, Step 2* with 1-methylpiperazine replacing dimethylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{24}H_{29}N_6O_4$   $[M+H]^+$  m/z: 465.2; found: 465.2.

55

## Example 23


3-(2-Chloro-3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0256]



Step 1: 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid


[0257]



[0258] To a cooled (0 °C) solution of 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (107 mg, 0.224 mmol) in acetonitrile (3 mL) was added a solution of sulfuryl chloride (18 μL, 0.224 mmol) in methylene chloride (1 mL) dropwise. After stirring at 0 °C for 5 min, the reaction was quenched with water then extracted with EtOAc. The organic layer was then washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure and the residue was dissolved in tetrahydrofuran (3 mL) and cooled to -78 °C then LDA solution (freshly prepared, 1 M in THF, 0.78 mL, 0.78 mmol) was added. The resulting yellow solution was stirred at -78 °C for 30 min then dry CO<sub>2</sub> gas (prepared from dry ice by passing through a drying tube) was bubbled into the reaction mixture for 30 min. The mixture was warmed to room temperature slowly and acidified with 1 N HCl then extracted with EtOAc. The organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure. The residue was used in the next step without further purification. LC-MS calculated for C<sub>25</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>7</sub>S [M+H]<sup>+</sup> m/z: 557.1; found: 557.1.

Step 2: 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid

[0259]



[0260] To a solution of 3-(2-chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (20 mg, 0.04 mmol) in tetrahydrofuran (3 mL, 40 mmol) was added potassium tert-butoxide (1 M in THF, 0.2 mL, 0.2 mmol). The resulting yellow solution was stirred at room temperature for 30 min then quenched with water and acidified with 1 N HCl. The mixture was extracted with EtOAc. The organic layers were combined then washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure to afford the crude product which was used in the next step without further purification. LC-MS calculated for C<sub>19</sub>H<sub>18</sub>ClN<sub>4</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 417.1; found: 417.1.


*Step 3: 3-(2-chloro-3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide*

[0261] To a solution of the crude product from *Step 2* and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (17 mg, 0.039 mmol) in N,N-dimethylformamide (4 mL) was added triethylamine (25 μL, 0.18 mmol) and methylamine (2M in THF, 54 μL, 0.11 mmol). The mixture was stirred at room temperature for 30 min, at which time LC-MS indicated the reaction was complete. The mixture was diluted with MeOH then purified by RP-HPLC (pH = 10) to afford the desired product as a white solid. LC-MS calculated for C<sub>20</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 430.1; found: 430.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.11 (s, 1H), 8.46 (d, *J* = 4.6 Hz, 1H), 8.06 (s, 1H), 7.46 (s, 1H), 6.78 (d, *J* = 2.7 Hz, 1H), 6.72 (d, *J* = 2.7 Hz, 1H), 4.86 (d, *J* = 13.4 Hz, 1H), 4.64 (d, *J* = 13.4 Hz, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.66 (s, 3H), 2.83 (d, *J* = 4.6 Hz, 3H).

#### Example 24

**3-(2-Chloro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide**

[0262]




[0263] This compound was prepared using procedures analogous to those for *Example 23, Step 3* with dimethylamine (2 M in THF) replacing methylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>21</sub>H<sub>23</sub>ClN<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 444.1; found: 444.1.

#### Example 25

**3-(2-Chloro-3,5-dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0264]




**[0265]** This compound was prepared using procedure analogous to those for *Example 23, Step 3* with azetidin-3-ol hydrochloride replacing methylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{22}H_{23}ClN_5O_5$   $[M+H]^+$  m/z: 472.1; found: 472.2.

### Example 26

**3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0266]**




**[0267]** This compound was prepared using procedures analogous to those for *Example 23, Step 3* with 1-methylpiperazine replacing methylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{24}H_{28}ClN_6O_4$   $[M+H]^+$  m/z: 499.2; found: 499.2.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  11.50 (br, 1H), 8.31 (s, 1H), 7.32 (s, 1H), 6.80 (d,  $J = 2.7$  Hz, 1H), 6.74 (d,  $J = 2.7$  Hz, 1H), 4.95 (d,  $J = 13.9$  Hz, 1H), 4.73 (d,  $J = 13.9$  Hz, 1H), 4.50 (br, 2H), 3.86 (s, 3H), 3.79 (s, 3H), 3.72 (s, 3H), 3.52 (br, 2H), 3.42 (br, 2H), 3.13 (br, 2H), 2.87 (s, 3H).

### Example 27


**N-Cyclopropyl-3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide**

**[0268]**



*Step 1: 3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid*

**[0269]**



5  
10  
15  
20  
[0270] To a stirred solution of 3-(3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (125 mg, 0.239 mmol) in acetonitrile (5 mL) was added 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane ditetrafluoroborate (from Aldrich, cat#439479, 102 mg, 0.287 mmol). The resulting yellow solution was stirred at room temperature for 2 h, at which time LCMS indicated completion of the reaction to the desired product. The reaction mixture was diluted with EtOAc then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated. The residue was dissolved in tetrahydrofuran (5 mL) then potassium tert-butoxide (1M in THF, 1.2 mL, 1.2 mmol) was added. The mixture was stirred at room temperature for 20 min then acidified with 1 N HCl. The mixture was extracted with DCM/IPA (2:1) and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>19</sub>H<sub>18</sub>FN<sub>4</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 401.1; found: 401.1.


Step 2: *N*-cyclopropyl-3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

25  
30  
[0271] To a solution of 3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (6 mg, 0.015 mmol) and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (8 mg, 0.018 mmol) in *N,N*-dimethylformamide (2.5 mL) was added triethylamine (20 μL, 0.1 mmol) and cyclopropylamine (5.2 μL, 0.075 mmol). The resulting yellow solution was stirred at room temperature for 30 min, at which time LC-MS indicated the reaction was complete. The mixture was diluted with MeOH then purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>22</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 440.2; found: 440.1.

### Example 28

35  
3-(2-Fluoro-3,5-dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0272]




40  
45  
50  
55  
[0273] This compound was prepared using procedures analogous to those for *Example 27*, *Step 2* with azetidin-3-ol hydrochloride replacing cyclopropylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>22</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 456.2; found: 456.2.

## Example 29

1-[[3-(2-Fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]carbonyl]pyrrolidine-3-carbonitrile

[0274]




[0275] This compound was prepared using procedures analogous to those for *Example 27, Step 2* with pyrrolidine-3-carbonitrile hydrochloride replacing cyclopropylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{24}H_{24}FN_6O_4$   $[M+H]^+$  m/z: 479.2; found: 479.2.

## Example 30

3-(2-Fluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0276]




[0277] This compound was prepared using procedures analogous to those for *Example 27, Step 2* with 1-methylpiperazine replacing cyclopropylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{24}H_{28}FN_6O_4$   $[M+H]^+$  m/z: 483.2; found: 483.2.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.32 (s, 1H), 8.11 (s, 1H), 7.07 (s, 1H), 6.69 (dd,  $J$  = 6.7, 2.9 Hz, 1H), 6.62 (dd,  $J$  = 6.7, 2.9 Hz, 1H), 4.81 (s, 2H), 4.50 (br, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.65 (s, 3H), 3.49 (br, 2H), 3.39 (br, 2H), 3.14 (br, 2H), 2.86 (s, 3H).

## Example 31

3-(2-Fluoro-3,5-dimethoxyphenyl)-8-[(3-hydroxypiperidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0278]




**[0279]** This compound was prepared using procedures analogous to those for *Example 27, Step 2* with piperidin-3-ol replacing cyclopropylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{24}H_{27}FN_5O_5$   $[M+H]^+$  m/z: 484.2; found: 484.2.

### Example 32


#### 3-(2-Fluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0280]**



*Step 1: 3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*


**[0281]**



**[0282]** To a solution of 3-(3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 7, Step 1*: 63.0 mg, 0.132 mmol) in acetonitrile (9 mL) was added 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane ditetrafluoroborate (95.6 mg, 0.270 mmol). The suspension was stirred at room temperature overnight. Then the resulting solution was concentrated to remove solvents. The residue was dissolved in AcOEt, and washed with  $NaHCO_3$  aqueous solution, brine then dried over  $MgSO_4$ . The solvents were removed under reduced pressure to afford the desired compound which was used in the next step without further purification. LC-MS calculated for  $C_{24}H_{22}FN_4O_5S$   $[M+H]^+$  m/z: 497.1; found: 497.1.

*Step 2: 3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0283]**




[0284] To a solution of the above residue in *Step 1* in THF (2 mL) was added 1.0 M potassium tert-butoxide in THF (390  $\mu$ L, 0.39 mmol). The solution was stirred at r.t. 30 min, then concentrated to remove solvent. The residue was dissolved in MeOH and purified by RP-HPLC (pH = 2) to afford the desired product. LC-MS calculated for  $C_{18}H_{18}FN_4O_3$   $[M+H]^+$  m/z: 357.1; found: 357.1.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.10 (s, 1H), 8.08 (s, 1H), 7.53 - 7.49 (m, 1H), 6.85 (d,  $J = 2.3$  Hz, 1H), 6.70 (dd,  $J = 6.7, 2.9$  Hz, 1H), 6.63 (dd,  $J = 5.2, 2.9$  Hz, 1H), 4.82 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.65 (s, 3H).

### Example 33

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0285]




[0286] This compound was formed in the same reaction as described for *Example 32*. LC-MS calculated for  $C_{18}H_{17}F_2N_4O_3$   $[M+H]^+$  m/z: 375.1; found: 375.2.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  11.98 (s, 1H), 8.03 (s, 1H), 7.52 - 7.46 (m, 1H), 7.04 (t,  $J = 8.1$  Hz, 1H), 6.82 (d,  $J = 2.0$  Hz, 1H), 4.78 (s, 2H), 3.89 (s, 6H), 3.65 (s, 3H).

### Example 34


3-(2-Fluoro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0287]



Step 1: 3-(2-fluoro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0288]



To a solution of N,N-diisopropylamine (1.0E2  $\mu$ L, 0.76 mmol) in THF (0.5 mL) was added 2.5 M n-butyllithium in hexanes (0.30 mL, 0.76 mmol) dropwise at -78 °C. The mixture was stirred at -78 °C for 5 min, then warmed up to 0 °C and stirred for 20 min. then cooled to -78 °C again.

[0289] To a solution of 3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (75.0 mg, 0.151 mmol) (mixed with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, *Example 32, Step 1*) in tetrahydrofuran (1.0 mL) was added prepared LDA solution dropwise at -78 °C. The resulting yellow suspension was stirred at -78 °C for 50 min, then a solution of N,N-dimethylcarbonyl chloride (70  $\mu$ L, 0.76 mmol) in tetrahydrofuran (1.0 mL) was added dropwise. The reaction mixture was stirred at -20 °C for 1 hour then quenched with saturated  $\text{NH}_4\text{Cl}$  solution, and then extracted with AcOEt twice. The combined organic phase was washed with brine and dried over  $\text{MgSO}_4$ . The solvents were removed under reduced pressure to afford the desired compound which was used in the next step without further purification. LC-MS calculated for  $\text{C}_{27}\text{H}_{27}\text{FN}_5\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$  m/z: 568.2; found: 568.2.


Step 2: 3-(2-fluoro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0290] To a solution of the above residue made in *Step 1* in THF (2 mL) was added 1.0 M potassium tert-butoxide in THF (450  $\mu$ L, 0.45 mmol). The solution was stirred at r.t. 30 min, then concentrated to remove solvent. The residue was dissolved in MeOH and purified by RP-HPLC (pH = 2) to afford the desired product. LC-MS calculated for  $\text{C}_{21}\text{H}_{23}\text{FN}_5\text{O}_4$   $[\text{M}+\text{H}]^+$  m/z: 428.2; found: 428.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  12.27 (s, 1H), 8.10 (s, 1H), 7.07 (s, 1H), 6.72 - 6.66 (m, 1H), 6.64 - 6.60 (m, 1H), 4.81 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.64 (s, 3H), 3.35 - 2.95 (m, 6H).

### Example 35

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide

[0291]



[0292] This compound was formed in the same reaction as described for *Example 34*, LC-MS calculated for  $\text{C}_{21}\text{H}_{22}\text{F}_2\text{N}_5\text{O}_4$   $[\text{M}+\text{H}]^+$  m/z: 446.2; found: 446.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  12.23 (s, 1H), 8.07 (s, 1H), 7.08 - 7.00


## EP 2 861 595 B9

(m, 2H), 4.78 (s, 2H), 3.89 (s, 6H), 3.65 (s, 3H), 3.36 - 2.92 (m, 6H).

### Example 36


5 **3-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0293]



20 *Step 1: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

[0294]



35 **[0295]** To a solution of 3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (290.0 mg, 0.5841 mmol) in acetonitrile (8 mL) was added a solution of sulfuryl chloride (49.6  $\mu$ L, 0.613 mmol) in methylene chloride (2 mL) dropwise at 0 °C. The resulting solution was stirred at 0 °C for 10 min. The reaction was quenched with water then extracted with EtOAc. The organic layer was then washed with  
40 water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under reduced pressure to afford the desired compound which was used in the next step without further purification. LC-MS calculated for C<sub>24</sub>H<sub>21</sub>ClFN<sub>4</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 531.1; found: 531.1.


45 *Step 2: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0296]** To a solution of the above residue formed in *Step 2* in THF (3 mL) was added 1.0 M potassium tert-butoxide in THF (1.8 mL, 1.8 mmol). The solution was stirred at r.t. 30 min, then concentrated to remove solvent. The residue was dissolved in MeOH and purified by RP-HPLC (pH = 2) to afford the desired product. LC-MS calculated for  
50 C<sub>18</sub>H<sub>17</sub>ClFN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 391.1; found: 391.1. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  12.10 (s, 1H), 8.07 (s, 1H), 7.52 (s, 1H), 7.03 (d, *J* = 7.7 Hz, 1H), 6.86 (d, *J* = 3.2 Hz, 1H), 4.79 - 4.71 (m, 2H), 3.94 (s, 3H), 3.91 (s, 3H), 3.66 (s, 3H).

### Example 37


55 **3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

[0297]



Step 1: 9,9-Dibromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione and 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

**[0298]**



**[0299]** Pyridinium tribromide (120 mg, 0.37 mmol) was added to a mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d] pyrimidin-2-one (40.0 mg, 0.107 mmol) in tert-butyl alcohol (1.2 mL) and then the reaction was stirred at 30 °C overnight. The mixture was diluted with ethyl acetate, washed with saturated NaHCO<sub>3</sub>, water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated to provide the crude product as a mixture of the above two products which were used in the next step directly. LCMS (M+H)<sup>+</sup>: m/z = 549.0, 471.0.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

**[0300]** Zinc (10 mg, 0.2 mmol) was added to a mixture of 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d] pyrimidine-2,8-dione (10.0 mg, 0.0213 mmol) and 9,9-dibromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d] pyrimidine-2,8-dione (10.0 mg, 0.0182 mmol) in methanol (0.3 mL) / acetic acid (0.3 mL), then the mixture was stirred at room temperature for 3 h. The reaction mixture was filtered and then the product was purified by RP-HPLC (pH = 2). LC-MS calculated for C<sub>18</sub>H<sub>17</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 391.1; found: 391.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.82 (s, 1H), 7.03 (t, J = 8.1 Hz, 1H), 4.60 (s, 2H), 4.00 (s, 2H), 3.88 (s, 6H), 3.39 (s, 3H).

**Example 38**


**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4-dihydrothieno[2',3':5,6]pyrido[4,3-d]pyrimidin-2(1H)-one**

**[0301]**



## Step 1: 7-chlorothieno[3,2-b]pyridine-6-carbaldehyde

[0302]




[0303] To a solution of ethyl 7-chlorothieno[3,2-b]pyridine-6-carboxylate (CAS # 90690-94-1) purchased from Syntho-nix, Inc, cat#E4282, 409 mg, 1.69 mmol) in tetrahydrofuran (5.0 mL) at 0 °C was added diisobutylaluminum hydride (1.0 M in hexane, 5.1 mL, 5.1 mmol). The resulting mixture was stirred at this temperature for 2 h before it was quenched with MeOH (5 mL) and NaHCO<sub>3</sub> solution (10 mL). The aqueous phase was extracted with EtOAc (3 × 10 mL), and it was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude alcohol was used without further purification. LC-MS calculated for C<sub>8</sub>H<sub>7</sub>ONSCI [M+H]<sup>+</sup> m/z: 200.1; found 200.1.

[0304] To a solution of the alcohol obtained above in methylene chloride (5.0 mL) was added sodium bicarbonate (710 mg, 8.5 mmol) and Dess-Martin periodinane (860 mg, 2.0 mmol). The resulting mixture was stirred for 1 h before it was quenched with Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (5 mL) and NaHCO<sub>3</sub> solution (5 mL). The aqueous phase was extracted with methylene chloride (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude mixture was purified by flash column (MeOH/DCM, 3%~20%) to afford the aldehyde (237 mg, 72% for two steps) as a white solid. LC-MS calculated for C<sub>8</sub>H<sub>5</sub>ONSCI [M+H]<sup>+</sup> m/z: 198.1; found 198.1.

## Step 2: 7-(methylamino)thieno[3,2-b]pyridine-6-carbaldehyde


[0305]



[0306] A solution of 7-chlorothieno[3,2-b]pyridine-6-carbaldehyde (237 mg, 1.20 mmol) in methylamine (33% in ethanol, 2.0 mL, 16.0 mmol) was heated to 110 °C for 3 h. After cooling to room temperature, the solution was concentrated in vacuo. The crude imine was dissolved in hydrogen chloride (1.0 M in water, 3.6 mL, 3.6 mmol), and the resulting mixture was stirred at 60 °C for 3 h. The solution was neutralized with NaOH (2.0 M, 1.7 mL, 3.4 mmol) and NaHCO<sub>3</sub> sat. solution. After it was filtered and dried over high vacuum, the pure 7-(methylamino)thieno[3,2-b]pyridine-6-carbaldehyde (150 mg, 65%) was obtained as a yellow solid. LC-MS calculated for C<sub>9</sub>H<sub>9</sub>ON<sub>2</sub>S [M+H]<sup>+</sup> m/z: 193.2; found 193.2.

## Step 3: 6-[[3,5-dimethoxyphenyl]amino]methyl]-N-methylthieno[3,2-b]pyridin-7-amine

[0307]



[0308] To a solution of 7-(methylamino)thieno[3,2-b]pyridine-6-carbaldehyde (75 mg, 0.39 mmol) in ethanol (3.0 mL) was added 3,5-dimethoxyaniline (120 mg, 0.78 mmol) and acetic acid (0.223 mL, 3.92 mmol). The resulting mixture was stirred at 90 °C for 2 h before it was cooled to room temperature. Sodium cyanoborohydride (120 mg, 2.0 mmol) was added to the solution and the mixture was stirred for another 2 h. The reaction mixture was diluted with MeOH and purified by RF-HPLC (pH 10) to afford 6-[[3,5-dimethoxyphenyl]amino]methyl]-N-methylthieno[3,2-b]pyridin-7-amine (96 mg, 74%) as a white solid. LC-MS calculated for C<sub>17</sub>H<sub>20</sub>O<sub>2</sub>N<sub>3</sub>S [M+H]<sup>+</sup> m/z: 330.1; found 330.1.


## EP 2 861 595 B9

Step 4: 3-(3,5-dimethoxyphenyl)-1-methyl-3,4-dihydrothieno[2',3':5,6]pyrido[4,3-d]pyrimidin-2(1H)-one

[0309]

5

10



15 [0310] To a solution of 6-[(3,5-dimethoxyphenyl)amino]methyl-N-methylthieno[3,2-b]pyridin-7-amine (96 mg, 0.13 mmol) in CH<sub>3</sub>CN (3.0 mL) was added 1,1'-thiocarbonyldiimidazole (210 mg, 1.2 mmol). The resulting mixture was stirred at 110 °C for 12 h before it was concentrated in vacuo. The crude mixture was purified by flash column (MeOH/DCM 5%~20%) to afford 3-(3,5-dimethoxyphenyl)-1-methyl-3,4-dihydrothieno[2',3':5,6]pyrido[4,3-d]pyrimidin-2(1H)-one (120 mg, 86%) as a yellow solid. LC-MS calculated for C<sub>18</sub>H<sub>18</sub>O<sub>3</sub>N<sub>3</sub>S [M+H]<sup>+</sup> m/z: 356.1; found 356.1.

20

Step 5: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4-dihydrothieno[2',3':5,6]pyrido[4,3-d]pyrimidin-2(1H)-one

25 [0311] To a solution of 3-(3,5-dimethoxyphenyl)-1-methyl-3,4-dihydrothieno[2',3':5,6]pyrido[4,3-d]pyrimidin-2(1H)-one (10.0 mg, 0.0281 mmol) in CH<sub>3</sub>CN (1.0 mL) was added 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane ditetrafluoroborate (Selectfluor®) (24.9 mg, 0.0703 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h before it was diluted with MeOH (9 mL). The compound was purified by RF-HPLC (pH = 10) to afford 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3,4-dihydrothieno[2',3':5,6]pyrido[4,3-d]pyrimidin-2(1H) (3.0 mg, 27%) as a white solid. LC-MS calculated for C<sub>18</sub>H<sub>16</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup> m/z: 392.1; found 392.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.40 (s, 1H), 8.15 (d, J = 5.6 Hz, 1H), 7.55 (d, J = 5.6 Hz, 1H), 7.05 (t, J = 8.2 Hz, 1H), 4.85 (s, 2H), 3.89 (s, 6H), 3.71 (s, 3H).

30


### Example 39

35 **3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(tetrahydro-2H-pyran-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0312]

40

45




50 Step 1: 5-[(E)-[(2,6-difluoro-3,5-dimethoxyphenyl)imino]methyl]-N-methyl-1H-pyrrolo[2,3-b]pyridin-4-amine

50

[0313]

55


EP 2 861 595 B9



**[0314]** A mixture of 4-(methylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (1.98 g, 11.3 mmol, prepared as described in *Example 1, Step 1*), 2,6-difluoro-3,5-dimethoxyaniline (2.6 g, 14 mmol) and D-(+)-10-camphorsulfonic acid (Aldrich, cat # 21360: 0.72 g, 3.1 mmol) in toluene (200 mL) was heated to reflux with azeotropic removal of water via a Dean-stark trap for 48 h. The reaction mixture was concentrated and the residue was used in the next step without further purification. LC-MS calculated for  $C_{17}H_{17}F_2N_4O_2$   $[M+H]^+$  m/z: 347.1; found 347.1.

*Step 2: 5-((2,6-difluoro-3,5-dimethoxyphenyl)amino)methyl)-N-methyl-1H-pyrrolo[2,3-b]pyridine-4-amine*


**[0315]**



**[0316]** The crude product from *Step 1* was dissolved in tetrahydrofuran (200 mL) and cooled to 0 °C then  $LiAlH_4$  (0.86 g, 23 mmol) was added. The reaction mixture was warmed to 50 °C and stirred overnight. The reaction was quenched by addition of a minimum amount of water at 0 °C then filtered through Celite and washed with THF. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluted with 0-5 % methanol in dichloromethane to afford the desired product (2.00, 51%) as a yellow solid. LC-MS calculated for  $C_{17}H_{19}F_2N_4O_2$   $[M+H]^+$  m/z: 349.1; found 349.1.

*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0317]**




**[0318]** Triphosgene (2.0 g, 6.8 mmol) was added to a solution of the product from *Step 2* and triethylamine (7.9 mL, 56 mmol) in tetrahydrofuran (160 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 h, then 1M NaOH (50 mL) was added. After stirring for 30 min at room temperature, saturated aqueous solution of  $NH_4Cl$  (10 mL) was added. The mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine, dried over  $MgSO_4$ , filtered and concentrated under reduced pressure. The mixture was used for next step without further purification. LC-MS calculated for  $C_{18}H_{17}F_2N_4O_3$   $[M+H]^+$  m/z: 375.1; found 375.0.

EP 2 861 595 B9

Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0319]



[0320] To a stirred solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (2.30 g, 6.14 mmol) in tetrahydrofuran (30 mL) was added NaH (60 % in mineral oil, 0.344 g, 8.60 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min then benzenesulfonyl chloride (0.94 mL, 7.4 mmol) was added. After stirring at 0 °C for 1 h, the reaction was quenched with saturated aqueous solution of NH<sub>4</sub>Cl then extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, then filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluted with ethyl acetate in DCM (0-30%) to afford the desired product (1.89 g, 68.8%). LC-MS calculated for C<sub>24</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 515.1; found 515.0.

Step 5: 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0321]




(1) Preparation of LDA solution: To a stirred solution of N,N-diisopropylamine (0.632 mL, 4.51 mmol) in tetrahydrofuran (10 mL) at -78 °C was added 2.5 M n-butyllithium in hexanes (1.6 mL, 4.0 mmol) dropwise. After a white precipitate formed, the mixture was warmed up to 0 °C and stirred for 10 min.

(2) To a stirred solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (1.60 g, 3.11 mmol) in tetrahydrofuran (100 mL) at -78 °C was added the freshly prepared LDA solution dropwise. After 30 min, a solution of 1,2-dibromo-1,1,2,2-tetrachloroethane (1.06 g, 3.26 mmol) in tetrahydrofuran (6 mL) was added dropwise. The resulting clear yellow solution was stirred at -78 °C for 1 h. The reaction mixture was quenched with saturated aqueous solution of NH<sub>4</sub>Cl then extracted with ethyl acetate (3 x 40 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc in DCM (0-10 %) to afford the desired product (1.50 g, 81.3 %). LC-MS calculated for C<sub>24</sub>H<sub>20</sub>BrF<sub>2</sub>N<sub>4</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 593.0; found 592.9.

Step 6: 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0322]



**[0323]** To a stirred solution of 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (1.50 g) in tetrahydrofuran (10 mL) was added 5.0 M sodium methoxide in methanol (1.9 mL, 9.3 mmol). After stirring at room temperature for 1 h, the mixture was diluted with water and adjusted to pH = 8 with 1 N HCl, then concentrated to remove THF. The solid was filtered, washed with water and dried in vacuum to afford the desired product (0.83 g). LC-MS calculated for  $C_{18}H_{16}BrF_2N_4O_3$   $[M+H]^+$  m/z: 453.0; found 453.0.

*Step 7: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3,6-dihydro-2H-pyran-4-yl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0324]**



**[0325]** A mixture of 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (10.0 mg, 0.0221 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyran (6.0 mg, 0.029 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1) (2 mg, 0.003 mmol) and potassium carbonate (9.1 mg, 0.066 mmol) in 1,4-dioxane (0.80 mL) and water (0.20 mL) was degassed and filled with nitrogen. After stirring at 95 °C for 3 h, the reaction mixture was diluted with MeOH, and filtered. The solution was used in the next step. LC-MS calculated for  $C_{23}H_{23}F_2N_4O_4$   $[M+H]^+$  m/z: 457.2; found 457.1.


*Step 8: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(tetrahydro-2H-pyran-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0326]** Palladium on activated carbon (10 wt %, 10 mg) was added to the solution of product from *Step 7* in methanol (5 mL) and the reaction mixture was stirred at room temperature under a balloon of  $H_2$  for 2 h. The mixture was filtered and purified by RP-HPLC (pH = 2) to afford the desired product. LC-MS calculated for  $C_{23}H_{25}F_2N_4O_4$   $[M+H]^+$  m/z: 459.2; found 459.1.

#### Example 40


**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0327]**



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid


**[0328]**



**[0329]** To a stirred solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (700 mg, 1.36 mmol) in tetrahydrofuran (20 mL) was added freshly prepared LDA solution (1M in THF, 1.95 mL, 1.4 eq) at -78 °C. The mixture was stirred at -78 °C for 30 min then dry CO<sub>2</sub> gas (prepared from dry ice by passing through a drying tube) was bubbled into the reaction mixture for 30 min. The reaction was then quenched with 1N HCl at -78 °C. After warming to room temperature, the reaction mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column: 0 to 5 % MeOH/DCM, to give the desired product (519 mg, 68 %). LC-MS calculated for C<sub>25</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>7</sub>S [M+H]<sup>+</sup> m/z: 559.1; found 559.1.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid

**[0330]**



**[0331]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (762 mg, 1.36 mmol) in tetrahydrofuran (23 mL) was added 1.0 M potassium tert-butoxide in THF (6.0 mL, 6.0 mmol). The resulting light yellow suspension was stirred at room temperature for 30 min at which time LC-MS indicated the reaction was complete to the desired product. The reaction was quenched with water then extracted with EtOAc. The aqueous layer was acidified with 1N HCl and the white precipitate was collected via filtration and dried to afford the pure product (528 mg, 93 %) as a white solid. LC-MS calculated for C<sub>19</sub>H<sub>17</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 419.1; found 419.1.


Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl) carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0332] To a stirred solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxylic acid (207 mg, 0.495 mmol) in N,N-dimethylformamide (15 mL) was added triethylamine (210  $\mu$ L, 1.5 mmol), followed by benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (230 mg, 0.52 mmol). The mixture was stirred for 5 min at room temperature then 1-methylpiperazine (160  $\mu$ L, 1.5 mmol) was added. After stirred at room temperature for 30 min, the reaction mixture was diluted with MeOH then purified by RP-HPLC (pH = 2) to give the desired product (200 mg, 81 %) as a white solid. LC-MS calculated for  $C_{24}H_{27}F_2N_6O_4$   $[M+H]^+$  m/z: 501.2; found 501.1.

#### Example 41

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylcarbonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0333]




[0334] This compound was prepared using procedures analogous to those for *Example 40*, Step 3 with morpholine replacing 1-methylpiperazine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{23}H_{24}F_2N_5O_5$   $[M+H]^+$  m/z: 488.2; found: 488.2.

#### Example 42

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-8-[(4,4-difluoropiperidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0335]




[0336] This compound was prepared using procedure analogous to those for *Example 40*, Step 3 with 4,4-difluoropiperidine hydrochloride replacing 1-methylpiperazine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{24}H_{24}F_4N_5O_4$   $[M+H]^+$  m/z: 522.2; found: 522.1.

## Example 43


3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-9-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0337]



Step 1: 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0338]



[0339] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (168.0 mg, 0.4488 mmol) in N,N-dimethylformamide (4 mL) was added a solution of N-bromo-succinimide (88 mg, 0.49 mmol) in N,N-dimethylformamide (0.56 mL) dropwise at 0 °C. The resulting solution was stirred at room temperature for 2 h. The reaction was quenched with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed under reduced pressure to afford the desired compound which was used in the next step without further purification. LC-MS calculated for C<sub>18</sub>H<sub>16</sub>BrF<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 453.0; found: 453.1.

Step 2: *tert*-butyl 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydro-7H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-7-carboxylate

[0340]



[0341] To a stirred solution of 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (200 mg, 0.4 mmol) in methylene chloride (3 mL) was added di-*tert*-butyl carbonate (180 mg, 1.0 mmol) and 4-dimethylaminopyridine (10.8 mg, 0.088 mmol). The resulting solution was stirred at

room temperature for 2 h at which time LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated and the residue was purified by flash chromatography on a silica gel column eluting with 10% AcOEt in CH<sub>2</sub>Cl<sub>2</sub> to afford the desired compound (170 mg, 70 %). LC-MS calculated for C<sub>23</sub>H<sub>24</sub>BrF<sub>2</sub>N<sub>4</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 553.1; found: 553.0.

5

*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-9-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0342]** A mixture of tert-butyl 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydro-7H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-7-carboxylate (35.0 mg, 0.063 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (26 mg, 0.13 mmol), bis(tri-*t*-butylphosphine)palladium (6 mg, 0.01 mmol), and *N,N*-diisopropylethylamine (33 μL, 0.19 mmol) in 1,4-dioxane (1.7 mL) and water (0.2 mL) was degassed then filled with nitrogen. After stirring at 120 °C for 2 h, the reaction mixture was filtered and concentrated to dryness. The residue was dissolved in TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1, 1 mL) and stirred at room temperature for 1 h. The reaction mixture was concentrated and the residue was dissolved in MeOH and purified by RP-HPLC (pH = 2) to afford the desired product. LC-MS calculated for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 455.2; found: 455.1.

15


#### Example 44

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

20

#### [0343]

25




30

*Step 1: 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

35

#### [0344]

40



45

**[0345]** This compound was prepared by using procedures analogous to those described for the synthesis of *Example 39, Steps 1-3*, with 4-(allylamino)-1H-pyrrolo[2,3-*b*]pyridine-5-carbaldehyde (prepared according to *Example 1, Step 1*) replacing 4-(methylamino)-1H-pyrrolo[2,3-*b*]pyridine-5-carbaldehyde. LC-MS calculated for C<sub>20</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 401.1; found: 401.1.


50

*Step 2: 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

55

#### [0346]


EP 2 861 595 B9



**[0347]** To a solution of 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (0.35 g, 0.89 mmol) in DMF (4 mL) was added sodium hydride ((60% dispersion in mineral oil, 0.053 g, 1.3 mmol) at 0 °C. The mixture was stirred for 20 minutes then benzenesulfonyl chloride (0.14 mL, 1.1 mmol) was added and the reaction was stirred for another 1 h at 0 °C. The mixture was diluted with water and the formed precipitate was collected via filtration then washed with water and dried to provide the desired product. LC-MS calculated for  $C_{26}H_{23}F_2N_4O_5S$   $[M+H]^+$  m/z: 541.1; found: 541.1.

Step 3. [3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]acetaldehyde

**[0348]**




**[0349]** To a solution of 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (120 mg, 0.22 mmol) in tert-butyl alcohol (2 mL) was added N-methylmorpholine N-oxide (28.6 mg, 0.244 mmol) and water (0.70 mL, 39 mmol). To this solution was then added aqueous osmium tetroxide (0.070 mL, 0.011 mmol, 4%). Another portion of N-methylmorpholine N-oxide (28.6 mg, 0.244 mmol) was added after 3 h. The reaction mixture was stirred at room temperature for 3 days. The solution was diluted with water, extracted with methylene chloride. The combined organic layers were dried over  $MgSO_4$ , filtered then concentrated.

**[0350]** The residue was dissolved in THF (1.7 mL) / water (0.83 mL) and then sodium periodate (0.14 g, 0.66 mmol) was added, followed by acetic acid (0.0032 mL, 0.055 mmol) at 0 °C. After stirring for 2 h, the reaction mixture was diluted with water, extracted with methylene chloride. The organic layer was washed with brine, dried over  $MgSO_4$ , filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/ $CH_2Cl_2$  (0 to 20%). LC-MS calculated for  $C_{25}H_{21}F_2N_4O_6S$   $[M+H]^+$  m/z: 543.1; found: 543.1.

Step 4. 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0351]**



**[0352]** To a solution of [3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl] acetaldehyde (50.0 mg, 0.0922 mmol) in methanol (1.5 mL) was added sodium tetrahydroborate (7.0 mg, 0.18 mmol). After stirring at room temperature for 30 min, the mixture was diluted with methylene chloride then washed with saturated aqueous solution of NaHCO<sub>3</sub>, water, and brine, and then the mixture was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to provide the product which was used in the next step directly. LC-MS calculated for C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S [M+H]<sup>+</sup> m/z: 545.1; found: 545.1.


*Step 5. 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0353]** 6.0 M Potassium hydroxide in water (0.1 mL, 0.6 mmol) was added to a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (30.0 mg, 0.0551 mmol) in THF (0.6 mL) and then the mixture was stirred at 70 °C overnight. The product was purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for C<sub>19</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 405.1; found: 405.2. <sup>1</sup>H NMR (400 MHz, DMSO) δ 12.03 (s, 1H), 8.03 (s, 1H), 7.54 (s, 1H), 7.04 (t, J = 8.0 Hz, 3H), 6.73 (s, 1H), 4.78 (s, 2H), 4.23 (t, J = 6.8 Hz, 2H), 3.89 (s, 6H), 3.70 (t, J = 6.8 Hz, 2H).

#### Example 45


**1-Cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0354]**



*Step 1: N-[(1E)-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methylene]-2,6-difluoro-3,5-dimethoxyaniline*

**[0355]**




EP 2 861 595 B9

**[0356]** A mixture of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (5.00 g, 27.7 mmol), 2,6-difluoro-3,5-dimethoxyaniline (6.3 g, 33 mmol) and p-toluenesulfonic acid monohydrate (1.1 g, 5.8 mmol) in toluene (300 mL) was heated to reflux with azeotropic removal of water via a Dean-Stark trap. After stirred for overnight, the reaction mixture was concentrated and the residue was used in the next step without further purification.

*Step 2: N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline*


**[0357]**



**[0358]** The crude product from *Step 1* was dissolved in tetrahydrofuran (300 mL) and cooled to 0 °C then LiAlH<sub>4</sub> (3.6 g, 96 mmol) was added. The reaction mixture was warmed to 50 °C and stirred overnight. The reaction was then quenched with a minimum amount of water and diluted with ethyl acetate. The mixture was filtered through Celite and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with methanol in dichloromethane (0-5%) to afford the desired product (7.00 g, 71.5%). LC-MS calculated for C<sub>16</sub>H<sub>15</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> m/z: 354.1; found 354.0.

*Step 3: N-cyclopropyl-5-[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl-1H-pyrrolo[2,3-b]pyridin-4-amine*

**[0359]**



**[0360]** A mixture of of N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (0.25 g, 0.71 mmol), cyclopropylamine (0.088 mL, 1.3 mmol), palladium acetate (16 mg, 0.071 mmol), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (44 mg, 0.071 mmol), and cesium carbonate (0.70 g, 2.1 mmol) in 1,4-dioxane (10 mL) was degassed then filled with nitrogen. After stirring at 160 °C overnight, the reaction mixture was diluted with ethyl acetate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with MeOH in DCM (0-5%) to afford the desired product (0.17 g, 64 %). LC-MS calculated for C<sub>19</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> m/z: 375.2; found 375.1.

*Step 4: 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0361]** Triphosgene (0.20 g, 0.6 mmol) was added to a solution of N-cyclopropyl-5-[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl-1H-pyrrolo[2,3-b]pyridin-4-amine (0.17 g, 0.44 mmol) and triethylamine (590 μL, 4.2 mmol) in tetrahydrofuran (5 mL) at 0 °C. The reaction mixture was stirred at room temperature for 30 min, then 2 N NaOH (2.0 mL) was added. After stirring at room temperature for 1 h, the reaction mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with MeOH in DCM (0-5%) to afford the desired product. LC-MS calculated for C<sub>20</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 401.1; found 401.1. <sup>1</sup>H NMR (400 MHz, DMSO)


## EP 2 861 595 B9

$\delta$  11.97 (s, 1H), 8.04 (s, 1H), 7.52 - 7.46 (m, 1H), 7.03 (t,  $J = 8.2$  Hz, 1H), 6.97 - 6.93 (m, 1H), 4.66 (s, 2H), 3.88 (s, 6H), 3.38 - 3.28 (m, 1H), 1.13 - 1.03 (m, 2H), 0.70 - 0.62 (m, 2H).

### Example 46

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0362]




[0363] This compound was prepared using procedures analogous to those for *Example 45* with tetrahydro-2H-pyran-4-amine replacing cyclopropylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{22}H_{23}F_2N_4O_4$   $[M+H]^+$  m/z: 445.2; found 445.0.  $^1H$  NMR (300 MHz, DMSO)  $\delta$  11.95 (s, 1H), 8.03 (s, 1H), 7.56 - 7.49 (m, 1H), 7.03 (t,  $J = 8.2$  Hz, 1H), 6.45 - 6.36 (m, 1H), 4.69 (s, 2H), 4.48 - 4.32 (m, 1H), 4.03 - 3.92 (m, 2H), 3.88 (s, 6H), 3.52 - 3.37 (m, 2H), 2.82 - 2.62 (m, 2H), 1.94 - 1.83 (m, 2H).

### Example 47

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-phenyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0364]




[0365] This compound was prepared using procedures analogous to those for *Example 45* with aniline replacing cyclopropylamine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{23}H_{19}F_2N_4O_3$   $[M+H]^+$  m/z: 437.1; found 437.1.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  11.81 (s, 1H), 8.11 (s, 1H), 7.57 - 7.51 (m, 3H), 7.50 - 7.44 (m, 2H), 7.13 - 7.09 (m, 1H), 7.06 (t,  $J = 8.2$  Hz, 1H), 4.99 (s, 2H), 4.31 - 4.27 (m, 1H), 3.89 (s, 6H).

### Example 48

1-Cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0366]

EP 2 861 595 B9




**[0367]** This compound was prepared using procedures analogous to those for *Example 37* with 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 45*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. Purified by RP-HPLC (pH = 10) to afford the desired product as a white solid. LC-MS calculated for  $C_{20}H_{19}F_2N_4O_4$   $[M+H]^+$  m/z: 417.1; found 417.0.  $^1H$  NMR (300 MHz, DMSO)  $\delta$  11.03 (s, 1H), 7.82 (s, 1H), 7.02 (t,  $J$  = 8.2 Hz, 1H), 4.48 (s, 2H), 3.99 (s, 2H), 3.87 (s, 6H), 3.14 - 3.00 (m, 1H), 1.08 - 0.94 (m, 2H), 0.69 - 0.58 (m, 2H).

**Example 49**


**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

**[0368]**



*Step 1: 4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde*


**[0369]**



**[0370]** A mixture of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (CAS # 958230-19-8, Lakestar Tech, Lot: 124-132-29: 3.0 g, 17 mmol) and ethylamine (10M in water, 8.3 mL, 83 mmol) in 2-methoxyethanol (20 mL, 200 mmol) was heated to 130 °C and stirred overnight. The mixture was cooled to room temperature then concentrated under reduced pressure. The residue was treated with 1N HCl (30 mL) and stirred at room temperature for 1 h then neutralized with saturated  $NaHCO_3$  aqueous solution. The precipitate was collected via filtration then washed with water and dried to provide the desired product (2.9 g, 92 %). LC-MS calculated for  $C_{10}H_{12}N_3O$   $[M+H]^+$  m/z: 190.1; found: 190.1.

*Step 2: 5-[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl]-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine*


**[0371]**



5  
10  
15  
20  
[0372] A mixture of 4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (7.0 g, 37 mmol), 2,6-difluoro-3,5-dimethoxyaniline (9.1 g, 48 mmol) and [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid (Aldrich, cat# 21360: 2 g, 7 mmol) in xylenes (250 mL) was heated to reflux with azeotropic removal of water using Dean-Stark for 2 days at which time LC-MS showed the reaction was complete. The mixture was cooled to room temperature and the solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (500 mL) and then 2.0 M lithium tetrahydroaluminate in THF (37 mL, 74 mmol) was added slowly and the resulting mixture was stirred at 50 °C for 3 h then cooled to room temperature. The reaction was quenched by addition of water, 15% aqueous NaOH and water. The mixture was filtered and washed with THF. The filtrate was concentrated and the residue was washed with CH<sub>2</sub>Cl<sub>2</sub> and then filtered to get the pure product (11 g, 82 %). LC-MS calculated for C<sub>18</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> m/z: 363.2; found: 363.1.

Step 3: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

25 [0373]



30  
35  
40  
45  
[0374] A solution of triphosgene (5.5 g, 18 mmol) in tetrahydrofuran (30 mL) was added slowly to a mixture of 5-[[2,6-difluoro-3,5-dimethoxyphenyl]amino]methyl)-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine (5.6 g, 15 mmol) in tetrahydrofuran (100 mL) at 0 °C and then the mixture was stirred at room temperature for 6 h. The mixture was cooled to 0 °C and then 1.0 M sodium hydroxide in water (100 mL, 100 mmol) was added slowly. The reaction mixture was stirred at room temperature overnight and the formed precipitate was collected via filtration, washed with water, and then dried to provide the first batch of the purified desired product. The organic layer in the filtrate was separated and the aqueous layer was extracted with methylene chloride. The combined organic layer was concentrated and the residue was triturated with methylene chloride then filtered and dried to provide another batch of the product (total 5.5 g, 92 %). LC-MS calculated for C<sub>19</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 389.1; found: 389.1.

Step 4: 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

50  
55  
[0375] To a mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (3.0 g, 7.7 mmol) in isopropyl alcohol (70 mL, 900 mmol)/water (7 mL, 400 mmol) was added pyridinium tribromide (11 g, 31 mmol). Then the reaction mixture was stirred at 40 °C for 3 h. The mixture was cooled to room temperature and then acetic acid (10 mL, 200 mmol) and zinc (5.05 g, 77.2 mmol) were added. The resulting mixture was stirred at room temperature overnight then filtered. The filtrate was concentrated and the residue was triturated with water (100 mL)/AcCN (10 mL) and stirred for 30 min. The solid was collected via filtration then dried. The solid was then stirred with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100 mL/10 mL) for 30 min then filtered and dried to provide the pure desired product. The filtrate was concentrated and the residue was stirred with AcCN/Water (40 mL/5 mL) at 40 °C for 10 min then filtered and dried to provide another batch of pure product. LC-MS calculated for C<sub>19</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 405.1; found:


## EP 2 861 595 B9

405.2.  $^1\text{H}$  NMR (500 MHz,  $\text{DMSO-}d_6$ ):  $\delta$  1.19 (t, 3H), 3.86 (m, 2H), 3.88 (s, 6H), 3.90 (m, 2H), 4.61 (s, 2H), 7.03(m, 1H), 7.83 (s, 1H), 11.01 (s, 1H) ppm.

### Example 50

1-(Cyclopropylmethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0376]




[0377] This compound was prepared by using procedure analogous to those described for the synthesis of *Example 49* with 4-(cyclopropylmethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (prepared according to *Example 1, Step 1*) replacing 4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde. LC-MS calculated for  $\text{C}_{21}\text{H}_{21}\text{F}_2\text{N}_4\text{O}_4$   $[\text{M}+\text{H}]^+$   $m/z$ : 431.2; found: 431.1.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  11.03 (s, 1H), 7.85 (s, 1H), 7.04 (t,  $J = 8.1$  Hz, 1H), 4.62 (s, 2H), 3.19 - 3.87 (m, 8H), 3.83 (d,  $J = 6.6$  Hz, 2H), 1.16 - 1.07 (m, 1H), 0.50 - 0.43 (m, 2H), 0.31 - 0.24 (m, 2H).

### Example 51


3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0378]



Step 1: 5-[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl-1-(4-methoxybenzyl)-N-methyl-1H-pyrazolo[3,4-b]pyridin-4-amine


[0379]



**[0380]** This compound was prepared using procedures analogous to those for *Example 39, Steps 1-2*, from 1-(4-methoxybenzyl)-4-(methylamino)-1H-pyrazolo[3,4-b]pyridine-5-carbaldehyde (Prepared by the same method as described in WO 2007/134259). The crude mixture was purified by flash column (MeOH/DCM, 3%~20%) to afford the aniline as a white solid. LC-MS calculated for  $C_{24}H_{26}F_2N_5O_3$   $[M+H]^+$  m/z: 470.2; found 470.2.

*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(4-methoxybenzyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0381]**



**[0382]** This compound was prepared using procedures analogous to those for *Example 39, Step 3*. The product was purified by flash column (EtOAc/hexanes, 30%~80%) to afford the urea as a white solid. LC-MS calculated for  $C_{25}H_{24}F_2N_5O_4$   $[M+H]^+$  m/z: 496.2; found 496.1.


*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0383]** A solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(4-methoxybenzyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (300 mg, 0.6 mmol) in TFA (4.0 mL) was heated to 70 °C for 2 h. The solution was cooled to room temperature and concentrated under reduced pressure. The residue was purified by RP-HPLC (pH 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{17}H_{16}O_3N_5F_2$   $[M+H]^+$  m/z: 376.1; found 376.1.  $^1H$  NMR (300 MHz, DMSO)  $\delta$  13.67 (s, 1H), 8.41 (s, 1H), 8.24 (s, 1H), 7.06 (t,  $J = 8.2$  Hz, 1H), 4.83 (s, 2H), 3.89 (s, 6H), 3.66 (s, 3H).

## Example 52


**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1,9-dimethyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0384]**



Step 1: 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0385]**



**[0386]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (250.0 mg, 0.6661 mmol) in CH<sub>3</sub>CN (6.0 mL) at 0 °C was added N-bromosuccinimide (150 mg, 0.86 mmol). The mixture was stirred for 2 h before concentrated under reduced pressure. The residue was purified by column (MeOH/DCM, 3%~30%) to afford the product (300.0 mg, 99 %) as a white solid. LC-MS calculated for C<sub>17</sub>H<sub>15</sub>BrO<sub>3</sub>N<sub>5</sub>F<sub>2</sub> [M+H]<sup>+</sup> m/z: 454.0; found 454.1.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,9-dimethyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0387]** To a solution of 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (80.0 mg, 0.176 mmol) in 1,4-dioxane (2.0 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (20.0 mg, 0.0245 mmol). To this solution was added ZnMe<sub>2</sub> (0.50 mL, 2.0 M solution in toluene, 1.0 mmol). The resulting mixture was heated to 100 °C for 1 h before it was diluted with MeOH and purified by RP-HPLC (pH 2). LC-MS calculated for C<sub>18</sub>H<sub>18</sub>O<sub>3</sub>N<sub>5</sub>F<sub>2</sub> [M+H]<sup>+</sup> m/z: 390.1; found 390.1. <sup>1</sup>H NMR (300 MHz, DMSO) δ 8.22 (s, 1H), 7.03 (t, J = 9.0 Hz, 1H), 4.78 (s, 2H), 3.88 (s, 6H), 3.55 (s, 3H), 2.67 ppm (s, 3H).

**Example 53**

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidine-9-carbonitrile**

**[0388]**




**[0389]** To a solution of 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (15.0 mg, 0.033 mmol) in DMF (1.0 mL) was added zinc cyanide (12.0 mg, 0.099 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (5.0 mg, 0.007 mmol). The resulting mixture was heated to 180 °C for 1 h before it was diluted with MeOH and purified by RP-HPLC (pH 2). LC-MS calculated for C<sub>18</sub>H<sub>15</sub>O<sub>3</sub>N<sub>6</sub>F<sub>2</sub> [M+H]<sup>+</sup> m/z: 401.1; found 401.1.

#### Example 54

**[3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-9-yl]acetonitrile**

**[0390]**




**[0391]** To a mixture of (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (3.3 mg, 0.0057 mmol), tris(dibenzylideneacetone)dipalladium(0) (2.6 mg, 0.0029 mmol), 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (13.0 mg, 0.0286 mmol) in N,N-dimethylformamide (1.0 mL, 13 mmol) under an atmosphere of nitrogen was added (trimethylsilyl)acetonitrile (12 μL, 0.086 mmol), followed by zinc difluoride (5.9 mg, 0.057 mmol). The reaction mixture was stirred at 140 °C for 4.5 h under microwave conditions. The mixture was diluted with MeOH and purified by RP-HPLC (pH 2) to afford the product. LC-MS calculated for C<sub>19</sub>H<sub>17</sub>O<sub>3</sub>N<sub>6</sub>F<sub>2</sub> [M+H]<sup>+</sup> m/z: 415.1; found 415.1. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.82 (s, 1H), 8.26 (s, 1H), 7.04 (t, J = 8.1 Hz, 1H), 4.80 (s, 2H), 4.59 (s, 2H), 3.88 (s, 6H), 3.52 (s, 3H).

#### Example 55

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-9-(1-methylpiperidin-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0392]**




**[0393]** This compound was prepared from 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydro-pyridine using procedures analogous to those for *Examples 39, step 7-8*. The residue was purified by RP-HPLC (pH 2) to afford the product as a white solid. LC-MS calculated for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 473.2; found 473.2.

## Example 56

## 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-9-(2-hydroxyethyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0394]




[0395] A mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (13.6 mg, 0.0881 mmol) 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (20.0 mg, 0.0440 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complexed with dichloromethane (1:1) (5.4 mg, 0.0066 mmol) and potassium carbonate (18.0 mg, 0.13 mmol) in 1,4-dioxane (0.80 mL, 10. mmol) / water (0.20 mL, 11 mmol) was heated at 88 °C. After 1.5 h, the reaction was quenched with water, extracted with DCM, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude mixture was purified via flash column chromatography (MeOH/DCM, 3%~30%) to afford 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-9-vinyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one.

[0396] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-9-vinyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (17.0 mg, 0.036 mmol) in THF (1.0 mL) was added BH<sub>3</sub>-THF (0.40 mmol). The resulting mixture was stirred at room temperature for 12 h before it was quenched with NaOH (2 N, 0.2 mL) and H<sub>2</sub>O<sub>2</sub> (0.2 mL). The mixture was diluted with MeOH and purified by RP-HPLC (pH 2) to afford the product as a white solid. LC-MS calculated for C<sub>19</sub>H<sub>20</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 420.1; found 420.1.

## Example 57

## 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0397]




[0398] This compound was prepared using procedures analogous to those for Example 51. The residue was purified by RP-HPLC (pH 2) to afford the product as a white solid. LC-MS calculated for C<sub>18</sub>H<sub>18</sub>O<sub>3</sub>N<sub>5</sub>F<sub>2</sub> [M+H]<sup>+</sup> m/z: 390.1; found 390.1. <sup>1</sup>H NMR (300 MHz, DMSO) δ 13.71 (s, 1H), 8.29 (s, 1H), 8.23 (s, 1H), 7.06 (t, J = 8.2 Hz, 1H), 4.83 (s, 2H), 4.19 (q, J = 6.8 Hz, 2H), 3.89 (s, 6H), 1.32 (t, J = 6.8 Hz, 3H).

## Example 58

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0399]




[0400] This compound was prepared using procedures analogous to those for Example 44. The residue was purified by RP-HPLC (pH 2) to afford the product as a white solid. LC-MS calculated for  $C_{18}H_{18}O_4N_5F_2$   $[M+H]^+$  m/z: 406.1; found 406.1.

## Example 59


3'-(2,6-Difluoro-3,5-dimethoxyphenyl)-1'-methyl-4',7'-dihydrospiro [cyclopropane-1,9'-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine]-2',8'(1'H,3'H)-dione

[0401]



Step 1. 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0402]




[0403] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (0.10 g, 0.27 mmol) in DMF (0.8 mL) was added sodium hydride (60 wt % dispersion in mineral oil, 0.013 g, 0.32 mmol) at 0 °C and stirred for 20 minutes. Then (trimethylsilyl)ethoxymethyl chloride (0.057 mL, 0.32 mmol) was added and the reaction mixture was stirred for 1 h at 0 °C. The mixture was diluted with ethyl acetate and

then washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The product was isolated by chromatography eluted with 0 to 40 % EtOAc/CH<sub>2</sub>Cl<sub>2</sub>. LC-MS calculated for C<sub>24</sub>H<sub>31</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub>Si (M+H)<sup>+</sup> m/z: 505.2; found 505.2.

Step 2. 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-methyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0404]



[0405] Pyridinium tribromide (0.299 g, 0.841 mmol) was added to a mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (0.12 g, 0.24 mmol) in isopropyl alcohol (2 mL)/water (0.12 mL), and then the reaction mixture was stirred at 50 °C for 2 h. The mixture was cooled to room temperature and then acetic acid (0.9 mL) and zinc (0.157 g, 2.40 mmol) were added. The mixture was stirred for 6 h then filtered and the solvent was removed. The residue was diluted with methylene chloride, and then washed with saturated NaHCO<sub>3</sub>, water, and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then filtered and concentrated. The residue was purified by chromatography eluted with 0 to 50 % EtOAc/CH<sub>2</sub>Cl<sub>2</sub>. LC-MS calculated for C<sub>24</sub>H<sub>31</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub>Si (M+H)<sup>+</sup> m/z: 521.2; found: 521.1.


Step 3. 3'-(2,6-Difluoro-3,5-dimethoxyphenyl)-1'-methyl-4',7'-dihydrospiro[cyclopropane-1,9'-pyrrolo(3',2':5,6)pyrido[4,3-d]pyrimidine]-2',8'(1'H,3'H)-dione

[0406] Nitrogen was bubbled through a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione (100.0 mg, 0.192 mmol) in DMF (2.0 mL) for 20 minutes then cesium carbonate (190 mg, 0.58 mmol) and 1-bromo-2-chloroethane (48 μL, 0.58 mmol) were added under nitrogen. After stirred at room temperature overnight, the mixture was filtered and then the solvent was removed under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) and then TFA (0.8 mL) was added and the reaction mixture was stirred for 1 h. The solvent was removed and the residue was dissolved in methanol (2 mL) and then ethylenediamine (0.15 mL) was added and the mixture was stirred at room temperature for 2 h. The product was purified by prep-HPLC (pH 2). LC-MS calculated for C<sub>20</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 417.1; found: 417.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.31 (s, 1H), 7.90 (s, 1H), 7.01 (t, J = 8.1 Hz, 1H), 4.59 (s, 2H), 3.87 (s, 6H), 3.14 (s, 3H), 1.92 - 1.87 (m, 2H), 1.49 - 1.43 (m, 2H).

Example 60


7-(2,6-difluoro-3,5-dimethoxyphenyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0407]



Step 1. *N*-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline


[0408]



[0409] To a solution of *N*-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (0.35 g, 0.99 mmol) in DMF (3.0 mL) was added sodium hydride (60 wt % dispersion in mineral oil, 48 mg, 1.19 mmol) at 0 °C. The mixture was stirred for 20 minutes then trimethylsilylethoxymethyl chloride (0.210 mL, 1.19 mmol) was added and the reaction mixture was stirred for 1 h at 0 °C. The mixture was diluted with ethyl acetate and then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was isolated by chromatography eluted with 0 to 10 % EtOAc/CH<sub>2</sub>Cl<sub>2</sub>. LC-MS calculated for C<sub>22</sub>H<sub>29</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Si (M+H)<sup>+</sup> m/z: 484.2; found: 484.2.

Step 2. 7-(2,6-Difluoro-3,5-dimethoxyphenyl)-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8*H*-pyrrolo[2,3-*c*]-2,7-naphthyridin-8-one

[0410]



[0411] Preparation of potassium ethyl malonate: A 100 mL two-necked round-bottom flask was charged with diethyl malonate (22.0 mmol), water (20.5 mmol) and ethanol (20 mL), and then the reaction mixture was stirred at 40 °C. A solution of potassium *tert*-butoxide (2.24 g, 20.0 mmol) in ethanol (20 mL) was added dropwise over 30 minutes. After completion of addition, the reaction mixture was stirred at 40 °C until consumption of the starting material. The reaction mixture was concentrated then diethyl ether (20 mL) was added. The resulting solid was collected by filtration, washed sequentially with 1:1 mixture of diethyl ether and ethanol, then diethyl ether. The solid was dried to give the potassium salt.

[0412] A mixture of *N*-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (200.0 mg, 0.4132 mmol), potassium ethyl malonate (140 mg, 0.83 mmol), dicyclohexyl(2',6'-diisopropoxybiphenyl-2-yl)phosphine (5.8 mg, 0.012 mmol) and  $\pi$ -allylpalladium chloride dimer (14 mg, 0.037 mmol) in mesitylene (2.0 mL) was evacuated and refilled with nitrogen for 3 times. The reaction mixture was stirred at 160 °C overnight. The mixture was cooled to room temperature and filtered then washed with ethyl acetate. The filtrate was concentrated. The residue was purified by chromatography eluted with 0 to 40 % EtOAc/CH<sub>2</sub>Cl<sub>2</sub>. LC-MS calculated for C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>Si (M+H)<sup>+</sup> m/z: 490.2; found: 490.2.

Step 3. 7-(2,6-Difluoro-3,5-dimethoxyphenyl)-3,6,7,9-tetrahydro-8*H*-pyrrolo[2,3-*c*]-2,7-naphthyridin-8-one


[0413] Trifluoroacetic acid (1.0 mL) was added to a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8*H*-pyrrolo[2,3-*c*]-2,7-naphthyridin-8-one (60.0 mg, 0.122 mmol) in methylene chloride (1.0 mL). The mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved

in methanol (1.0 mL) then ethylenediamine (0.2 mL) was added. The mixture was stirred at room temperature for overnight. The product was purified by prep-HPLC (pH 2). LC-MS calculated for  $C_{18}H_{16}F_2N_3O_3$  (M+H)<sup>+</sup> m/z: 360.1; found: 360.2. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  11.77 (s, 1H), 8.17 (s, 1H), 7.53 - 7.48 (m, 1H), 7.05 (t, *J* = 8.2 Hz, 1H), 6.64 - 6.60 (m, 1H), 4.90 (s, 2H), 4.06 (s, 2H), 3.89 (s, 6H).

**Example 61**


**7-(2,6-difluoro-3,5-dimethoxyphenyl)-9-methyl-3,6,7,9-tetrahydro-8H-imidazo[4',5':5,6]pyrido[4,3-d]pyrimidin-8-one**

[0414]



Step 1: 6-bromo-7-chloro-3-[[2-(trimethylsilyl)ethoxy]methyl]-3H-imidazo[4,5-b]pyridine


[0415]



[0416] To a solution of 6-bromo-7-chloro-3H-imidazo[4,5-b]pyridine (560 mg, 2.4 mmol, PharmaBlock Inc., Cat# PB02862) in *N,N*-dimethylformamide (10 mL) was added sodium hydride (60% NaH dispersion in mineral oil, 125 mg, 3.13 mmol) portion-wise at 0 °C. The resulting mixture was stirred at 0 °C for 30 minutes. Then [ $\beta$ -(Trimethylsilyl)ethoxy]methylchloride (0.51 mL, 2.89 mmol) was added and the reaction mixture was stirred for 2 h at 0 °C. The reaction was quenched with saturated  $NH_4Cl$  aqueous solution then extracted with ethyl acetate. The organic layer was washed with water, brine then dried over  $Na_2SO_4$  and concentrated. The residue was purified by chromatography on a silica gel column eluted with 0 to 10 % EtOAc/DCM to afford the desired product (615 mg, 70 %) as a yellow oil. LC-MS calculated for  $C_{12}H_{18}BrClN_3OSi$  [M+H]<sup>+</sup> m/z: 362.0; found: 362.0.

Step 2: 7-chloro-3-[[2-(trimethylsilyl)ethoxy]methyl]-6-vinyl-3H-imidazo[4,5-b]pyridine

[0417]




[0418] A solution of 6-bromo-7-chloro-3-[[2-(trimethylsilyl)ethoxy]methyl]-3H-imidazo[4,5-b]pyridine (615 mg, 1.70 mmol), 4-methyl-2,6-dioxo-8-vinyltetrahydro[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-4-ium-8-uide (326 mg, 1.78 mmol), potassium carbonate (470 mg, 3.4 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium (II) (Aldrich, Cat# 678740; 36 mg, 0.05mmol) in 1,4-dioxane (9 mL, 100 mmol) and water (1 mL, 60 mmol) was evacuated then filled with nitrogen for three times. The resulting mixture was heated to 95 °C and stirred for 5 h, at which

## EP 2 861 595 B9

time LC-MS indicated the reaction was complete. The mixture was cooled to room temperature, diluted with EtOAc then washed with water and brine. The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by chromatography on a silica gel column eluted with 0 to 10 % EtOAc/DCM to afford the desired product (454 mg, 86 %) as a yellow oil. LC-MS calculated for  $\text{C}_{14}\text{H}_{21}\text{ClN}_3\text{OSi}$   $[\text{M}+\text{H}]^+$   $m/z$ : 310.1; found: 310.0.

Step 3: 7-chloro-3-[[2-(trimethylsilyl)ethoxy]methyl]-3H-imidazo[4,5-b]pyridine-6-carbaldehyde


### [0419]



[0420] To a solution of 7-chloro-3-[[2-(trimethylsilyl)ethoxy]methyl]-6-vinyl-3H-imidazo[4,5-b]pyridine (454 mg, 1.46 mmol) in *tert*-butyl alcohol (10 mL, 100 mmol) and water (2 mL, 100 mmol) was added N-methylmorpholine N-oxide (257 mg, 2.20 mmol), followed by Osmium tetroxide (4wt % in water, 0.46 mL, 0.073 mmol). The reaction mixture was stirred at room temperature for overnight. The mixture was then diluted with water and extracted with EtOAc. The organic layer was washed with brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was dissolved in tetrahydrofuran (11 mL, 140 mmol) and water (5.5 mL, 3.0E2 mmol) then cooled to 0 °C. To the solution was added sodium periodate (940 mg, 4.4 mmol) and acetic acid (21  $\mu\text{L}$ , 0.37 mmol). After stirred at 0 °C for 2 h, the reaction mixture was diluted with water then extracted with EtOAc. The organic layer was washed with brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by chromatography on a silica gel column eluted with 0 to 20 % EtOAc/DCM to afford the desired product (290 mg, 63 %) as a white solid. LC-MS calculated for  $\text{C}_{13}\text{H}_{19}\text{ClN}_3\text{O}_2\text{Si}$   $[\text{M}+\text{H}]^+$   $m/z$ : 312.1; found: 312.0.

Step 4: 7-(methylamino)-3H-imidazo[4,5-b]pyridine-6-carbaldehyde

### [0421]




[0422] To a solution of 7-chloro-3-[[2-(trimethylsilyl)ethoxy]methyl]-3H-imidazo[4,5-b]pyridine-6-carbaldehyde (225 mg, 0.722 mmol) in 2-methoxyethanol (2 mL) was added methylamine (33wt % in EtOH, 2 mL, 16 mmol). The mixture was stirred at 110 °C in a sealed tube overnight. The mixture was concentrated and the residue was dissolved in 10 mL 0.5 N HCl and stirred at room temperature for 1 h. The mixture was neutralized with saturated  $\text{NaHCO}_3$  aqueous solution. The resulting white precipitate was collected via filtration then dried.

The above solid was dissolved in 3 mL DCM and 3 mL TFA was added. The resulting clear solution was stirred at room temperature for 1 h. The reaction mixture was concentrated then dried in vacuo. The crude product was used in the next step without further purification. LC-MS calculated for  $\text{C}_8\text{H}_9\text{N}_4\text{O}$   $[\text{M}+\text{H}]^+$   $m/z$ : 177.1; found: 177.1.

Step 5: 6-[[2,6-difluoro-3,5-dimethoxyphenyl]amino]methyl]-N-methyl-3H-imidazo[4,5-b]pyridin-7-amine

### [0423]



5  
10  
15  
20  
[0424] A mixture of 7-(methylamino)-3H-imidazo[4,5-b]pyridine-6-carbaldehyde (100 mg, 0.6 mmol), 2,6-difluoro-3,5-dimethoxyaniline (160 mg, 0.85 mmol) and D-(+)-10-camphorsulfonic acid (40 mg, 0.2 mmol) in toluene (20 mL, 200 mmol) was heated to reflux with azeotropic removal of water with a Dean-Stark trap. The mixture was refluxed for 24 h then cooled to room temperature and concentrated. The residue was dissolved in tetrahydrofuran (15 mL, 180 mmol) and cooled to 0 °C then lithium tetrahydroaluminate (75 mg, 2.0 mmol) was added portion-wise. The reaction mixture was warmed to 45 °C and stirred for 1 h. The reaction was quenched by addition of 0.1 mL of water then 0.1 mL of 15 % NaOH solution followed by 0.3 mL of water. The mixture was stirred for 10 min then filtered. The filtrate was concentrated and the residue was purified by column eluted with 0 to 10 % MeOH/DCM to afford the desired product (155 mg, 80 %) as a yellow solid. LC-MS calculated for C<sub>16</sub>H<sub>18</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M+H]<sup>+</sup> m/z: 350.1; found: 350.0.


Step 6: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9-methyl-3,6,7,9-tetrahydro-8H-imidazo[4,5-b]pyrido[4,3-d]pyrimidin-8-one

25  
30  
[0425] To the solution of 6-((2,6-difluoro-3,5-dimethoxyphenyl)amino)methyl-Nmethyl-3H-imidazo[4,5-b]pyridin-7-amine (155 mg, 0.44 mmol) in tetrahydrofuran (5 mL, 60 mmol) was added triethylamine (0.31 mL, 2.2 mmol), followed by triphosgene (140 mg, 0.49 mmol). The resulting yellow suspension was stirred at room temperature for 1 h then 5 mL of 1N NaOH aqueous solution was added. After stirred at room temperature for 30 min, the mixture was diluted with EtOAc. The organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was dissolved in MeOH and purified by prep HPLC (pH 2, ACN/water) to give the desired product as a white solid. LC-MS calculated for C<sub>17</sub>H<sub>16</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 376.1; found: 376.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.41 (s, 1H), 8.10 (s, 1H), 7.05 (t, J = 8.2 Hz, 1H), 4.83 (s, 2H), 3.89 (s, 6H), 3.85 (s, 3H).

### Example 62


35  
3-((2,6-difluoro-3,5-dimethoxyphenyl)-4,7-dihydropyrazolo[4',3':5,6]pyrido[3,4-e] [1,3]oxazin-2(3H)-one

[0426]



40  
45  
50  
Step 1: 4-chloro-5-(chloromethyl)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine

[0427]




EP 2 861 595 B9

**[0428]** To a stirred solution of [4-chloro-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methanol (2.70 g, 8.9 mmol) (Lakestar Tech: Lot #123-017-22) in methylene chloride (30 mL, 500 mmol) were added *N,N*-diisopropylethylamine (3.10 mL, 17.8 mmol) and methanesulfonyl chloride (820  $\mu$ L, 11 mmol) sequentially at 0 °C. After 15 minutes, the reaction mixture was warmed up to room temperature. After another 2 hours, the reaction was quenched with saturated aq. NaHCO<sub>3</sub>, then extracted with methylene chloride. The combined organic layers were dried over MgSO<sub>4</sub>, and then concentrated. The residue (2.50 g) was used directly in the next step without further purification. LC-MS calculated for C<sub>15</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>3</sub>O (M+H)<sup>+</sup>: m/z = 322.1; Found: 322.1.

Step 2: *N*-[4-chloro-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methyl]-2,6-difluoro-3,5-dimethoxyaniline


**[0429]**



**[0430]** A stirred slurry of 2,6-difluoro-3,5-dimethoxyaniline (0.88 g, 4.6 mmol) and 4-chloro-5-(chloromethyl)-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridine (1.00 g, 3.10 mmol) in *N,N*-diisopropylethylamine (15 mL) was heated to 90 °C. After 8 hours, the volatiles were removed under reduced pressure and the residue was purified on flash column (eluting with 0-45% EtOAc in hexanes) to afford the desired product as a white solid (1.02 g, 71%). LC-MS calculated for C<sub>23</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>3</sub> (M+H)<sup>+</sup>: m/z = 475.1; Found: 475.1.

Step 3: *N*-[4-(allyloxy)-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methyl]-2,6-difluoro-3,5-dimethoxyaniline


**[0431]**



**[0432]** To a stirred solution of 2-propen-1-ol (43  $\mu$ L, 0.63 mmol) in *N,N*-dimethylformamide (9 mL, 100 mmol) was added sodium hydride (60 wt % in mineral oil, 34 mg, 0.84 mmol) at 0 °C. After 15 minutes, *N*-[4-chloro-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methyl]-2,6-difluoro-3,5-dimethoxyaniline (200 mg, 0.4 mmol) was added and the resulted mixture was heated to 100 °C. After stirred at 100 °C for 30 minutes, the reaction mixture was cooled to room temperature and quenched with saturated aq. NH<sub>4</sub>Cl, then extracted with methylene chloride. The combined organic layers were dried over MgSO<sub>4</sub>, and then concentrated. The residue (0.2 g, 96%) was used directly in the next step without further purification. LC-MS calculated for C<sub>26</sub>H<sub>27</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> (M+H)<sup>+</sup>: m/z = 497.2; Found: 497.1

Step 4: {[4-(allyloxy)-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methyl}(2,6-difluoro-3,5-dimethoxyphenyl)carbamate chloride

**[0433]**



5

10 **[0434]** To a stirred solution of *N*-[[4-(allyloxy)-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methyl]-2,6-difluoro-3,5-dimethoxyaniline (150 mg, 0.30 mmol) in THF (6 mL) were added triethylamine (84.2  $\mu$ L, 0.604 mmol) and triphosgene (134 mg, 0.453 mmol) sequentially at room temperature. After 3 hours, the reaction mixture was quenched with saturated aq.  $\text{NH}_4\text{Cl}$ , then extracted with methylene chloride. The combined organic layers were dried over  $\text{MgSO}_4$ , and then concentrated. The residue (0.16 g, 95%) was used directly in the next step without further purification. LC-MS calculated for  $\text{C}_{27}\text{H}_{25}\text{ClF}_2\text{N}_4\text{O}_5$  ( $\text{M}+\text{H}$ )<sup>+</sup>:  $m/z = 559.2$ ; Found: 559.2.

15

*Step 5: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-4,7-dihydropyrazolo[4;3':5,6]pyrido[3,4-*e*][1,3]oxazin-2(3*H*)-one*

20 **[0435]** To a stirred solution of crude {[4-(allyloxy)-1-(4-methoxybenzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-5-yl]methyl}(2,6-difluoro-3,5-dimethoxyphenyl)carbamic chloride (0.16 g, 0.287 mmol) in THF (0.5 mL) /1-propanol (3 mL, 40 mmol) was added rhodium chloride trihydrate (7.95 mg, 0.0302 mmol). The mixture was then warmed up to 90 °C. After 2 hours, the reaction was quenched with saturated aq.  $\text{NH}_4\text{Cl}$ , then extracted with methylene chloride. The combined organic layers were dried over  $\text{MgSO}_4$ , and then concentrated. The residue was dissolved in trifluoroacetic acid (2 mL, 20 mmol) and was heated to 75 °C for 1 hour. The volatiles were then removed under reduced pressure and the residue was purified on RP-HPLC (XBridge C18 column, eluting with a gradient of acetonitrile/water containing 0.05% TFA, at flow rate of 60 mL/min) to give the desired product (50 mg, 46%) as its TFA salt. LC-MS calculated for  $\text{C}_{16}\text{H}_{13}\text{F}_2\text{N}_4\text{O}_4$  ( $\text{M}+\text{H}$ )<sup>+</sup>:  $m/z = 363.1$ ; Found: 363.1; <sup>1</sup>H NMR (500 MHz,  $\text{DMSO}-d_6$ ):  $\delta$  8.41(s, 1 H), 8.26 (s, 1 H), 7.14 (t,  $J = 10.0$  Hz, 1 H), 4.99 (s, 2 H), 3.92 (s, 6 H) ppm.


25

30

### Example 63

#### 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4,7,9-tetrahydro-1*H*-pyrrolo[3',2':5,6]pyrido[4,3-*d*]pyrimidine-2,8-dione

35 **[0436]**




40

45

*Step 1: N-(2-fluoro-3,5-dimethoxyphenyl)acetamide*

50 **[0437]**



55


**[0438]** To a solution of *N*-(3,5-dimethoxyphenyl)acetamide (14.8 g, 75.8 mmol) in acetonitrile (200 mL) was added

## EP 2 861 595 B9

1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane ditetrafluoroborate (Alfa Aesar, cat # L17003: 29 g, 81 mmol). The resulting suspension was stirred at room temperature overnight then concentrated under reduced pressure. The residue was dissolved in ethyl acetate (AcOEt) then washed with saturated NaHCO<sub>3</sub> aqueous solution and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then filtered and concentrated. The residue was purified by chromatography eluted with 0 to 50 % AcOEt in hexanes to give the desired product (7.8 g, 48 %). LC-MS calculated for C<sub>10</sub>H<sub>13</sub>FNO<sub>3</sub> (M+H)<sup>+</sup> m/z: 214.1; found 214.0.

Step 2: *N*-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)acetamide


[0439]



[0440] To a solution of *N*-(2-fluoro-3,5-dimethoxyphenyl)acetamide (3.50 g, 16.4 mmol) in acetonitrile (40 mL) was added sulfonyl chloride (1.3 mL, 16 mmol) dropwise at 0 °C. The resulting yellow solution was warmed to room temperature and stirred for 30 min. Then the reaction was quenched by dropwise addition of saturated NaHCO<sub>3</sub> solution (25 mL). The precipitate was collected via filtration then washed with water, and dried to afford the desired product (3.0 g, 77 %). LC-MS calculated for C<sub>10</sub>H<sub>12</sub>ClFNO<sub>3</sub> (M+H)<sup>+</sup> m/z: 248.0; found 248.0.

Step 3: *2-chloro-6-fluoro-3,5-dimethoxyaniline*


[0441]



[0442] To a solution of *N*-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)acetamide (3.0 g, 12 mmol) in ethanol (120 mL) was added 2.0 M potassium hydroxide in water (60 mL). The resulting solution was refluxed overnight then cooled to room temperature and concentrated to remove ethanol. The precipitate was collected via filtration then washed with water and hexanes, then dried to give the product (1.44 g, 58 %). LC-MS calculated for C<sub>8</sub>H<sub>10</sub>ClFNO<sub>2</sub> (M+H)<sup>+</sup> m/z: 206.0; found 206.1.

Step 4: *5-[(2-chloro-6-fluoro-3,5-dimethoxyphenyl)amino]methyl-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine*

[0443]




[0444] A mixture of 4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (Example 49, Step 1: 1.6 g, 8.3 mmol), 2-chloro-6-fluoro-3,5-dimethoxyaniline (1.7 g, 8.3 mmol) and [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid (Aldrich, cat # 21360: 0.6 g, 2 mmol) in toluene (200 mL, 2000 mmol) was heated to reflux with azotropic

## EP 2 861 595 B9

removal of water using a Dean-Stark trap for 4 days. The reaction mixture was cooled to room temperature and concentrated. The residue was dissolved in tetrahydrofuran (40 mL) and then lithium tetrahydroaluminate (0.78 g, 21 mmol) was added dropwise. The mixture was stirred at 50 °C for 3 h then cooled to room temperature. The reaction was quenched by addition of water (0.8 mL), 15 % aqueous NaOH (0.8 mL) then water (2.4 mL). The mixture was filtered and washed with THF. The filtrate was concentrated and the residue was purified by chromatography eluted with 0 to 5 % MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give the desired product (1.1 g, 35 %). LC-MS calculated for C<sub>18</sub>H<sub>21</sub>ClFN<sub>4</sub>O<sub>2</sub> (M+H)<sup>+</sup> m/z: 379.1; found 379.1.

Step 5: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

### [0445]



[0446] To a mixture of 5-[[2-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)amino]methyl]-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine (1.55 g, 4.09 mmol) in tetrahydrofuran (30 mL) at 0 °C was added triethylamine (2.8 mL, 20 mmol), followed by a solution of triphosgene (1.8 g, 6.1 mmol) in tetrahydrofuran (8 mL). The resulting mixture was stirred at room temperature for 3 h then cooled to 0 °C and then 1.0 M sodium hydroxide in water (30 mL) was added slowly. After stirring at room temperature overnight, the reaction mixture was then extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by chromatography eluted with 0 to 5 % MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give the desired product (1.1 g, 66 %). LC-MS calculated for C<sub>19</sub>H<sub>19</sub>ClFN<sub>4</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 405.1; found: 405.1.


Step 6: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0447] To a mixture of 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (1.14 g, 2.82 mmol) in isopropyl alcohol (10 mL, 100 mmol) and water (0.8 mL, 40 mmol) was added pyridinium tribromide (3.5 g, 9.8 mmol). The resulting mixture was stirred at 30 °C overnight then cooled to room temperature and acetic acid (10 mL, 200 mmol) and zinc (1.84 g, 28.2 mmol) were added. After stirring at room temperature for 2 h, the mixture was filtered and the filtrate was concentrated. The residue was titrated with water and the precipitate was collected via filtration then washed with water. The solid was purified by chromatography eluted with 0 to 5 % MeOH in CH<sub>2</sub>Cl<sub>2</sub> to give the desired product. LC-MS calculated for C<sub>19</sub>H<sub>19</sub>ClFN<sub>4</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 421.1; found: 421.0. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.02 (s, 1H), 7.83 (s, 1H), 7.01 (d, J = 7.7 Hz, 1H), 4.56 (s, 2H), 3.94 - 3.85 (m, 10 H), 1.19 (t, J = 7.0 Hz, 3H).

### Example 64


1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

### [0448]



Step 1: 1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0449]**



**[0450]** This compound was prepared using procedures analogous to those for *Example 45* with cyclobutylamine replacing cyclopropylamine. LC-MS calculated for  $C_{21}H_{21}F_2N_4O_3$  (M+H)<sup>+</sup> m/z: 415.2; found: 415.1.


Step 2: 1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

**[0451]** This compound was prepared using procedures analogous to those for *Example 63, Step 6* with 1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one replacing 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{21}H_{21}F_2N_4O_4$  (M+H)<sup>+</sup> m/z: 431.2; found: 431.1. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  11.00 (s, 1H), 7.86 (s, 1H), 7.02 (t, *J* = 8.2 Hz, 1H), 4.53 (s, 2H), 4.51 - 4.42 (m, 1H), 3.88 (s, 6H), 3.80 (s, 2H), 2.64 - 2.53 (m, 2H), 2.32 - 2.22 (m, 2H), 1.77 - 1.64 (m, 2H).

**Example 65**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorobenzyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

**[0452]**



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorobenzyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0453]



[0454] This compound was prepared using procedures analogous to those for *Example 45* with 1-(3-fluorophenyl)methanamine replacing cyclopropylamine. LC-MS calculated for  $C_{24}H_{20}F_3N_4O_3$  (M+H)<sup>+</sup> m/z: 469.1; found: 469.1.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorobenzyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3'2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0455] This compound was prepared using procedures analogous to those for *Example 63, Step 6* with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorobenzyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one replacing 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{24}H_{20}F_3N_4O_4$  (M+H)<sup>+</sup> m/z: 485.1; found: 485.0. <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.99 (s, 1H), 7.89 (s, 1H), 7.44 - 7.37 (m, 1H), 7.12 - 6.96 (m, 4H), 5.18 (s, 2H), 4.77 (s, 2H), 3.88 (s, 6H), 3.41 (s, 2H).

#### Example 66

7'-(2,6-difluoro-3,5-dimethoxyphenyl)-6',7'-dihydrospiro[cyclopropane-1,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one

[0456]




[0457] Nitrogen was bubbled through a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (40 mg, 0.082 mmol) in N,N-dimethylformamide (0.85 mL, 11 mmol) for 20 min and then cesium carbonate (80 mg, 0.24 mmol) and 1-bromo-2-chloro-ethane (20.3 μL, 0.245 mmol) were added under nitrogen. After stirred at room temperature overnight, the reaction mixture was filtered and then concentrated. The residue was dissolved in  $CH_2Cl_2$  (1 mL) and then TFA (1 mL) was added. After stirred at room temperature for 1 h, the mixture was concentrated and the residue was dissolved in methanol (2 mL) and then ethylene diamine (0.15 mL) was added. The mixture was stirred at room temperature for 2 h. The product was purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{20}H_{18}F_2N_3O_3$  (M+H)<sup>+</sup> m/z: 386.1; found: 386.1.

## Example 67

7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0458]




[0459] This compound prepared using procedures analogous to those for *Example 66* with methyl iodide replacing 1-bromo-2-chloroethane. The product was purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{20}H_{20}F_2N_3O_3$  (M+H)<sup>+</sup> m/z: 388.1; found: 388.0. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  11.82 (s, 1H), 8.12 (s, 1H), 7.56 - 7.46 (m, 1H), 7.07 (t, *J* = 8.2 Hz, 1H), 6.73 - 6.70 (m, 1H), 4.90 (s, 2H), 3.90 (s, 6H), 1.72 (s, 6H).

## Example 68


1-(4-chloro-2-fluorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0460]



Step 1: 1-(4-chloro-2-fluorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0461]



[0462] This compound was prepared using procedures analogous to those for *Example 45* with 4-chloro-2-fluoroaniline replacing cyclopropylamine. LC-MS calculated for  $C_{23}H_{17}ClF_3N_4O_3$  [M+H]<sup>+</sup> m/z: 489.1; found 489.0.

## EP 2 861 595 B9


Step 2: 1-(4-chloro-2-fluorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2,8-dione

[0463] This compound was prepared using procedures analogous to those for Example 63, Step 6 with 1-(4-chloro-2-fluorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one replacing 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{23}H_{17}ClF_3N_4O_4$  (M+H)<sup>+</sup> m/z: 505.1; found: 505.0. <sup>1</sup>H NMR (300 MHz, DMSO)  $\delta$  11.03 (s, 1H), 7.95 (s, 1H), 7.73 - 7.62 (m, 2H), 7.50 - 7.41 (m, 1H), 7.06 (t, *J* = 8.2 Hz, 1H), 4.93 (d, *J* = 14.0 Hz, 1H), 4.76 (d, *J* = 14.0 Hz, 1H), 3.88 (s, 6H), 2.58 - 2.34 (m, 2H).

### Example 69

3-(2,6-difluoro-3,5-dimethoxyphenyl)-9-[4-(4-ethylpiperazin-1-yl)phenyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0464]




[0465] To a solution of 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (30.0 mg, 0.066 mmol) and 1-ethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine (31.0 mg, 0.099 mmol) in 1,4-dioxane (0.75 mL) and water (0.25 mL) were added potassium carbonate (36.0 mg, 0.26 mmol) and tetrakis(triphenylphosphine)palladium(0) (7.6 mg, 0.0066 mmol). The resulting mixture was heated to 100 °C for 12 h before it was diluted with MeOH and purified by RP-HPLC (pH 2). LC-MS calculated for  $C_{29}H_{32}F_2N_7O_3$  [M+H]<sup>+</sup> m/z: 564.3; found 564.3. <sup>1</sup>H NMR (300 MHz, DMSO)  $\delta$  13.8 (s, 1H), 8.27 (s, 1H), 7.42 (d, *J* = 9.0 Hz, 2H), 7.13 (d, *J* = 9.0 Hz, 2H), 7.03 (t, *J* = 6.0 Hz, 1H), 4.82 (s, 2H), 3.98 (d, *J* = 9.0 Hz, 2H), 3.88 (s, 6H), 3.59 (d, *J* = 9.0 Hz, 2H), 3.22-2.98 (m, 6H), 2.78 (s, 3H), 1.24 (t, *J* = 6.0 Hz, 3H).

### Example 70


3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0466]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde


[0467]



[0468] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (Example 39, Step 4: 885 mg, 1.72 mmol) in tetrahydrofuran (20 mL) cooled to -78 °C was added a freshly prepared lithium diisopropylamide (LDA) solution (1 M in THF, 2.6 mL). The resulting yellow suspension was stirred at -78 °C for 30 min then N,N-dimethylformamide (2 mL) was added. The mixture was stirred at -78 °C for 1 h then quenched with 1N HCl. The reaction mixture was then warmed to room temperature and extracted with EtOAc. The organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography on a silica gel column eluted with 0 to 10 % EtOAc in DCM to afford the desired product (730 mg, 78 %) as a white solid. LC-MS calculated for C<sub>25</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S [M+H]<sup>+</sup> m/z: 543.1; found 543.1.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0469]



[0470] To a solution of sodium triacetoxyborohydride (680 mg, 3.2 mmol) in trifluoroacetic acid (2.1 mL, 28 mmol) cooled to 0 °C was added 3 mL of dichloromethane (DCM) then 1-ethylpiperazine (580 μL, 4.6 mmol) was added to give a yellow solution. Then a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (500 mg, 0.92 mmol) in DCM (10 mL) was dropwise over 5 min. The mixture was stirred at 0 °C for 2 h then warmed to room temperature and stirred for overnight. The mixture was poured into saturated NaHCO<sub>3</sub> then extracted with DCM. The organic layer was then washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography on a silica gel column eluted with 0 to 10 % MeOH in DCM to afford the desired product (590 mg, 100 %) as a white solid. LC-MS calculated for C<sub>31</sub>H<sub>35</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 641.2; found 641.2.

Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0471] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (590 mg, 0.92 mmol) in 25 mL of THF was added potassium tert-butoxide (1 M in THF, 4.6 mL). The mixture was stirred at room temperature for 1 h then the reaction was quenched with saturated NH<sub>4</sub>Cl solution and extracted with EtOAc. The organic layer was washed with

water, brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by prep HPLC (pH = 2, ACN/ $\text{H}_2\text{O}$  to give the desired product as a white solid. LC-MS calculated for  $\text{C}_{25}\text{H}_{31}\text{F}_2\text{N}_6\text{O}_3$   $[\text{M}+\text{H}]^+$  m/z: 501.2; found 501.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  12.01 (s, 1H), 8.00 (s, 1H), 7.04 (t,  $J = 8.1$  Hz, 1H), 6.77 (s, 1H), 4.77 (s, 2H), 3.89 (s, 8H), 3.63 (s, 3H), 3.49 (br, 2H), 3.21-2.91 (m, 6H), 2.57 (br, 2H), 1.19 (t,  $J = 7.3$  Hz, 3H).

### Example 71


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0472]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(Z)-2-ethoxyvinyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0473]



[0474] A flask containing a mixture of 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (Example 39, Step 5: 120 mg, 0.20 mmol), 2-[(Z)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Synthonix, Cat # E2791: 79 mg, 0.40 mmol), [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) complexed with dichloromethane (1:1) (Aldrich, cat # 379670: 20 mg, 0.02 mmol) and potassium carbonate (83 mg, 0.60 mmol) in 1,4-dioxane (5 mL, 60 mmol) and water (0.5 mL, 30 mmol) was evacuated then filled with nitrogen three times. The reaction mixture was stirred at 95 °C for 1 h then cooled to room temperature and concentrated. The residue was purified by flash chromatography on a silica gel column eluted with 0 to 20 % EtOAc in hexanes to afford the desired product (106 mg, 91 %). LC-MS calculated for  $\text{C}_{28}\text{H}_{27}\text{F}_2\text{N}_4\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$  m/z: 585.2; found 585.1.

Step 2: [3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8yl]acetaldehyde


[0475]



**[0476]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(Z)-2-ethoxyvinyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (97 mg, 0.16 mmol) in tetrahydrofuran (10 mL, 100 mmol) was added 1.0 M hydrogen chloride in water (1.6 mL, 1.6 mmol). The mixture was stirred at 60 °C for 2 h then cooled to room temperature and neutralized with saturated NaHCO<sub>3</sub> solution. The mixture was extracted with EtOAc. The organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>26</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S [M+H]<sup>+</sup> m/z: 557.1; found 557.1.

*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0477]**



**[0478]** To a solution of [3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]acetaldehyde (30 mg, 0.054 mmol) in methylene chloride (2 mL) were added 1-ethylpiperazine (21 μL, 0.16 mmol) and acetic acid (100 μL). The resulting yellow solution was stirred at room temperature for 2 h then sodium triacetoxyborohydride (35 mg, 0.16 mmol) was added and the reaction mixture was stirred at room temperature overnight. The mixture was neutralized with saturated Na<sub>2</sub>CO<sub>3</sub> then extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, then concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>32</sub>H<sub>37</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 655.3; found 655.2.


*Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0479]** The crude product from step 3 was dissolved in tetrahydrofuran (3 mL) then 1.0 M potassium tert-butoxide in THF (0.20 mL, 0.20 mmol) was added. The resulting yellow suspension was stirred at room temperature for 30 min then diluted with MeOH and purified by prep HPLC (pH 2, ACN/H<sub>2</sub>O) to give the desired product as a white solid. LC-MS calculated for C<sub>26</sub>H<sub>33</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 515.3; found 515.2. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.43 (s, 1H), 7.91 (s, 1H), 7.00 (t, J = 8.2 Hz, 1H), 6.57 (s, 1H), 4.74 (s, 2H), 3.89 (s, 6H), 3.65 (s, 3H), 3.18 (br, 4H), 3.07 (q, J = 7.3 Hz, 2H), 3.02 - 2.93 (m, 4H), 2.88 (br, 4H), 1.22 (t, J = 7.3 Hz, 3H).

## Example 72


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[3-(4-ethylpiperazin-1-yl)propyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0480]**



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-hydroxyprop-1yn-1-yl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


**[0481]**



**[0482]** A flask containing a mixture of 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (40 mg, 0.088 mmol), tetrakis(triphenylphosphine)palladium(0) (10 mg, 0.009 mmol) and copper(I) iodide (3 mg, 0.02 mmol) in N,N-dimethylformamide (2 mL, 20 mmol) was evacuated then filled with nitrogen. Then 2-propyn-1-ol (26  $\mu$ L, 0.44 mmol) and N,N-diisopropylethylamine (77  $\mu$ L, 0.44 mmol) were added. The resulting solution was heated to 80 °C and stirred for 1 h. The mixture was cooled to room temperature and filtered then purified by prep HPLC (pH 2, ACN/H<sub>2</sub>O) to give the desired product as a yellow solid. LC-MS calculated for C<sub>21</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 429.1; found 429.1.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-hydroxypropyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


**[0483]**



**[0484]** The product from step 1 was dissolved in tetrahydrofuran (3 mL, 60 mmol) and methanol (3 mL, 100 mmol) then palladium (10 wt % on carbon, 20 mg) was added. The mixture was stirred under a balloon of hydrogen for 2 h at room temperature then filtered through celite and concentrated to give the crude product, which was used in the next step without further purification. LC-MS calculated for C<sub>21</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 433.2; found 433.2.

Step 3: 3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8yl]propanal

**[0485]**



**[0486]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-hydroxypropyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (40. mg, 0.092 mmol) in methylene chloride (5 mL, 80 mmol) was added Dess-Martin periodinane (59 mg, 0.14 mmol). The mixture was stirred at room temperature for 2 h then the reaction was quenched with saturated NaHCO<sub>3</sub> solution and extracted with EtOAc. The organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>21</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M+H]<sup>+</sup> m/z: 431.2; found 431.1.


*Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[3-(4-ethylpiperazin-1-yl)propyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0487]** The crude product from step 3 was dissolved in methanol (10 mL) then 1-ethylpiperazine (59 μL, 0.46 mmol) and acetic acid (100 μL, 2 mmol) were added. The mixture was stirred at room temperature for 1 h then sodium cyanoborohydride (29 mg, 0.46 mmol) was added. The reaction mixture was stirred at room temperature overnight then the reaction was quenched with saturated Na<sub>2</sub>CO<sub>3</sub> solution and extracted with EtOAc. The organic layer was washed with water, brine, then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was dissolved in MeOH then purified by prep HPLC (pH 2, ACN/H<sub>2</sub>O) to give the desired product as a white solid. LC-MS calculated for C<sub>27</sub>H<sub>35</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 529.3; found 529.3. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.37 (s, 1H), 7.89 (s, 1H), 7.00 (t, J = 8.2 Hz, 1H), 6.49 (s, 1H), 4.73 (s, 2H), 3.89 (s, 6H), 3.64 (s, 3H), 3.09 (br, 4H), 3.03 - 2.94 (m, 2H), 2.87 (br, 4H), 2.80 (t, J = 7.4 Hz, 2H), 2.73 - 2.64 (m, 2H), 2.02 - 1.92 (m, 2H), 1.19 (t, J = 7.3 Hz, 3H).

### Example 73


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(1-ethylpiperidin-4-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0488]**



*Step 1: {[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}(iodo)zinc*

**[0489]**




**[0490]** To a slurry of zinc (255 mg, 3.90 mmol) and celite P65 (50 mg) in N,N-dimethylformamide (0.6 mL, 8 mmol)

EP 2 861 595 B9

was added dropwise a 7:5 V/V mixture (81  $\mu$ L) of chlorotrimethylsilane : 1,2-dibromoethane over five minutes. The slurry was stirred at 15 min at room temperature then a solution of tert-butyl 4-(iodomethyl)piperidine-1-carboxylate (prepared using reported procedures as described in WO 2007/030366: 976 mg, 3.00 mmol) in N,N-dimethylformamide (1.5 mL, 19 mmol) was added dropwise. After completion of addition, the reaction mixture was heated at 65 °C for 5 min then cooled to room temperature and stirred for 30 min. The mixture was filtered and the filtrate was used directly in the next step.

Step 2: tert-butyl 4-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperidine-1-carboxylate


[0491]



[0492] A flask containing a mixture of 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (163 mg, 0.275 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1:1) (22 mg, 0.027 mmol) and copper(I) iodide (16 mg, 0.082 mmol) in N,N-dimethylformamide (5 mL) was evacuated then filled with nitrogen. The solution from step 1 (0.82 mL) was added then the reaction mixture was evacuated again and filled with nitrogen. The resulting mixture was heated to 85 °C, and stirred for overnight. The mixture was cooled to room temperature then filtered through celite and washed with EtOAc. The filtrate was then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography on a silica gel column eluted with 0 to 30 % EtOAc in DCM to afford the desired product (148 mg, 76 %) as a light yellow solid. LC-MS calculated for C<sub>35</sub>H<sub>40</sub>F<sub>2</sub>N<sub>5</sub>O<sub>7</sub>S [M+H]<sup>+</sup> m/z: 712.3; found 712.1.

Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(piperidin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0493]



[0494] To a solution of tert-butyl 4-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperidine-1-carboxylate (140 mg, 0.20 mmol) in tetrahydrofuran (5 mL, 60 mmol) was added 1.0 M potassium tert-butoxide in THF (1.0 mL). The mixture was stirred at room temperature for 1 h. The reaction was quenched with saturated NH<sub>4</sub>Cl solution then extracted with EtOAc. The organic layer was washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated. The residue was dissolved in 2 mL of DCM then 2 mL of TFA was added. The resulting mixture was stirred at room temperature for 1 h and concentrated. The residue was dissolved in EtOAc then washed with saturated NaHCO<sub>3</sub> solution. The organic layer was washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated to give the desired product as a yellow solid, which was used in the next step without further purification. LC-MS calculated for C<sub>24</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 472.2; found 472.1.

EP 2 861 595 B9


Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(1-ethylpiperidin-4-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0495] To a stirred solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(piperidin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (17 mg, 0.035 mmol) in MeOH (2 mL) and THF (2 mL) was added 5.0 M acetaldehyde in THF (35  $\mu$ L). The mixture was stirred at room temperature for 30 min then sodium cyanoborohydride (11 mg, 0.18 mmol) was added. The resulting mixture was stirred at room temperature for 1 h then purified by prep HPLC (pH 2, ACN/H<sub>2</sub>O) to give the desired product as a white solid. LC-MS calculated for C<sub>26</sub>H<sub>32</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 500.2; found 500.2.

Example 74


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0496]



Step 1: N-[(1R,2R)-2-(benzyloxy)cyclopentyl]-5-[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl-1H-pyrrolo[2,3-b]pyridin-4-amine


[0497]



[0498] A mixture of N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (prepared as described in Example 45, Step 1-2: 100. mg, 0.283 mmol), (1R,2R)-2-(benzyloxy)cyclopentanamine (Aldrich, Cat # 671533: 81.1 mg, 0.424 mmol), palladium acetate (6 mg, 0.03 mmol), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (20 mg, 0.03 mmol), and cesium carbonate (280 mg, 0.85 mmol) in 1,4-dioxane (3 mL, 40 mmol) was evacuated then filled with nitrogen. The mixture was heated to 160 °C and stirred for overnight. After cooled to room temperature, the mixture was diluted with EtOAc and filtered then concentrated under reduced pressure. The residue was purified by flash chromatography eluted with 0 to 5 % MeOH in DCM to give the desired product (63 mg, 44 %) as a yellow solid. LC-MS calculated for C<sub>28</sub>H<sub>31</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> m/z: 509.2; found 509.3.

Step 2: 1-[(1R,2R)-2-(benzyloxy)cyclopentyl]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0499]



**[0500]** To a solution of the product from *Step 1* in tetrahydrofuran (3 mL, 40 mmol) was added triethylamine (90  $\mu$ L, 0.65 mmol) and triphosgene (56 mg, 0.19 mmol). The resulting yellow suspension was stirred at room temperature for 1 h then 3 mL of 1 N NaOH was added. The mixture was stirred at room temperature for another 1 h then diluted with EtOAc. The organic layer was washed with water, brine, then dried over  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The residue was purified by flash chromatography eluted with 0 to 5 % MeOH in DCM to give the desired product as a yellow solid. LC-MS calculated for  $\text{C}_{29}\text{H}_{29}\text{F}_2\text{N}_4\text{O}_4$   $[\text{M}+\text{H}]^+$  m/z: 535.2; found 535.1.


*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0501]** To a solution of the product from *Step 2* in methanol (5 mL) and tetrahydrofuran (5 mL) was added palladium (10 wt % on activated carbon, 20 mg) and a few drops of concentrated HCl. The mixture was stirred under a balloon of hydrogen at room temperature for 6 h then filtered through celite and concentrated. The residue was purified by prep HPLC (pH 2, ACN/ $\text{H}_2\text{O}$ ) to give the desired product as a white solid. LC-MS calculated for  $\text{C}_{22}\text{H}_{23}\text{F}_2\text{N}_4\text{O}_4$   $[\text{M}+\text{H}]^+$  m/z: 445.2; found 445.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  11.93 (s, 1H), 8.04 (s, 1H), 7.54 - 7.47 (m, 1H), 7.03 (t,  $J$  = 8.1 Hz, 1H), 6.86 - 6.81 (m, 1H), 4.83 (d,  $J$  = 13.2 Hz, 1H), 4.63 (d,  $J$  = 13.2 Hz, 1H), 4.61 - 4.55 (m, 1H), 4.54 - 4.47 (m, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 2.29 - 2.12 (m, 2H), 2.06 - 1.96 (m, 1H), 1.86 - 1.66 (m, 2H), 1.56 - 1.44 (m, 1H).

### Example 75

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

**[0502]**




**[0503]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 74*: 8 mg, 0.02 mmol) in isopropyl alcohol (5 mL) and water (0.25 mL) was added pyridinium tribromide (29 mg, 0.09 mmol). The resulting yellow solution was warmed up to 30  $^\circ\text{C}$  and stirred for overnight. The reaction mixture was cooled to room temperature then zinc (24 mg, 0.37 mmol) and acetic acid (0.2 mL, 4 mmol) were added. The mixture was stirred at room temperature for 2 h then filtered and concentrated. The residue was dissolved in MeOH then purified by prep HPLC (pH 2, ACN/ $\text{H}_2\text{O}$ ) to give the desired product as a white solid. LC-MS calculated for  $\text{C}_{22}\text{H}_{23}\text{F}_2\text{N}_4\text{O}_5$   $[\text{M}+\text{H}]^+$  m/z: 461.2; found 461.2.

## Example 76

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0504]




[0505] This compound was prepared using procedures analogous to those for *Example 45* with 2,3-difluoroaniline replacing cyclopropylamine. LC-MS calculated for  $C_{23}H_{17}F_4N_4O_3$  (M+H)<sup>+</sup> m/z: 473.1; found: 473.0. <sup>1</sup>H NMR (300 MHz, DMSO)  $\delta$  11.84 (s, 1H), 8.09 (s, 1H), 7.77 - 7.65 (m, 1H), 7.57 - 7.48 (m, 1H), 7.45 - 7.35 (m, 1H), 7.23 - 7.17 (m, 1H), 7.07 (t,  $J$  = 8.2 Hz, 1H), 5.15 - 4.85 (m, 2H), 4.48 - 4.42 (m, 1H), 3.90 (s, 6H).

## Example 77

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0506]




[0507] This compound was prepared using procedures analogous to those for *Example 75* with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 76*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{23}H_{17}F_4N_4O_4$  (M+H)<sup>+</sup> m/z: 489.1; found: 489.0. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  11.01 (s, 1H), 7.96 (s, 1H), 7.66 (q,  $J$  = 8.4 Hz, 1H), 7.48 (t,  $J$  = 7.2 Hz, 1H), 7.36 (q,  $J$  = 7.2 Hz, 1H), 7.06 (t,  $J$  = 8.1 Hz, 1H), 4.95 (d,  $J$  = 14.0 Hz, 1H), 4.77 (d,  $J$  = 14.0 Hz, 1H), 3.89 (s, 6H), 2.55 (d,  $J$  = 21.7 Hz, 1H), 2.35 (d,  $J$  = 21.7 Hz, 1H).

## Example 78

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(pyridin-2-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0508]

EP 2 861 595 B9




[0509] This compound was prepared using procedures analogous to those for *Example 45* with 2-pyridinemethanamine replacing cyclopropylamine. LC-MS calculated for  $C_{23}H_{20}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 452.2; found: 452.1. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  11.65 (s, 1H), 8.54 (d, *J* = 4.2 Hz, 1H), 8.01 (s, 1H), 7.71 (td, *J* = 7.7, 1.7 Hz, 1H), 7.27 - 7.20 (m, 2H), 7.17 (d, *J* = 7.9 Hz, 1H), 7.04 (t, *J* = 8.1 Hz, 1H), 6.11 - 6.06 (m, 1H), 5.44 (s, 2H), 4.91 (s, 2H), 3.89 (s, 6H).

**Example 79**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(pyridin-2-ylmethyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

[0510]




[0511] This compound was prepared using procedures analogous to those for *Example 75* with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(pyridin-2-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 78*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{23}H_{20}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 468.1; found: 468.1.

**Example 80**

**1-(4-chlorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**


[0512]



Step 1: 1-(4-chlorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0513]

EP 2 861 595 B9



[0514] This compound was prepared using procedures analogous to those for *Example 45* with p-chloroaniline replacing cyclopropylamine. LC-MS calculated for  $C_{23}H_{18}ClF_2N_4O_3$  (M+H)<sup>+</sup> m/z: 471.1; found: 471.0.


Step 2: 1-(4-chlorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0515] This compound was prepared using procedures analogous to those for *Example 75* with 1-(4-chlorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{23}H_{18}ClF_2N_4O_4$  (M+H)<sup>+</sup> m/z: 487.1; found: 487.1. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.97 (s, 1H), 7.93 (s, 1H), 7.60 - 7.54 (m, 2H), 7.52 - 7.46 (m, 2H), 7.05 (t, J = 8.2 Hz, 1H), 4.83 (s, 2H), 3.88 (s, 6H), 2.36 (s, 2H).

Example 81


1-(5-chloropyridin-2-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione

[0516]



Step 1: 1-(5-chloropyridin-2-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0517]



[0518] This compound was prepared using procedures analogous to those for *Example 45* with 2-amino-5-chloropyridine replacing cyclopropylamine. LC-MS calculated for  $C_{22}H_{17}ClF_2N_5O_3$  (M+H)<sup>+</sup> m/z: 472.1; found: 472.0.

## EP 2 861 595 B9


Step 2: 1-(5-chloropyridin-2-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2,8-dione

[0519] This compound was prepared using procedures analogous to those for *Example 75* with 1-(5-chloropyridin-2-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{22}H_{17}ClF_2N_5O_4$  (M+H)<sup>+</sup> m/z: 488.1; found: 488.1.

### Example 82

3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]benzotrile

[0520]




[0521] This compound was prepared using procedures analogous to those for *Example 45* with 3-amino-benzotrile replacing cyclopropylamine. LC-MS calculated for  $C_{24}H_{18}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 462.1; found: 462.1.

### Example 83

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-pyridin-3-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0522]




[0523] This compound was prepared using procedures analogous to those for *Example 45* with 3-pyridinamine replacing cyclopropylamine. LC-MS calculated for  $C_{22}H_{18}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 438.1; found: 438.1. <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  11.84 (s, 1H), 8.75 - 8.68 (m, 2H), 8.11 (s, 1H), 8.03 - 7.97 (m, 1H), 7.67 - 7.60 (m, 1H), 7.19 - 7.13 (m, 1H), 7.07 (t, *J* = 8.2 Hz, 1H), 5.01 (s, 2H), 4.31 - 4.26 (m, 1H), 3.90 (s, 6H).

### Example 84

1-(3-chloro-2-fluorophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0524]

EP 2 861 595 B9




[0525] This compound was prepared using procedures analogous to those for *Example 45* with 3-chloro-2-fluoroaniline replacing cyclopropylamine. LC-MS calculated for  $C_{23}H_{17}ClF_3N_4O_3$  (M+H)<sup>+</sup> m/z: 489.1; found: 489.0.

**Example 85**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3'-d]pyrimidin-2-one**

[0526]



Step 1: 5-[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl]-1-(4-methoxybenzyl)-N-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine

[0527]



[0528] A container having a mixture of N-[4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-2,6-difluoro-3,5-dimethoxyaniline (prepared as described in *Example 62, step 2*; 100 mg, 0.2 mmol), 1-methyl-1H-pyrazol-4-amine (Astatech, Cat # CL4553: 31 mg, 0.32 mmol), cesium carbonate (380 mg, 1.2 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (24 mg, 0.042 mmol) and palladium acetate (9.4 mg, 0.042 mmol) in toluene (3 mL) was evacuated then filled with nitrogen. The mixture was stirred at 150 °C for 1 hour then cooled to room temperature and diluted with ethyl acetate, washed with water. The organic layer was dried over  $Na_2SO_4$  and concentrated. The residue was used in the next step without further purification. LC-MS calculated for  $C_{27}H_{28}F_2N_7O_3$  (M+H)<sup>+</sup> m/z: 536.2; found: 536.2.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(4-methoxybenzyl)-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0529]

5

10

15



[0530] The crude product from step 1 was dissolved in tetrahydrofuran (3 mL, 40 mmol) and cooled to 0 °C then triphosgene (75 mg, 0.25 mmol) and triethylamine (150 μL, 1.0 mmol) were added. The mixture was stirred at room temperature for 1 hour then concentrated. The residue was purified by flash chromatography to give the desired product. LC-MS calculated for C<sub>28</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 562.2; found: 562.2.

20

Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

25

[0531] The product from Step 2 was dissolved in trifluoroacetic acid (2 mL, 20 mmol) and the resulting solution stirred at 70 °C for 1 hour. Then it was concentrated and the residue was purified by prep HPLC (pH 2, ACN/H<sub>2</sub>O) to give the desired product as a white solid. LC-MS calculated for C<sub>20</sub>H<sub>18</sub>F<sub>2</sub>N<sub>7</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 442.1; found: 442.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.30 (s, 1H), 8.06 (s, 1H), 7.62 (s, 1H), 7.07 (t, J = 8.1 Hz, 1H), 6.26 (s, 1H), 4.97 (s, 2H), 3.96 (s, 3H), 3.90 (s, 6H).

30


#### Example 86

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(pyridin-2-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

35

[0532]

40



45

[0533] This compound was prepared using procedures analogous to those for Example 85 with 2-pyridinemethanamine replacing 1-methyl-1H-pyrazol-4-amine in Step 1. LC-MS calculated for C<sub>22</sub>H<sub>19</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 453.1; found: 453.1. <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.61 - 8.55 (m, 1H), 8.29 (s, 1H), 7.85 (td, J = 7.8, 1.7 Hz, 1H), 7.78 (s, 1H), 7.39 - 7.31 (m, 2H), 7.06 (t, J = 8.1 Hz, 1H), 5.54 (s, 2H), 4.98 (s, 2H), 3.89 (s, 6H).


50

#### Example 87

1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

55

[0534]




**[0535]** This compound was prepared using procedures analogous to those for *Example 85* with cyclopropylamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{19}H_{18}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 402.1; found: 402.1. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  13.58 (br, 1H), 8.47 (s, 1H), 8.24 (s, 1H), 7.04 (t, *J* = 8.2 Hz, 1H), 4.70 (s, 2H), 3.88 (s, 6H), 3.38-3.29 (m, 1H), 1.9 -1.12 (m, 2H), 0.73 - 0.66 (m, 2H).

#### Example 88

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(3S)-tetrahydro-2H-pyran-3-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0536]**




**[0537]** This compound was prepared using procedures analogous to those for *Example 85* with (3S)-tetrahydro-2H-pyran-3-amine hydrochloride (J & W PharmLab, Cat # 20-1041S) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{21}H_{22}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 446.2; found: 446.1.

#### Example 89

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(3S)-tetrahydrofuran-3-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0538]**




**[0539]** This compound was prepared using procedures analogous to those for *Example 85* with (3S)-tetrahydrofuran-3-amine hydrochloride (Advanced ChemBlocks, Cat # F4071) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{20}H_{20}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 432.1; found: 432.2.

## Example 90

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(3R)-tetrahydrofuran-3-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0540]




[0541] This compound was prepared using procedures analogous to those for *Example 85* with (3R)-tetrahydrofuran-3-amine hydrochloride (Advanced ChemBlocks, Cat # F4072) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{20}H_{20}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 432.1; found: 432.1.

## Example 91

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-isopropyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0542]




[0543] This compound was prepared using procedures analogous to those for *Example 85* with 2-propanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{19}H_{20}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 404.2; found: 404.1.

## Example 92

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[2-(trifluoromethoxy)phenyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0544]




**[0545]** This compound was prepared using procedures analogous to those for *Example 85* with 2-(trifluoromethoxy)aniline replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{23}H_{17}F_5N_5O_4$  (M+H)<sup>+</sup> m/z: 522.1; found: 522.1.

5 **Example 93**

**3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]benzotrile**

10 **[0546]**




**[0547]** This compound was prepared using procedures analogous to those for *Example 85* with 3-aminobenzotrile replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{23}H_{17}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 463.1; found: 463.0.

25 **Example 94**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-pyridin-3-yl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

30 **[0548]**



**[0549]** This compound was prepared using procedures analogous to those for *Example 85* with 3-pyridinamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{21}H_{17}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 439.1; found: 439.2. <sup>1</sup>H NMR (500 MHz, DMSO) δ 13.68 (s, 1H), 8.80 (dd, *J* = 4.8, 1.4 Hz, 1H), 8.76 (d, *J* = 2.3 Hz, 1H), 8.35 (s, 1H), 8.08 - 8.03 (m, 1H), 7.71 - 7.66 (m, 1H), 7.11 - 7.05 (m, 1H), 5.72 (s, 1H), 5.06 (s, 2H), 3.90 (s, 6H).

45

**Example 95**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-methyl-2H-tetrazol-5-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

50

**[0550]**

55

EP 2 861 595 B9




[0551] This compound was prepared using procedures analogous to those for *Example 85* with 2-methyl-2H-tetrazol-5-amine (Ark Pharm, Cat # AK-25219) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{18}H_{16}F_2N_9O_3$  (M+H)<sup>+</sup> m/z: 444.1; found: 444.1. <sup>1</sup>H NMR (300 MHz, DMSO)  $\delta$  13.84 (s, 1H), 8.39 (s, 1H), 7.11 (t, *J* = 8.2 Hz, 1H), 6.07 (s, 1H), 5.12 (s, 2H), 4.59 (s, 3H), 3.91 (s, 6H).

**Example 96**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-quinolin-8-yl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0552]




[0553] This compound was prepared using procedures analogous to those for *Example 85* with 8-quinolinamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{25}H_{19}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 489.1; found: 489.2.

**Example 97**

**1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-9-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0554]




[0555] This compound was prepared using procedures analogous to those for *Example 52* with 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 87*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one in *Step 1*. LC-MS calculated for  $C_{20}H_{20}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 416.2; found: 416.1.

## Example 98

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-9-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0556]




[0557] This compound was prepared using procedures analogous to those for *Example 52* with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 57*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one in *Step 1*. LC-MS calculated for  $C_{19}H_{20}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 404.2; found: 404.2. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  13.35 (s, 1H), 8.24 (s, 1H), 7.04 (t, *J* = 8.1 Hz, 1H), 4.74 (s, 2H), 4.13 (q, *J* = 6.9 Hz, 2H), 3.88 (s, 6H), 2.65 (s, 3H), 1.21 (t, *J* = 6.9 Hz, 3H).

## Example 99


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0558]



*Step 1*: 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(4-methoxybenzyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0559]




[0560] This compound was prepared using procedures analogous to those for *Example 51*, *Step 1-2*. LC-MS calculated for  $C_{27}H_{26}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 522.2; found: 522.2.

## EP 2 861 595 B9

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(4-methoxybenzyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0561]



[0562] To a solution of 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(4-methoxybenzyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (30.0 mg, 0.0575 mmol) in ethanol (1.0 mL, 17 mmol) and N-ethylethanamine (1.0 mL, 9.7 mmol) under nitrogen were added 1,4-bis(diphenylphosphino)butane (7.6 mg, 0.017 mmol) and tris(dibenzylideneacetone)dipalladium(0) (16 mg, 0.017 mmol). The resulting mixture was heated to 90 °C and stirred for 6 h then concentrated. The residue was purified by column eluted with 1 to 10 % MeOH in DCM to afford the desired product. LC-MS calculated for C<sub>24</sub>H<sub>22</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 482.2; found: 482.2.


Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4,3-d]pyrimidin-2-one

[0563] The product from step 2 was dissolved in TFA (1 mL) then heated to 75 °C and stirred for 1 h. The mixture was cooled to room temperature and concentrated. The residue was purified by prep HPLC (pH 2, acetonitrile/water) to give the desired product. LC-MS calculated for C<sub>16</sub>H<sub>14</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 362.1; found: 362.2.

### Example 100

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-9-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one


[0564]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-9-[(Z)-2-ethoxyvinyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0565]


EP 2 861 595 B9



**[0566]** A mixture of 2-[(Z)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (157 mg, 0.792 mmol), 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one (180.0 mg, 0.3963 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1:1) (48 mg, 0.059 mmol) and potassium carbonate (160 mg, 1.2 mmol) in 1,4-dioxane (3.0 mL) /water (1.0 mL) was heated at 88 °C for 1.5 h. The mixture was cooled to room temperature then diluted with water, extracted with DCM. The organic layer was washed with brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified via flash column to afford the desired product. LC-MS calculated for C<sub>21</sub>H<sub>22</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 446.2; found: 446.1.

*Step 2: [3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-9-yl-acetaldehyde*

**[0567]**



**[0568]** The product from *Step 2* was dissolved in acetone (2 mL) and ten drops of concentrated HCl was added. The resulting mixture was stirred at room temperature for 5 h then diluted with EtOAc and washed with saturated NaHCO<sub>3</sub> and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification.


*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-9-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0569]** To a solution of the product from step 1 in MeOH was added morpholine (3 eq.) and sodium cyanoborohydride (3 eq.). The resulting mixture was stirred at room temperature for 1 h then purified by prep HPLC (pH 2, acetonitrile/water) to give the desired product. LC-MS calculated for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 489.2; found: 489.2. <sup>1</sup>H NMR (300 MHz, DMSO) δ 13.67 (s, 1H), 8.25 (s, 1H), 7.04 (t, *J* = 8.2 Hz, 1H), 4.81 (s, 2H), 4.07 - 3.97 (m, 2H), 3.88 (s, 6H), 3.77 - 3.46 (m, 11H), 3.30 - 3.13 (m, 2H).

**Example 101**


**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclopropyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0570]**



Step 1: 2-chloro-N-([4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl)-6-fluoro-3,5-dimethoxyaniline

**[0571]**



**[0572]** This compound was prepared using procedures analogous to those for *Example 62, Step 2* with 2-chloro-6-fluoro-3,5-dimethoxyaniline replacing 2,6-difluoro-3,5-dimethoxyaniline. LC-MS calculated for  $C_{23}H_{22}Cl_2FN_4O_3$  (M+H)<sup>+</sup> m/z: 491.1; found: 491.1.


Step 2: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclopropyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0573]** This compound was prepared using procedures analogous to those for *Example 85* with 2-chloro-N-([4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl)-6-fluoro-3,5-dimethoxyaniline replacing N-([4-chloro-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl)-2,6-difluoro-3,5-dimethoxyaniline and cyclopropylamine replacing 1-methyl-1H-pyrazol-4-amine dihydrochloride. LC-MS calculated for  $C_{19}H_{18}ClFN_5O_3$  (M+H)<sup>+</sup> m/z: 418.1; found: 418.0.

**Example 102**

**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclobutyl-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0574]**




**[0575]** This compound was prepared using procedures analogous to those for *Example 101* with cyclobutylamine replacing cyclopropylamine. LC-MS calculated for  $C_{20}H_{20}ClFN_5O_3$  (M+H)<sup>+</sup> m/z: 432.1; found: 432.1. <sup>1</sup>H NMR (500 MHz,

DMSO)  $\delta$  13.63 (s, 1H), 8.29 (s, 2H), 7.01 (d,  $J = 7.7$  Hz, 1H), 4.90 - 4.80 (m, 1H), 4.69 (s, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 2.55 - 2.45 (m, 2H), 2.40 - 2.30 (m, 2H), 1.88 - 1.71 (m, 2H).

### Example 103

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0576]




[0577] A mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 44, Step 4*: 52 mg, 0.095 mmol) and 1.0 M potassium tert-butoxide in THF (1.0 mL, 1.0 mmol) was stirred at room temperature for 1 h. The mixture was diluted with methylene chloride, washed with saturated  $\text{NaHCO}_3$ , water and brine. The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was dissolved in methanol and Pd/C (10%, 10 mg) was added and the reaction mixture was stirred under hydrogen balloon for 3 h. The mixture was filtered and the filtrate was purified by prep-HPLC (pH 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $\text{C}_{17}\text{H}_{15}\text{F}_2\text{N}_4\text{O}_3$  ( $\text{M}+\text{H}$ )<sup>+</sup> m/z: 361.1; found: 361.1.

### Example 104


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,9-dimethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0578]



*Step 1: tert-butyl 3-(2,6-difluoro-3,5-dimethoxyphenyl)-9-iodo-1-methyl-2-oxo-1,2,3,4-tetrahydro-7H-pyrrolo[3;2':5,6]pyrido[4,3-d]pyrimidine-7-carboxylate*

[0579]



**[0580]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 33*: 0.99 g, 2.6 mmol) in N,N-dimethylformamide (20 mL, 200 mmol) was added potassium hydroxide (160 mg, 2.9 mmol). The mixture was stirred at room temperature for 15 min then iodine (1.0 g, 4.0 mmol) was added. The resulting solution was stirred at room temperature for 1 h then di-tert-butylidicarbonate (860 mg, 4.0 mmol) and 4-dimethylaminopyridine (60 mg, 0.5 mmol) were added. The reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with EtOAc then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column eluted with 0 to 10 % AcOEt in CH<sub>2</sub>Cl<sub>2</sub>. LC-MS calculated for C<sub>23</sub>H<sub>24</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub> (M+H)<sup>+</sup> m/z: 601.1; found: 601.0.


*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1,9-dimethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0581]** A mixture of tert-butyl 3-(2,6-difluoro-3,5-dimethoxyphenyl)-9-iodo-1-methyl-2-oxo-1,2,3,4-tetrahydro-7H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-7-carboxylate (100.0 mg, 0.1666 mmol), 2.0 M dimethylzinc in toluene (0.17 mL, 0.33 mmol), bis(tri-*t*-butylphosphine)palladium (5 mg, 0.01 mmol) in tetrahydrofuran (5 mL, 60 mmol) was evacuated and filled with nitrogen. The reaction mixture was stirred at 65 °C for 2.5 h then cooled to room temperature and filtered. The filtrate was diluted with methanol and purified with prep-HPLC (pH 2, acetonitrile/water) to give the desired product. LC-MS calculated for C<sub>19</sub>H<sub>19</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 389.1; found: 389.0. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.78 (s, 1H), 8.02 (s, 1H), 7.35 (s, 1H), 7.02 (t, *J* = 8.1 Hz, 1H), 4.76 (s, 2H), 3.88 (s, 6H), 3.51 (s, 3H), 2.42 (s, 3H).

### Example 105


**[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-9-yl]acetonitrile**

**[0582]**



*Step 1: 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-[(2-(trimethylsilyl)ethoxy)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0583]**



**[0584]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 33*: 400 mg, 1.07 mmol) in N,N-dimethylformamide (10 mL) was added N-bromosuccinimide (210 mg, 1.2 mmol). The resulting red solution was stirred at room temperature for 2 h. The reaction was quenched with water and extracted with DCM. The organic layer was washed with brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was dissolved in DMF (5mL) and cooled to 0 °C, then NaH in mineral oil (60 wt %, 0.13 g,

## EP 2 861 595 B9

3.2 mmol) was added. The mixture was stirred at 0 °C for 30 min then [ $\beta$ -(trimethylsilyl)ethoxy]methyl chloride (0.36 g, 2.1 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then diluted with water and extracted with DCM. The organic layer was washed with water, brine, then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by column eluted with 0 to 10% AcOEt in DCM to give the desired product. LC-MS calculated for  $\text{C}_{24}\text{H}_{30}\text{BrF}_2\text{N}_4\text{O}_4\text{Si}$  ( $\text{M}+\text{H}$ )<sup>+</sup> m/z: 583.1; found: 583.0.


*Step 2: [3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-9-yl]acetonitrile*

**[0585]** To a mixture of 9-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (60 mg, 0.10 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (1.2 mg, 0.002 mmol), tris(dibenzylideneacetone)dipalladium(0) (1.9 mg, 0.002 mmol), in N,N-dimethylformamide (2 mL) was added (trimethylsilyl)acetonitrile (17.6  $\mu\text{L}$ , 0.128 mmol), followed by zinc difluoride (8.50 mg, 0.0823 mmol). The mixture was evacuated then filled with nitrogen. The reaction mixture was stirred at 110 °C for overnight then cooled to room temperature and diluted with water. The mixture was extracted with EtOAc. The organic layer was washed with water, brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was dissolved in DCM (2 mL) and TFA (2 mL) was added. The resulting solution was stirred at room temperature for 1 h then concentrated. The residue was dissolved in MeOH then ethylenediamine was added. The mixture was stirred at room temperature for 1 h then purified by prep HPLC (pH 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $\text{C}_{20}\text{H}_{18}\text{F}_2\text{N}_5\text{O}_3$  ( $\text{M}+\text{H}$ )<sup>+</sup> m/z: 414.1; found: 414.1.

### Example 106


**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclobutyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

#### [0586]



*Step 1: 4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde*


#### [0587]



**[0588]** To a solution of 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (2.0 g, 11 mmol) in N,N-dimethylformamide (20 mL) was added sodium hydride (60 wt % in mineral oil, 580 mg, 14 mmol) portion-wise at 0 °C. The mixture was stirred at 0 °C for 30 min then [ $\beta$ -(Trimethylsilyl)ethoxy]methyl chloride (2.4 mL, 13 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 1.5 h then quenched with saturated  $\text{NH}_4\text{Cl}$  solution. The mixture was then extracted with EtOAc. The combined organic layer was washed with water, brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by column eluted with 0 to 20 % EtOAc in Hexanes to give the desired product (2.3 g, 67 %) as a white solid. LC-MS calculated for  $\text{C}_{14}\text{H}_{20}\text{ClN}_2\text{O}_2\text{Si}$  ( $\text{M}+\text{H}$ )<sup>+</sup> m/z: 311.1; found: 311.0.

Step 2: 2-chloro-N-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-6-fluoro-3,5-dimethoxyaniline


[0589]



[0590] To a solution of sodium triacetoxyborohydride (1.8 g, 8.8 mmol) in trifluoroacetic acid (4 mL) at 0 °C was added dropwise a solution of 4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (600 mg, 1.9 mmol) and 2-chloro-6-fluoro-3,5-dimethoxyaniline (400.0 mg, 1.945 mmol) in methylene chloride (10 mL). The reaction mixture was stirred at 0 °C for 1 h then poured into ice-water and neutralized with NaHCO<sub>3</sub>. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column eluted with 0 to 5% AcOEt in CH<sub>2</sub>Cl<sub>2</sub> to give the desired product (0.6 g, 60 %). LC-MS calculated for C<sub>22</sub>H<sub>29</sub>Cl<sub>2</sub>FN<sub>3</sub>O<sub>3</sub>Si (M+H)<sup>+</sup> m/z: 500.1; found: 500.0.

Step 3: 5-[[2-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)amino]methyl]-N-cyclobutyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-amine


[0591]



[0592] A mixture of 2-chloro-N-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-6-fluoro-3,5-dimethoxyaniline (0.10 g, 0.20 mmol), cyclobutylamine (34 μL, 0.40 mmol), palladium acetate (4.5 mg, 0.020 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (10 mg, 0.02 mmol), and cesium carbonate (2.0 x 10<sup>2</sup> mg, 0.60 mmol) in 1,4-dioxane (2 mL, 20 mmol) was evacuated then filled with nitrogen. The mixture was stirred at 160 °C for overnight. The reaction mixture was cooled to room temperature then diluted with ethyl acetate (20 mL), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluted with MeOH in DCM (0-5%) to afford the desired product. LC-MS calculated for C<sub>26</sub>H<sub>37</sub>ClFN<sub>4</sub>O<sub>3</sub>Si (M+H)<sup>+</sup> m/z: 535.2; found: 535.1.

Step 4: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclobutyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0593]



**[0594]** To a solution of 5-[[2-chloro-6-fluoro-3,5-dimethoxyphenyl]amino]methyl-N-cyclobutyl-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-amine (82 mg, 0.15 mmol) in THF (5 mL) at 0 °C was added triethylamine (110  $\mu$ L, 0.76 mmol), followed by triphosgene (68 mg, 0.23 mmol). The resulting mixture was stirred at 0 °C for 30 min then 1 N NaOH (2 mL) was added. The mixture was stirred at 0 °C for 10 min then diluted with water and extracted with EtOAc. The organic layer was washed with brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was used in the next step without further purification. LC-MS calculated for  $\text{C}_{27}\text{H}_{35}\text{ClFN}_4\text{O}_4\text{Si}$  (M+H)<sup>+</sup> m/z: 561.2; found: 561.1.


*Step 5: 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclobutyl-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2,8-dione*

**[0595]** To a mixture of 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-cyclobutyl-7-[[2-(trimethylsilyl)ethoxy]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (82 mg, 0.15 mmol) in isopropyl alcohol (0.6 mL) and water (0.04 mL) was added pyridinium tribromide (180 mg, 0.51 mmol). The resulting solution was stirred at 30 °C for 2 h then cooled to room temperature and acetic acid (0.5 mL, 9 mmol) and zinc (95 mg, 1.5 mmol) were added. The mixture was stirred at room temperature for 2 h then filtered and the filtrate was concentrated. The residue was dissolved in DCM (1 mL) and TFA (1 mL) was added. The resulting solution was stirred at room temperature for 1 h then concentrated. The residue was dissolved in MeOH (2 mL) then ethylenediamine (0.2 mL) was added. The mixture was stirred at room temperature for 1 h then purified by prep HPLC (pH 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $\text{C}_{21}\text{H}_{21}\text{ClFN}_4\text{O}_4$  (M+H)<sup>+</sup> m/z: 447.1; found: 447.0.

#### Example 107

**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0596]**




**[0597]** This compound was prepared using procedures analogous to those for *Example 45* with 2-chloro-6-fluoro-3,5-dimethoxyaniline replacing 2,6-difluoro-3,5-dimethoxyaniline in *Step 1* and 1-methyl-1H-pyrazol-4-amine dihydrochloride replacing cyclopropylamine in *Step 3*. LC-MS calculated for  $\text{C}_{21}\text{H}_{19}\text{ClFN}_6\text{O}_3$  (M+H)<sup>+</sup> m/z: 457.1; found: 457.0.

#### Example 108

**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-pyridin-3-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0598]**




**[0599]** This compound was prepared using procedures analogous to those for *Example 107* with 3-pyridinamine replacing 1-methyl-1H-pyrazol-4-amine dihydrochloride. LC-MS calculated for  $C_{22}H_{18}ClFN_5O_3$  (M+H)<sup>+</sup> m/z: 454.1; found: 454.1.

### Example 109

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-pyridazin-3-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0600]**




**[0601]** This compound was prepared using procedures analogous to those for *Example 45* with pyridazin-3-amine replacing cyclopropylamine in *Step 3*. LC-MS calculated for  $C_{21}H_{17}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 439.1; found: 439.2.

### Example 110


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0602]**



*Step 1:* 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0603]**



**[0604]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (*Example 70, Step 1*: 1.09 g, 2.01 mmol) in methylene chloride (30 mL) was added morpholine (880  $\mu$ L, 10. mmol), followed by acetic acid (1.0 mL, 18 mmol). The resulting yellow solution was stirred at room temperature overnight, then sodium triacetoxyborohydride (1.3 g, 6.0 mmol) was added. The mixture was stirred at room temperature for 4 h at which time LC-MS indicated the reaction completed to the desired product. The reaction was quenched with saturated  $\text{NaHCO}_3$  solution then extracted with DCM. The organic extracts were combined then washed with water and brine. The organic layer was dried over  $\text{Na}_2\text{SO}_4$  then concentrated. The residue was purified by column eluted with 0 to 40 % EtOAc/DCM to give the desired product as white solid (930 mg, 75 %). LC-MS calculated for  $\text{C}_{29}\text{H}_{30}\text{F}_2\text{N}_5\text{O}_6\text{S}$  ( $\text{M}+\text{H}$ )<sup>+</sup>  $m/z$ : 614.2; found: 614.0.


*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0605]** The product from *Step 1* was dissolved in tetrahydrofuran (65 mL) then 1.0 M tetra-*n*-butylammonium fluoride in THF (4.5 mL, 4.5 mmol) was added. The mixture was heated to 60 °C and stirred for 1.5 h at which time LC-MS indicated the reaction completed to the desired product. The mixture was cooled to room temperature then quenched with water and extracted with DCM. The combined extracts were combined then washed with water and brine. The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by column eluted with 0 to 10 % MeOH/DCM to give the desired product (649 mg, 68 %) which was further purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $\text{C}_{23}\text{H}_{26}\text{F}_2\text{N}_5\text{O}_4$  ( $\text{M}+\text{H}$ )<sup>+</sup>  $m/z$ : 474.2; found: 474.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  11.75 (s, 1H), 8.04 (s, 1H), 7.03 (t,  $J$  = 8.2 Hz, 1H), 6.95 (s, 1H), 4.77 (s, 2H), 4.39 (s, 2H), 3.89 (s, 6H), 3.81 (br, 4H), 3.67 (s, 3H), 3.18 (br, 4H).

### Example 111

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-hydroxypiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0606]**




**[0607]** This compound was prepared using procedures analogous to those for *Example 70* with 4-hydroxypiperidine replacing 1-ethylpiperazine in *Step 2*. LC-MS calculated for  $\text{C}_{24}\text{H}_{28}\text{F}_2\text{N}_5\text{O}_4$  ( $\text{M}+\text{H}$ )<sup>+</sup>  $m/z$ : 488.2; found: 488.1.

## Example 112

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4,4-difluoropiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0608]



[0609] This compound was prepared using procedures analogous to those for *Example 70* with 4,4-difluoropiperidine hydrochloride replacing 1-ethylpiperazine in *Step 2*. LC-MS calculated for  $C_{24}H_{26}F_4N_5O_3$  (M+H)<sup>+</sup> m/z: 508.2; found: 508.2.

## Example 113

[0610] 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(3,3-difluoropiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one




[0611] This compound was prepared using procedures analogous to those for *Example 70* with 3,3-difluoropiperidine hydrochloride replacing 1-ethylpiperazine in *Step 2*. LC-MS calculated for  $C_{24}H_{26}F_4N_5O_3$  (M+H)<sup>+</sup> m/z: 508.2; found: 508.2.

## Example 114


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0612]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-morpholin-4-ylethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0613]



[0614] To a solution of [3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]acetaldehyde (*Example 71, Step 2*: 522 mg, 0.938 mmol) in methylene chloride (25 mL, 390 mmol) was added morpholine (0.41 mL, 4.7 mmol), followed by acetic acid (0.32 mL, 5.6 mmol). The mixture was stirred at room temperature for 1 h then sodium triacetoxyborohydride (696 mg, 3.28 mmol) was added. The resulting mixture was stirred at room temperature for 1 h at which time LC-MS indicated the reaction completed to the desired product. The mixture was neutralized with saturated  $\text{NaHCO}_3$  then extracted with DCM. The combined extracts were washed with brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by column eluted with 0 to 50 % EtOAc/DCM then 0 to 10 % MeOH/DCM to give the desired product (483 mg, 82 %) as a yellow solid. LC-MS calculated for  $\text{C}_{30}\text{H}_{32}\text{F}_2\text{N}_5\text{O}_6\text{S}$  (M+H)<sup>+</sup> m/z: 628.2; found: 628.0.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0615] The product from *Step 1* was dissolved in tetrahydrofuran (25 mL) then 1.0 M potassium tert-butoxide in THF (2.3 mL, 2.3 mmol) was added. The resulting mixture was stirred at room temperature for 30 min at which time LC-MS indicated the reaction completed to the desired product. The reaction was quenched with saturated  $\text{NH}_4\text{Cl}$  solution then extracted with EtOAc. The combined extracts were washed with water and brine then dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by column eluted with 0 to 10 % MeOH/DCM, to give the desired product (258 mg, 56 %) as a white solid which was further purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $\text{C}_{24}\text{H}_{28}\text{F}_2\text{N}_5\text{O}_4$  (M+H)<sup>+</sup> m/z: 488.2; found: 488.2.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  11.88 (s, 1H), 7.95 (s, 1H), 7.04 (t,  $J$  = 8.2 Hz, 1H), 6.67 (s, 1H), 4.75 (s, 2H), 4.06 - 3.95 (m, 2H), 3.88 (s, 6H), 3.73 - 3.64 (m, 2H), 3.62 (s, 3H), 3.57 - 3.46 (m, 4H), 3.22 - 3.09 (m, 4H).

#### Example 115

8-(2-azetidin-1-ylethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0616]




[0617] This compound was prepared using procedures analogous to those for *Example 71* with azetidine hydrochloride replacing 1-ethylpiperazine in *Step 3*. LC-MS calculated for  $\text{C}_{23}\text{H}_{26}\text{F}_2\text{N}_5\text{O}_3$  (M+H)<sup>+</sup> m/z: 458.3; found: 458.3.

## Example 116

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyrrolidin-1-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0618]




[0619] This compound was prepared using procedures analogous to those for *Example 71* with pyrrolidine replacing 1-ethylpiperazine in *Step 3*. LC-MS calculated for  $C_{24}H_{28}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 472.2; found: 472.3.

## Example 117

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(3-morpholin-4-ylpropyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0620]




[0621] This compound was prepared using procedures analogous to those for *Example 72* with morpholine replacing 1-ethylpiperazine in *Step 4*. LC-MS calculated for  $C_{25}H_{30}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 502.2; found: 502.2.

## Example 118

8-[3-(4-cyclopropylpiperazin-1-yl)propyl]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0622]



[0623] This compound was prepared using procedures analogous to those for *Example 72* with 1-cyclopropylpiperazine


## EP 2 861 595 B9

dihydrochloride (Oakwood, Cat # 029229) replacing 1-ethylpiperazine in *Step 4*. LC-MS calculated for  $C_{28}H_{35}F_2N_6O_3$  ( $M+H$ )<sup>+</sup> m/z: 541.3; found: 541.2.

### Example 119

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0624]




[0625] This compound was prepared using procedures analogous to those for *Example 40, Step 3* with 1-ethylpiperazine replacing 1-methylpiperazine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{25}H_{29}F_2N_6O_4$  [ $M+H$ ]<sup>+</sup> m/z: 515.2; found: 515.2.

### Example 120

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(3R,5S)-3,5-dimethylpiperazin-1-yl]carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0626]




[0627] This compound was prepared using procedures analogous to those for *Example 40, Step 3* with cis-2,6-dimethylpiperazine (Aldrich, Cat # D179809) replacing 1-methylpiperazine. Purified by RP-HPLC (pH = 2) to afford the desired product as a white solid. LC-MS calculated for  $C_{25}H_{29}F_2N_6O_4$  [ $M+H$ ]<sup>+</sup> m/z: 515.2; found: 515.1.

### Example 121

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0628]




**[0629]** This compound was prepared as described in *Example 49, Steps 1-3*. LC-MS calculated for  $C_{19}H_{19}F_2N_5O_3$   $[M+H]^+$   $m/z$ : 389.1; found: 389.1.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  11.86 (s, 1H), 7.99 (s, 1H), 7.52 - 7.46 (m, 1H), 7.04 (t,  $J = 8.2$  Hz, 1H), 6.67 - 6.62 (m, 1H), 4.76 (s, 2H), 4.18 (q,  $J = 6.9$  Hz, 2H), 3.89 (s, 6H), 1.34 (t,  $J = 6.9$  Hz, 3H).

### Example 122


**4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2,8-dioxo-2,3,4,7,8,9-hexahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]benzotrile**

**[0630]**



*Step 1: 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]benzotrile*

**[0631]**



**[0632]** This compound was prepared using procedures analogous to those for *Example 45* with 4-aminobenzotrile replacing cyclopropylamine. LC-MS calculated for  $C_{24}H_{18}F_2N_5O_3$   $(M+H)^+$   $m/z$ : 462.1; found: 462.0.


*Step 2: 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2,8-dioxo-2,3,4,7,8,9-hexahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]benzotrile*

**[0633]** This compound was prepared using procedures analogous to those for *Example 75* with 4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]benzotrile (prepared in *Step 1*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(1R,2R)-2-hydroxycyclopentyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one. LC-MS calculated for  $C_{24}H_{18}F_2N_5O_4$   $(M+H)^+$   $m/z$ : 478.1; found: 478.0.

## Example 123


3-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2,8-dioxo-2,3,4,7,8,9-hexahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]methyl]benzonitrile

[0634]



Step 1: N-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline


[0635]



[0636] To a solution of sodium triacetoxyborohydride (6.2 g, 29 mmol) in trifluoroacetic acid (10.0 mL, 1.30E2 mmol) at 0 °C was added a solution of 2,6-difluoro-3,5-dimethoxyaniline (1.52 g, 8.03 mmol) in methylene chloride (10 mL), followed by a solution of 4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (*Example 106, Step 1*: 2.27 g, 7.30 mmol) in methylene chloride (40 mL, 700 mmol). The reaction mixture was stirred at 0 °C for 1 h then poured into a cold aqueous solution of NaHCO<sub>3</sub> and then extracted with methylene chloride. The organic phase was washed with brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography eluted with 0 to 40 % EtOAc in DCM to give the desired product as a yellow oil which solidified on standing (3.32 g, 94 %). LC-MS calculated for C<sub>22</sub>H<sub>29</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Si (M+H)<sup>+</sup> m/z: 484.2; found: 484.1.

Step 2: 3-[[5-[[2-(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl]-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]amino]methyl]benzonitrile


[0637]



**[0638]** A mixture of N-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (110 mg, 0.23 mmol), 3-(aminomethyl)benzotrile (45.0 mg, 0.341 mmol), palladium acetate (5.1 mg, 0.023 mmol), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (14 mg, 0.023 mmol), and cesium carbonate (220 mg, 0.68 mmol) in 1,4-dioxane (3 mL, 40 mmol) was evacuated then filled with nitrogen. The resulting mixture was stirred at 150 °C for 2 h then cooled to room temperature and diluted with water and extracted with EtOAc. The organic layer was washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>30</sub>H<sub>36</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>Si (M+H)<sup>+</sup> m/z: 580.3; found: 580.2.

Step 3: 3-[(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-7-[[2-(trimethylsilyl)ethoxy]methyl]-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl)methyl]benzotrile

**[0639]**



**[0640]** The crude product from step 2 was dissolved in tetrahydrofuran (5 mL, 60 mmol) then triethylamine (0.16 mL, 1.1 mmol) was added, followed by triphosgene (74 mg, 0.25 mmol). The resulting brown suspension was stirred at room temperature for 30 min and then the reaction was quenched with 3 mL of 1N NaOH solution. The mixture was stirred at room temperature for 20 min then extracted with EtOAc. The organic layer was then washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column eluted with 0 to 50 % EtOAc in hexanes to give the desired product. LC-MS calculated for C<sub>31</sub>H<sub>34</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub>Si (M+H)<sup>+</sup> m/z: 606.2; found: 606.3.

Step 4: 3-[(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2,8-dioxo-2,3,4,7,8,9-hexahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl)methyl]benzotrile


**[0641]** To a solution of 3-[(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-7-[[2-(trimethylsilyl)ethoxy]methyl]-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl)methyl]benzotrile (60. mg, 0.099 mmol) in isopropyl alcohol (5 mL, 60 mmol) and water (0.5 mL, 30 mmol) was added pyridinium tribromide (160 mg, 0.50 mmol). The resulting yellow solution was stirred at 35 °C for 1 h then cooled to room temperature and zinc (130 mg, 2.0 mmol) and acetic acid (0.11 mL, 2.0 mmol) were added. The reaction mixture was stirred at room temperature for 2 h then filtered and washed with MeOH/DCM. The filtrate was concentrated and the residue was triturated with water and the white solid was collected via filtration then washed with water and dried.

**[0642]** The above solid was dissolved in 2 mL of DCM then 2 mL of TFA was added. The resulting yellow solution was stirred at room temperature 2 h then concentrated. The residue was dissolved in 5 mL of MeOH then ethylenediamine (0.33 mL, 5.0 mmol) was added. The resulting yellow solution was stirred at room temperature for 2 h then purified by prep HPLC (pH 2, acetonitrile/water) to give the desired product as a white solid. LC-MS calculated for C<sub>25</sub>H<sub>20</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 492.1; found: 492.1.

#### Example 124

**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

**[0643]**




**[0644]** This compound was prepared using procedures analogous to those for *Example 106* with 2,3-difluoroaniline replacing cyclobutylamine in *Step 3*. LC-MS calculated for  $C_{23}H_{17}ClF_3N_4O_4$  (M+H)<sup>+</sup> m/z: 505.1; found: 505.0.

### Example 125

**4-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2,8-dioxo-2,3,4,7,8,9-hexahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-1-yl]-3-fluorobenzonitrile**

**[0645]**




**[0646]** This compound was prepared using procedures analogous to those for *Example 123* with 4-amino-3-fluorobenzonitrile replacing 3-(aminomethyl)benzonitrile in *Step 2*. LC-MS calculated for  $C_{24}H_{17}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 496.1; found: 496.0.

### Example 126


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0647]**



*Step 1:* 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


**[0648]**



**[0649]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 49, Step 3*: 900 mg, 2.32 mmol) in N,N-dimethylformamide (20 mL) cooled to 0 °C was added sodium hydride (185 mg, 4.63 mmol, 60 wt % in mineral oil). The resulting mixture was stirred at 0 °C for 30 min then benzenesulfonyl chloride (0.444 mL, 3.48 mmol) was added. The reaction mixture was stirred at 0 °C for 1.5 h at which time LC-MS showed the reaction completed to the desired product. The reaction was quenched with saturated NH<sub>4</sub>Cl solution and diluted with water. The white precipitate was collected via filtration then washed with water and hexanes, dried to afford the desired product (1.2 g, 98 %) as a white solid which was used in the next step without further purification. LC-MS calculated for C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 529.1; found: 529.1.

*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde*


**[0650]**



**[0651]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (1.75 g, 3.31 mmol) in tetrahydrofuran (80 mL) at -78 °C was added freshly prepared lithium diisopropylamide (1M in tetrahydrofuran (THF), 3.48 mL, 3.48 mmol). The resulting mixture was stirred at -78 °C for 30 min then N,N-dimethylformamide (1.4 mL, 18 mmol) was added slowly. The reaction mixture was stirred at -78 °C for 30 min then quenched with water and extracted with EtOAc. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography eluted with 0 to 20 % EtOAc in DCM to give the desired product as a white solid (1.68 g, 91 %). LC-MS calculated for C<sub>26</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 557.1; found: 556.9.

*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0652]**



**[0653]** To a solution 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (1.73 g, 3.11 mmol) in dichloromethane (50 mL) was added morpholine (0.95 mL, 11 mmol), followed by acetic acid (2 mL, 30 mmol). The resulting yellow solution was stirred at room temperature overnight then sodium triacetoxyborohydride (2.3 g, 11 mmol) was added. The mixture was stirred at room temperature for 3 h at which time LC-MS showed the reaction went to completion to the desired product. The reaction was quenched with saturated NaHCO<sub>3</sub> then extracted with ethyl acetate (EtOAc). The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography eluted with 0 to 40 % EtOAc in DCM to give the desired product as a yellow solid (1.85 g, 95 %). LC-MS calculated for C<sub>30</sub>H<sub>32</sub>F<sub>2</sub>N<sub>5</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 628.2; found: 628.0.


*Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0654]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (1.5 g, 2.4 mmol) in tetrahydrofuran (40 mL) was added tetra-n-butylammonium fluoride (1M in THF, 7.2 mL, 7.2 mmol). The resulting solution was stirred at 50 °C for 1.5 h then cooled to room temperature and quenched with water. The mixture was extracted with dichloromethane (DCM) and the organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by flash chromatography eluted with 0 to 10 % MeOH in DCM to give the desired product as a white solid, which was further purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>24</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 488.2; found: 488.0. <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.09 (s, 1H), 8.06 (s, 1H), 7.05 (t, J = 8.1 Hz, 1H), 6.87 (s, 1H), 4.78 (s, 2H), 4.50 (s, 2H), 4.17 (q, J = 6.8 Hz, 2H), 3.97 (br, 2H), 3.89 (s, 6H), 3.65 (br, 2H), 3.37 (br, 2H), 3.15 (br, 2H), 1.37 (t, J = 6.8 Hz, 3H).

### Example 127

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0655]**




**[0656]** This compound was prepared using procedures analogous to those for *Example 126* with 1-methylpiperazine replacing morpholine in *Step 3*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>25</sub>H<sub>31</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 501.2; found: 501.1.

## Example 128

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0657]




[0658] This compound was prepared using procedures analogous to those for *Example 126* with 1-ethylpiperazine replacing morpholine in *Step 3*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>26</sub>H<sub>33</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 515.3; found: 515.1.

## Example 129

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0659]




[0660] This compound was prepared using procedures analogous to those for *Example 126* starting with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (*Example 70, Step 1*) and 1-methylpiperazine. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>24</sub>H<sub>29</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 487.2; found: 487.1.

## Example 130


3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0661]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde

**[0662]**




**[0663]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (*Example 70, step 1*: 500 mg, 0.9 mmol) in a mixture of tetrahydrofuran (25 mL), isopropyl alcohol (2.5 mL) and water (2.5 mL) was added 6.0 M potassium hydroxide in water (1.54 mL, 9.24 mmol). The resulting yellow solution was stirred at room temperature overnight then warmed to 40 °C and stirred for 1 h. The reaction mixture was cooled to room temperature and neutralized with 1 N HCl then saturated NH<sub>4</sub>Cl solution was added. The resulting light yellow precipitate was collected via filtration and dried to give the product (350 mg, 90 %) as a light yellow solid which was used in the next step without further purification. LC-MS calculated for C<sub>19</sub>H<sub>17</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 403.1; found: 402.9.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

**[0664]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (13 mg, 0.032 mmol) in methylene chloride (3 mL) was added 1-piperazine-ethanol (20 μL, 0.16 mmol), followed by acetic acid (55 μL, 0.97 mmol). The resulting yellow suspension was stirred at room temperature for 3 h then sodium triacetoxyborohydride (40. mg, 0.19 mmol) was added. The mixture was stirred at room temperature overnight. The reaction was quenched with saturated NaHCO<sub>3</sub> solution then extracted with methylene chloride. The organic extracts were combined then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O) to give the desired product as a white solid. LC-MS calculated for C<sub>25</sub>H<sub>31</sub>F<sub>2</sub>N<sub>6</sub>O<sub>a</sub> (M+H)<sup>+</sup> m/z: 517.2; found: 517.1.

**Example 131**

**[0665]** 3-(4-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperazin-1-yl)propanenitrile




**[0666]** This compound was prepared using procedures analogous to those for *Example 130* with 3-piperazin-1-ylpropanenitrile replacing 1-piperazine-ethanol in *Step 2*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>26</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 526.2; found: 526.1.

### Example 132

**1-([3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl)methyl]piperidine-4-carbonitrile**

**[0667]**




**[0668]** This compound was prepared using procedures analogous to those for *Example 130* with piperidine-4-carbonitrile replacing 1-piperazine-ethanol in *Step 2*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>25</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 497.2; found: 496.9.

### Example 133

**(3S)-1-([3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl)methyl]pyrrolidine-3-carbonitrile**

**[0669]**




**[0670]** This compound was prepared using procedures analogous to those for *Example 130* with (3S)-pyrrolidine-3-carbonitrile hydrochloride replacing 1-piperazineethanol in *Step 2*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>24</sub>H<sub>25</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 483.2; found: 483.2.

## Example 134

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[[[(1-methylpiperidin-4-yl)amino]methyl]-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0671]




[0672] This compound was prepared using procedures analogous to those for *Example 130* with 1-methylpiperidin-4-amine replacing 1-piperazine-ethanol in *Step 2*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>25</sub>H<sub>31</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 501.2; found: 501.0.

## Example 135

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[[[(3S)-tetrahydrofuran-3-ylamino]methyl]-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0673]




[0674] This compound was prepared using procedures analogous to those for *Example 130* with (3S)-tetrahydrofuran-3-amine hydrochloride replacing 1-piperazine-ethanol in *Step 2*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>23</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 474.2; found: 474.0.

## Example 136

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[[[(3R)-tetrahydrofuran-3-ylamino]methyl]-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0675]




EP 2 861 595 B9

[0676] This compound was prepared using procedures analogous to those for *Example 130* with (3R)-tetrahydrofuran-3-amine hydrochloride replacing 1-piperazine-ethanol in *Step 2*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>23</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 474.2; found: 474.2.

5 **Example 137**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(1H-imidazol-1-ylmethyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

10 **[0677]**



*Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(hydroxymethyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

25 **[0678]**



[0679] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (*Example 70, step 1*: 101 mg, 0.186 mmol) in tetrahydrofuran (5 mL) cooled to 0 °C was added sodium tetrahydroborate (21 mg, 0.56 mmol). The resulting mixture was stirred at 0 °C for 2 h and quenched with water then extracted with EtOAc. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>25</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 545.1; found: 545.0.


45 *Step 2: 8-(chloromethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0680]**

50

55


EP 2 861 595 B9



**[0681]** The crude product from *Step 1* was dissolved in methylene chloride (5 mL) and cooled to 0 °C then N,N-diisopropylethylamine (65  $\mu$ L, 0.37 mmol) was added, followed by methanesulfonyl chloride (19  $\mu$ L, 0.24 mmol). The resulting mixture was warmed to room temperature and stirred overnight. The reaction was quenched with water then extracted with EtOAc. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>25</sub>H<sub>22</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>5</sub>S (M+H)<sup>+</sup> m/z: 563.1; found: 562.9.

*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(1H-imidazol-1-ylmethyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0682]**



**[0683]** A mixture of 8-(chloromethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (30. mg, 0.053 mmol), 1H-imidazole (18 mg, 0.27 mmol) and cesium carbonate (87 mg, 0.27 mmol) in acetonitrile (3 mL) was stirred at 60 °C for overnight at which time LC-MS indicated the reaction went to completion to the desired product. The mixture was cooled to room temperature and diluted with dichloromethane then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>28</sub>H<sub>25</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>S (M+H)<sup>+</sup> m/z: 595.2; found: 595.2.


*Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(1H-imidazol-1-ylmethyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0684]** The crude product from *Step 3* was dissolved in tetrahydrofuran (3 mL) then 1.0 M tetra-nbutylammonium fluoride in THF (0.27 mL, 0.27 mmol) was added. The mixture was stirred at 60 °C for 30 min at which time LC-MS indicated the reaction went to completion to the desired product. The reaction mixture was cooled to room temperature then quenched with water and extracted with dichloromethane. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated. The residue was dissolved in MeOH then purified by prep HPLC (pH =2, acetonitrile/H<sub>2</sub>O) to give the desired product as a white solid. LC-MS calculated for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 455.2; found: 455.1.

## Example 138

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(1H-pyrazol-1-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0685]




[0686] This compound was prepared using procedures analogous to those for *Example 137* with 1H-pyrazole replacing 1H-imidazole and the reaction mixture was stirred at 80 °C in *Step 3*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 455.2; found: 454.9.

## Example 139


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methyl-1H-pyrazol-4-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0687]



*Step 1*: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[hydroxy(1-methyl-1H-pyrazol-4-yl)methyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0688]




[0689] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (70.0 mg, 0.136 mmol) in tetrahydrofuran (2 mL) at -78 °C was added freshly prepared lithium diisopropylamide (0.5 M in THF, 0.3 mL, 0.15 mmol). The resulting mixture was stirred at -78 °C for 30 min then a solution of 1-methyl-1H-pyrazole-4-carbaldehyde (45 mg, 0.41 mmol) in THF (0.5 mL) was added. The

## EP 2 861 595 B9

reaction mixture was stirred at -78 °C for 30 min then the reaction was quenched with water. The mixture was warmed to room temperature then extracted with EtOAc. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>29</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 625.2; found: 624.9.

*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methyl-1H-pyrazol-4-yl)methyl]-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

### [0690]



**[0691]** A container having a mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[hydroxy(1-methyl-1H-pyrazol-4-yl)methyl]-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (crude product from *Step 1*: 50 mg, 0.08 mmol), 2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (32 mg, 0.080 mmol) and molybdenum hexacarbonyl (6 mg, 0.02 mmol) in 1,4-dioxane (1 mL) was evacuated then filled with nitrogen. The resulting mixture was stirred at 190 °C for 2 h then cooled to room temperature and quenched with water then extract with EtOAc. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>29</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>S (M+H)<sup>+</sup> m/z: 609.2; found: 609.0.


*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methyl-1H-pyrazol-4-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0692]** The crude product from *Step 2* was dissolved in THF (2 mL) then 1.0 M potassium tert-butoxide in THF (0.40 mL, 0.40 mmol) was added. The resulting mixture was stirred at room temperature for 30 min then diluted with MeOH and purified by prep-HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>23</sub>H<sub>23</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 469.2; found: 469.0.

### Example 140


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyridin-2-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

### [0693]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-8-[(E)-2-pyridin-2-ylvinyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0694]



[0695] A container having a mixture of 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (40.0 mg, 0.0674 mmol), 2-vinylpyridine (21 mg, 0.20 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complexed with dichloromethane (1:1) (3 mg, 0.004 mmol), and barium hydroxide octahydrate (42 mg, 0.13 mmol) in N,N-dimethylformamide (1 mL, 20 mmol) and a few drops of water was evacuated then filled with nitrogen. The resulting mixture was stirred at 100 °C for 5 h then cooled to room temperature. The mixture was diluted with water then extracted with EtOAc. The organic extracts were combined then washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>31</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>5</sub>S (M+H)<sup>+</sup> m/z: 618.2; found: 617.9.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(E)-2-pyridin-2-ylvinyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0696]



[0697] The crude product from Step 1 was dissolved in THF (2 mL) then 1.0 M tetra-n-butylammonium fluoride in THF (674 μL, 0.674 mmol) was added. The resulting mixture was stirred at 60 °C for 2 h then cooled to room temperature and diluted with EtOAc. The mixture was washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>25</sub>H<sub>22</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 478.2; found: 478.1.


Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyridin-2-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0698] The crude product from Step 2 was dissolved in MeOH (2 mL) then Palladium (10 wt % on activated carbon, 30 mg) was added. The mixture was stirred under a balloon of hydrogen at room temperature for 2 h then filtered and concentrated. The residue was dissolved in MeOH then purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>25</sub>H<sub>24</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 480.2; found: 480.0.

## Example 141

3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0699]




[0700] This compound was prepared using procedures analogous to those for *Example 126* with 3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 63, Step 5*) replacing 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/H<sub>2</sub>O). LC-MS calculated for C<sub>24</sub>H<sub>28</sub>ClFN<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 504.2; found: 504.0.

## Example 142

8-[2-(diethylamino)ethyl]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0701]




[0702] This compound was prepared using procedures analogous to those for *Example 71* with diethylamine replacing 1-ethylpiperazine in *Step 3*. LC-MS calculated for C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 474.2; found: 474.0.

## Example 143

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(3-fluoroazetidin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0703]




**[0704]** This compound was prepared using procedures analogous to those for *Example 71* with 3-fluoroazetidinium hydrochloride replacing 1-ethylpiperazine in *Step 3*. LC-MS calculated for  $C_{23}H_{25}F_3N_5O_3$  (M+H)<sup>+</sup> m/z: 476.2; found: 476.0.

#### Example 144

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(3-methoxyazetidin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0705]**




**[0706]** This compound was prepared using procedures analogous to those for *Example 71* with 3-methoxy-azetidinium hydrochloride replacing 1-ethylpiperazine in *Step 3*. LC-MS calculated for  $C_{24}H_{28}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 488.2; found: 488.0.

#### Example 145

**3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0707]**




**[0708]** This compound was prepared using procedures analogous to those for *Example 101* with 1-methyl-1H-pyrazol-4-amine replacing cyclopropylamine. LC-MS calculated for  $C_{20}H_{18}ClFN_7O_3$  (M+H)<sup>+</sup> m/z: 458.1; found: 457.9. <sup>1</sup>H NMR (500 MHz, DMSO)  $\delta$  13.56 (s, 1H), 8.29 (s, 1H), 8.05 (s, 1H), 7.60 (s, 1H), 7.04 (d, *J* = 7.7 Hz, 1H), 6.23 (s, 1H), 4.91 (d, *J* = 4.4 Hz, 2H), 3.95 (s, 3H), 3.94 (s, 3H), 3.92 (s, 3H).

## Example 146


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0709]



Step 1: 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde


[0710]



[0711] 4-Chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (1.08 g, 6.00 mmol) and cesium carbonate (3.91 g, 12.0 mmol) were dissolved in N,N-dimethylformamide (10 mL), light yellow suspension. The mixture was stirred at room temperature for 20 min then benzenesulfonyl chloride (1.53 mL, 12.0 mmol) was added dropwise. After completion of the addition, white-pinkish suspension was obtained. The mixture was stirred at room temperature for 2 h at which time LC-MS indicated the reaction completed to the desired product. The reaction mixture was diluted with water. The solid was collected via filtration and washed with water then dried to give white solid (1.92 g, *quant.*), which was used in the next step without further purification. LC-MS calculated for  $C_{14}H_{10}ClN_2O_3S$  (M+H)<sup>+</sup> m/z: 321.0; found: 320.9.

Step 2: N-[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]methyl)-2,6-difluoro-3,5-dimethoxyaniline

[0712]




[0713] This compound was prepared using procedures analogous to those for *Example 123, step 1* with 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde replacing 4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde. LC-MS calculated for  $C_{22}H_{19}ClF_2N_3O_4S$  (M+H)<sup>+</sup> m/z: 494.1; found: 494.1.

EP 2 861 595 B9

Step 3: *N*-(2-([*tert*-butyl(dimethyl)silyl]oxy)ethyl)-5-[[2,6-difluoro-3,5-dimethoxyphenyl]amino]methyl]-1-(phenylsulfonyl)-1Hpyrrolo[2,3-*b*]pyridin-4-amine


[0714]



[0715] A container having a mixture of *N*-[[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-*b*]pyridin-5-yl]methyl]-2,6-difluoro-3,5-dimethoxyaniline (480 mg, 0.97 mmol), 2-([*tert*-butyl(dimethyl)silyl]oxy)ethanamine (337 mg, 1.92 mmol), palladium acetate (22 mg, 0.097 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (56 mg, 0.097 mmol), and cesium carbonate (630 mg, 1.94 mmol) in toluene (10 mL) was degassed then filled with nitrogen. The resulting mixture was stirred at 120 °C for 2 h at which time LC-MS indicated the reaction completed to the desired product. The mixture was cooled to room temperature then diluted with DCM and filtered. The filtrate was concentrated and the residue was purified by column eluted with 0 to 30 % EtOAc/DCM to give the desired product (625 mg, *quant.*). LC-MS calculated for  $C_{30}H_{39}F_2N_4O_5SSi$  (M+H)<sup>+</sup> *m/z*: 633.2; found: 633.1.

Step 4: 1-(2-([*tert*-butyl(dimethyl)silyl]oxy)ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-*d*]pyrimidin-2-one


[0716]



[0717] The product from Step 3 was dissolved in tetrahydrofuran (10 mL) then triethylamine (0.70 mL, 5.0 mmol) was added, followed by triphosgene (290 mg, 0.97 mmol). The resulting suspension was stirred at room temperature for 30 min then the reaction was quenched with 10 mL of 1N NaOH solution. The mixture was stirred at room temperature for 2 h then extracted with EtOAc. The combined extract was then washed with water, brine and dried over  $Na_2SO_4$  and concentrated. The residue was purified by column eluted with 0 to 30 % EtOAc/DCM to give the desired product (313 mg, 49 %). LC-MS calculated for  $C_{31}H_{37}F_2N_4O_6SSi$  (M+H)<sup>+</sup> *m/z*: 659.2; found: 659.2.

Step 5: 8-bromo-1-(2-([*tert*-butyl(dimethyl)silyl]oxy)ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2Hpyrrolo[3',2':5,6]pyrido[4,3-*d*]pyrimidin-2-one


[0718]



**[0719]** To a solution of 1-(2-{{tert-butyl(dimethyl)silyl}oxy}ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (313 mg, 0.475 mmol) in tetrahydrofuran (8 mL) at -78 °C was added freshly prepared lithium diisopropylamine solution (1M in THF, 0.5 mL, 0.5 mmol). The mixture was stirred at -78 °C for 30 min, then a solution of 1,2-dibromo-1,1,2,2-tetrachloroethane (155 mg, 0.475 mmol) in 1 mL of THF was added. The mixture was stirred at -78 °C for 1 h then quenched with saturated NH<sub>4</sub>Cl solution. The mixture was warmed to room temperature and extracted with EtOAc. The combined extract was then washed with water, brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column eluted with 0 to 20 % EtOAc/DCM to give the desired product (320 mg, 91 %). LC-MS calculated for C<sub>31</sub>H<sub>36</sub>BrF<sub>2</sub>N<sub>4</sub>O<sub>6</sub>SSi (M+H)<sup>+</sup> m/z: 737.1; found: 736.9.

*Step 6: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(2-morpholin-4-ylethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0720]**



**[0721]** This compound was prepared using procedures analogous to those for *Example 71, Step 1-3* starting with 8-bromo-1-(2-{{tert-butyl(dimethyl)silyl}oxy}ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from Step 5) and morpholine. LC-MS calculated for C<sub>31</sub>H<sub>34</sub>F<sub>2</sub>N<sub>5</sub>O<sub>7</sub>S (M+H)<sup>+</sup> m/z: 658.2; found: 658.2.


*Step 7: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0722]** To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(2-morpholin-4-ylethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (16 mg, 0.024 mmol) in tetrahydrofuran (2 mL) was added 1.0 M tetra-n-butylammonium fluoride in THF (120 μL, 0.12 mmol). The resulting yellow solution was stirred at 50 °C for 20 min at which time LC-MS indicated the reaction completed to the desired product. The mixture was cooled to room temperature then quenched with a few drops of TFA. The mixture was diluted with MeOH then purified by prep HPLC (pH = 2, acetonitrile/water) to give the product as a white solid. LC-MS calculated for C<sub>25</sub>H<sub>30</sub>F<sub>2</sub>N<sub>5</sub>O<sub>5</sub> (M+H)<sup>+</sup> m/z: 518.2; found: 518.0.

#### Example 147

**1-(3-chloropyridin-2-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-3,4,7,9-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-2,8-dione**

**[0723]**




**[0724]** This compound was prepared using procedures analogous to those for *Example 123* with 3-chloropyridin-2-amine replacing 3-(aminomethyl)benzotrile in *Step 2*. LC-MS calculated for  $C_{22}H_{17}ClF_2N_5O_4$  ( $M+H$ )<sup>+</sup>  $m/z$ : 488.1; found: 488.1.

#### Example 148

**7'-(2,6-difluoro-3,5-dimethoxyphenyl)-6',7'-dihydrospiro[cyclobutane-1,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one**

**[0725]**




**[0726]** This compound prepared using procedures analogous to those for *Example 66* with 1,3-dibromopropane replacing 1-bromo-2-chloroethane. The product was purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{21}H_{20}F_2N_3O_3$  ( $M+H$ )<sup>+</sup>  $m/z$ : 400.1; found: 400.0.

#### Example 149

**7'-(2,6-difluoro-3,5-dimethoxyphenyl)-6',7'-dihydrospiro[cyclopentane-1,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one**

**[0727]**




**[0728]** This compound prepared using procedures analogous to those for *Example 66* with 1,4-dibromobutane replacing 1-bromo-2-chloroethane. The product was purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{22}H_{22}F_2N_3O_3$  ( $M+H$ )<sup>+</sup>  $m/z$ : 414.2; found: 414.1.

## Example 150

7'-(2,6-difluoro-3,5-dimethoxyphenyl)-2,3,5,6,6',7'-hexahydrospiro[pyran-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one

[0729]




[0730] This compound prepared using procedures analogous to those for *Example 66* with bis(2-bromoethyl) ether replacing 1-bromo-2-chloroethane. The product was purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{22}H_{22}F_2N_3O_4$  (M+H)<sup>+</sup> m/z: 430.2; found: 430.0.

## Example 151


7'-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-6',7'-dihydrospiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one

[0731]



Step 1: *tert*-Butyl-7'-(2,6-difluoro-3,5-dimethoxyphenyl)-8'-oxo-3'-[2-(trimethylsilyl)ethoxy]methyl-3',6',7',8'-tetrahydro-1*H*-spiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridine]-1-carboxylate

[0732]




[0733] Nitrogen was bubbled through a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-[2-(trimethylsilyl)ethoxy]methyl-3,6,7,9-tetrahydro-8*H*-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (*Example 60*, Step 2: 50.0 mg, 0.102 mmol) in DMF (1.1 mL) for 10 min and then cesium carbonate (100.0 mg, 0.31 mmol) and *tert*-butyl-bis(2-chloroethyl)carbamate (0.0742 g, 0.306 mmol) were added under nitrogen and then the mixture was stirred at 50 °C for overnight. The

mixture was filtered and then concentrated. The residue was used in the next step without further purification. LC-MS calculated for  $C_{33}H_{45}F_2N_4O_6Si$  (M+H)<sup>+</sup> m/z: 659.3; found: 659.4.

Step 2: 7'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-[2-(trimethylsilyl)ethoxy]methyl]-6',7'-dihydrospiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one


**[0734]**



**[0735]** To a solution of tert-butyl-7'-(2,6-difluoro-3,5-dimethoxyphenyl)-8'-oxo-3'-[2-(trimethylsilyl)ethoxy]methyl]-3',6',7',8'-tetrahydro-1H-spiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridine]-1-carboxylate (95.5 mg, 0.145 mmol) (crude product from Step 1) in methylene chloride (0.5 mL) was added hydrogen chloride (4M in 1,4-dioxane, 0.5 mL, 2 mmol) and the mixture was stirred at room temperature for 45 min. Then the solvent was removed under reduced pressure and the residue was used in the next step without further purification. LC-MS calculated for  $C_{28}H_{37}F_2N_4O_4Si$  (M+H)<sup>+</sup> m/z: 559.3; found: 559.3.

Step 3: 7'-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3'-[2-(trimethylsilyl)ethoxy]methyl]-6',7'-dihydrospiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one

**[0736]**



**[0737]** A mixture of 7'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-[2-(trimethylsilyl)ethoxy]methyl]-6',7'-dihydrospiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one (20.0 mg, 0.0358 mmol) and formaldehyde (9.0 M in water, 12  $\mu$ L, 0.11 mmol) in methylene chloride (0.5 mL) was stirred at room temperature for 5 min and then sodium triacetoxyborohydride (23 mg, 0.11 mmol) was added. The reaction mixture was stirred at room temperature for 30 min then diluted with methylene chloride and washed with 1 N NaOH, water and brine. The organic layer was dried over  $Na_2SO_4$  filtered and concentrated to give the crude product which was used in the next step without further purification. LC-MS calculated for  $C_{29}H_{39}F_2N_4O_4Si$  (M+H)<sup>+</sup> m/z: 573.3; found: 573.3.

Step 4: 7'-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-6',7'-dihydrospiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one

**[0738]** To a solution of 7'-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-3'-[2-(trimethylsilyl)ethoxy]methyl]-6',7'-dihydrospiro[piperidine-4,9'-pyrrolo[2,3-c][2,7]naphthyridin]-8'(3'H)-one (20.0 mg, 0.035 mmol) in methylene chloride (0.3 mL) was added TFA (0.2 mL). The mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in methanol (0.3 mL) and then ethylenediamine (0.2 mL) was added. The mixture was stirred at 50 °C for 1.5 h then cooled to room temperature and purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product.

LC-MS calculated for  $C_{23}H_{25}F_2N_4O_3$  (M+H)<sup>+</sup> m/z: 443.2; found: 443.2.


**Example 152**

5 **7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(morpholin-4-ylmethyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

[0739]

10

15




20 *Step 1: ethyl 3-[[[4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl](2,6-difluoro-3,5-dimethoxyphenyl)amino]-3-oxopropanoate*

[0740]

25

30

35



40

[0741] A mixture of N-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (*Example 123, Step 1*: 1.45 g, 3.00 mmol) and triethylamine (0.84 mL, 6.0 mmol) in ethyl malonate (5.0 mL, 33 mmol) was stirred at 165 °C for 4 h then cooled to room temperature. The mixture was concentrated under reduced pressure then purified by column eluted with 0 to 40 % EtOAc/Hexanes to give the desired product (0.8 g, 44 %). LC-MS calculated for  $C_{27}H_{35}ClF_2N_3O_6Si$  (M+H)<sup>+</sup> m/z: 598.2; found: 598.0.


*Step 2: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one*

45

[0742]

50

55




EP 2 861 595 B9

**[0743]** To a solution of ethyl 3-[(4-chloro-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl](2,6-difluoro-3,5-dimethoxyphenyl)amino]-3-oxopropanoate (1.60 g, 2.68 mmol) in toluene (10 mL) was added sodium bis(trimethylsilyl)amide (589 mg, 3.21 mmol) and the mixture was stirred for 15 min at room temperature under nitrogen. Then dibromobis(tri-*t*-butylphosphino)dipalladium (I) (Aldrich, cat #677728: 62 mg, 0.080 mmol) was added and the mixture was evacuated then refilled with nitrogen for three times. The reaction mixture was then stirred at 115 °C for overnight. The mixture was cooled to room temperature then diluted with methylene chloride, washed with saturated NaHCO<sub>3</sub>, water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then concentrated. The residue was purified by column eluted with 0 to 40 % EtOAc/Hexanes to give the desired product (0.81 g, 62 %). LC-MS calculated for C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>Si (M+H)<sup>+</sup> m/z: 490.2; found: 490.1.

Step 3: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one


**[0744]**



**[0745]** Nitrogen was bubbled through a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (1.00 g, 2.04 mmol) in N,N-dimethylformamide (10 mL) for 20 min and then cesium carbonate (2.0 g, 6.1 mmol) and methyl iodide (509 μL, 8.17 mmol) were added under nitrogen. The resulting mixture was stirred at room temperature overnight. The mixture was filtered and then concentrated. The residue was purified by column eluted with 0 to 40 % EtOAc/Hexanes to give the desired product (0.95 g, 90 %). LC-MS calculated for C<sub>26</sub>H<sub>34</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>Si (M+H)<sup>+</sup> m/z: 518.2; found: 518.2.

Step 4: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one


**[0746]**



**[0747]** To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-[[2-(trimethylsilyl)ethoxy]methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (1.0 g, 1.9 mmol) in methylene chloride (4 mL) was added trifluoroacetic acid (4 mL, 50 mmol). The mixture was stirred at room temperature for 2 h then concentrated under reduced pressure. The residue was dissolved in methanol (6 mL) and then ethylenediamine (3 mL) was added. The mixture was stirred at 50 °C for 2.5 h then cooled to room temperature and concentrated. The residue was triturated with water and the precipitate was collected via filtration then washed with water and dried to give the desired product (0.67 g, 90 %). LC-MS calculated for C<sub>20</sub>H<sub>20</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub> (M+H)<sup>+</sup> m/z: 388.1; found: 388.2.

Step 5: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one


[0748]



[0749] To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (0.070 g, 0.18 mmol) in dimethylformamide (DMF) (1.0 mL) was added sodium hydride (0.0108 g, 0.271 mmol) (60% NaH dispersion in mineral oil) at 0 °C and the resulting mixture was stirred for 15 min. At this time benzenesulfonyl chloride (25.4 μL, 0.199 mmol) was added and the reaction mixture was stirred for 1 h at 0 °C. The reaction was quenched by addition of saturated NH<sub>4</sub>Cl aqueous solution then extracted with methylene chloride. The combined extract was then washed with saturated NaHCO<sub>3</sub>, water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column eluted with ethyl acetate in DCM (0 to 10 %) to afford the desired product. LC-MS calculated for C<sub>26</sub>H<sub>24</sub>F<sub>2</sub>N<sub>3</sub>O<sub>5</sub>S [M+H]<sup>+</sup> m/z: 528.1; found 528.1.

Step 6: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-8-oxo-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-pyrrolo[2,3-c]-2,7-naphthyridine-2-carbaldehyde

[0750]




[0751] To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (0.80 g, 1.5 mmol) in tetrahydrofuran (4 mL) at -78 °C was added freshly prepared lithium diisopropylamide (1M in THF, 2.3 mL, 2.3 mmol). The mixture was stirred for 0.5 h and then N,N-dimethylformamide (0.69 mL, 8.9 mmol) was added. The mixture was stirred at -78 °C for 1 h then quenched with water and warmed to room temperature. The mixture was diluted with methylene chloride, washed with saturated NaHCO<sub>3</sub>, water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and then concentrated. The mixture was used in the next step without further purification.

LC-MS calculated for C<sub>27</sub>H<sub>24</sub>F<sub>2</sub>N<sub>3</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 556.1; found: 556.0.

Step 7: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(morpholin-4-ylmethyl)-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0752]



**[0753]** To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-8-oxo-3-(phenylsulfonyl)-6,7,9-tetrahydro-3H-pyrrolo[2,3-c]-2,7-naphthyridine-2-carbaldehyde (0.50 g, 0.90 mmol) in 1,2-dichloroethane (12 mL) was added morpholine (0.47 mL, 5.4 mmol), followed by acetic acid (0.15 mL, 2.7 mmol). The mixture was stirred at room temperature overnight then sodium triacetoxyborohydride (570 mg, 2.7 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with methylene chloride, then washed with 1N NaOH, water and brine. The organic layer was dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The residue was purified by column eluted with 0 to 20 % EtOAc/DCM to give the desired product (0.40 g, 71 %). LC-MS calculated for  $\text{C}_{31}\text{H}_{33}\text{F}_2\text{N}_4\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$  m/z: 627.2; found 627.3.


*Step 8: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(morpholin-4-ylmethyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one*

**[0754]** To a mixture of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(morpholin-4-ylmethyl)-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (0.48 g, 0.76 mmol) in tetrahydrofuran (8.0 mL) was added 1.0 M tetra-n-butylammonium fluoride in THF (4.5 mL, 4.5 mmol). The reaction mixture was stirred at 60 °C for 1 h then cooled to room temperature and quenched with water. The product was purified by prep-HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $\text{C}_{25}\text{H}_{29}\text{F}_2\text{N}_4\text{O}_4$   $(\text{M}+\text{H})^+$  m/z: 487.2; found: 487.0.  $^1\text{H}$  NMR (500 MHz, DMSO)  $\delta$  11.81 (s, 1H), 8.19 (s, 1H), 7.06 (t,  $J=8.2$  Hz, 1H), 6.91 (s, 1H), 4.91 (s, 2H), 4.40 (s, 2H), 3.90 (s, 6H), 3.81 (s, 4H), 3.17 (s, 4H), 1.75 (s, 6H).

### Example 153


**7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-[(4-methylpiperazin-1-yl)methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

**[0755]**



*Step 1: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-[(4-methylpiperazin-1-yl)methyl]-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one*

**[0756]**



**[0757]** This compound was prepared using procedures analogous to those for *Example 152, Step 7* with *N*-methyl piperazine replacing morpholine. LC-MS calculated for  $C_{32}H_{36}F_2N_5O_5S$  ( $M+H$ )<sup>+</sup> *m/z*: 640.2; found: 640.3.


15 *Step 2: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-[(4-methylpiperazin-1-yl)methyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one*

**[0758]** To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-[(4-methylpiperazin-1-yl)methyl]-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (25.0 mg) in THF (1.0 mL) was added 1 M TBAF in THF (0.1 mL). The mixture was stirred at 60 °C for 30 min then cooled to room temperature and purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{26}H_{32}F_2N_5O_3$  ( $M+H$ )<sup>+</sup> *m/z*: 500.2; found: 500.0.

#### Example 154

25 **7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(4-ethylpiperazin-1-yl)methyl]-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

**[0759]**




**[0760]** This compound was prepared using procedures analogous to those for *Example 153* with *N*-ethyl piperazine replacing *N*-methyl piperazine. LC-MS calculated for  $C_{27}H_{34}F_2N_5O_3$  ( $M+H$ )<sup>+</sup> *m/z*: 514.3; found: 514.0. <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.92 (s, 1H), 8.12 (s, 1H), 7.08 (t, *J* = 8.2 Hz, 1H), 6.69 (s, 1H), 4.90 (s, 2H), 3.94 (s, 2H), 3.90 (s, 6H), 3.51 (br, 2H), 3.24 - 3.08 (m, 4H), 3.03 (br, 2H), 2.57 (br, 2H), 1.71 (s, 6H), 1.18 (t, *J* = 7.3 Hz, 3H).

#### Example 155

50 **1-[[7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-8-oxo-6,7,8,9-tetrahydro-3H-pyrrolo[2,3-c]-2,7-naphthyridin-2-yl]methyl]piperidine-4-carbonitrile**

**[0761]**




**[0762]** This compound was prepared using procedures analogous to those for *Example 153* with piperidine-4-carbonitrile replacing *N*-methyl piperazine. LC-MS calculated for  $C_{27}H_{30}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 510.2; found: 510.0.

#### Example 156

**7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

**[0763]**




**[0764]** This compound prepared using procedures analogous to those for *Example 153* with (3S)-N,N-dimethylpyrrolidin-3-amine replacing *N*-methyl piperazine. LC-MS calculated for  $C_{27}H_{34}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 514.3; found: 514.1.

#### Example 157

**7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]methyl-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

**[0765]**




**[0766]** This compound prepared using procedures analogous to those for *Example 153* with (3R)-N,N-dimethylpyrrolidin-3-amine replacing *N*-methyl piperazine. LC-MS calculated for  $C_{27}H_{34}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 514.3; found: 514.1.

## Example 158


7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(2-morpholin-4-ylethyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0767]



Step 1: 2-bromo-7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one


[0768]



[0769] To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (*Example 152, Step 5*: 0.25 g, 0.47 mmol) in tetrahydrofuran (5 mL) at -78 °C was added freshly prepared lithium diisopropylamide solution (1M in THF, 0.7 mL). The mixture was stirred at -78 °C for 30 min then a solution of 1,2-dibromo-1,1,2,2-tetrachloroethane (0.23 g, 0.71 mmol) in THF (1 mL) was added. The resulting mixture was stirred at -78 °C for 1 h then quenched with water and warmed to room temperature. The mixture was extracted with EtOAc. The combined extract was washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column eluted with 0 to 10 % EtOAc/DCM to give the desired product. LC-MS calculated for C<sub>26</sub>H<sub>23</sub>BrF<sub>2</sub>N<sub>3</sub>O<sub>5</sub>S (M+H)<sup>+</sup> m/z: 606.1; found: 605.8.

Step 2: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(E)-2-ethoxyvinyl]-9,9-dimethyl-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0770]




EP 2 861 595 B9

**[0771]** To a mixture of 2-bromo-7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (0.10 g, 0.16 mmol), 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Aldrich, cat# 731528: 0.033 g, 0.16 mmol) and sodium carbonate (0.035 g, 0.33 mmol) in 1,4-dioxane (1 mL, 10 mmol)/water (0.2 mL, 10 mmol) was added dichloro(bis {di-tert-butyl[4-(dimethylamino)phenyl]phosphoranyl})palladium (3.5 mg, 0.0049 mmol). The mixture was evacuated then refilled with N<sub>2</sub> for three times. The reaction mixture was then stirred at 95 °C for overnight then cooled to room temperature and diluted with DCM. The mixture was washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column eluted with 0 to 10 % EtOAc/DCM to give the desired product.

LC-MS calculated for C<sub>33</sub>H<sub>30</sub>N<sub>3</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 598.2; found: 598.2.

*Step 3: (7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-8-oxo-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-pyrrolo[2,3-c]-2,7-naphthyridin-2-yl)acetaldehyde*


**[0772]**



**[0773]** The product from *Step 2* was dissolved in tetrahydrofuran (1.0 mL) and then concentrated HCl (0.1 mL) was added and the mixture was stirred at room temperature for 2 h. The mixture was diluted with methylene chloride then washed with saturated NaHCO<sub>3</sub>, water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to provide the product which was used in the next step without further purification. LC-MS calculated for C<sub>28</sub>H<sub>26</sub>F<sub>2</sub>N<sub>3</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 570.1; found: 570.0.

*Step 4: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one*

**[0774]**



**[0775]** A mixture of [7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-8-oxo-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-pyrrolo[2,3-c]-2,7-naphthyridin-2-yl]acetaldehyde (30.0 mg, 0.0527 mmol), morpholine (0.06 mL, 0.7 mmol) and acetic acid (0.030 mL) in methylene chloride (0.8 mL, 10 mmol) was stirred at room temperature for 1 h and then sodium triacetoxyborohydride (33 mg, 0.16 mmol) was added. The reaction mixture was stirred at room temperature overnight then diluted with methylene chloride, washed with saturated NaHCO<sub>3</sub>, water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was used in the next step without further purification. LC-MS calculated for C<sub>32</sub>H<sub>35</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 641.2; found: 641.0.

## EP 2 861 595 B9


Step 5: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(2-morpholin-4-ylethyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0776] To a solution of 7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one (25.0 mg) in THF (0.5 mL) was added 1 M potassium t-butoxide in THF (0.2 mL). The mixture was stirred at room temperature for 30 min then purified by prep-HPLC (pH = 2, acetonitrile/water) to give the desired product. LC-MS calculated for  $C_{26}H_{31}F_2N_4O_4$  (M+H)<sup>+</sup> m/z: 501.2; found: 501.0.

### Example 159

7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[2-(4-ethylpiperazin-1-yl)ethyl]-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0777]




[0778] This compound was prepared using procedures analogous to those for *Example 158* with *N*-ethyl piperazine replacing morpholine in *Step 4*. LC-MS calculated for  $C_{28}H_{36}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 528.3; found: 528.0.

### Example 160

7-(2,6-difluoro-3,5-dimethoxyphenyl)-9,9-dimethyl-2-[2-(4-methylpiperazin-1-yl)ethyl]-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one

[0779]




[0780] This compound was prepared using procedures analogous to those for *Example 158* with *N*-methyl piperazine replacing morpholine in *Step 4*. LC-MS calculated for  $C_{27}H_{34}F_2N_5O_3$  (M+H)<sup>+</sup> m/z: 514.3; found: 514.0.

### Example 161

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(1,3-oxazol-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0781]

EP 2 861 595 B9




**[0782]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(1,3-oxazol-4-yl)methanamine hydrochloride replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{20}H_{17}F_2N_6O_4$  (M+H)<sup>+</sup> m/z: 443.1; found: 443.1.

**Example 162**

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(isoxazol-3-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0783]**




**[0784]** This compound was prepared using procedures analogous to those for *Example 85* with 1-isoxazol-3-ylmethanamine hydrochloride replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{20}H_{17}F_2N_6O_4$  (M+H)<sup>+</sup> m/z: 443.1; found: 443.1.

**Example 163**

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(1,3-thiazol-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0785]**




**[0786]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(1,3-thiazol-4-yl)methanamine hydrochloride replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{20}H_{17}F_2N_6O_3S$  (M+H)<sup>+</sup> m/z: 459.1; found: 459.0.

## Example 164

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-[2-(difluoromethoxy)phenyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0787]




[0788] This compound was prepared using procedures analogous to those for *Example 85* with 2-(difluoromethoxy)aniline replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{23}H_{18}F_4N_5O_4$  (M+H)<sup>+</sup> m/z: 504.1; found: 503.9.

## Example 165

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-[2-(1H-pyrazol-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0789]




[0790] This compound was prepared using procedures analogous to those for *Example 85* with 2-(1H-pyrazol-1-yl)ethanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{20}F_2N_7O_3$  (M+H)<sup>+</sup> m/z: 456.2; found: 456.0.

## Example 166

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0791]

EP 2 861 595 B9




**[0792]** This compound was prepared using procedures analogous to those for *Example 85* with 1-[(2R)-tetrahydrofuran-2-yl]methanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{22}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 446.2; found: 445.9.

**Example 167**

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-[(2S)-tetrahydrofuran-2-ylmethyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0793]**




**[0794]** This compound was prepared using procedures analogous to those for *Example 85* with 1-[(2S)-tetrahydrofuran-2-yl]methanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{22}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 446.2; found: 446.0.

**Example 168**

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-pyrazin-2-ylethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0795]**




**[0796]** This compound was prepared using procedures analogous to those for *Example 85* with 2-pyrazin-2-ylethan-amine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 10, acetonitrile/water). LC-MS calculated for  $C_{22}H_{20}F_2N_7O_3$  (M+H)<sup>+</sup> m/z: 468.2; found: 468.0.

## Example 169

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-pyridin-2-ylethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0797]




[0798] This compound was prepared using procedures analogous to those for *Example 85* with 2-pyridine-ethanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{23}H_{21}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 467.2; found: 467.1.

## Example 170

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-pyridin-3-ylethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0799]




[0800] This compound was prepared using procedures analogous to those for *Example 85* with 2-pyridin-3-ylethanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{23}H_{21}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 467.2; found: 467.1.

## Example 171

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-pyridin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0801]




[0802] This compound was prepared using procedures analogous to those for *Example 85* with 2-pyridin-4-ylethan-amine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 10, acetonitrile/water). LC-MS calculated for  $C_{23}H_{21}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 467.2; found: 467.0.

5 **Example 172**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(1-ethyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

10 [0803]



[0804] This compound was prepared using procedures analogous to those for *Example 85* with 1-ethyl-1H-pyrazol-4-amine (Ark Pharm, Cat # AK-43711) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{20}F_2N_7O_3$  (M+H)<sup>+</sup> m/z: 456.2; found: 456.2.


25

**Example 173**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

30

[0805]




35

40

*Step 1: 1-(2-[(tert-butyl(dimethyl)silyl]oxy)-2-methylpropyl]-1H-pyrazol-4-amine*

45

[0806]



50

55

[0807] A mixture of 4-nitro-1H-pyrazole (0.50 g, 4.4 mmol), 2,2-dimethyl-oxirane (1.1 mL, 13 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (1.3 mL, 8.8 mmol) in acetonitrile (5 mL) was stirred at 70 °C for 1 hour. After cooling to room temperature, the mixture was diluted with water and extracted with EtOAc. The combined extracts were washed with water and brine. The organic layer was dried over  $Na_2SO_4$ , filtered and concentrated. The residue was dissolved in

## EP 2 861 595 B9

tetrahydrofuran (20 mL) then tert-butyldimethylsilyl chloride (0.73 g, 4.9 mmol), 1H-imidazole (30 mg, 0.44 mmol) and triethylamine (2.5 mL, 18 mmol) were added. The mixture was stirred at room temperature overnight then diluted with water and extracted with EtOAc. The combined extracts were washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> then filtered and concentrated. The residue was dissolved in methanol (30 mL) then palladium (10 wt % on carbon, 110 mg, 0.10 mmol) was added. The suspension was stirred under H<sub>2</sub> atmosphere (balloon) at room temperature for overnight. The mixture was filtered and the filtrate was concentrated to yield the desired product, which was used in the next step without further purification.


*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0808]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(2-[[tert-butyl(dimethyl)silyl]oxy]-2-methylpropyl)-1H-pyrazol-4-amine (product from step 1) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for C<sub>23</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 500.2; found: 500.0.

### Example 174


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0809]**



*Step 1: 1-(2-methoxyethyl)-1H-pyrazol-4-amine*

**[0810]**



**[0811]** A mixture of 4-nitro-1H-pyrazole (0.5 g, 4 mmol), Ethane, 1-bromo-2-methoxy (0.84 mL, 8.8 mmol), and potassium carbonate (1.2 g, 8.8 mmol) in N,N-dimethylformamide (8 mL, 100 mmol) was stirred at 70 °C for 1 hour. After cooling to room temperature, the mixture was diluted with water then extracted with EtOAc. The combined extracts were washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered then concentrated. The residue was dissolved in methanol (10 ml) then a catalytic amount of palladium (10 wt % on activated carbon) was added. The suspension was stirred under a balloon of H<sub>2</sub> at room temperature for 2 hours then filtered and concentrated. The residue was used in the next step without further purification.

*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0812]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(2-methoxyethyl)-1H-pyrazol-4-amine (product from step 1) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified

## EP 2 861 595 B9


by prep HPLC (pH= 2, acetonitrile/water). LC-MS calculated for  $C_{22}H_{22}F_2N_7O_4$  (M+H)<sup>+</sup> m/z: 486.2; found: 486.2.

### Example 175

5 **3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0813]

10




15

20

Step 1: 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine

[0814]

25



30

[0815] A mixture of 4-nitro-1H-pyrazole (0.25 g, 2.2 mmol), 1,1-difluoro-2-iodoethane (0.23 mL, 2.4 mmol), and potassium carbonate (0.61 g, 4.4 mmol) in acetonitrile (8 mL, 200 mmol) was stirred at 70 °C for 1 hour. After cooling to room temperature, the mixture was diluted with water then extracted with EtOAc. The combined extracts were washed with water and brine. The organic layer was dried over  $Na_2SO_4$  then concentrated. The residue was dissolved in methanol (8 mL) then palladium (10 wt % on activated carbon, 50 mg) was added. The suspension was stirred under  $H_2$  atmosphere (balloon) at room temperature for 2 hours then filtered and concentrated. The residue was used in the next step without further purification.

35

40 Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-1,3,4,7-tetrahydro-2H-pyrazolo(4',3':5,6)pyrido[4,3-d]pyrimidin-2-one

[0816] This compound was prepared using procedures analogous to those for *Example 85* with 1-(2,2-difluoroethyl)-1H-pyrazol-4-amine (product from step 1) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH=2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{18}F_4N_7O_3$  (M+H)<sup>+</sup> m/z: 492.1; found: 492.0.


45

### Example 176

50 **3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(6-methoxypyridin-2-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0817]

55




**[0818]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(6-methoxypyridin-2-yl)methanamine (Ark Pharm, cat # AK-28243) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{23}H_{21}F_2N_6O_4$  (M+H)<sup>+</sup> m/z: 483.2; found: 483.0.

#### Example 177

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0819]**




**[0820]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(2-methoxypyridin-4-yl)methanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{23}H_{21}F_2N_6O_4$  (M+H)<sup>+</sup> m/z: 483.2; found: 483.0.

#### Example 178

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(3R)-tetrahydrofuran-3-ylmethyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0821]**




**[0822]** This compound was prepared using procedures analogous to those for *Example 85* with 1-[(3R)-tetrahydrofuran-3-yl]methanamine (AstaTech, cat # 68889) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{22}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 446.2; found: 446.0.

## Example 179

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(3S)-tetrahydrofuran-3-ylmethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one

[0823]




[0824] This compound was prepared using procedures analogous to those for *Example 85* with 1-[(3S)-tetrahydrofuran-3-yl]methanamine (AstaTech, cat # 68891) replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{22}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 446.2; found: 446.0.

## Example 180


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0825]



*Step 1*: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0826]



[0827] This compound was prepared using procedures analogous to those for *Example 146*, *step 1-4* with 2-fluorobenzenamine replacing 2-[[tert-butyl(dimethyl)silyl]oxy]ethanamine in *Step 3*. LC-MS calculated for  $C_{29}H_{22}F_3N_4O_5S$  (M+H)<sup>+</sup> m/z: 595.1; found: 595.1.

## EP 2 861 595 B9


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0828] This compound was prepared using procedures analogous to those for *Example 126, step 2-4* starting with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from step 1). The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{28}H_{27}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 554.2; found: 553.9.

### Example 181

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-(2-fluorophenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0829]




[0830] This compound was prepared using procedures analogous to those for *Example 180* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{32}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 581.2; found: 581.0.

### Example 182

1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0831]




[0832] This compound was prepared using procedures analogous to those for *Example 180* with cyclobutylamine replacing 2-fluorobenzeneamine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{26}H_{30}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 514.2; found: 514.0.

### Example 183

1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0833]




**[0834]** This compound was prepared using procedures analogous to those for *Example 146* with cyclobutylamine replacing 2-[[tert-butyl(dimethyl)silyl]oxy]ethanamine in *Step 3*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{27}H_{32}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 528.2; found: 528.0.

15 **Example 184**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-propyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

20 **[0835]**



*Step 1: 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*


35 **[0836]**



**[0837]** This compound was prepared using procedures analogous to those for *Example 126*, *Step 1-3* starting with 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from *Example 44*, *Step 2*). LC-MS calculated for  $C_{31}H_{32}F_2N_5O_6S$  [M+H]<sup>+</sup> m/z: 640.2; found 640.2.

*Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1-propyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

55 **[0838]**



**[0839]** To a solution of 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (20.0 mg, 0.0313 mmol) in methanol (1.0 mL) was added palladium hydroxide (20 wt. % on carbon, 5.0 mg). The resulting mixture was stirred under hydrogen atmosphere for 2 h before it was filtered and concentrated *in vacuo*. The crude product was used directly in the next step without further purification. LC-MS calculated for  $C_{31}H_{34}F_2N_5O_6S$   $[M+H]^+$   $m/z$ : 642.2; found 642.2.


*Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-propyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0840]** This compound was synthesized by the same method described in *Example 126, Step 4* by using 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1-propyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from *Step 2*) as starting material. LC-MS calculated for  $C_{25}H_{30}F_2N_5O_4$   $[M+H]^+$   $m/z$ : 502.2; found 502.2.

#### Example 185


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0841]**



*Step 1: 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0842]**



**[0843]** This compound was prepared using procedures analogous to those for *Example 39, step 5* starting with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from *Example 126, step 1*). LC-MS calculated for  $C_{25}H_{22}BrF_2N_4O_5S$   $[M+H]^+$  m/z: 607.0; found 607.0.


5 *Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0844]** This compound was prepared using procedures analogous to those for *Example 71* starting with 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from step 1) and morpholine. LC-MS calculated for  $C_{25}H_{30}F_2N_5O_4$   $[M+H]^+$  m/z: 502.2; found 502.0.  $^1H$  NMR (500 MHz, DMSO)  $\delta$  12.01 (s, 1H), 7.97 (s, 1H), 7.04 (t,  $J = 8.1$  Hz, 1H), 6.55 (s, 1H), 4.75 (s, 2H), 4.16 (q,  $J = 6.8$  Hz, 2H), 4.06 - 3.94 (m, 2H), 3.89 (s, 6H), 3.73 - 3.61 (m, 2H), 3.58 - 3.43 (m, 4H), 3.25 - 3.07 (m, 4H), 1.34 (t,  $J = 6.8$  Hz, 3H).

15 **Example 186**

**1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

20 **[0845]**



**[0846]** This compound was prepared using procedures analogous to those for *Example 180* with cyclopropylamine replacing 2-fluorobenzeneamine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{25}H_{28}F_2N_5O_4$   $(M+H)^+$  m/z: 500.2; found: 500.0.


35

**Example 187**

**1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

40

**[0847]**




**[0848]** This compound was prepared using procedures analogous to those for *Example 186* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{26}H_{31}F_2N_6O_3$   $(M+H)^+$  m/z: 513.2; found: 513.0.

55

## Example 188

1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0849]




[0850] This compound was prepared using procedures analogous to those for *Example 186* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{27}H_{33}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 527.3; found: 527.1.

## Example 189

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0851]




[0852] This compound was prepared using procedures analogous to those for *Example 180* with *p*-fluoroaniline replacing 2-fluorobenzenamine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{28}H_{27}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 554.2; found: 554.0.

## Example 190

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0853]




**[0854]** This compound was prepared using procedures analogous to those for *Example 189* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{29}H_{30}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 567.2; found: 567.0.

5 **Example 191**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

10 **[0855]**



**[0856]** This compound was prepared using procedures analogous to those for *Example 189* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{32}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 581.2; found: 581.1.


25

**Example 192**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

30

**[0857]**



**[0858]** This compound was prepared using procedures analogous to those for *Example 190* with 2,3-difluoroaniline replacing 4-fluoroaniline. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{29}H_{29}F_4N_6O_3$  (M+H)<sup>+</sup> m/z: 585.2; found: 585.0.

45

**Example 193**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

50

**[0859]**

55

EP 2 861 595 B9




[0860] This compound was prepared using procedures analogous to those for *Example 192* with 1-ethylpiperazine replacing 1-methylpiperazine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{31}F_4N_6O_3$  (M+H)<sup>+</sup> m/z: 599.2; found: 599.0.

**Example 194**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-pyridin-4-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0861]




[0862] This compound was prepared using procedures analogous to those for *Example 180* with 4-pyridinamine replacing 2-fluorobenzamine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{27}H_{27}F_2N_6O_4$  (M+H)<sup>+</sup> m/z: 537.2; found: 537.0.

**Example 195**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1-pyridin-4-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

[0863]




[0864] This compound was prepared using procedures analogous to those for *Example 194* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{28}H_{30}F_2N_7O_3$  (M+H)<sup>+</sup> m/z: 550.2; found: 550.1.

## Example 196


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0865]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(2-morpholin-4-ylethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0866]



[0867] This compound was prepared using procedures analogous to those for Example 146, step 1-6 with 2-fluorobenzenamine replacing 2-[[tert-butyl(dimethyl)silyl]oxy]ethanamine in step 3. LC-MS calculated for  $C_{35}H_{33}F_3N_5O_6S$  ( $M+H$ )<sup>+</sup> m/z: 708.2; found: 708.2.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0868] The product from Step 1 was dissolved in tetrahydrofuran then potassium tert-butoxide (1M in THF, 5 eq.) was added. The resulting mixture was stirred at room temperature for 30 min then quenched with a few drops of TFA and purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{29}H_{29}F_3N_5O_4$  ( $M+H$ )<sup>+</sup> m/z: 568.2; found: 568.2.

## Example 197

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0869]




**[0870]** This compound was prepared using procedures analogous to those for *Example 196* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{32}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 581.2; found: 581.2.

**Example 198**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0871]**




**[0872]** This compound was prepared using procedures analogous to those for *Example 196* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{31}H_{34}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 595.3; found: 595.2.

**Example 199**


**3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-2-fluoro-N-isopropylbenzamide**

**[0873]**



*Step 1: methyl 3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-2-fluorobenzoate*


**[0874]**



**[0875]** This compound was prepared using procedures analogous to those for *Example 85* with methyl 3-amino-2-fluorobenzoate replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{24}H_{19}F_3N_5O_5$  (M+H)<sup>+</sup> m/z: 514.1; found: 514.0.

*Step 2: 3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-2-fluorobenzoic acid*

**[0876]**



**[0877]** The product from *Step 1* was dissolved in tetrahydrofuran (10 mL) and water (5 mL) then lithium hydroxide monohydrate (0.11 g, 2.5 mmol) was added. The reaction mixture was stirred at 50 °C overnight then cooled to room temperature and adjusted to pH = 5 with aqueous 2N HCl. The mixture was extracted with EtOAc for three times. The combined organic layers were washed with brine, dried over  $MgSO_4$ , filtered and concentrated under reduced pressure to afford the desired product, which was used in the next step without further purification. LC-MS calculated for  $C_{23}H_{17}F_3N_5O_5$  (M+H)<sup>+</sup> m/z: 500.1; found: 499.9.

*Step 3: 3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-2-fluoro-N-isopropylbenzamide*

**[0878]** To a mixture of 3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-2-fluorobenzoic acid (8.9 mg, 0.018 mmol), 2-propanamine (1.6 mg, 0.027 mmol) and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (8.7 mg, 0.020 mmol) in N,N-dimethylformamide (0.5 mL) was added N,N-diisopropylethylamine (9.3  $\mu$ L, 0.054 mmol). The reaction mixture was stirred at room temperature for 3 h and then purified by prep HPLC (pH = 10, acetonitrile/water) to afford the desired product. LC-MS calculated for  $C_{26}H_{24}F_3N_6O_4$  (M+H)<sup>+</sup> m/z: 541.2; found: 541.0.


### Example 200

**N-cyclopropyl-3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-2-fluorobenzamide**

**[0879]**

5

10



**[0880]** This compound was prepared using procedures analogous to those for *Example 199* with cyclopropylamine replacing 2-propanamine in *Step 3*. The product was purified by prep HPLC (pH = 10, acetonitrile/water). LC-MS calculated for  $C_{26}H_{22}F_3N_6O_4$  (M+H)<sup>+</sup> m/z: 539.2; found: 539.0.

15

### Example 201

**3-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-pyrazolo[4,3':5,6]pyrido[4,3-d]pyrimidin-1-yl]-N-ethyl-2-fluorobenzamide**


20

**[0881]**

25

30

35



**[0882]** This compound was prepared using procedures analogous to those for *Example 199* with ethylamine (2.0 M in THF) replacing 2-propanamine in *Step 3*. The product was purified by prep HPLC (pH = 10, acetonitrile/water). LC-MS calculated for  $C_{25}H_{22}F_3N_6O_4$  (M+H)<sup>+</sup> m/z: 527.2; found: 527.0.

40

### Example 202


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

45

**[0883]**


50

55



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0884]



[0885] To a solution of 1-allyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (18.0 mg, 0.028 mmol, from *Example 184, Step 1*) in tetrahydrofuran (0.6 mL) and dimethylamine (0.6 mL) were added 1,4-bis(diphenylphosphino)butane (10.0 mg, 0.0227 mmol) and tris(dibenzylideneacetone)dipalladium(O) (10.0 mg, 0.0109 mmol). The reaction was stirred at 90 °C overnight before it was concentrated *in vacuo* and purified by column to afford the product. LC-MS calculated for C<sub>28</sub>H<sub>28</sub>F<sub>2</sub>N<sub>5</sub>O<sub>6</sub>S [M+H]<sup>+</sup> m/z: 600.2; found 600.1.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0886]



[0887] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (10.0 mg, 0.0167 mmol, from *Step 1*), (2-methoxypyridin-4-yl)methanol (23.2 mg, 0.167 mmol, purchased from Ark Pharma, catalog number: AK-28607) in tetrahydrofuran (1.0 mL, 12 mmol) were added triphenylphosphine (26.0 mg, 0.0991 mmol) and diethyl azodicarboxylate (16 μL, 0.10 mmol). The resulting mixture was stirred at 60 °C for 12 h. The reaction was diluted with MeOH (4.0 mL) and purified by RP-HPLC (pH 10) to afford the product. LC-MS calculated for C<sub>35</sub>H<sub>35</sub>F<sub>2</sub>N<sub>6</sub>O<sub>7</sub>S [M+H]<sup>+</sup> m/z: 721.2; found 721.0.


Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0888] This compound was synthesized by the same method described in *Example 126, Step 4* by using 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (product from *Step 2*) as starting material. LC-MS calculated for C<sub>29</sub>H<sub>31</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub> [M+H]<sup>+</sup> m/z: 581.2; found 581.1.

## Example 203

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0889]




[0890] This compound was prepared using procedures analogous to those for *Example 180* with 1-methyl-1H-pyrazol-4-amine (Astatech Inc, catalog # CL4553) replacing 2-fluorobenzeneamine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{26}H_{28}F_2N_7O_4$  (M+H)<sup>+</sup> m/z: 540.2; found: 540.1.

## Example 204

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0891]




[0892] This compound was prepared using procedures analogous to those for *Example 203* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{27}H_{31}F_2N_8O_3$  (M+H)<sup>+</sup> m/z: 553.2; found: 553.2.

## Example 205

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0893]




**[0894]** This compound was prepared using procedures analogous to those for *Example 203* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{28}H_{33}F_2N_8O_3$  (M+H)<sup>+</sup> m/z: 567.3; found: 567.0.

5 **Example 206**

**7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3-hydroxyazetid-1-yl)methyl]-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

10 **[0895]**

15



20


**[0896]** This compound was prepared using procedures analogous to those for *Example 152* with azetid-3-ol hydrochloride replacing morpholine in *Step 7*. LC-MS calculated for  $C_{24}H_{27}F_2N_4O_4$  (M+H)<sup>+</sup> m/z: 473.2; found: 473.1.

25 **Example 207**

**7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3-fluoroazetid-1-yl)methyl]-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one**

30 **[0897]**

35



40


**[0898]** This compound was prepared using procedures analogous to those for *Example 152* with 3-fluoroazetidine hydrochloride replacing morpholine in *Step 7*. LC-MS calculated for  $C_{24}H_{26}F_3N_4O_3$  (M+H)<sup>+</sup> m/z: 475.2; found: 475.0.

45 **Example 208**

**1-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]azetidine-3-carbonitrile**

50 **[0899]**

55




**[0900]** This compound was prepared using procedures analogous to those for *Example 70* with azetidine-3-carbonitrile hydrochloride replacing 1-ethylpiperazine in *Step 2*. LC-MS calculated for  $C_{23}H_{23}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 469.2; found: 469.0.

### Example 209

**(3R)-1-1-((3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl)methyl)pyrrolidine-3-carbonitrile**

**[0901]**




**[0902]** This compound was prepared using procedures analogous to those for *Example 70* with (3R)-pyrrolidine-3-carbonitrile hydrochloride replacing 1-ethylpiperazine in *Step 2*. LC-MS calculated for  $C_{24}H_{25}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 483.2; found: 483.0.

### Example 210

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(3-fluoroazetid-1-yl)ethyl]-1-(2-hydroxyethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0903]**




**[0904]** This compound was prepared using procedures analogous to those for *Example 146* with 3-fluoroazetidine hydrochloride replacing morpholine in *step 6*. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{24}H_{27}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 506.2; found: 506.0.

## Example 211

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0905]




[0906] This compound was prepared using procedures analogous to those for *Example 192* with morpholine replacing 1-methylpiperazine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{28}H_{26}F_4N_5O_4$  (M+H)<sup>+</sup> m/z: 572.2; found: 571.9.

## Example 212

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0907]




[0908] This compound was prepared by using procedures analogous to those for *Example 180* with 3-fluorobenzenamine replacing 2-fluorobenzenamine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{28}H_{27}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 554.2; found: 554.2.

## Example 213

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0909]




**[0910]** This compound was prepared using procedures analogous to those for *Example 212* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{29}H_{30}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 567.2; found: 567.2.

5 **Example 214**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

10 **[0911]**



**[0912]** This compound was prepared using procedures analogous to those for *Example 212* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{29}H_{30}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 567.2; found: 567.2.


25

**Example 215**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-9-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

30

**[0913]**



**[0914]** This compound was prepared using procedures analogous to those for *Example 69* with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole replacing 1-ethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{21}H_{20}F_2N_7O_3$  (M+H)<sup>+</sup> m/z: 456.2; found: 456.1.

45

**Example 216**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(6-fluoropyridin-2-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**

50

**[0915]**

55


EP 2 861 595 B9



**[0916]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(6-fluoropyridin-2-yl)methanamine hydrochloride replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{22}H_{18}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 471.1; found: 471.0.

**Example 217**


**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(6-methylpyridin-2-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**



**[0917]** This compound was prepared using procedures analogous to those for *Example 85* with 1-(6-methylpyridin-2-yl)methanamine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{23}H_{21}F_2N_6O_3$  (M+H)<sup>+</sup> m/z: 467.2; found: 466.9.

**Example 218**

**3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(3-fluoropyridin-2-yl)-1,3,4,7-tetrahydro-2H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-2-one**




**[0919]** This compound was prepared by using procedures analogous to those for *Example 85* with 3-fluoropyridin-2-amine replacing 1-methyl-1H-pyrazol-4-amine in *Step 1*. LC-MS calculated for  $C_{21}H_{16}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 457.1; found: 457.1.

## Example 219


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(2-oxopyridin-1(2H)-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0921]



Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(hydroxymethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0922]



[0923] To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbaldehyde (0.60 g, 1.1 mmol, from *Example 126, Step 2*) in methylene chloride (20 mL) was added sodium triacetoxy-borohydride (0.80 g, 3.8 mmol). The mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with saturated aqueous NaHCO<sub>3</sub>, and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with MeOH in DCM (0-5%) to afford the desired product (0.40 g, 66%). LC-MS calculated for C<sub>26</sub>H<sub>25</sub>F<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S (M+H)<sup>+</sup> m/z: 559.1; found: 558.9.


Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(2-oxopyridin-1(2H)-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0924] Triphenylphosphine (21 mg, 0.079 mmol) was added to a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(hydroxymethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (22 mg, 0.039 mmol) and 2-hydroxypyridine (7.4 mg, 0.078 mmol) in tetrahydrofuran (0.5 mL) at room temperature. A solution of diethyl azodicarboxylate (12 μL, 0.079 mmol) in tetrahydrofuran (0.3 mL) was added. The reaction mixture was stirred at room temperature overnight. A solution of NaOMe in MeOH (25wt%, 0.1 mL) was added. The reaction mixture was stirred at room temperature for 1 h. The mixture was purified by RP-HPLC (pH = 10) to afford the desired product. LC-MS calculated for C<sub>25</sub>H<sub>24</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> (M+H)<sup>+</sup> m/z: 496.2; found: 496.0.

## Example 220

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(pyridin-3-yloxy)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0925]




**[0926]** This compound was prepared by using procedures analogous to those for *Example 219* with 3-pyridinol replacing 2-hydroxypyridine in *Step 2*. LC-MS calculated for  $C_{25}H_{24}F_2N_5O_4$  (M+H)<sup>+</sup> m/z: 496.2; found: 496.0.

#### Example 221

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0927]**




**[0928]** This compound was prepared by using procedures analogous to those for *Example 126 (Step 2-4)* with 1-(2-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (from *Example 146, Step 4*) as starting material. LC-MS calculated for  $C_{24}H_{28}F_2N_5O_5$  (M+H)<sup>+</sup> m/z: 504.2; found: 504.0.

#### Example 222

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0929]**




**[0930]** This compound was prepared using procedures analogous to those for *Example 196, Steps 1-2* with 2,3-difluoroaniline replacing 2-fluoro-benzenamine in *Step 1*. LC-MS calculated for  $C_{29}H_{28}F_4N_5O_4$  (M+H)<sup>+</sup> m/z: 586.2; found: 586.0.

## Example 223

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0931]




[0932] This compound was prepared using procedures analogous to those for *Example 222* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{31}F_4N_6O_3$  (M+H)<sup>+</sup> m/z: 599.2; found: 599.0.

## Example 224

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0933]




[0934] This compound was prepared using procedures analogous to those for *Example 222* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{31}H_{33}F_4N_6O_3$  (M+H)<sup>+</sup> m/z: 613.2; found: 613.0.

## Example 225

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0935]




**[0936]** This compound was prepared using procedures analogous to those for *Example 196, Steps 1-2* with 4-fluorobenzenamine replacing 2-fluoro-benzenamine in *Step 1*. LC-MS calculated for  $C_{29}H_{29}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 568.2; found: 568.0.

5 **Example 226**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

10 **[0937]**

15



20

**[0938]** This compound was prepared using procedures analogous to those for *Example 225* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{32}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 581.2; found: 581.0.

25


**Example 227**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

30

**[0939]**

35



40

**[0940]** This compound was prepared using procedures analogous to those for *Example 196, Steps 1-2* with 3-fluorobenzenamine replacing 2-fluoro-benzenamine in *step 1*. LC-MS calculated for  $C_{29}H_{29}F_3N_5O_4$  (M+H)<sup>+</sup> m/z: 568.2; found: 568.0.

45


**Example 228**

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

50

**[0941]**

55




**[0942]** This compound was prepared using procedures analogous to those for *Example 227* with 1-methylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{30}H_{32}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 581.2; found: 581.0.

#### Example 229

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0943]**




**[0944]** This compound was prepared using procedures analogous to those for *Example 227* with 1-ethylpiperazine replacing morpholine. The product was purified by prep HPLC (pH = 2, acetonitrile/water). LC-MS calculated for  $C_{31}H_{34}F_3N_6O_3$  (M+H)<sup>+</sup> m/z: 595.3; found: 595.0.

#### Example 230

**1-{2-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]ethyl}azetidine-3-carbonitrile**

**[0945]**




**[0946]** This compound was prepared using procedures analogous to those for *Example 71* starting with 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 185, Step 1*) and azetidine-3-carbonitrile hydrochloride. LC-MS calculated for  $C_{25}H_{27}F_2N_6O_3$  [M+H]<sup>+</sup> m/z: 497.2; found 496.9.

## Example 231

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[2-(3-fluoroazetidin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0947]




[0948] This compound was prepared using procedures analogous to those for *Example 71* starting with 8-bromo-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (*Example 185, Step 1*) and 3-fluoroazetidine hydrochloride. LC-MS calculated for  $C_{24}H_{27}F_3N_5O_3$   $[M+H]^+$   $m/z$ : 490.2; found 489.9.

## Example 232


3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0949]



Step 1: 1-(2-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde

[0950]




[0951] To a solution of 1-(2-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (456 mg, 0.69 mmol) (*Example 146, Step 4*) in tetrahydrofuran (10 mL) at  $-78^\circ\text{C}$  was added LDA (freshly prepared, 1 M in THF, 1.44 mL). The mixture was stirred at  $-78^\circ\text{C}$  for 30 min, then *N,N*-dimethylformamide (0.77 mL) was added. The mixture was stirred at

EP 2 861 595 B9

-78 °C for 1 h, and then quenched with saturated NH<sub>4</sub>Cl solution at -78 °C. The mixture was warmed to room temperature and extracted with EtOAc. The combined extracts were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to give the desired product (452 mg) as yellow solid, which was directly used in the next step without further purification. LC-MS calculated for C<sub>32</sub>H<sub>37</sub>F<sub>2</sub>N<sub>4</sub>O<sub>7</sub>SSi [M+H]<sup>+</sup> m/z: 687.2; found 687.2.

Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-2-oxo-1-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde


[0952]



[0953] To a solution of 1-(2-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (430 mg, 0.63 mmol) in tetrahydrofuran (10 mL) and water (2 mL) was added 12.0 M hydrogen chloride in water (1.04 mL). The resulting yellow solution was stirred at room temperature for 1.5 h. The reaction mixture was neutralized with saturated NaHCO<sub>3</sub> solution, and extracted with EtOAc. The combined extracts were washed with brine dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by silica gel column eluting with EtOAc in DCM (gradient: 0 to 60 %) to afford the desired product (265 mg) as light yellow solid. LC-MS calculated for C<sub>26</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>7</sub>S [M+H]<sup>+</sup> m/z: 573.1; found 572.9.

Step 3: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one


[0954]



[0955] This compound was prepared using procedures analogous to those for Example 110, Step 1 starting with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde and morpholine. LC-MS calculated for C<sub>30</sub>H<sub>32</sub>F<sub>2</sub>N<sub>5</sub>O<sub>7</sub>S [M+H]<sup>+</sup> m/z: 644.2; found 644.0.

Step 4: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one

[0956]



**[0957]** 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (from *Step 3*) was dissolved in DCM (3 mL). To the solution was added diethylaminosulfur trifluoride (40.0  $\mu$ L, 0.303 mmol). The mixture was stirred at r.t. for 2 h, quenched with water, and extracted with DCM. The organic layers were washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with methanol in DCM (0 -10%) to give the desired product. LC-MS calculated for  $\text{C}_{30}\text{H}_{31}\text{F}_3\text{N}_5\text{O}_6\text{S}$   $[\text{M}+\text{H}]^+$  m/z: 646.2; found 646.0.


*Step 5: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3,2':5,6]pyrido[4,3-d]pyrimidin-2-one*

**[0958]** 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-(morpholin-4-ylmethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one (from *Step 4*) was dissolved in THF (2.0 mL), then 1.0 M TBAF in THF solution (0.40 mL) was added. The resulting solution was stirred at 60  $^\circ\text{C}$  for 1 h. After cooling, the solution was quenched with a few drops of TFA, diluted with methanol, and purified by RP-HPLC (pH = 2) to afford the desired product as TFA salt. LC-MS calculated for  $\text{C}_{24}\text{H}_{27}\text{F}_3\text{N}_5\text{O}_4$   $[\text{M}+\text{H}]^+$  m/z: 506.2; found 506.0.

### Example 233

**3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one**

**[0959]**



**[0960]** This compound was prepared using procedures analogous to those for *Example 232* starting with 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde (*Example 232, Step 2*) and 1-methyl-piperazine replacing morpholine in *Step 3*. LC-MS calculated for  $\text{C}_{25}\text{H}_{30}\text{F}_3\text{N}_6\text{O}_3$   $[\text{M}+\text{H}]^+$  m/z: 519.2; found 519.0.

### Example A

#### FGFR Enzymatic Assay

**[0961]** The inhibitor potency of the exemplified compounds was measured in an enzyme assay that measures peptide phosphorylation using FRET measurements to detect product formation. Inhibitors were serially diluted in DMSO and a volume of 0.5  $\mu$ L was transferred to the wells of a 384-well plate. For FGFR3, a 10  $\mu$ L volume of FGFR3 enzyme (Millipore) diluted in assay buffer (50 mM HEPES, 10 mM  $\text{MgCl}_2$ , 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated for 5-10 minutes. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate. The assay was initiated by the addition of a 10  $\mu$ L solution containing biotinylated

EP 2 861 595 B9

EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP (final concentrations of 500 nM and 140 μM respectively) in assay buffer to the wells. The plate was incubated at 25 °C for 1 hr. The reactions were ended with the addition of 10 μL/well of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 30 mM EDTA with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin). The plate was allowed to equilibrate for ~1 hr before scanning the wells on a PheraStar plate reader (BMG Labtech).

[0962] FGFR1 and FGFR2 were measured under equivalent conditions with the following changes in enzyme and ATP concentrations: FGFR1, 0.02 nM and 210 μM, respectively and FGFR2, 0.01 nM and 100 μM, respectively. The enzymes were purchased from Millipore or Invitrogen.

[0963] GraphPad prism3 was used to analyze the data. The IC<sub>50</sub> values were derived by fitting the data to the equation for a sigmoidal dose-response with a variable slope.  $Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogIC}_{50} - X) * \text{HillSlope}))}$  where X is the logarithm of concentration and Y is the response. Compounds having an IC<sub>50</sub> of 1 μM or less are considered active.

[0964] The compounds of the invention were found to be inhibitors of one or more of FGFR1, FGFR2, and FGFR3 according to the above-described assay. IC<sub>50</sub> data is provided below in Table 1. The symbol "+" indicates an IC<sub>50</sub> less than 100 nM and the symbol "++" indicates an IC<sub>50</sub> of 100 to 500 nM.

Table 1

Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)
1	+	+	+
2	+	+	+
3	+	+	+
4	+	+	+
5	+	+	+
6	+	+	+
7	+	+	+
8	+	+	+
9	+	+	++
10	+	+	+
11	+	+	+
12	+	+	+
13	+	+	+
14	+	+	+
15	+	+	+
16	+	+	+
17	+	+	+
18	+	+	+
19	+	+	+
20	+	+	+
21	+	+	+
22	+	+	+
23	+	+	+
24	+	+	+
25	+	+	+
26	+	+	+
27	+	+	+
28	+	+	+

EP 2 861 595 B9

(continued)

Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)
29	+	+	+
30	+	+	+
31	+	+	+
32	+	+	+
33	+	+	+
34	+	+	+
35	+	+	+
36	+	+	+
37	+	+	+
38	+	+	+
39	+	+	+
40	+	+	+
41	+	+	+
42	+	+	+
43	+	+	+
44	+	+	+
45	+	+	+
46	+	+	+
47	+	+	+
48	+	+	+
49	+	+	+
50	+	+	+
51	+	+	+
52	+	+	+
53	+	+	+
54	+	+	+
55	+	+	+
56	+	+	+
57	+	+	+
58	+	+	+
59	+	+	+
60	+	+	+
61	+	+	+
62	++	++	+
63	+	+	+
64	+	+	+
65	+	+	+
66	+	+	+

EP 2 861 595 B9

(continued)

Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)	
5	67	+	+	+
	68	+	+	+
	69	+	+	+
	70	+	+	+
10	71	+	+	+
	72	+	+	+
	73	+	+	+
	74	+	+	+
15	75	+	+	+
	76	+	+	+
	77	+	+	+
20	78	+	+	+
	79	+	+	+
	80	+	+	+
	81	+	+	+
25	82	+	+	+
	83	+	+	+
	84	+	+	+
30	85	+	+	+
	86	+	+	+
	87	+	+	+
	88	+	+	+
35	89	+	+	+
	90	+	+	+
	91	+	+	+
40	92	+	+	+
	93	+	+	+
	94	+	+	+
	95	+	+	+
45	96	+	+	+
	97	+	+	+
	98	+	+	+
50	99	+	+	+
	100	+	+	+
	101	+	+	+
55	102	+	+	+
	103	+	+	+
	104	+	+	+

EP 2 861 595 B9

(continued)

	Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)
5	105	+	+	+
	106	+	+	+
	107	+	+	+
	108	+	+	+
10	109	+	+	+
	110	+	+	+
	111	+	+	+
15	112	+	+	+
	113	+	+	+
	114	+	+	+
	115	+	+	+
20	116	+	+	+
	117	+	+	+
	118	+	+	+
25	119	+	+	+
	120	+	+	+
	121	+	+	+
	122	+	+	+
30	123	+	+	+
	124	+	+	+
	125	+	+	+
35	126	+	+	+
	127	+	+	+
	128	+	+	+
	129	+	+	+
40	130	+	+	+
	131	+	+	+
	132	+	+	+
45	133	+	+	+
	134	+	+	+
	135	+	+	+
	136	+	+	+
50	137	+	+	+
	138	+	+	+
	139	+	+	+
55	140	+	+	+
	141	+	+	+
	142	+	+	+

EP 2 861 595 B9

(continued)

	Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)
5	143	+	+	+
	144	+	+	+
	145	+	+	+
	146	+	+	+
10	147	+	+	+
	148	+	+	+
	149	+	+	+
15	150	+	+	+
	151	+	+	+
	152	+	+	+
	153	+	+	+
20	154	+	+	+
	155	+	+	+
	156	+	+	+
25	157	+	+	+
	158	+	+	+
	159	+	+	+
	160	+	+	+
30	161	+	+	+
	162	+	+	+
	163	+	+	+
35	164	+	+	+
	165	+	+	+
	166	+	+	+
	167	+	+	+
40	168	+	+	+
	169	+	+	+
	170	+	+	+
45	171	+	+	+
	172	+	+	+
	173	+	+	+
	174	+	+	+
50	175	+	+	+
	176	+	+	+
	177	+	+	+
55	178	+	+	+
	179	+	+	+
	180	+	+	+

EP 2 861 595 B9

(continued)

Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)	
5	181	+	+	+
	182	+	+	+
	183	+	+	+
	184	+	+	+
10	185	+	+	+
	186	+	+	+
	187	+	+	+
	188	+	+	+
15	189	+	+	+
	190	+	+	+
	191	+	+	+
20	192	+	+	+
	193	+	+	+
	194	+	+	+
	195	+	+	+
25	196	+	+	+
	197	+	+	+
	198	+	+	+
30	199	+	+	+
	200	+	+	+
	201	+	+	+
	202	+	+	+
35	203	+	+	+
	204	+	+	+
	205	+	+	+
40	206	+	+	+
	207	+	+	+
	208	+	+	+
	209	+	+	+
45	210	+	+	+
	211	+	+	+
	212	+	+	+
50	213	+	+	+
	214	+	+	+
	215	+	+	+
55	216	+	+	+
	217	+	+	+
	218	+	+	+

EP 2 861 595 B9

(continued)

5  
10  
15  
20  
25

Example No.	FGFR1 IC50 (nM)	FGFR2 IC50 (nM)	FGFR3 IC50 (nM)
219	+	+	+
220	+	+	+
221	+	+	+
222	+	+	+
223	+	+	+
224	+	+	+
225	+	+	+
226	+	+	+
227	+	+	+
228	+	+	+
229	+	+	+
230	+	+	+
231	+	+	+
232	+	+	+
233	+	+	+

**Example B**

**FGFR Cell Proliferation/Survival Assays**

30  
35  
40  
45  
50

**[0965]** The ability of the example compounds to inhibit the growth of cells dependent on FGFR signaling for survival was measured using viability assays. A recombinant cell line over-expressing human FGFR3 was developed by stable transfection of the mouse pro-B Ba/F3 cells (obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen) with a plasmid encoding the full length human FGFR3. Cells were sequentially selected for puromycin resistance and proliferation in the presence of heparin and FGF 1. A single cell clone was isolated and characterized for functional expression of FGFR3. This Ba/F3-FGFR3 clone is used in cell proliferation assays, and compounds are screened for their ability to inhibit cell proliferation/survival. The Ba/F3-FGFR3 cells are seeded into 96 well, black cell culture plates at 3500 cells/well in RPMI1640 media containing 2 % FBS, 20 µg/mL Heparin and 5 ng/mL FGF1. The cells were treated with 10 µL of 10X concentrations of serially diluted compounds (diluted with medium lacking serum from 5 mM DMSO dots) to a final volume of 100 µL/well. After 72 hour incubation, 100 µL of Cell Titer Glo® reagent (Promega Corporation) that measures cellular ATP levels is added to each well. After 20 minute incubation with shaking, the luminescence is read on a plate reader. The luminescent readings are converted to percent inhibition relative to DMSO treated control wells, and the IC<sub>50</sub> values are calculated using GraphPad Prism software by fitting the data to the equation for a sigmoidal dose-response with a variable slope. Compounds having an IC<sub>50</sub> of 10 µM or less are considered active. Cell lines representing a variety of tumor types including KMS-11 (multiple myeloma, FGFR3 translocation), RT112 (bladder cancer, FGFR3 overexpression), Katolll (gastric cancer, FGFR2 gene amplification), and H-1581 (lung, FGFR1 gene amplification) are used in similar proliferation assays. In some experiments, MTS reagent, Cell Titer 96® Aqueous One Solution Reagent (Promega Corporation) is added to a final concentration of 333 µg/mL in place Cell Titer Glo and read at 490/650 nm on a plate reader. Compounds having an IC<sub>50</sub> of 5 µM or less are considered active.

**Example C**

**Cell-Based FGFR Phosphorylation Assays**

55

**[0966]** The inhibitory effect of compounds on FGFR phosphorylation in relevant cell lines (Ba/F3-FGFR3, KMS-11, RT112, Katolll, H-1581 cancer cell lines and HUVEC cell line) can be assessed using immunoassays specific for FGFR phosphorylation. Cells are starved in media with reduced serum (0.5%) and no FGF1 for 4 to 18 h depending upon the cell line then treated with various concentrations of individual inhibitors for 1-4 hours. For some cell lines, such as Ba/F3-

FGFR3 and KMS-11, cells are stimulated with Heparin (20  $\mu\text{g}/\text{mL}$ ) and FGF1 (10  $\text{ng}/\text{mL}$ ) for 10 min. Whole cell protein extracts are prepared by incubation in lysis buffer with protease and phosphatase inhibitors [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM  $\text{MgCl}_2$ , 10% Glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM sodium fluoride, aprotinin (2  $\mu\text{g}/\text{mL}$ ), leupeptin (2  $\mu\text{g}/\text{mL}$ ), pepstatin A (2  $\mu\text{g}/\text{mL}$ ), and phenylmethylsulfonyl fluoride (1 mM)] at 4°C. Protein extracts are cleared of cellular debris by centrifugation at 14,000  $\times$  g for 10 minutes and quantified using the BCA (bicinchoninic acid) microplate assay reagent (Thermo Scientific).

**[0967]** Phosphorylation of FGFR receptor in protein extracts was determined using immunoassays including western blotting, enzyme-linked immunoassay (ELISA) or bead-based immunoassays (Luminex). For detection of phosphorylated FGFR2, a commercial ELISA kit DuoSet IC Human Phospho-FGF R2 $\alpha$  ELISA assay (R&D Systems, Minneapolis, MN) can be used. For the assay KatolIII cells are plated in 0.2% FBS supplemented Iscove's medium (50,000 cells / well/ per 100  $\mu\text{L}$ ) into 96-well flat-bottom tissue culture treated plates (Corning, Corning, NY), in the presence or absence of a concentration range of test compounds and incubated for 4 hours at 37 °C, 5%  $\text{CO}_2$ . The assay is stopped with addition of 200  $\mu\text{L}$  of cold PBS and centrifugation. The washed cells are lysed in Cell Lysis Buffer (Cell Signaling, #9803) with Protease Inhibitor (Calbiochem, #535140) and PMSF (Sigma, #P7626) for 30 min on wet ice. Cell lysates were frozen at -80 °C before testing an aliquot with the DuoSet IC Human Phospho-FGF R2 $\alpha$  ELISA assay kit. GraphPad prism3 was used to analyze the data. The  $\text{IC}_{50}$  values were derived by fitting the data to the equation for a sigmoidal dose-response with a variable slope.

**[0968]** For detection of phosphorylated FGFR3, a bead based immunoassay was developed. An anti-human FGFR3 mouse mAb (R&D Systems, cat#MAB7661) was conjugated to Luminex MAGplex microspheres, bead region 20 and used as the capture antibody. RT-112 cells were seeded into multi-well tissue culture plates and cultured until 70% confluence. Cells were washed with PBS and starved in RPMI + 0.5% FBS for 18 hr. The cells were treated with 10  $\mu\text{L}$  of 10X concentrations of serially diluted compounds for 1 hr at 37 °C, 5%  $\text{CO}_2$  prior to stimulation with 10  $\text{ng}/\text{mL}$  human FGF1 and 20  $\mu\text{g}/\text{mL}$  Heparin for 10 min. Cells were washed with cold PBS and lysed with Cell Extraction Buffer (Invitrogen) and centrifuged. Clarified supernatants were frozen at -80 °C until analysis.

**[0969]** For the assay, cell lysates are diluted 1:10 in Assay Diluent and incubated with capture antibody-bound beads in a 96-well filter plate for 2 hours at room temperature on a plate shaker. Plates are washed three times using a vacuum manifold and incubated with anti-phospho-FGF R1-4 (Y653/Y654) rabbit polyclonal antibody (R&D Systems cat# AF3285) for 1 hour at RT with shaking. Plates are washed three times. The diluted reporter antibody, goat anti-rabbit-RPE conjugated antibody (Invitrogen Cat. # LHB0002) is added and incubated for 30 minutes with shaking. Plates are washed three times. The beads are suspended in wash buffer with shaking at room temperature for 5 minutes and then read on a Luminex 200 instrument set to count 50 events per sample, gate settings 7500-13500. Data is expressed as mean fluorescence intensity (MFI). MFI from compound treated samples are divided by MFI values from DMSO controls to determine the percent inhibition, and the  $\text{IC}_{50}$  values are calculated using the GraphPad Prism software. Compounds having an  $\text{IC}_{50}$  of 1  $\mu\text{M}$  or less are considered active.

## Example D

### FGFR Cell-Based Signaling Assays

**[0970]** Activation of FGFR leads to phosphorylation of Erk proteins. Detection of pErk is monitored using the Cellu'Erk HTRF (Homogeneous Time Resolved Fluorescence) Assay (CisBio) according to the manufacturer's protocol. KMS-11 cells are seeded into 96-well plates at 40,000 cells/well in RPMI medium with 0.25% FBS and starved for 2 days. The medium is aspirated and cells are treated with 30  $\mu\text{L}$  of 1X concentrations of serially diluted compounds (diluted with medium lacking serum from 5 mM DMSO dots) to a final volume of 30  $\mu\text{L}/\text{well}$  and incubated for 45 min at room temperature. Cells are stimulated by addition of 10  $\mu\text{L}$  of Heparin (100  $\mu\text{g}/\text{mL}$ ) and FGF1 (50  $\text{ng}/\text{mL}$ ) to each well and incubated for 10 min at room temperature. After lysis, an aliquot of cell extract is transferred into 384-well low volume plates, and 4  $\mu\text{L}$  of detection reagents are added followed by incubation for 3 hr at room temperature. The plates are read on a PheraStar instrument with settings for HTRF. The normalized fluorescence readings are converted to percent inhibition relative to DMSO treated control wells, and the  $\text{IC}_{50}$  values are calculated using the GraphPad Prism software. Compounds having an  $\text{IC}_{50}$  of 1  $\mu\text{M}$  or less are considered active.

## Example E

### VEGFR2 Kinase Assay

**[0971]** 40  $\mu\text{L}$  Enzyme reactions are run in black 384 well polystyrene plates for 1 hour at 25 °C. Wells are dotted with 0.8  $\mu\text{L}$  of test compound in DMSO. The assay buffer contains 50 mM Tris, pH 7.5, 0.01% Tween-20, 10 mM  $\text{MgCl}_2$ , 1 mM EGTA, 5 mM DTT, 0.5  $\mu\text{M}$  Biotin-labeled EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1), 1 mM ATP,

## EP 2 861 595 B9

and 0.1 nM enzyme (Millipore catalogue number 14-630). Reactions are stopped by addition of 20  $\mu$ L Stop Buffer (50 mM Tris, pH= 7.8, 150 mM NaCl, 0.5 mg/mL BSA, 45 mM EDTA) with 225 nM LANCE Streptavidin Surelight® APC (PerkinElmer catalogue number CR130-100) and 4.5 nM LANCE Eu-W1024 anti phosphotyrosine (PY20) antibody (PerkinElmer catalogue number AD0067). After 20 minutes of incubation at room temperature, the plates are read on a PheraStar FS plate reader (BMG Labtech). IC<sub>50</sub> values can be calculated using GraphPad Prism by fitting the data to the equation for a sigmoidal dose-response with a variable slope. Compounds having an IC<sub>50</sub> of 1  $\mu$ M or less are considered active.

### SEQUENCE LISTING

#### [0972]

<110> Incyte Corporation

<120> SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS

<130> 20443-0257WO1

<160> 1

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

<220>


<223> synthetic peptide

<400> 1

Glu Gln Glu Asp Glu Pro Glu Gly Asp Tyr Phe Glu Trp Leu Glu  
1 5 10 15

### Claims

1. A compound of Formula II:



II

or a pharmaceutically acceptable salt thereof, wherein:

W is NR<sup>9</sup>;

X is CR<sup>15</sup> or N;

R<sup>1</sup> is H, NR<sup>A</sup>R<sup>B</sup>, halo, and C<sub>1-3</sub> alkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from H, CN, C(O)NR<sup>c</sup>R<sup>d</sup>, and C<sub>1-7</sub> alkyl, wherein said C<sub>1-7</sub> alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, OR<sup>a</sup>, CN, NR<sup>c</sup>R<sup>d</sup>, and C(O)NR<sup>c</sup>R<sup>d</sup>;

or R<sup>2</sup> and R<sup>3</sup> together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring or a 4-7 membered heterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, OR<sup>a</sup>, SR<sup>a</sup>, C(O)R<sup>b</sup>, C(O)NR<sup>c</sup>R<sup>d</sup>, C(O)OR<sup>a</sup>, OC(O)R<sup>b</sup>, OC(O)NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>C(O)R<sup>b</sup>, and NR<sup>c</sup>C(O)OR<sup>a</sup>;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each independently selected from H, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(=NR<sup>e1</sup>)R<sup>b1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>S(O)R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1</sup>R<sup>d1</sup>, S(O)<sub>2</sub>R<sup>b1</sup>, and S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>; wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>S(O)R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1</sup>R<sup>d1</sup>, S(O)<sub>2</sub>R<sup>b1</sup>, and S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>;

R<sup>9</sup> is H, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, or (4-10 membered heterocycloalkyl)-C<sub>1-4</sub> alkyl, wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, and (4-10 membered heterocycloalkyl)-C<sub>1-4</sub> alkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R<sup>9a</sup>;

each R<sup>9a</sup> is independently selected from Cy<sup>1</sup>, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a2</sup>, SR<sup>a2</sup>, C(O)R<sup>b2</sup>, C(O)NR<sup>c2</sup>R<sup>d2</sup>, C(O)OR<sup>a2</sup>, OC(O)R<sup>b2</sup>, OC(O)NR<sup>c2</sup>R<sup>d2</sup>, C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(O)R<sup>b2</sup>, NR<sup>c2</sup>C(O)OR<sup>a2</sup>, NR<sup>c2</sup>C(O)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>S(O)R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, S(O)R<sup>b2</sup>, S(O)NR<sup>c2</sup>R<sup>d2</sup>, S(O)<sub>2</sub>R<sup>b2</sup>, and S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>1</sup>, halo, CN, NO<sub>2</sub>, OR<sup>a2</sup>, SR<sup>a2</sup>, C(O)R<sup>b2</sup>, C(O)NR<sup>c2</sup>R<sup>d2</sup>, C(O)OR<sup>a2</sup>, OC(O)R<sup>b2</sup>, OC(O)NR<sup>c2</sup>R<sup>d2</sup>, C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(O)R<sup>b2</sup>, NR<sup>c2</sup>C(O)OR<sup>a2</sup>, NR<sup>c2</sup>C(O)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>S(O)R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, S(O)R<sup>b2</sup>, S(O)NR<sup>c2</sup>R<sup>d2</sup>, S(O)<sub>2</sub>R<sup>b2</sup>, and S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>;

R<sup>10</sup> is selected from halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)R<sup>b3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>; wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R<sup>10a</sup>;

R<sup>15</sup> is selected from H, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)R<sup>b3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>; wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from R<sup>10a</sup>;

each R<sup>10a</sup> is independently selected from Cy<sup>2</sup>, halo, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>1-6</sub> haloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl are each optionally substituted with 1, 2, or 3 substituents independently selected from Cy<sup>2</sup>, halo, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup>, and S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>;

R<sup>A</sup> and R<sup>B</sup> are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>6-10</sub>



membered heterocycloalkyl, C<sub>6-10</sub> aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c3</sup> and R<sup>d3</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

or any R<sup>c5</sup> and R<sup>d5</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, 5-6 membered heteroaryl, C<sub>1-6</sub> haloalkyl, halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, wherein said C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, 4-7 membered heterocycloalkyl, C<sub>6-10</sub> aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR<sup>a6</sup>, SR<sup>a6</sup>, C(O)R<sup>b6</sup>, C(O)NR<sup>c6</sup>R<sup>d6</sup>, C(O)OR<sup>a6</sup>, OC(O)R<sup>b6</sup>, OC(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)R<sup>b6</sup>, NR<sup>c6</sup>C(O)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(O)OR<sup>a6</sup>, C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, NR<sup>c6</sup>C(=NR<sup>e6</sup>)NR<sup>c6</sup>R<sup>d6</sup>, S(O)R<sup>b6</sup>, S(O)NR<sup>c6</sup>R<sup>d6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>R<sup>b6</sup>, NR<sup>c6</sup>S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>;

each R<sup>e1</sup>, R<sup>e2</sup>, R<sup>e3</sup>, and R<sup>e5</sup> is independently selected from H, C<sub>1-4</sub> alkyl, CN, OR<sup>a6</sup>, SR<sup>b6</sup>, S(O)<sub>2</sub>R<sup>b6</sup>, C(O)R<sup>b6</sup>, S(O)<sub>2</sub>NR<sup>c6</sup>R<sup>d6</sup>, and C(O)NR<sup>c6</sup>R<sup>d6</sup>;

each R<sup>a6</sup>, R<sup>b6</sup>, R<sup>c6</sup>, and R<sup>d6</sup> is independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl, C<sub>2-4</sub> alkenyl, and C<sub>2-4</sub> alkynyl, wherein said C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, and C<sub>2-4</sub> alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylamino, di(C<sub>1-4</sub> alkyl)amino, C<sub>1-4</sub> haloalkyl, and C<sub>1-4</sub> haloalkoxy;

or any R<sup>c6</sup> and R<sup>d6</sup> together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C<sub>1-6</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylamino, di(C<sub>1-4</sub> alkyl)amino, C<sub>1-4</sub> haloalkyl, and C<sub>1-4</sub> haloalkoxy; and

each R<sup>e6</sup> is independently selected from H, C<sub>1-4</sub> alkyl, and CN.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:-

- a) R<sup>9</sup> is H, C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, or (4-10 membered heterocycloalkyl)-C<sub>1-4</sub> alkyl, wherein said C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>3-10</sub> cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, (5-10 membered heteroaryl)-C<sub>1-4</sub> alkyl, and (4-10 membered heterocycloalkyl)-C<sub>1-4</sub> alkyl are each optionally substituted with R<sup>9a</sup>; or
- b) R<sup>9</sup> is H, C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, 4-10 membered heterocycloalkyl, C<sub>6-10</sub> aryl-C<sub>1-4</sub> alkyl, or C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl; or
- c) R<sup>9</sup> is C<sub>1-6</sub> alkyl; or
- d) R<sup>9</sup> is methyl.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein each of R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> is H.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:-

- a) R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each independently selected from H, halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, and OR<sup>a1</sup>; or
- b) R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each independently selected from H, halo, and methoxy; or
- c) R<sup>5</sup> and R<sup>7</sup> are both methoxy and R<sup>4</sup>, R<sup>6</sup>, and R<sup>8</sup> are each independently selected from H and halo; or

d) R<sup>4</sup> is halo, R<sup>5</sup> is methoxy, R<sup>6</sup> is H, R<sup>7</sup> is methoxy, and R<sup>8</sup> is halo.


5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein:-

- 5 a) X is CR<sup>15</sup>; or  
b) X is CH.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R<sup>15</sup> is H or 5-10 membered heteroaryl optionally substituted by C<sub>1-6</sub> alkyl.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof wherein R<sup>10</sup> is C<sub>1-6</sub> alkyl optionally substituted with 4-7 membered heterocycloalkyl wherein said 4-7 membered heterocycloalkyl is selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydrofuranyl, and azetidiny, and wherein said 4-7 membered heterocycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, OR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, and NR<sup>c5</sup>C(O)R<sup>b5</sup>.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having Formula IIa:



IIa.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R<sup>4</sup> is halo, R<sup>5</sup> is methoxy, R<sup>6</sup> is H, R<sup>7</sup> is methoxy, and R<sup>8</sup> is halo.

10. The compound of claim 8 or 9, or a pharmaceutically acceptable salt thereof, wherein R<sup>9</sup> is C<sub>1-6</sub> alkyl.

11. The compound of any one of claims 8 to 10, or a pharmaceutically acceptable salt thereof wherein R<sup>10</sup> is C<sub>1-6</sub> alkyl optionally substituted with 4-7 membered heterocycloalkyl wherein said 4-7 membered heterocycloalkyl is selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, tetrahydrofuranyl, and azetidiny, and wherein said 4-7 membered heterocycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, CN, OR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, and NR<sup>c5</sup>C(O)R<sup>b5</sup>.

12. The compound of claim 1 which is selected from:

3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(3,5-Dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Chloro-3,5-dimethoxyphenyl)-8-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-5-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimi-

dine-8-carbonitrile;

3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methylpiperidin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(3,5-Dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

3-(3,5-Dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(3,5-Dimethoxyphenyl)-8-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(3,5-Dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Chloro-3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

3-(2-Chloro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

3-(2-Chloro-3,5-dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Chloro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

N-Cyclopropyl-3-(2-fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

3-(2-Fluoro-3,5-dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; 1-[[3-(2-Fluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]carbonyl]pyrrolidine-3-carbonitrile;

3-(2-Fluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Fluoro-3,5-dimethoxyphenyl)-8-[(3-hydroxypiperidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-Fluoro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

3-(2,6-Difluoro-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide;

or a pharmaceutically acceptable salt of any of the aforementioned.

### 13. The compound of claim 1:-

a) selected from:

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(tetrahydro-2H-pyran-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylcarbonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4,4-difluoropiperidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

or a pharmaceutically acceptable salt of any of the aforementioned; or

b) selected from:

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[3-(4-ethylpiperazin-1-yl)propyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(1-ethylpiperidin-4-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

5 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-hydroxypiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4,4-difluoropiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

10 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(3,3-difluoropiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

8-(2-azetidin-1-ylethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

15 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyrrolidin-1-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(3-morpholin-4-ylpropyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

8-[3-(4-cyclopropylpiperazin-1-yl)propyl]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

20 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[[3(R,5S)-3,5-dimethylpiperazin-1-yl]carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

25 or a pharmaceutically acceptable salt of any of the aforementioned; or

c) selected from:

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

30 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

35 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

40 3-(4-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperazin-1-yl)propanenitrile; 1-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperidine-4-carbonitrile;

(3S)-1-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]pyrrolidine-3-carbonitrile;

45 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methylpiperidin-4-yl)amino]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[[3(S)-tetrahydrofuran-3-ylamino]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

50 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[[3(R)-tetrahydrofuran-3-ylamino]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(1H-imidazol-1-ylmethyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(1H-pyrazol-1-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

55 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methyl-1H-pyrazol-4-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyridin-2-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;

3-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 8-[2-(diethylamino)ethyl]-3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 5 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(3-fluoroazetid-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(3-methoxyazetid-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 10 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-(2-fluorophenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 15 1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 1-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-propyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 20 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 25 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 1-cyclopropyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 30 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 35 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-pyridin-4-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 40 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1-pyridin-4-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 45 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluorophenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 50 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 55 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 1-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]azetid-3-carbonitrile;

- (3R)-1-[[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]pyrrolidine-3-carbonitrile;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[2-(3-fluoroazetidin-1-yl)ethyl]-1-(2-hydroxyethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 5 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 10 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(2-oxopyridin-1(2H)-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 15 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[(pyridin-3-yloxy)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 20 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 25 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2,3-difluorophenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 30 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(4-fluorophenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3-fluorophenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 35 1-[2-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]ethyl]azetidine-3-carbonitrile;  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-[2-(3-fluoroazetidin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 40 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; and  
 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(2-fluoroethyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one;  
 or a pharmaceutically acceptable salt of any of the aforementioned.
- 45 **14.** The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.
- 15.** The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
- 50 **16.** The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.
- 17.** The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
- 55 **18.** The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
- 5 20. The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.
21. The compound of claim 1 which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
- 10 22. A pharmaceutical composition comprising:-
- (a) a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; or
- 15 (b) a compound of any one of claims 14, 16, 18 or 20, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier; or
- (c) a compound of any one of claims 15, 17, 19, or 21 and at least one pharmaceutically acceptable carrier.
23. A method of inhibiting an FGFR enzyme comprising contacting *in vitro* said enzyme with:-
- 20 (a) a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof; or
- (b) a compound of any one of claims 14, 16, 18 or 20, or a pharmaceutically acceptable salt thereof; or
- (c) a compound of any one of claims 15, 17, 19, or 21.
24. A compound of any one of claims 1 to 13, 14, 16, 18 or 20, or a pharmaceutically acceptable salt thereof, for use in:-
- 25 a) treating cancer; or
- b) treating cancer, wherein said cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer,
- 30 skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglobulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.
25. A compound of any one of claims 1 to 13, 14, 16, 18 or 20, or a pharmaceutically acceptable salt thereof, for use in:-
- 35 a) treating a myeloproliferative disorder; or
- b) treating a myeloproliferative disorder, wherein said myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
- 40 26. A compound of any one of claims 1 to 13, 14, 16, 18 or 20, or a pharmaceutically acceptable salt thereof, for use in:-
- a) treating a skeletal or chondrocyte disorder; or
- b) treating a skeletal or chondrocyte disorder, wherein said skeletal or chondrocyte disorder is selected from achondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosyn-
- 45 ostosis syndrome.
27. A compound of any one of claims 1 to 13, 14, 16, 18 or 20, or a pharmaceutically acceptable salt thereof, for use in:-
- 50 a) treating a hypophosphatemia disorder; or
- b) treating a hypophosphatemia disorder, wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia.
- 55 28. A compound of claim 15, 17, 19 or 21 for use in:-
- a) treating cancer; or
- b) treating cancer, wherein said cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal

cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglobulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

29. A compound of claim 15, 17, 19 or 21 for use in:-

- a) treating a myeloproliferative disorder; or
- b) treating a myeloproliferative disorder, wherein said myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

30. A compound of claim 15, 17, 19 or 21 for use in:-


- a) treating a skeletal or chondrocyte disorder; or
- b) treating a skeletal or chondrocyte disorder, wherein said skeletal or chondrocyte disorder is selected from achondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.

31. A compound of claim 15, 17, 19 or 21 for use in:-

- a) treating a hypophosphatemia disorder; or
- b) treating a hypophosphatemia disorder, wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia.

### Patentansprüche

1. Verbindung der Formel II:



oder ein pharmazeutisch unbedenkliches Salz davon, wobei:

- W für NR<sup>9</sup> steht,
- X für CR<sup>15</sup> oder N steht,
- R<sup>1</sup> für H, NR<sup>A</sup>R<sup>B</sup>, Halogen oder C<sub>1-3</sub>-Alkyl steht,
- R<sup>2</sup> und R<sup>3</sup> jeweils unabhängig voneinander aus H, CN, C(O)NR<sup>c</sup>R<sup>d</sup> und C<sub>1-7</sub>-Alkyl ausgewählt sind, wobei C<sub>1-7</sub>-Alkyl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Halogen, OR<sup>a</sup>, CN, NR<sup>c</sup>R<sup>d</sup> und

C(O)NR<sup>c</sup>R<sup>d</sup> ausgewählte Substituenten substituiert ist,  
 oder R<sup>2</sup> und R<sup>3</sup> zusammen mit dem Kohlenstoffatom, an das sie gebunden sind, einen 3- bis 7-gliedrigen  
 Cycloalkylring oder einen 4- bis 7-gliedrigen Heterocycloalkylring bilden, jeweils gegebenenfalls substituiert  
 durch 1, 2 oder 3 Substituenten unabhängig voneinander ausgewählt aus Halogen, C<sub>1-6</sub>-Alkyl, C<sub>1-6</sub>-Halogenalkyl,  
 CN, OR<sup>a</sup>, SR<sup>a</sup>, C(O)R<sup>b</sup>, C(O)NR<sup>c</sup>R<sup>d</sup>, C(O)OR<sup>a</sup>, OC(O)R<sup>b</sup>, OC(O)NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>C(O)R<sup>b</sup> und  
 NR<sup>c</sup>C(O)OR<sup>a</sup>,

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> und R<sup>8</sup> jeweils unabhängig voneinander aus H, Halogen, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl,  
 C<sub>1-6</sub>-Halogenalkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 4- bis 10-gliedrigem Heterocycloalkyl,  
 CN, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>,  
 NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(=NR<sup>e1</sup>)R<sup>b1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>,  
 NR<sup>c1</sup>S(O)R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1</sup>R<sup>d1</sup>, S(O)<sub>2</sub>R<sup>b1</sup> und S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup> aus-  
 gewählt sind, wobei C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedriges Heteroaryl und 4- bis 10-gliedriges Heterocycloalkyl jeweils gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus Halogen, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>1-6</sub>-Halogenalkyl, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>,  
 C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>,  
 NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>S(O)R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>R<sup>b1</sup>,  
 NR<sup>c1</sup>S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1</sup>R<sup>d1</sup>, S(O)<sub>2</sub>R<sup>b1</sup>, und S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup> ausgewählte Substituenten substituiert sind,

R<sup>9</sup> für H, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl, C<sub>6-10</sub>-Aryl-C<sub>1-4</sub>-alkyl, C<sub>3-10</sub>-Cycloalkyl-C<sub>1-4</sub>-alkyl, (5- bis 10-gliedriges Heteroaryl)-C<sub>1-4</sub>-alkyl oder (4- bis 10-gliedriges Heterocycloalkyl)-C<sub>1-4</sub>-alkyl steht, wobei C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl, C<sub>6-10</sub>-Aryl-C<sub>1-4</sub>-alkyl, C<sub>3-10</sub>-Cycloalkyl-C<sub>1-4</sub>-alkyl, (5- bis 10-gliedriges Heteroaryl)-C<sub>1-4</sub>-alkyl und (4- bis 10-gliedriges Heterocycloalkyl)-C<sub>1-4</sub>-alkyl jeweils gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus R<sup>9a</sup> ausgewählte Substituenten substituiert sind,

R<sup>9a</sup> jeweils unabhängig aus Cy<sup>1</sup>, Halogen, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>1-6</sub>-Halogenalkyl, CN, NO<sub>2</sub>, OR<sup>a2</sup>, SR<sup>a2</sup>, C(O)R<sup>b2</sup>, C(O)NR<sup>c2</sup>R<sup>d2</sup>, C(O)OR<sup>a2</sup>, OC(O)R<sup>b2</sup>, OC(O)NR<sup>c2</sup>R<sup>d2</sup>, C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(O)R<sup>b2</sup>, NR<sup>c2</sup>C(O)OR<sup>a2</sup>, NR<sup>c2</sup>C(O)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>S(O)R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, S(O)R<sup>b2</sup>, S(O)NR<sup>c2</sup>R<sup>d2</sup>, S(O)<sub>2</sub>R<sup>b2</sup> und S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup> ausgewählt ist, wobei C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl und C<sub>2-6</sub>-Alkyl jeweils gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Cy<sup>1</sup>, Halogen, CN, NO<sub>2</sub>, OR<sup>a2</sup>, SR<sup>a2</sup>, C(O)R<sup>b2</sup>, C(O)NR<sup>c2</sup>R<sup>d2</sup>, C(O)OR<sup>a2</sup>, OC(O)R<sup>b2</sup>, OC(O)NR<sup>c2</sup>R<sup>d2</sup>, C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(O)R<sup>b2</sup>, NR<sup>c2</sup>C(O)OR<sup>a2</sup>, NR<sup>c2</sup>C(O)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>S(O)R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, S(O)R<sup>b2</sup>, S(O)NR<sup>c2</sup>R<sup>d2</sup>, S(O)<sub>2</sub>R<sup>b2</sup> und S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup> ausgewählte Substituenten substituiert sind,

R<sup>10</sup> aus Halogen, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>1-6</sub>-Halogenalkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 4- bis 10-gliedrigem Heterocycloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)R<sup>b3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup> und S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup> ausgewählt ist, wobei C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl jeweils gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus R<sup>10a</sup> ausgewählte Substituenten substituiert sind,

R<sup>15</sup> aus H, Halogen, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>1-6</sub>-Halogenalkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 4- bis 10-gliedrigem Heterocycloalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)R<sup>b3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup> und S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup> ausgewählt ist, wobei C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>6-10</sub>-Aryl, C<sub>3-10</sub>-Cycloalkyl, 5- bis 10-gliedriges Heteroaryl und 4- bis 10-gliedriges Heterocycloalkyl jeweils gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus R<sup>10a</sup> ausgewählte Substituenten substituiert sind,

R<sup>10a</sup> jeweils unabhängig aus Cy<sup>2</sup>, Halogen, C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl, C<sub>2-6</sub>-Alkyl, C<sub>1-6</sub>-Halogenalkyl, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup> und S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup> ausgewählt ist, wobei C<sub>1-6</sub>-Alkyl, C<sub>2-6</sub>-Alkenyl und C<sub>2-6</sub>-Alkyl jeweils gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Cy<sup>2</sup>, Halogen, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(=NR<sup>e3</sup>)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>, NR<sup>c3</sup>C(O)OR<sup>a3</sup>, NR<sup>c3</sup>C(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>S(O)R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>R<sup>b3</sup>, NR<sup>c3</sup>S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup>, S(O)R<sup>b3</sup>, S(O)NR<sup>c3</sup>R<sup>d3</sup>, S(O)<sub>2</sub>R<sup>b3</sup> und S(O)<sub>2</sub>NR<sup>c3</sup>R<sup>d3</sup> ausgewählte Substituenten substituiert sind,

gewählte Substituenten substituiert sind,

$R^A$  und  $R^B$  jeweils unabhängig voneinander aus H,  $C_{1-4}$ -Alkyl,  $C_{1-4}$ -Halogenalkyl,  $C_{2-4}$ -Alkenyl,  $C_{2-4}$ -Alkynyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 4- bis 10-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl,  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl, (5- bis 10-gliedriges Heteroaryl)- $C_{1-4}$ -alkyl und, (4- bis 10-gliedriges Heterocycloalkyl)- $C_{1-4}$ -alkyl ausgewählt sind, wobei  $C_{1-4}$ -Alkyl,  $C_{2-4}$ -Alkenyl,  $C_{2-4}$ -Alkynyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl,  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl, (5- bis 10-gliedriges Heteroaryl)- $C_{1-4}$ -alkyl und (4- bis 10-gliedriges Heterocycloalkyl)- $C_{1-4}$ -alkyl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus OH, CN, Amino, Halogen,  $C_{1-4}$ -Alkyl,  $C_{1-4}$ -Alkoxy,  $C_{1-4}$ -Alkylthio,  $C_{1-4}$ -Alkylamino, Di( $C_{1-4}$ -alkyl) amino,  $C_{1-4}$ -Halogenalkyl und  $C_{1-4}$ -Halogenalkoxy ausgewählte Substituenten substituiert sind,  $Cy^1$  und  $Cy^2$  jeweils unabhängig voneinander aus  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 4- bis 10-gliedrigem Heterocycloalkyl ausgewählt sind, die jeweils gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus Halogen,  $C_{1-6}$ -Alkyl,  $C_{2-6}$ -Alkenyl,  $C_{2-6}$ -Alkynyl,  $C_{1-6}$ -Halogenalkyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 3- bis 10-gliedrigem Heterocycloalkyl, CN,  $NO_2$ ,  $OR^{a5}$ ,  $SR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5R^{d5}}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $OC(O)NR^{c5R^{d5}}$ ,  $NR^{c5R^{d5}}$ ,  $NR^{c5C(O)R^{b5}}$ ,  $NR^{c5C(O)OR^{a5}}$ ,  $NR^{c5C(O)NR^{c5R^{d5}}}$ ,  $C(=NR^{e5})R^{b5}$ ,  $C(=NR^{e5})NR^{c5R^{d5}}$ ,  $NR^{c5C(=NR^{e5})NR^{c5R^{d5}}}$ ,  $NR^{c5S(O)R^{b5}}$ ,  $NR^{c5S(O)_2R^{b5}}$ ,  $NR^{c5S(O)_2NR^{c5R^{d5}}}$ ,  $S(O)R^{b5}$ ,  $S(O)NR^{c5R^{d5}}$ ,  $S(O)_2R^{b5}$  und  $S(O)_2NR^{c5R^{d5}}$  ausgewählte Substituenten substituiert sind, wobei  $C_{1-6}$ -Alkyl,  $C_{2-6}$ -Alkenyl,  $C_{2-6}$ -Alkynyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedriges Heteroaryl und 4- bis 10-gliedriges Heterocycloalkyl jeweils gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus Halogen,  $C_{1-6}$ -Alkyl,  $C_{2-6}$ -Alkenyl,  $C_{2-6}$ -Alkynyl,  $C_{1-6}$ -Halogenalkyl, CN,  $NO_2$ ,  $OR^{a5}$ ,  $SR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5R^{d5}}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $OC(O)NR^{c5R^{d5}}$ ,  $C(=NR^{e5})NR^{c5R^{d5}}$ ,  $NR^{c5C(=NR^{e5})NR^{c5R^{d5}}}$ ,  $NR^{c5C(O)R^{b5}}$ ,  $NR^{c5C(O)OR^{a5}}$ ,  $NR^{c5C(O)NR^{c5R^{d5}}}$ ,  $NR^{c5S(O)R^{b5}}$ ,  $NR^{c5S(O)_2R^{b5}}$ ,  $NR^{c5S(O)_2NR^{c5R^{d5}}}$ ,  $S(O)R^{b5}$ ,  $S(O)NR^{c5R^{d5}}$ ,  $S(O)_2R^{b5}$  und  $S(O)_2NR^{c5R^{d5}}$  ausgewählte Substituenten substituiert sind,

$R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^{a1}$ ,  $R^{b1}$ ,  $R^{c1}$ ,  $R^{d1}$ ,  $R^{a2}$ ,  $R^{b2}$ ,  $R^{c2}$ ,  $R^{d2}$ ,  $R^{a3}$ ,  $R^{b3}$ ,  $R^{c3}$ ,  $R^{d3}$ ,  $R^{a5}$ ,  $R^{b5}$ ,  $R^{c5}$  und  $R^{d5}$  jeweils unabhängig voneinander aus H,  $C_{1-6}$ -Alkyl,  $C_{1-4}$ -Halogenalkyl,  $C_{2-6}$ -Alkenyl,  $C_{2-6}$ -Alkynyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedrigem Heteroaryl, 4- bis 10-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl,  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl, (5- bis 10-gliedriges Heteroaryl)- $C_{1-4}$ -alkyl und (4- bis 10-gliedriges Heterocycloalkyl)- $C_{1-4}$ -alkyl ausgewählt sind, wobei  $C_{1-6}$ -Alkyl,  $C_{2-6}$ -Alkenyl,  $C_{2-6}$ -Alkynyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5- bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl,  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl, (5- bis 10-gliedriges Heteroaryl)- $C_{1-4}$ -alkyl und (4- bis 10-gliedriges Heterocycloalkyl)- $C_{1-4}$ -alkyl gegebenenfalls durch 1, 2, 3, 4 oder 5 unabhängig voneinander aus  $C_{1-4}$ -Alkyl,  $C_{1-4}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6R^{d6}}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6R^{d6}}$ ,  $NR^{c6R^{d6}}$ ,  $NR^{c6C(O)R^{b6}}$ ,  $NR^{c6C(O)NR^{c6R^{d6}}}$ ,  $NR^{c6C(O)OR^{a6}}$ ,  $C(=NR^{e6})NR^{c6R^{d6}}$ ,  $NR^{c6C(=NR^{e6})NR^{c6R^{d6}}}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6R^{d6}}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6S(O)_2R^{b6}}$ ,  $NR^{c6S(O)_2NR^{c6R^{d6}}}$  und  $S(O)_2NR^{c6R^{d6}}$  ausgewählte Substituenten substituiert sind,

oder beliebige  $R^c$  und  $R^d$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl, 5- bis 6-gliedrigem Heteroaryl,  $C_{1-6}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6R^{d6}}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6R^{d6}}$ ,  $NR^{c6R^{d6}}$ ,  $NR^{c6C(O)R^{b6}}$ ,  $NR^{c6C(O)NR^{c6R^{d6}}}$ ,  $NR^{c6C(O)OR^{a6}}$ ,  $C(=NR^{e6})NR^{c6R^{d6}}$ ,  $NR^{c6C(=NR^{e6})NR^{c6R^{d6}}}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6R^{d6}}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6S(O)_2R^{b6}}$ ,  $NR^{c6S(O)_2NR^{c6R^{d6}}}$  und  $S(O)_2NR^{c6R^{d6}}$  ausgewählte Substituenten, bilden, wobei  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl und 5- bis 6-gliedriges Heteroaryl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6R^{d6}}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6R^{d6}}$ ,  $NR^{c6R^{d6}}$ ,  $NR^{c6C(O)R^{b6}}$ ,  $NR^{c6C(O)NR^{c6R^{d6}}}$ ,  $NR^{c6C(O)OR^{a6}}$ ,  $C(=NR^{e6})NR^{c6R^{d6}}$ ,  $NR^{c6C(=NR^{e6})NR^{c6R^{d6}}}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6R^{d6}}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6S(O)_2R^{b6}}$ ,  $NR^{c6S(O)_2NR^{c6R^{d6}}}$  und  $S(O)_2NR^{c6R^{d6}}$  ausgewählte Substituenten substituiert sind,

oder beliebige  $R^{c1}$  und  $R^{d1}$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl, 5- bis 6-gliedrigem Heteroaryl,  $C_{1-6}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6R^{d6}}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6R^{d6}}$ ,  $NR^{c6R^{d6}}$ ,  $NR^{c6C(O)R^{b6}}$ ,  $NR^{c6C(O)NR^{c6R^{d6}}}$ ,  $NR^{c6C(O)OR^{a6}}$ ,  $C(=NR^{e6})NR^{c6R^{d6}}$ ,  $NR^{c6C(=NR^{e6})NR^{c6R^{d6}}}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6R^{d6}}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6S(O)_2R^{b6}}$ ,  $NR^{c6S(O)_2NR^{c6R^{d6}}}$  und  $S(O)_2NR^{c6R^{d6}}$  ausgewählte Substituenten, bilden, wobei  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl und 5- bis 6-gliedriges Heteroaryl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6R^{d6}}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6R^{d6}}$ ,  $NR^{c6R^{d6}}$ ,  $NR^{c6C(O)R^{b6}}$ ,  $NR^{c6C(O)NR^{c6R^{d6}}}$ ,  $NR^{c6C(O)OR^{a6}}$ ,  $C(=NR^{e6})NR^{c6R^{d6}}$ ,  $NR^{c6C(=NR^{e6})NR^{c6R^{d6}}}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6R^{d6}}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6S(O)_2R^{b6}}$ ,  $NR^{c6S(O)_2NR^{c6R^{d6}}}$  und  $S(O)_2NR^{c6R^{d6}}$  ausgewählte Substituenten substituiert sind, oder beliebige  $R^{c2}$  und  $R^{d2}$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus

$C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl, 5- bis 6-gliedrigem Heteroaryl,  $C_{1-6}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$  und  $S(O)_2NR^{c6}R^{d6}$  ausgewählte Substituenten, bilden, wobei  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl und 5- bis 6-gliedriges Heteroaryl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$  und  $S(O)_2NR^{c6}R^{d6}$  ausgewählt Substituenten substituiert sind, oder beliebige  $R^{c3}$  und  $R^{d3}$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl, 5- bis 6-gliedrigem Heteroaryl,  $C_{1-6}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$  und  $S(O)_2NR^{c6}R^{d6}$  ausgewählte Substituenten substituiert sind, oder beliebige  $R^{c5}$  und  $R^{d5}$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl, 5- bis 6-gliedrigem Heteroaryl,  $C_{1-6}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$  und  $S(O)_2NR^{c6}R^{d6}$  ausgewählte Substituenten substituiert sind, oder beliebige  $R^{c6}$  und  $R^{d6}$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus  $C_{1-6}$ -Alkyl,  $C_{3-7}$ -Cycloalkyl, 4- bis 7-gliedrigem Heterocycloalkyl,  $C_{6-10}$ -Aryl, 5- bis 6-gliedrigem Heteroaryl,  $C_{1-6}$ -Halogenalkyl, Halogen, CN,  $OR^{a6}$ ,  $SR^{a6}$ ,  $C(O)R^{b6}$ ,  $C(O)NR^{c6}R^{d6}$ ,  $C(O)OR^{a6}$ ,  $OC(O)R^{b6}$ ,  $OC(O)NR^{c6}R^{d6}$ ,  $NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)R^{b6}$ ,  $NR^{c6}C(O)NR^{c6}R^{d6}$ ,  $NR^{c6}C(O)OR^{a6}$ ,  $C(=NR^{e6})NR^{c6}R^{d6}$ ,  $NR^{c6}C(=NR^{e6})NR^{c6}R^{d6}$ ,  $S(O)R^{b6}$ ,  $S(O)NR^{c6}R^{d6}$ ,  $S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2R^{b6}$ ,  $NR^{c6}S(O)_2NR^{c6}R^{d6}$  und  $S(O)_2NR^{c6}R^{d6}$  ausgewählte Substituenten substituiert sind,  $R^{e1}$ ,  $R^{e2}$ ,  $R^{e3}$  und  $R^{e5}$  jeweils unabhängig voneinander aus H,  $C_{1-4}$ -alkyl, CN,  $OR^{a6}$ ,  $SR^{b6}$ ,  $S(O)_2R^{b6}$ ,  $C(O)R^{b6}$ ,  $S(O)_2NR^{c6}R^{d6}$  und  $C(O)NR^{c6}R^{d6}$  ausgewählt sind,  $R^{a6}$ ,  $R^{b6}$ ,  $R^{c6}$  und  $R^{d6}$  jeweils unabhängig voneinander aus H,  $C_{1-4}$ -Alkyl,  $C_{1-4}$ -Halogenalkyl,  $C_{2-4}$ -Alkenyl und  $C_{2-4}$ -Alkyl ausgewählt sind, wobei  $C_{1-4}$ -Alkyl,  $C_{2-4}$ -Alkenyl und  $C_{2-4}$ -Alkyl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus OH, CN, Amino, Halogen,  $C_{1-4}$ -Alkyl,  $C_{1-4}$ -Alkoxy,  $C_{1-4}$ -Alkylthio,  $C_{1-4}$ -Alkylamino, Di( $C_{1-4}$ -alkyl)amino,  $C_{1-4}$ -Halogenalkyl und  $C_{1-4}$ -Halogenalkoxy ausgewählte Substituenten substituiert sind, oder beliebige  $R^{c6}$  und  $R^{d6}$  zusammen mit dem N-Atom, an das sie gebunden sind, eine 4-, 5-, 6- oder 7-gliedrige Heterocycloalkylgruppe, gegebenenfalls substituiert durch 1, 2 oder 3 unabhängig voneinander aus OH, CN, Amino, Halogen,  $C_{1-6}$ -Alkyl,  $C_{1-4}$ -Alkoxy,  $C_{1-4}$ -Alkylthio,  $C_{1-4}$ -Alkylamino, Di( $C_{1-4}$ -alkyl)amino,  $C_{1-4}$ -Halogenalkyl und  $C_{1-4}$ -Halogenalkoxy ausgewählte Substituenten, bilden und  $R^{e6}$  jeweils unabhängig aus H,  $C_{1-4}$ -Alkyl und CN ausgewählt ist.

2. Verbindung nach Anspruch 1 oder ein pharmazeutisch unbedenkliches Salz davon, wobei:

- a)  $R^9$  für H,  $C_{1-6}$ -Alkyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5-bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl,  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl, (5- bis 10-gliedriges Heteroaryl) - $C_{1-4}$ -alkyl oder (4- bis 10-gliedriges Heterocycloalkyl)- $C_{1-4}$ -alkyl steht, wobei  $C_{1-6}$ -Alkyl,  $C_{6-10}$ -Aryl,  $C_{3-10}$ -Cycloalkyl, 5-bis 10-gliedriges Heteroaryl, 4- bis 10-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl,  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl, (5- bis 10-gliedriges Heteroaryl)- $C_{1-4}$ -alkyl und (4- bis 10-gliedriges Heterocycloalkyl)- $C_{1-4}$ -alkyl jeweils gegebenenfalls durch  $R^{9a}$  substituiert sind, oder  
 b)  $R^9$  für H,  $C_{1-6}$ -Alkyl,  $C_{3-10}$ -Cycloalkyl, 4- bis 10-gliedriges Heterocycloalkyl,  $C_{6-10}$ -Aryl- $C_{1-4}$ -alkyl oder  $C_{3-10}$ -Cycloalkyl- $C_{1-4}$ -alkyl steht oder  
 c)  $R^9$  für  $C_{1-6}$ -Alkyl steht oder  
 d)  $R^9$  für Methyl steht.

3. Verbindung nach Anspruch 1 oder 2 oder ein pharmazeutisch unbedenkliches Salz davon, wobei  $R^1$ ,  $R^2$  und  $R^3$  jeweils für H stehen.

4. Verbindung nach einem der Ansprüche 1 bis 3 oder ein pharmazeutisch unbedenkliches Salz davon, wobei:

- a)  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  und  $R^8$  jeweils unabhängig voneinander aus H, Halogen,  $C_{1-6}$ -Alkyl,  $C_{1-6}$ -Halogenalkyl, CN und  $OR^{a1}$  ausgewählt sind oder
- b)  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  und  $R^8$  jeweils unabhängig voneinander aus H, Halogen und Methoxy ausgewählt sind oder
- c)  $R^5$  und  $R^7$  beide für Methoxy stehen und  $R^4$ ,  $R^6$  und  $R^8$  jeweils unabhängig voneinander aus H und Halogen ausgewählt sind oder
- d)  $R^4$  für Halogen steht,  $R^5$  für Methoxy steht,  $R^6$  für H steht,  $R^7$  für Methoxy steht und  $R^8$  für Halogen steht.


5. Verbindung nach einem der Ansprüche 1 bis 4 oder ein pharmazeutisch unbedenkliches Salz davon, wobei:

- a) X für  $CR^{15}$  steht oder
- b) X für CH steht.

6. Verbindung nach einem der Ansprüche 1 bis 5 oder ein pharmazeutisch unbedenkliches Salz davon, wobei  $R^{15}$  für H oder 5- bis 10-gliedriges Heteroaryl, gegebenenfalls substituiert durch  $C_{1-6}$ -Alkyl, steht.

7. Verbindung nach einem der Ansprüche 1 bis 6 oder ein pharmazeutisch unbedenkliches Salz davon, wobei  $R^{10}$  für gegebenenfalls durch 4- bis 7-gliedriges Heterocycloalkyl substituiertes  $C_{1-6}$ -Alkyl steht, wobei das 4- bis 7-gliedrige Heterocycloalkyl aus Morpholinyl, Piperazinyl, Piperidinyl, Pyrrolidinyl, Tetrahydrofuranyl und Azetidinyll ausgewählt ist und wobei das 4- bis 7-gliedrige Heterocycloalkyl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Halogen,  $C_{1-6}$ -Alkyl,  $C_{1-6}$ -Halogenalkyl, CN,  $OR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5}R^{d5}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $NR^{c5}R^{d5}$  und  $NR^{c5}C(O)R^{b5}$  ausgewählte Substituenten substituiert ist.

8. Verbindung nach Anspruch 1 oder ein pharmazeutisch unbedenkliches Salz davon, mit der Formel IIa:



IIa.

9. Verbindung nach Anspruch 8 oder ein pharmazeutisch unbedenkliches Salz davon, wobei  $R^4$  für Halogen steht,  $R^5$  für Methoxy steht,  $R^6$  für H steht,  $R^7$  für Methoxy steht und  $R^8$  für Halogen steht.

10. Verbindung nach Anspruch 8 oder 9 oder ein pharmazeutisch unbedenkliches Salz davon, wobei  $R^9$  für  $C_{1-6}$ -Alkyl steht.

11. Verbindung nach einem der Ansprüche 8 bis 10 oder ein pharmazeutisch unbedenkliches Salz davon, wobei  $R^{10}$  für gegebenenfalls durch 4- bis 7-gliedriges Heterocycloalkyl substituiertes  $C_{1-6}$ -Alkyl steht, wobei das 4- bis 7-gliedrige Heterocycloalkyl aus Morpholinyl, Piperazinyl, Piperidinyl, Pyrrolidinyl, Tetrahydrofuranyl und Azetidinyll ausgewählt ist und wobei das 4- bis 7-gliedrige Heterocycloalkyl gegebenenfalls durch 1, 2 oder 3 unabhängig voneinander aus Halogen,  $C_{1-6}$ -Alkyl,  $C_{1-6}$ -Halogenalkyl, CN,  $OR^{a5}$ ,  $C(O)R^{b5}$ ,  $C(O)NR^{c5}R^{d5}$ ,  $C(O)OR^{a5}$ ,  $OC(O)R^{b5}$ ,  $NR^{c5}R^{d5}$  und  $NR^{c5}C(O)R^{b5}$  ausgewählte Substituenten substituiert ist.

12. Verbindung nach Anspruch 1, ausgewählt aus:

- 3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(3,5-Dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 5 3-(2-Chlor-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2-Chlor-3,5-dimethoxyphenyl)-8-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 10 3-(2-Chlor-3,5-dimethoxyphenyl)-1-methyl-8-(1-methyl-1H-pyrazol-5-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2-Chlor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäurenitril,  
 3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 15 3-(3,5-Dimethoxyphenyl)-1-methyl-8-(1-methylpiperidin-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(3,5-Dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 20 3-(3,5-Dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(3,5-Dimethoxyphenyl)-8-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(3,5-Dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 25 3-(2-Chlor-3,5-dimethoxyphenyl)-N,1-dimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 3-(2-Chlor-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 30 3-(2-Chlor-3,5-dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2-Chlor-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 N-Cyclopropyl-3-(2-fluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 35 3-(2-Fluor-3,5-dimethoxyphenyl)-8-[(3-hydroxyazetidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 1-[[3-(2-Fluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]carbonyl]pyrrolidin-3-carbonsäurenitril,  
 3-(2-Fluor-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 40 3-(2-Fluor-3,5-dimethoxyphenyl)-8-[(3-hydroxypiperidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2-Fluor-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 45 3-(2,6-Difluor-3,5-dimethoxyphenyl)-N,N,1-trimethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-carbonsäureamid,  
 oder ein pharmazeutisch unbedenkliches Salz einer der oben stehenden Verbindungen.

### 13. Verbindung nach Anspruch 1:

- 50 a) ausgewählt aus:
- 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(tetrahydro-2H-pyran-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 55 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)carbonyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylcarbonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,

3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4,4-difluorpiperidin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
oder ein pharmazeutisch unbedenkliches Salz einer der oben stehenden Verbindungen, oder

5 b) ausgewählt aus:

3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
10 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[3-(4-ethylpiperazin-1-yl)propyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(1-ethylpiperidin-4-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
15 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-hydroxypiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4,4-difluorpiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
20 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(3,3-difluorpiperidin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
25 8-(2-Azetidin-1-ylethyl)-3-(2,6-difluor-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyrrolidin-1-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
30 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(3-morpholin-4-ylpropyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
8-[3-(4-Cyclopropylpiperazin-1-yl)propyl]-3-(2,6-difluor-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
35 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(3R,5S)-3,5-dimethylpiperazin-1-yl]carbonyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
oder ein pharmazeutisch unbedenkliches Salz einer der oben stehenden Verbindungen, oder

40 c) ausgewählt aus:

3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
45 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-(2-hydroxyethyl)piperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
50 3-(4-[[3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperazin-1-yl)propionitril,  
1-[[3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]piperidin-4-carbonsäurenitril,  
55 (3S)-1-[[3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]pyrrolidin-3-carbonsäurenitril,  
3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methylpiperidin-4-yl)amino]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,

3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-[(3S)-tetrahydrofuran-3-ylamino]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-[(3R)-tetrahydrofuran-3-ylamino]methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 5 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-(1H-imidazol-1-ylmethyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(1H-pyrazol-1-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 10 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-[(1-methyl-1H-pyrazol-4-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(2-pyridin-2-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2-Chlor-6-fluor-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 15 8-[2-(Diethylamino)ethyl]-3-(2,6-difluor-3,5-dimethoxyphenyl)-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[2-(3-fluorazetidin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[2-(3-methoxyazetidin-1-yl)ethyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 20 3-(2,6-difluor-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-fluorphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 25 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-(2-fluorphenyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 1-Cyclobutyl-3-(2,6-difluor-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 1-Cyclobutyl-3-(2,6-difluor-3,5-dimethoxyphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 30 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-propyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 35 1-Cyclopropyl-3-(2,6-difluor-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 1-Cyclopropyl-3-(2,6-difluor-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 1-Cyclopropyl-3-(2,6-difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 40 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(4-fluorphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(4-fluorphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3d]pyrimidin-2-on,  
 45 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(4-fluorphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2,3-difluorphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2,3-difluorphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 50 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-(morpholin-4-ylmethyl)-1-pyridin-4-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1-pyridin-4-yl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 55 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-fluorphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-fluorphenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,

3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-fluorphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-[(2-methoxypyridin-4-yl)methyl]-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 5 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(1-methyl-1H-pyrazol-4-yl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 10 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-(1-methyl-1H-pyrazol-4-yl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 1-[[3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]azetidin-3-carbonsäurenitril,  
 (3R)-1-[[3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]methyl]pyrrolidin-3-carbonsäurenitril,  
 15 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[2-(3-fluorazetidin-1-yl)ethyl]-1-(2-hydroxyethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2,3-difluorphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 20 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(3-fluorphenyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on,  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(3-fluorphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(3-fluorphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 25 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-[(2-oxopyridin-1(2H)-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-[(pyridin-3-yloxy)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 30 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-hydroxyethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2,3-difluorphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2,3-difluorphenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 35 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2,3-difluorphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(4-fluorphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(4-fluorphenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 40 3-(2,6-difluor-3,5-dimethoxyphenyl)-1-(3-fluorphenyl)-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(3-fluorphenyl)-8-[2-(4-methylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 45 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(3-fluorphenyl)-8-[2-(4-ethylpiperazin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 1-[2-[3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]ethyl]azetidin-3-carbonsäurenitril;  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-[2-(3-fluorazetidin-1-yl)ethyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 50 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-fluorethyl)-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on und  
 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-(2-fluorethyl)-8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on;  
 55 oder ein pharmazeutisch unbedenkliches Salz einer der oben stehenden Verbindungen.

14. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt, oder ein pharmazeutisch unbedenkliches Salz einer der oben stehenden Verbindungen.

denkliches Salz davon.

- 5
15. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt.
- 10
16. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt, oder ein pharmazeutisch unbedenkliches Salz davon.
- 15
17. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-8-[(4-ethylpiperazin-1-yl)methyl]-1-methyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt.
18. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt, oder ein pharmazeutisch unbedenkliches Salz davon.
- 20
19. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-methyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt.
- 25
20. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt, oder ein pharmazeutisch unbedenkliches Salz davon.
21. Verbindung nach Anspruch 1, bei der es sich um 3-(2,6-Difluor-3,5-dimethoxyphenyl)-1-ethyl-8-(2-morpholin-4-ylethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-on handelt.
22. Pharmazeutische Zusammensetzung, umfassend:
- 30
- (a) eine Verbindung nach einem der Ansprüche 1 bis 13 oder ein pharmazeutisch unbedenkliches Salz davon und mindestens einen pharmazeutisch unbedenklichen Träger oder
- (b) eine Verbindung nach einem der Ansprüche 14, 16, 18 oder 20 oder ein pharmazeutisch unbedenkliches Salz davon und mindestens einen pharmazeutisch unbedenklichen Träger oder
- (c) eine Verbindung nach einem der Ansprüche 15, 17, 19 oder 21 und mindestens einen pharmazeutisch unbedenklichen Träger.
- 35
23. Verfahren zur Inhibierung eines FGFR-Enzyms, bei dem man das Enzym in vitro mit:
- (a) einer Verbindung nach einem der Ansprüche 1 bis 13 oder einem pharmazeutisch unbedenklichen Salz davon oder
- 40
- (b) einer Verbindung nach einem der Ansprüche 14, 16, 18 oder 20 oder einem pharmazeutisch unbedenklichen Salz davon oder
- (c) einer Verbindung nach einem der Ansprüche 15, 17, 19 oder 21 in Kontakt bringt.
- 45
24. Verbindung nach einem der Ansprüche 1 bis 13, 14, 16, 18 oder 20 oder ein pharmazeutisch unbedenkliches Salz davon, zur Verwendung bei:
- 50
- a) der Behandlung von Krebs oder
- b) der Behandlung von Krebs, wobei die Krebserkrankung aus Blasenkrebs, Brustkrebs, Gebärmutterhalskrebs, Kolorektalkrebs, Endometriumkrebs, Magenkrebs, Kopf- und Halskrebs, Nierenkrebs, Leberkrebs, Lungenkrebs, Eierstockkrebs, Prostatakrebs, Speiseröhrenkrebs, Gallenblasenkrebs, Bauchspeicheldrüsenkrebs, Schilddrüsenkrebs, Hautkrebs, Leukämie, multiplem Myelom, chronischem lymphatischem Lymphom, adulter T-Zell-Leukämie, B-Zell-Lymphom, akuter myeloischer Leukämie, Hodgkin- oder Non-Hodgkin-Lymphom, Waldenström-Makroglobulinämie, Haarzelllymphom, Burkett-Lymphom, Glioblastom, Melanom und Rhabdosarkom ausgewählt ist.
- 55
25. Verbindung nach einem der Ansprüche 1 bis 13, 14, 16, 18 oder 20 oder ein pharmazeutisch unbedenkliches Salz davon zur Verwendung bei:

## EP 2 861 595 B9

- a) der Behandlung einer myeloproliferativen Erkrankung oder
- b) der Behandlung einer myeloproliferativen Erkrankung, wobei die myeloproliferative Erkrankung aus Polycythemia vera, essenzieller Thrombozytämie und primärer Myelofibrose ausgewählt ist.

5 26. Verbindung nach einem der Ansprüche 1 bis 13, 14, 16, 18 oder 20 oder ein pharmazeutisch unbedenkliches Salz davon zur Verwendung bei:

- a) der Behandlung einer Skelett- oder Chondrozytenerkrankung oder
- b) der Behandlung einer Skelett- oder Chondrozytenerkrankung, wobei die Skelett- oder Chondrozytenerkrankung aus Achondroplasie, Hypochondroplasie, Kleinwuchs, thanatophorer Dysplasie (TD), Apert-Syndrom, Crouzon-Syndrom, Jackson-Weiss-Syndrom, Beare-Stevenson-Cutis-gyrata-Syndrom, Pfeiffer-Syndrom und Kraniosynostosesyndrom ausgewählt ist.

15 27. Verbindung nach einem der Ansprüche 1 bis 13, 14, 16, 18 oder 20 oder ein pharmazeutisch unbedenkliches Salz davon zur Verwendung bei:

- a) der Behandlung einer Hypophosphatämieerkrankung oder
- b) der Behandlung einer Hypophosphatämieerkrankung, wobei es sich bei der Hypophosphatämieerkrankung um X-gebundene hypophosphatämische Rachitis, autosomalrezessive hypophosphatämische Rachitis, autosomaldominante hypophosphatämische Rachitis oder tumorinduzierte Osteomalazie handelt.

28. Verbindung nach Anspruch 15, 17, 19 oder 21 zur Verwendung bei:

- a) der Behandlung von Krebs oder
- b) der Behandlung von Krebs, wobei die Krebserkrankung aus Blasenkrebs, Brustkrebs, Gebärmutterhalskrebs, Kolorektalkrebs, Endometriumkrebs, Magenkrebs, Kopf- und Halskrebs, Nierenkrebs, Leberkrebs, Lungenkrebs, Eierstockkrebs, Prostatakrebs, Speiseröhrenkrebs, Gallenblasenkrebs, Bauchspeicheldrüsenkrebs, Schilddrüsenkrebs, Hautkrebs, Leukämie, multiplem Myelom, chronischem lymphatischem Lymphom, adulter T-Zell-Leukämie, B-Zell-Lymphom, akuter myeloischer Leukämie, Hodgkin- oder Non-Hodgkin-Lymphom, Waldenström-Makroglobulinämie, Haarzelllymphom, Burkett-Lymphom, Glioblastom, Melanom und Rhabdosarkom ausgewählt ist.

29. Verbindung nach Anspruch 15, 17, 19 oder 21 zur Verwendung bei:

- a) der Behandlung einer myeloproliferativen Erkrankung oder
- b) der Behandlung einer myeloproliferativen Erkrankung, wobei die myeloproliferative Erkrankung aus Polycythemia vera, essenzieller Thrombozytämie und primärer Myelofibrose ausgewählt ist.

30. Verbindung nach Anspruch 15, 17, 19 oder 21 zur Verwendung bei:


- a) der Behandlung einer Skelett- oder Chondrozytenerkrankung oder
- b) der Behandlung einer Skelett- oder Chondrozytenerkrankung, wobei die Skelett- oder Chondrozytenerkrankung aus Achondroplasie, Hypochondroplasie, Kleinwuchs, thanatophorer Dysplasie (TD), Apert-Syndrom, Crouzon-Syndrom, Jackson-Weiss-Syndrom, Beare-Stevenson-Cutis-gyrata-Syndrom, Pfeiffer-Syndrom und Kraniosynostosesyndrom ausgewählt ist.

31. Verbindung nach Anspruch 15, 17, 19 oder 21 zur Verwendung bei:

- a) der Behandlung einer Hypophosphatämieerkrankung oder
- b) der Behandlung einer Hypophosphatämieerkrankung, wobei es sich bei der Hypophosphatämieerkrankung um X-gebundene hypophosphatämische Rachitis, autosomalrezessive hypophosphatämische Rachitis, autosomaldominante hypophosphatämische Rachitis oder tumorinduzierte Osteomalazie handelt.

## 55 Revendications

1. Composé de formule II :



II

ou sel pharmaceutiquement acceptable de celui-ci, dans lequel :

W est NR<sup>9</sup> ;

X est CR<sup>15</sup> ou N ;

R<sup>1</sup> est H, NR<sup>A</sup>R<sup>B</sup>, halogéno, et alkyle en C<sub>1-3</sub> ;

R<sup>2</sup> et R<sup>3</sup> sont chacun indépendamment choisis parmi H, CN, C(O)NR<sup>c</sup>R<sup>d</sup>, et alkyle en C<sub>1-7</sub>, où ledit alkyle en C<sub>1-7</sub> est facultativement substitué par 1, 2 ou 3 substituants indépendamment choisis parmi halogéno, OR<sup>a</sup>, CN, NR<sup>c</sup>R<sup>d</sup>, et C(O)NR<sup>c</sup>R<sup>d</sup> ;

ou R<sup>2</sup> et R<sup>3</sup> conjointement avec l'atome de carbone auquel ils sont liés forment un cycle cycloalkyle de 3 à 7 chaînons ou un cycle hétérocycloalkyle de 4 à 7 chaînons, chacun facultativement substitué par 1, 2, ou 3 substituants indépendamment choisis parmi halogéno, alkyle en C<sub>1-6</sub>, halogénoalkyle en C<sub>1-6</sub>, CN, OR<sup>a</sup>, SR<sup>a</sup>, C(O)R<sup>b</sup>, C(O)NR<sup>c</sup>R<sup>d</sup>, C(O)OR<sup>a</sup>, OC(O)R<sup>b</sup>, OC(O)NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>R<sup>d</sup>, NR<sup>c</sup>C(O)R<sup>b</sup>, et NR<sup>c</sup>C(O)OR<sup>a</sup> ;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, et R<sup>8</sup> sont chacun indépendamment choisis parmi H, halogéno, alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, halogénoalkyle en C<sub>1-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, hétérocycloalkyle de 4 à 10 chaînons, CN, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(=NR<sup>e1</sup>)R<sup>b1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>S(O)R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1</sup>R<sup>d1</sup>, S(O)<sub>2</sub>R<sup>b1</sup>, et S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup> ; où lesdits alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, et hétérocycloalkyle de 4 à 10 chaînons sont chacun facultativement substitués par 1, 2, 3, 4 ou 5 substituants indépendamment choisis parmi halogéno, alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, halogénoalkyle en C<sub>1-6</sub>, CN, NO<sub>2</sub>, OR<sup>a1</sup>, SR<sup>a1</sup>, C(O)R<sup>b1</sup>, C(O)NR<sup>c1</sup>R<sup>d1</sup>, C(O)OR<sup>a1</sup>, OC(O)R<sup>b1</sup>, OC(O)NR<sup>c1</sup>R<sup>d1</sup>, C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(=NR<sup>e1</sup>)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>C(O)R<sup>b1</sup>, NR<sup>c1</sup>C(O)OR<sup>a1</sup>, NR<sup>c1</sup>C(O)NR<sup>c1</sup>R<sup>d1</sup>, NR<sup>c1</sup>S(O)R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>R<sup>b1</sup>, NR<sup>c1</sup>S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup>, S(O)R<sup>b1</sup>, S(O)NR<sup>c1</sup>R<sup>d1</sup>, S(O)<sub>2</sub>R<sup>b1</sup>, et S(O)<sub>2</sub>NR<sup>c1</sup>R<sup>d1</sup> ;

R<sup>9</sup> est H, alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, hétérocycloalkyle de 4 à 10 chaînons, (aryle en C<sub>6-10</sub>) - (alkyle en C<sub>1-4</sub>), (cycloalkyle en C<sub>3-10</sub>)-(alkyle en C<sub>1-4</sub>), (hétéroaryle de 5 à 10 chaînons)-(alkyle en C<sub>1-4</sub>), ou (hétérocycloalkyle de 4 à 10 chaînons)-(alkyle en C<sub>1-4</sub>), où lesdits alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, hétérocycloalkyle de 4 à 10 chaînons, (aryle en C<sub>6-10</sub>)-(alkyle en C<sub>1-4</sub>), (cycloalkyle en C<sub>3-10</sub>)-(alkyle en C<sub>1-4</sub>), (hétéroaryle de 5 à 10 chaînons)-(alkyle en C<sub>1-4</sub>), et (hétérocycloalkyle de 4 à 10 chaînons)-(alkyle en C<sub>1-4</sub>) sont chacun facultativement substitués par 1, 2, 3, 4, ou 5 substituants indépendamment choisis parmi R<sup>9a</sup> ;

chaque R<sup>9a</sup> est indépendamment choisi parmi Cy<sup>1</sup>, halogéno, alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, halogénoalkyle en C<sub>1-6</sub>, CN, NO<sub>2</sub>, OR<sup>a2</sup>, SR<sup>a2</sup>, C(O)R<sup>b2</sup>, C(O)NR<sup>c2</sup>R<sup>d2</sup>, C(O)OR<sup>a2</sup>, OC(O)R<sup>b2</sup>, OC(O)NR<sup>c2</sup>R<sup>d2</sup>, C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(O)R<sup>b2</sup>, NR<sup>c2</sup>C(O)OR<sup>a2</sup>, NR<sup>c2</sup>C(O)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>S(O)R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, S(O)R<sup>b2</sup>, S(O)NR<sup>c2</sup>R<sup>d2</sup>, S(O)<sub>2</sub>R<sup>b2</sup>, et S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, où lesdits alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, et alcynyle en C<sub>2-6</sub> sont chacun facultativement substitués par 1, 2, ou 3 substituants indépendamment choisis parmi Cy<sup>1</sup>, halogéno, CN, NO<sub>2</sub>, OR<sup>a2</sup>, SR<sup>a2</sup>, C(O)R<sup>b2</sup>, C(O)NR<sup>c2</sup>R<sup>d2</sup>, C(O)OR<sup>a2</sup>, OC(O)R<sup>b2</sup>, OC(O)NR<sup>c2</sup>R<sup>d2</sup>, C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(=NR<sup>e2</sup>)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>C(O)R<sup>b2</sup>, NR<sup>c2</sup>C(O)OR<sup>a2</sup>, NR<sup>c2</sup>C(O)NR<sup>c2</sup>R<sup>d2</sup>, NR<sup>c2</sup>S(O)R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>R<sup>b2</sup>, NR<sup>c2</sup>S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup>, S(O)R<sup>b2</sup>, S(O)NR<sup>c2</sup>R<sup>d2</sup>, S(O)<sub>2</sub>R<sup>b2</sup>, et S(O)<sub>2</sub>NR<sup>c2</sup>R<sup>d2</sup> ;


R<sup>10</sup> est choisi parmi halogéno, alkyle en C<sub>1-6</sub>, alcényle en C<sub>2-6</sub>, alcynyle en C<sub>2-6</sub>, halogénoalkyle en C<sub>1-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, hétérocycloalkyle de 4 à 10 chaînons, CN, NO<sub>2</sub>, OR<sup>a3</sup>, SR<sup>a3</sup>, C(O)R<sup>b3</sup>, C(O)NR<sup>c3</sup>R<sup>d3</sup>, C(O)OR<sup>a3</sup>, OC(O)R<sup>b3</sup>, OC(O)NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>R<sup>d3</sup>, NR<sup>c3</sup>C(O)R<sup>b3</sup>,





en C<sub>2-4</sub>, et alcynyle en C<sub>2-4</sub>, sont facultativement substitués par 1, 2, ou 3 substituants indépendamment choisis parmi OH, CN, amino, halogéno, alkyle en C<sub>1-4</sub>, alcoxy en C<sub>1-4</sub>, (alkyle en C<sub>1-4</sub>)thio, (alkyle en C<sub>1-4</sub>) amino, di (alkyle en C<sub>1-4</sub>) amino, halogénoalkyle en C<sub>1-4</sub>, et halogénoalcoxy en C<sub>1-4</sub> ;  
 ou R<sup>c6</sup> et R<sup>d6</sup> quelconques conjointement avec l'atome N auquel ils sont liés forment un groupe hétérocycloalkyle de 4, 5, 6 ou 7 chaînons facultativement substitué par 1, 2, ou 3 substituants indépendamment choisis parmi OH, CN, amino, halogéno, alkyle en C<sub>1-6</sub>, alcoxy en C<sub>1-4</sub>, (alkyle en C<sub>1-4</sub>)thio, (alkyle en C<sub>1-4</sub>) amino, di (alkyle en C<sub>1-4</sub>) amino, halogénoalkyle en C<sub>1-4</sub>, et halogénoalcoxy en C<sub>1-4</sub> ; et chaque R<sup>e6</sup> est indépendamment choisi parmi H, alkyle en C<sub>1-4</sub>, et CN.

2. Composé de la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel :
- a) R<sup>9</sup> est H, alkyle en C<sub>1-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, hétérocycloalkyle de 4 à 10 chaînons, (aryle en C<sub>6-10</sub>)-(alkyle en C<sub>1-4</sub>) , (cycloalkyle en C<sub>3-10</sub>)-(alkyle en C<sub>1-4</sub>), (hétéroaryle de 5 à 10 chaînons) - (alkyle en C<sub>1-4</sub>), ou (hétérocycloalkyle de 4 à 10 chaînons) - (alkyle en C<sub>1-4</sub>), où lesdits alkyle en C<sub>1-6</sub>, aryle en C<sub>6-10</sub>, cycloalkyle en C<sub>3-10</sub>, hétéroaryle de 5 à 10 chaînons, hétérocycloalkyle de 4 à 10 chaînons, (aryle en C<sub>6-10</sub>)-(alkyle en C<sub>1-4</sub>), (cycloalkyle en C<sub>3-10</sub>)-(alkyle en C<sub>1-4</sub>), (hétéroaryle de 5 à 10 chaînons)-(alkyle en C<sub>1-4</sub>) , et (hétérocycloalkyle de 4 à 10 chaînons)-(alkyle en C<sub>1-4</sub>) sont chacun facultativement substitués par R<sup>9a</sup> ; ou
- b) R<sup>9</sup> est H, alkyle en C<sub>1-6</sub>, cycloalkyle en C<sub>3-10</sub>, hétérocycloalkyle de 4 à 10 chaînons, (aryle en C<sub>6-10</sub>)-(alkyle en C<sub>1-4</sub>), ou (cycloalkyle en C<sub>3-10</sub>)-(alkyle en C<sub>1-4</sub>) ; ou
- c) R<sup>9</sup> est alkyle en C<sub>1-6</sub> ; ou
- d) R<sup>9</sup> est méthyle.
3. Composé de la revendication 1 ou 2, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel chacun de R<sup>1</sup>, R<sup>2</sup>, et R<sup>3</sup> est H.
4. Composé de l'une quelconque des revendications 1 à 3, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel :
- a) R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, et R<sup>8</sup> sont chacun indépendamment choisis parmi H, halogéno, alkyle en C<sub>1-6</sub>, halogénoalkyle en C<sub>1-6</sub>, CN, et OR<sup>a1</sup> ; ou
- b) R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, et R<sup>8</sup> sont chacun indépendamment choisis parmi H, halogéno, et méthoxy ; ou
- c) R<sup>5</sup> et R<sup>7</sup> sont tous deux méthoxy et R<sup>4</sup>, R<sup>6</sup>, et R<sup>8</sup> sont chacun indépendamment choisis parmi H et halogéno ; ou
- d) R<sup>4</sup> est halogéno, R<sup>5</sup> est méthoxy, R<sup>6</sup> est H, R<sup>7</sup> est méthoxy, et R<sup>8</sup> est halogéno.
5. Composé de l'une quelconque des revendications 1 à 4, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel :
- a) X est CR<sup>15</sup> ; ou
- b) X est CH.
6. Composé de l'une quelconque des revendications 1 à 5, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel R<sup>15</sup> est H ou hétéroaryle de 5 à 10 chaînons facultativement substitué par alkyle en C<sub>1-6</sub>.
7. Composé de l'une quelconque des revendications 1 à 6, ou sel pharmaceutiquement acceptable de celui-ci dans lequel R<sup>10</sup> est alkyle en C<sub>1-6</sub> facultativement substitué par hétérocycloalkyle de 4 à 7 chaînons où ledit hétérocycloalkyle de 4 à 7 chaînons est choisi parmi morpholinyle, pipérazinyle, pipéridinyle, pyrrolidinyle, tétrahydrofuranyle, et azétidinyle, et où ledit hétérocycloalkyle de 4 à 7 chaînons est facultativement substitué par 1, 2, ou 3 substituants indépendamment choisis parmi halogéno, alkyle en C<sub>1-6</sub>, halogénoalkyle en C<sub>1-6</sub>, CN, OR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, et NR<sup>c5</sup>C(O)R<sup>b5</sup>.
8. Composé de la revendication 1, ou sel pharmaceutiquement acceptable de celui-ci, ayant la formule IIa :



IIa.

9. Composé de la revendication 8, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel R<sup>4</sup> est halogéno, R<sup>5</sup> est méthoxy, R<sup>6</sup> est H, R<sup>7</sup> est méthoxy, et R<sup>8</sup> est halogéno.

10. Composé de la revendication 8 ou 9, ou sel pharmaceutiquement acceptable de celui-ci, dans lequel R<sup>9</sup> est alkyle en C<sub>1-6</sub>.

11. Composé de l'une quelconque des revendications 8 à 10, ou sel pharmaceutiquement acceptable de celui-ci dans lequel R<sup>10</sup> est alkyle en C<sub>1-6</sub> facultativement substitué par un hétérocycloalkyle de 4 à 7 chaînons où ledit hétérocycloalkyle de 4 à 7 chaînons est choisi parmi morpholinyle, pipérazinyle, pipéridinyle, pyrrolidinyle, tétrahydrofuranyle, et azétidinyle, et où ledit hétérocycloalkyle de 4 à 7 chaînons est facultativement substitué par 1, 2, ou 3 substituants indépendamment choisis parmi halogéno, alkyle en C<sub>1-6</sub>, halogénoalkyle en C<sub>1-6</sub>, CN, OR<sup>a5</sup>, C(O)R<sup>b5</sup>, C(O)NR<sup>c5</sup>R<sup>d5</sup>, C(O)OR<sup>a5</sup>, OC(O)R<sup>b5</sup>, NR<sup>c5</sup>R<sup>d5</sup>, et NR<sup>c5</sup>C(O)R<sup>b5</sup>.

12. Composé de la revendication 1 qui est choisi parmi:

3-(3,5-diméthoxyphényl)-1-méthyl-8-(1-méthyl-1H-pyrazol-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(3,5-diméthoxyphényl)-N,1-diméthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide ;

3-(2-chloro-3,5-diméthoxyphényl)-1-méthyl-8-(1-méthyl-1H-pyrazol-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(2-chloro-3,5-diméthoxyphényl)-8-[1-(2-hydroxyéthyl)-1H-pyrazol-4-yl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(2-chloro-3,5-diméthoxyphényl)-1-méthyl-8-(1-méthyl-1H-pyrazol-5-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(2-chloro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbonitrile ;

3-(3,5-diméthoxyphényl)-1-méthyl-8-(1-méthyl-1,2,3,6-tétrahydropyridin-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(3,5-diméthoxyphényl)-1-méthyl-8-(1-méthylpipéridin-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(3,5-diméthoxyphényl)-N,N,1-triméthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide ;

3-(3,5-diméthoxyphényl)-8-[(3-hydroxyazétidin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(3,5-diméthoxyphényl)-8-[(3-hydroxypyrrolidin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(3,5-diméthoxyphényl)-1-méthyl-8-[(4-méthylpipérazin-1-yl)carbonyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(2-chloro-3,5-diméthoxyphényl)-N,1-diméthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide ;

3-(2-chloro-3,5-diméthoxyphényl)-N,N,1-triméthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-

d]pyrimidine-8-carboxamide ;  
 3-(2-chloro-3,5-diméthoxyphényl)-8-[(3-hydroxyazétidin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2-chloro-3,5-diméthoxyphényl)-1-méthyl-8-[(4-méthylpipérazin-1-yl)carbonyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 N-cyclopropyl-3-(2-fluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide ;  
 3-(2-fluoro-3,5-diméthoxyphényl)-8-[(3-hydroxyazétidin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 1-[[3-(2-fluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]carbonyl]pyrrolidine-3-carbonitrile ;  
 3-(2-fluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(4-méthylpipérazin-1-yl)carbonyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2-fluoro-3,5-diméthoxyphényl)-8-[(3-hydroxypipéridin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2-fluoro-3,5-diméthoxyphényl)-N,N,1-triméthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-N,N,1-triméthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carboxamide ;

ou sel pharmaceutiquement acceptable de l'un quelconque de ceux-ci.

### 13. Composé de la revendication 1 :

a) choisi parmi :

3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(tétrahydro-2H-pyran-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(4-méthylpipérazin-1-yl)carbonyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(morpholin-4-ylcarbonyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4,4-difluoropipéridin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 ou sel pharmaceutiquement acceptable de l'un quelconque de ceux-ci ; ou

b) choisi parmi :

3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[2-(4-éthylpipérazin-1-yl)éthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[3-(4-éthylpipérazin-1-yl)propyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(1-éthylpipéridin-4-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-hydroxypipéridin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4,4-difluoropipéridin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(3,3-difluoropipéridin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 8-(2-azétidin-1-yléthyl)-3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(2-pyrrolidin-1-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(3-morpholin-4-ylpropyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 5 8-[3-(4-cyclopropylpipérazin-1-yl)propyl]-3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 10 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(3R,5S)-3,5-diméthylpipérazin-1-yl]carbonyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 ou sel pharmaceutiquement acceptable de l'un quelconque de ceux-ci ; ou

c) choisi parmi:

15 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 20 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-[(4-éthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 25 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-(2-hydroxyéthyl)pipérazin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(4-[[3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]méthyl]pipérazin-1-yl)propanenitrile ;  
 1-[[3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]méthyl]pipéridine-4-carbonitrile ;  
 30 (3S)-1-[[3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]méthyl]pyrrolidine-3-carbonitrile ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(1-méthylpipéridin-4-yl)amino]méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(3S)-tétrahydrofurane-3-ylamino]méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 35 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(3R)-tétrahydrofurane-3-ylamino]méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-(1H-imidazol-1-ylméthyl)-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(1H-pyrazol-1-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 40 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-[(1-méthyl-1H-pyrazol-4-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(2-pyridin-2-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 45 3-(2-chloro-6-fluoro-3,5-diméthoxyphényl)-1-éthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 8-[2-(diéthylamino)éthyl]-3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[2-(3-fluoroazétidin-1-yl)éthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 50 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[2-(3-méthoxyazétidin-1-yl)éthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-hydroxyéthyl)-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 55 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-fluorophényl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1-(2-fluorophényl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

- 1-cyclobutyl-3-(2,6-difluoro-3,5-diméthoxyphényl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 1-cyclobutyl-3-(2,6-difluoro-3,5-diméthoxyphényl)-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 5 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-(morpholin-4-ylméthyl)-1-propyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 10 1-cyclopropyl-3-(2,6-difluoro-3,5-diméthoxyphényl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 1-cyclopropyl-3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 1-cyclopropyl-3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 15 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(4-fluorophényl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(4-fluorophényl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(4-fluorophényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 20 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2,3-difluorophényl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2,3-difluorophényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 25 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-(morpholin-4-ylméthyl)-1-pyridin-4-yl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1-pyridin-4-yl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 30 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-fluorophényl)-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-fluorophényl)-8-[2-(4-méthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-fluorophényl)-8-[2-(4-éthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 35 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-[(2-méthoxy-pyridin-4-yl)méthyl]-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(1-méthyl-1H-pyrazol-4-yl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1-(1-méthyl-1H-pyrazol-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 40 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1-(1-méthyl-1H-pyrazol-4-yl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 1-[[3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]méthyl]azétidine-3-carbonitrile ;
- 45 (3R)-1-[[3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]méthyl]pyrrolidine-3-carbonitrile ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[2-(3-fluoroazétidin-1-yl)éthyl]-1-(2-hydroxyéthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2,3-difluorophényl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 50 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(3-fluorophényl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(3-fluorophényl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 55 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(3-fluorophényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;
- 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-[(2-oxopyridin-1(2H)-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;

3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-[(pyridin-3-yloxy)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-hydroxyéthyl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2,3-difluorophényl)-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2,3-difluorophényl)-8-[2-(4-méthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2,3-difluorophényl)-8-[2-(4-éthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(4-fluorophényl)-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(4-fluorophényl)-8-[2-(4-méthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(3-fluorophényl)-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(3-fluorophényl)-8-[2-(4-méthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(3-fluorophényl)-8-[2-(4-éthylpipérazin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 1-[2-[3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-2-oxo-2,3,4,7-tétrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-8-yl]éthyl]azétidine-3-carbonitrile ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-[2-(3-fluoroazétidin-1-yl)éthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-fluoroéthyl)-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ; et  
 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-(2-fluoroéthyl)-8-[(4-méthylpipérazin-1-yl)méthyl]-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one ;  
 ou sel pharmaceutiquement acceptable de l'un quelconque de ceux-ci.

14. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, ou sel pharmaceutiquement acceptable de celui-ci.
15. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
16. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, ou sel pharmaceutiquement acceptable de celui-ci.
17. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-8-[(4-éthylpipérazin-1-yl)méthyl]-1-méthyl-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
18. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, ou sel pharmaceutiquement acceptable de celui-ci.
19. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-méthyl-8-(morpholin-4-ylméthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.
20. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, ou sel pharmaceutiquement acceptable de celui-ci.
21. Composé de la revendication 1 qui est 3-(2,6-difluoro-3,5-diméthoxyphényl)-1-éthyl-8-(2-morpholin-4-yléthyl)-1,3,4,7-tétrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one.

22. Composition pharmaceutique comprenant :

- (a) un composé de l'une quelconque des revendications 1 à 13, ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un véhicule pharmaceutiquement acceptable ; ou  
(b) un composé de l'une quelconque des revendications 14, 16, 18 ou 20, ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un véhicule pharmaceutiquement acceptable ; ou  
(c) un composé de l'une quelconque des revendications 15, 17, 19, ou 21 et au moins un véhicule pharmaceutiquement acceptable.

23. Procédé d'inhibition d'une enzyme FGFR comprenant la mise en contact *in vitro* de ladite enzyme avec :

- (a) un composé de l'une quelconque des revendications 1 à 13, ou un sel pharmaceutiquement acceptable de celui-ci ; ou  
(b) un composé de l'une quelconque des revendications 14, 16, 18 ou 20, ou sel pharmaceutiquement acceptable de celui-ci ; ou  
(c) un composé de l'une quelconque des revendications 15, 17, 19 ou 21.

24. Composé de l'une quelconque des revendications 1 à 13, 14, 16, 18 ou 20, ou sel pharmaceutiquement acceptable de celui-ci, pour utilisation dans :

- a) le traitement du cancer ; ou  
b) le traitement du cancer, ledit cancer étant choisi parmi un cancer de la vessie, un cancer du sein, un cancer du col de l'utérus, un cancer colorectal, un cancer de l'endomètre, un cancer de l'estomac, un cancer de la tête et du cou, un cancer du rein, un cancer du foie, un cancer du poulmon, un cancer de l'ovaire, un cancer de la prostate, un cancer de l'oesophage, un cancer de la vésicule biliaire, un cancer pancréatique, un cancer de la thyroïde, un cancer de la peau, une leucémie, un myélome multiple, un lymphome lymphocytaire chronique, une leucémie à cellules T de l'adulte, un lymphome à cellules B, une leucémie myéloïde aiguë, un lymphome hodgkinien ou non hodgkinien, la macroglubulinémie de Waldenstrom, un lymphome à tricholeucocytes, un lymphome de Burkett, un glioblastome, un mélanome et un rhabdosarcome.

25. Composé de l'une quelconque des revendications 1 à 13, 14, 16, 18 ou 20, ou sel pharmaceutiquement acceptable de celui-ci, pour utilisation dans :

- a) le traitement d'un trouble myéloprolifératif ; ou  
b) le traitement d'un trouble myéloprolifératif, ledit trouble myéloprolifératif étant choisi parmi une polycythémie vraie, une thrombocythémie essentielle, et une myélofibrose primaire.

26. Composé de l'une quelconque des revendications 1 à 13, 14, 16, 18 ou 20, ou sel pharmaceutiquement acceptable de celui-ci, pour utilisation dans :

- a) le traitement d'un trouble squelettique ou chondrocytaire ; ou  
b) le traitement d'un trouble squelettique ou chondrocytaire, ledit trouble squelettique ou chondrocytaire étant choisi parmi l'achondroplasie, l'hypocondroplasie, le nanisme, la dysplasie thanatophore (TD), le syndrome d'Apert, le syndrome de Crouzon, le syndrome de Jackson-Weiss, le syndrome de Beare-Stevenson, le syndrome de cutis gyrata, le syndrome de Pfeiffer, et le syndrome de craniosynostose.

27. Composé de l'une quelconque des revendications 1 à 13, 14, 16, 18 ou 20, ou sel pharmaceutiquement acceptable de celui-ci, pour utilisation dans :

- a) le traitement d'un trouble d'hypophosphatémie ; ou  
b) le traitement d'un trouble d'hypophosphatémie, ledit trouble d'hypophosphatémie étant le rachitisme hypophosphatémique lié à l'X, le rachitisme hypophosphatémique autosomique récessif, et le rachitisme hypophosphatémique autosomique dominant, ou une ostéomalacie induite par une tumeur.

28. Composé de la revendication 15, 17, 19 ou 21 pour utilisation dans :

- a) le traitement d'un cancer ; ou  
b) le traitement d'un cancer, ledit cancer étant choisi parmi un cancer de la vessie, un cancer du sein, un cancer

## EP 2 861 595 B9

du col de l'utérus, un cancer colorectal, un cancer de l'endomètre, un cancer de l'estomac, un cancer de la tête et du cou, un cancer du rein, un cancer du foie, un cancer du poumon, un cancer de l'ovaire, un cancer de la prostate, un cancer de l'oesophage, un cancer de la vésicule biliaire, un cancer pancréatique, un cancer de la thyroïde, un cancer de la peau, une leucémie, un myélome multiple, un lymphome lymphocytaire chronique, une leucémie à cellules T de l'adulte, un lymphome à cellules B, une leucémie myéloïde aiguë, un lymphome hodgkinien ou non hodgkinien, la macroglobulinémie de Waldenstrom, un lymphome à tricholeucocytes, un lymphome de Burkett, un glioblastome, un mélanome et un rhabdosarcome.

29. Composé de la revendication 15, 17, 19 ou 21 pour utilisation dans :

- a) le traitement d'un trouble myéloprolifératif ; ou
- b) le traitement d'un trouble myéloprolifératif, ledit trouble myéloprolifératif étant choisi parmi la polycythémie vraie, la thrombocythémie essentielle et la myélofibrose primaire.

30. Composé de la revendication 15, 17, 19 ou 21 pour utilisation dans :

- a) le traitement d'un trouble squelettique ou chondrocytaire ; ou
- b) le traitement d'un trouble squelettique ou chondrocytaire, ledit trouble squelettique ou chondrocytaire étant choisi parmi l'achondroplasie, l'hypocondroplasie, le nanisme, la dysplasie thanatophore (TD), le syndrome d'Apert, le syndrome de Crouzon, le syndrome de Jackson-Weiss, le syndrome de Beare-Stevenson, le syndrome de cutis gyrata, le syndrome de Pfeiffer, et le syndrome de craniosynostose.

31. Composé de la revendication 15, 17, 19 ou 21 pour utilisation dans :

- a) le traitement d'un trouble d'hypophosphatémie ; ou
- b) le traitement d'un trouble d'hypophosphatémie, ledit trouble d'hypophosphatémie étant le rachitisme hypophosphatémique lié à l'X, le rachitisme hypophosphatémique autosomique récessif, et le rachitisme hypophosphatémique dominant autosomique, ou l'ostéomalacie induite par tumeur.

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 2006124731 A [0004]
- WO 2007134259 A [0380]
- WO 2007030366 A [0490]
- WO 204430257 A [0972]

## Non-patent literature cited in the description

- **ESWARAKUMAR et al.** *Cytokine & Growth Factor Reviews*, 2005 [0002]
- **KNIGHTS ; COOK.** *Pharmacology & Therapeutics*, 2010 [0002]
- **TURNER ; GROSE.** *Nature Reviews Cancer*, 2010 [0002]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1985, 1418 [0105]
- *Journal of Pharmaceutical Science*, 1977, vol. 66, 2 [0105]
- **T.W. GREENE ; P.G.M. WUTS.** *Protective Groups in Organic Synthesis*. Wiley & Sons, Inc, 1999 [0108]
- Physicians' Desk Reference. Medical Economics Company, 1996 [0164]
- **K. BLOM.** Two-Pump At Column Dilution Configuration for Preparative LC-MS. *J. Combi. Chem.*, 2002, vol. 4, 295 [0186]
- **K. BLOM ; R. SPARKS ; J. DOUGHTY ; G. EVERLOF ; T. HAQUE ; A. COMBS.** Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification. *J. Combi. Chem.*, 2003, vol. 5, 670 [0186]
- **K. BLOM ; B. GLASS ; R. SPARKS ; A. COMBS.** Preparative LC-MS Purification: Improved Compound Specific Method Optimization. *J. Combi. Chem.*, 2004, vol. 6, 874-883 [0186]
- **K. BLOM ; B. GLASS ; R. SPARKS ; A. COMBS.** Preparative LCMS Purification: Improved Compound Specific Method Optimization. *J. Comb. Chem.*, 2004, vol. 6, 874-883 [0187]